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Abstract 
Patient nonadherence to medication harms patient outcomes and raises costs via wasted 
and unnecessary treatment (Osterberg and Blaschke, 2005). However, current adherence 
measures are far from optimal (Vitolins et al., 2000), and adherence enhancing 
interventions rarely successful (Haynes et al., 2008). This may be a reflection of 
inadequate patient targeting and adherence measurement. This thesis describes the 
development of questionnaires intended to be clinically useful by predicting patient risk 
of nonadherence. A scoping review with meta-analysis was undertaken to identify 
predictors objectively shown to be associated with nonadherence. Any pre-existing 
questionnaires to measure the selected predictors were identified via literature review. 
Pre-existing questionnaires incorporated were the Beliefs about Medicines Questionnaire 
(Horne et al., 1999), Perceived Stress Scale (Cohen et al., 1983), Patient Health 
Questionnaire (Kunik et al., 2007), and the Patient-Doctor Relationship Questionnaire 
(Van der Feltz-Cornelis et al., 2004). Novel items were developed to measure patient 
demographics, health literacy, mental health, risky health behaviours, beliefs about 
medicines, self-efficacy , social support, and access to medicines. These scales were 
incorporated into two novel questionnaires. The Patient and Lifestyle Scale (PALS), and 
the Wellbeing and Medications Scale (WAMS). A feasibility study was conducted with 16 
patients at a GP surgery to identify limitations in research design and perform preliminary 
psychometric assessment. Issues with participant identification were highlighted, 
however, indications were that PALS and WAMS could be used to predict self-reported 
and prospective refill adherence. A practitioner focus group appraised the clinical utility 
of the questionnaires whilst acceptability and validity were assessed via six participant 
interviews. The PALS and WAMS were perceived to be potentially clinically useful and 
most items were considered acceptable. Findings also indicated that mental distress is 
associated with nonadherence and that long term adherence may depend more upon 
integrating medicines into every day habits than rational cost-benefits appraisals. 
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Chapter 1 – Introduction 
 
1.1 General Introduction  
It is estimated that between 25% and 50% of all patients diagnosed with a chronic disease 
do not take their medication as prescribed (Sackett and Snow, 1979, DiMatteo, 2004c). 
This is a significant issue for the NHS, which dispensed 886 million prescriptions in 2009 at 
a cost of over £8.5 billion (NHS Information Centre, 2010). If a quarter of those medicines 
are not taken, this represents a significant waste of public resources and a high cost to 
public health. The UK’s Department of Health (2008) costs the number of unused and 
unwanted medications that are returned to pharmacies at approximately £100 million per 
year, while NICE (National Institute for Clinical Excellence, 2009) report that between 0.3 
and 1.2% of hospital admissions are directly related to patients not taking their medicine 
as prescribed, at a further cost of between £36 million to £196 million per year to the 
NHS. Osterberg and Blaschke (2005) estimate the cost of unnecessary admissions to 
hospital in the US caused by patients not taking medicines as prescribed to be 
approximately $100 billion per year, while Hovstadius and Petersson (2011) report that in 
Sweden over €1 billion are spent on medicines that are never taken. 
With such huge financial pressures attached to a major public health concern, the 
question of how and why patients do not take their medicines as prescribed has become 
a vast field of research. Despite the number of articles concerning whether patients take 
medication as prescribed now stretching into the tens of thousands (Martin et al., 2005), 
there is remarkably little cohesion in the field, and consequently, progress has been poor 
(Nunes et al., 2009). There is no definitive measure employed, nor a coherent picture of 
the key variables. Even the words used to describe the problem remain debated. Patient 
compliance, adherence, and concordance are used, often without definition or with due 
sensitivity given to their specific meanings. This lack of coherence further fragments an 
intricate and complicated research problem (Vermeire et al., 2001, Kyngäs et al., 2000). 
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1.2 Compliance, Adherence, and Concordance 
 
1.2.1 Compliance 
The two most common terms used to describe patients following the recommendations 
of health professionals are ‘adherence’ and ‘compliance’. Haynes et al.(1979) defined 
compliance as ‘the extent to which a person’s behavior [sic] (in terms of taking 
medications, following diets, or executing lifestyle changes) coincides with medical or 
health advice’. This definition assumes that the more patient behaviour coincides with 
medical advice then the ‘better behaved’ the patient(RPSGB and Merck Sharp & Dohme, 
1997). Words such as ‘comply’ or ‘obey’ can be perceived as reducing patients to ‘passive 
followers of doctors’ instructions (Stimson, 1974). Haynes et al.(1979) did stipulate that 
compliance is an appropriate response only where a diagnosis is correct, the treatment 
prescribed is effective, and where the patient has provided informed consent, however, 
others have not been so careful with the use of the term(Trostle, 1988). For example, one 
study defined ‘compliance’ as completing a treatment regime in a clinical trial whether or 
not doctors had advised participants to stop taking the medicines (Glynne-Jones et al., 
2008). 
Although ‘compliance’ is still frequently used in the literature, it has been largely replaced 
by the term ‘adherence’ which is considered less authoritarian (Sawyer and Aroni, 2003). 
 
1.2.2 Adherence 
Adherence is most commonly defined as ‘the extent to which a person’s behaviour – 
taking medication, following a diet, and/or executing lifestyle changes, corresponds with 
agreed recommendations from a healthcare provider’ (World Health Organisation, 2003). 
This definition emphasises the requirement of agreement, reflecting a trend towards 
seeing the patient as a partner in a therapeutic alliance (Kyngäs et al., 2000). 
The WHO definition of adherence does not fully articulate what is meant by a 
“nonadherent” patient. It would not make sense to label a patient who misses one dose 
of their medication at no cost to their health as nonadherent (Horne, 2000). Many 
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authors take the approach of dichotomising adherence into patients taking a sufficient 
proportion of their medicines to receive therapeutic benefit and those that are not 
(Chapman, 2004). For example, researchers investigating antiretroviral medications 
usually indicate that those taking less than 95% of their medications are nonadherent, 
because when adherence is below this proportion of medicines taken the benefits of 
antiretrovirals become dubious (Atkinson and Petrozzino, 2009). However, this method 
requires each medication regimen to have a different cut off for adherence. For example, 
Sackett and Snow (1979) report that only 30% of a prophylactic penicillin regime was 
required to offer protection from rheumatic fever, while 80% of an antihypertensive 
medication regimen must be taken before therapeutic benefit is conferred. When the 
required dose for each medication is not known it may be unproductive to stigmatise 
patients with the ‘nonadherent’ label when their behaviour may cause them no harm 
(Steiner and Earnest, 2000). It may be more appropriate to report mean proportions of 
medicines taken across all participants instead of reporting proportions of adherent 
versus nonadherent individuals (Horne, 2000). This would more accurately reflect the 
true rates of adherence and provide more accurate measurement. This would also 
remove an element of judgement placed upon the patient. However, judgements about 
adherence rates could only be performed at the population level which may lack clinical 
utility. Most authors define adherence rates in terms of proportions of adherent 
individuals (DiMatteo, 2004c). They also tend to do so using Sackett and Snow’s 80% cut 
off (Peterson et al., 2007). 
 
1.2.3 Concordance 
The traditional ‘paternalistic’ model of medicine defines the practitioner as an expert and 
the patient is expected to comply with their advice based on superior knowledge (Britten 
and Weiss, 2004, Charles et al., 1997). However, the priorities of patients may not be the 
same as the priorities of healthcare providers. Medical professionals’ priorities are to 
eradicate or prevent illness, while patients’ are more concerned with maintaining normal 
functioning (Pollock, 2005). Patients often cease to take medication once they feel better 
and this could be due to the medicines lowering quality of life via side effects and forced 
routines, more than they confer benefits by offering an improvement in health (Miller, 
1997). The concordance movement was initiated to encourage acknowledgement that 
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patients health beliefs could be internally valid and consistent yet contrary to that of the 
health care provider (Marinker, 2004). Concordance aims to promote a therapeutic 
alliance with patients ‘in which the most important determinations are agreed to be 
those that are made by the patient’(RPSGB and Merck Sharp & Dohme, 1997). Because 
concordance describes an approach to consultations it is improper to use the term as a 
synonym for adherence (Cushing and Metcalfe, 2007). 
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1.3 Measurement of adherence 
An accurate measure of adherence is necessary in order to identify which patients are 
nonadherent and to quantify the effects of any intervention (Insull Jr., 1984). However, 
there is no universally accepted ‘gold standard’ of adherence measurement. All measures 
have strengths and weaknesses in terms of practicality, accuracy, and acceptability 
(Vitolins et al., 2000).  
All attempts to measure adherence to medication will be susceptible to three types of 
bias unless covert measurement is used, which may not always be an ethically 
appropriate option. Reactivity bias refers to the phenomenon whereby observing 
behaviour, changes the behaviour that is being observed (Horne, 2000). White coat 
adherence refers to adherence improving in the period shortly before patients visit health 
professionals (Schwartz and Quigley, 2008, Rudd, 1998). Pygmalion effects refer to the 
phenomenon where researcher expectations may generate a self-fulfilling prophecy. For 
example, patients’ adherence may be improved when they are receiving an intervention 
to improve adherence because they receive preferential treatment to patients not 
receiving an intervention. Patients with a good relationship with their doctor may also 
receive a higher standard of treatment than those with lower quality relationships 
(Chapman, 2004). 
Measures of adherence may also differ in terms of their sensitivity and specificity. A 
measure of adherence is sensitive if it is able to correctly identify nonadherent patients 
and specific if it identifies only nonadherent patients as nonadherent. This can vary by 
measurement type. For example, when patients self-report as nonadherent this is usually 
accurate, but self-reports often incorrectly identify nonadherent patients as adherent 
(Farmer, 1999). In contrast, electronic monitoring devices are more likely to incorrectly 
label an adherent patient as nonadherent. Because of these various differences between 
the methods of measurement, DiMatteo (2004c) found significant differences in 
adherence rates reported by different measurement types. 
 
24 
 
1.3.1 Direct measurement of adherence 
The most obvious way of measuring adherence is to observe patients taking their 
medicines. However, this is impractical in the out-patient setting where the 
administration of medicine is under a greater degree of patient control (DiMatteo, 
2004c). Even in closely monitored clinical trials and in-patient settings, direct patient 
observation is imperfect, with some patients feigning adherence and removing 
medication from their mouths when no longer observed (Farmer, 1999). 
A more common direct measurement of patient adherence is to take a blood sample 
from a patient and detect whether the medicine or one of its metabolites is present in the 
blood (Horne, 2000). The primary advantage to this method is high sensitivity (Farmer, 
1999). However, due to individual variability in metabolism it is not possible to quantify 
how adherent a patient has been via this method (Mattson and Friedman, 1984, Kettler 
et al., 2002). For this reason direct measurement of adherence is particularly sensitive to 
white coat adherence because patients only need to take pills immediately before 
measurement to give the impression of adherence (Horne, 2000, Chapman, 2004, Cramer 
et al., 1989). 
It is also extremely difficult to directly measure metabolites of many medicines (Gordis, 
1979). One way to circumvent this issue is to develop a marker which can be added to the 
medicine preparation. Unfortunately developing an adequate marker is both expensive 
and difficult. An ideal marker must be chemically inert, pharmacologically inactive, non-
toxic, and must not accumulate in the body, with a half-life suitable for accurate 
detection but not so long that the test loses its sensitivity (Insull Jr., 1984). 
Further problems with using direct methods are that they are expensive, requiring 
collection, storage, and testing of blood samples, and they are also ethically dubious. 
Direct measurements are often uncomfortable and invasive for patients (Horne, 2000). 
Direct measurement of adherence is only practical for single-dose therapies, where 
administration of medication is intermittent, or when patients are hospitalised (Vermeire 
et al., 2001, Gordis, 1979). 
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1.3.2 Indirect measures of adherence 
 
1.3.2.1 Pill Counts 
One of the most popular methods of assessing adherence rates has been to determine 
how many pills patients have in their possession compared to how many they would have 
if they had perfect adherence. At least until the development of electronic monitoring 
systems, pill counts were considered the reference standard for all other adherence 
measures (Farmer, 1999). The measure is simple, requiring no advanced technology 
(Horne, 2000) and pill counts can also be adapted to other preparation modes by 
weighing powder or liquid preparations (Farmer, 1999). However, pill counts have a 
tendency to overestimate adherence because pills may be taken incorrectly, given to 
other people, moved to a different container, removed from the bottle and dropped, or 
lost prior to ingestion (Gordis, 1979). There is also no indication of the pattern of 
nonadherence a patient may display (Farmer, 1999). A patient may have missed 
occasional doses due to lapses of memory, or they may have taken a medicine holiday, or 
else they may have taken medication only in periods leading up to medical assessment 
(Gordis, 1979, Cramer et al., 1989). Doses may also be deliberately dumped where 
patients are aware their medication is being monitored (Gordis, 1979, Horne, 2000, 
Osterberg and Blaschke, 2005, Farmer, 1999, Vitolins et al., 2000, Rudd et al., 1989, Pullar 
et al., 1989). This measure is also dependent upon patients remembering to bring pill 
bottles for assessment which may increase reactivity biases (Vitolins et al., 2000, Haynes 
et al., 1980). Pill bottles can also be mislaid, confounding results (Cramer et al., 1989). 
Unannounced pill counts might generate more accurate estimates of adherence (Horne, 
2000, Pullar et al., 1989, Farmer, 1999, Haynes et al., 1980). 
 
1.3.2.2 Prescription refill rates 
Refill rates estimate adherence based upon either how much time patients had 
medication available to them or else estimating nonadherence based upon how many 
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days patients did not have access to medication (Steiner and Prochazka, 1997). 
Prescription refills are easy to quantify by various methods. This can make them 
adaptable, as they can measure total adherence rates over a whole regimen, or else 
provide a picture of the pattern of adherence over a long period of time if regular 
measurement intervals are used (Steiner and Prochazka, 1997). For example, if there is 
one large gap evident this may imply the patient had taken a medication holiday. 
Conversely persistent small delays may imply occasional missed doses. One of the major 
benefits of refill rates is that they allow a measure of adherence that can be taken 
without patient knowledge, sidestepping the problems of reactivity (Vitolins et al., 2000, 
Balkrishnan and Jayawant, 2007). The low cost of the measure also makes it a very 
popular method when dealing with large populations or for lengthy longitudinal studies 
(Van Wijk et al., 2006). 
However, refill rates do have significant limitations. There is a lack of consistency in 
measurement which can make refill rates difficult to interpret (Van Wijk et al., 2006). 
Refill rates are also an abstract measure of adherence because they measure acquisition 
of medication rather than its consumption (Feinstein, 1979, Steiner and Prochazka, 1997). 
Refill adherence give the maximum possible adherence a patient could have displayed 
(Sherman et al., 2000), and consequently offer high specificity but poor sensitivity 
(Steiner and Prochazka, 1997). Furthermore, when medicines are not prescribed in 
regular short intervals it can be difficult to describe the different patterns of 
nonadherence displayed by patients (Balkrishnan and Jayawant, 2007). Refill rates can be 
compromised if patients are able to acquire medicines from alternate sources to those in 
a study or from multiple pharmacies (Vitolins et al., 2000, Balkrishnan and Jayawant, 
2007). A final problem is that it can be difficult to determine whether changes in patients 
medication behaviour are due to nonadherence or a change in the medical advice they 
have been given (Van Wijk et al., 2006). 
 
1.3.2.3 Electronic monitoring devices 
Electronic monitors work by recording the time and date of each opening of a medicine 
container (Cramer et al., 1989). Records can also be transmitted remotely to prevent data 
loss (Sajatovic et al., 2010). Electronically monitoring adherence offers the possibility of 
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collecting the exact pattern of adherence participants exhibit (Cramer et al., 1989). 
Andrejak et al. (2000) used electronic monitors to compare two antihypertensive 
medicines, and although the proportion of medicines taken for each was comparable, use 
of electronic monitors was able to show how one medicine was more readily taken on 
schedule than another. Moreover, it can be seen whether a patient regularly misses a 
specific dose, misses doses sporadically, or has taken a longer break from medication 
(Farmer, 1999). No other method of adherence assessment allows an accurate 
assessment of this type of data, which can differentiate between dose and schedule 
adherence (Waterhouse et al., 1993, Smith et al., 2010). Some modern monitors can also 
offer extra clinical utility as adherence aids, capable of reminding participants to take 
their medicines (Haberer et al., 2012). 
Despite these strengths there are significant limitations with electronic monitoring 
devices. As with pill counts, actual ingestion of the medication once the pill box has been 
opened cannot be proven (Ingerski et al., 2011). Martin et al. (2007) found that 60% of 
participants in their sample required data to be deleted because they had opened the 
bottle for reasons other than to take a dose. For this reason electronically recorded data 
frequently gives lower adherence rates than alternative adherence measures (Liu et al., 
2001, Smith et al., 2010, Byerly et al., 2005). Some devices can partially correct for this by 
asking participants if they have opened the device to take a dose or not (Sajatovic et al., 
2010), and it has been demonstrated that pill counts correlate more strongly with 
electronic monitoring when this adjustment is made (Haberer et al., 2012). However, 
these adjustments do not account for patients who are intentionally nonadherent and 
opening the box only to dump the dose, although some inhaler monitors can note 
multiple uses in a short period of time to identify dumped doses (Ingerski et al., 2011). 
Data loss can and does happen, with malfunction rates ranging from 5 to 20% for bottle 
cap monitors and 8 to 21% for inhaler monitors (Ingerski et al., 2011). Wu et al. (2008) 
lost data from 13 patients in their sample because the monitor hardware or software 
malfunctioned, or because the patients lost or damaged the device. The bulk of the 
devices can cause problems for patients with some preferring to remove more than one 
dose per opening in order to move medication into more portable or less conspicuous 
packaging (Sajatovic et al., 2010). Smith et al. (2010) had one participant that opened 
their monitoring device only once per week to place medicine into a pill box. This resulted 
in their being classified as nonadherent by electronic device but 100% adherent via pill 
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count and self-report. Wetzels et al. (2006) found that there was almost no agreement 
between electronic monitoring of adherence and refill data. The primary cause of this was 
the very high adherence of patients over the 2 month period of electronic monitoring 
versus the arguably more natural behaviour of patients over the 12 month duration 
assessed by medication refill data. These difficulties mean that electronic monitoring can 
underestimate adherence when patients swap pill boxes (Liu et al., 2001) or overestimate 
adherence when measurement is over the short term (Wetzels et al., 2006). Often, a 
choice has to be made regarding which prescribed medication is electronically monitored 
due to the prohibitive costs of providing each patient with multiple monitoring devices 
(Sajatovic et al., 2010). These costs also prohibit their use in many naturalistic studies and 
practice settings, and limit their deployment primarily to clinical trials (Horne et al., 2005). 
Many current devices are also difficult to conceal, and so an explanation must be given to 
patients as to why their medication container appears different to normal if adherence is 
to be measured covertly (Waterhouse et al., 1993). The constant visual reminder of 
observation from electronic devices can exaggerate the reactivity biases and keep 
adherence rates artificially high for long periods of time (Chui et al., 2003). 
The wealth of data provided by electronic monitors makes them an attractive option 
when the resources are in place to allow their use. However, the limitations should not be 
underestimated and claims that they mark the gold standard of adherence measurement  
are premature (Smith et al., 2010). 
 
1.3.2.4 Therapeutic outcome 
A final objective measure of adherence is the use of therapeutic outcomes as an 
indication of adherence. This is dependent on a close relationship between adherence 
and outcome being true (Horne, 2000). This can be the case for some medicines, for 
example Cramer et al. (1989) could directly attribute epileptic episodes to missed doses 
of medication. However, while good adherence is associated with clinical outcome 
(DiMatteo et al., 2002), it does not logically follow that a good outcome must be the 
result of good adherence; nor is it true that other factors besides adherence do not affect 
outcome (Gordis, 1979). Clinical outcome is, therefore, a very abstract measure of 
adherence, and it would be highly judgemental to assume a poor outcome was due to 
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nonadherence on behalf of the patient. Balkrishnan and Jayawant (2007) also argue that 
the level of medication adherence required to maintain normal blood glucose levels in a 
patient with diabetes may be very different to the level of adherence below which 
patients may suffer negative consequences. The choice of therapeutic outcome measured 
may therefore have a significant impact upon how patients are classified. 
 
1.3.2.5 Physician estimates of adherence 
In the clinical setting physicians must determine whether or not treatment non-response 
is due to treatment failure or nonadherence. However, physician estimates barely differ 
from chance (Gordis, 1979, Paterson et al., 2000). Byerly et al. (2005) found that 
physicians failed to correctly identify a single nonadherent patient as assessed by 
electronic monitoring. This could result in patients being removed from or denied 
potentially effective therapy or being prescribed stronger doses than required (Paterson 
et al., 2002). It is therefore imperative that physicians are able to gather information from 
their patients that will improve the accuracy of judgements of nonadherence to ensure 
treatment decisions are appropriate. 
 
1.3.2.6 Patient self-reports of adherence 
Questionnaires, interviews and diaries can be used to obtain a subjective assessment of 
adherence directly from patients. Self-reports are inexpensive because they do not 
require any advanced technology, and they are generally easy to process (Vitolins et al., 
2000). However, the subjectivity of self-report measures makes absolute adherence rates 
impossible to calculate. Guénette et al. (2005) argue that self-reports can only adequately 
identify nonadherence and not adherence, because the authenticity of high self-reported 
adherence cannot be verified. Furthermore Wu et al. (2008) found that objectively rated 
adherence via electronic monitoring was related to health outcome, whereas patient self-
reported adherence was not. 
Recall biases prevent accurate quantification of self-report measures (Chung et al., 2008). 
Patients will be better able to recall recent events, making self-reports of adherence over 
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a short time period more accurate than more global assessments of adherence 
(Oppenheim, 1992). However, asking about adherence over the last couple of days makes 
it hard to determine a pattern of adherence behaviour (Paterson et al., 2002). Horne 
(2000) also argues that patients are more likely to remember positive events than 
negative events, such as not taking medication. Mental health and emotions are also 
known to influence memory and bias recall. For example, depressed patients are more 
likely to recall negative events and so may be more likely to self-report nonadherence 
(Payne and Corrigan, 2007). 
 
1.3.2.7 Adherence diaries 
Medication taking diaries are an uncommon method of adherence measurement. Diaries 
take longer to process than questionnaires and are highly susceptible to reactivity biases 
because patients must fill them in after each medication dosing event which may enhance 
adherence. Furthermore they are an additional behaviour patients may be intentionally 
or unintentionally non-adherent to (Horne, 2000). If a patient forgets to take their 
medication they may also be more likely forget to fill in their diary to note the omission. 
However, diaries are reported to correlate better to objective measures of adherence 
than do interviews (Garber et al., 2004). 
 
1.3.2.8 Interviews 
All self-reports are subject to patients wishing to present themselves in the best possible 
way (Furnham and Henderson, 1982). Being in the same room as a clinician or researcher 
heightens the motivation of the participant to appear socially desirable (Richman et al., 
1999). Haynes et al. (1980) found that interviews overestimated clinically measured 
adherence by 17%. It has been argued that interviews can feel like an “interrogation” to 
participants, exaggerating any self-presentation bias (Myers and Branthwaite, 1992, 
Farmer, 1999). Poor wording can make self-presentation biases even stronger. Myers and 
Branthwaite (1992) included questions such as ‘When you took the tablets, did you take 
the proper number each time, or did you vary it at all?’ which makes any deviation the 
patient may have made from the prescription ‘improper’. Non-judgemental phrasing and 
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having interviews administered by a third party not involved with the patients care can 
reduce self-presentation biases (Horne, 2000, Morisky et al., 1986b, Morisky et al., 2008, 
Paterson et al., 2002). 
The primary advantage of interviews over questionnaires is the ability to clarify 
ambiguities for participants and to ensure constant reporting. Participants have been 
reported to prefer someone on hand to clarify questionnaire items (Chesney et al., 2000). 
Furthermore interviews can offer a richness of data impossible by any other method (Cox, 
2003, Kelly et al., 2008). Haynes et al. (1980) found that while interviews had poor 
sensitivity and exaggerated patient adherence, they provide very high specificity. Patients 
who are willing to admit to nonadherence may also be those most suitable for 
intervention (Gordis, 1979). 
 
1.3.2.9 Questionnaires 
Questionnaires are the most common form of patient self-report and share many 
weaknesses of interviews including social desirability and recall biases (Furnham and 
Henderson, 1982, Farmer, 1999). The process of completing a questionnaire may also 
make patients reflect upon their adherence and change their behaviour (Chesney et al., 
2000). There have been a number of attempts to measure adherence via questionnaire, 
however all have significant weaknesses (Lavsa et al., 2011). 
 
1.3.2.9.1 Morisky et al. adherence scales (1986b, 2008) 
The most commonly employed self-report tool was developed by Morisky et al. (Morisky 
et al., 1986b). Despite its widespread usage, this scale has a number of substantial flaws. 
Although validated on over 400 patients, the sample was 91% black and 70% female, 
which is not representative of the population with hypertension (Roger et al., 2012). 
There are documented racial differences in adherence behaviour (Shenolikar et al., 2006, 
Williams et al., 2007a, Gerber et al., 2010) and therefore the tool may not be 
generalisable. Furthermore, there are only four questions offered to explain 
nonadherence, each with only a ‘yes’ or ‘no’ response. This type of assessment produces 
classification errors, and patients on the borderline are encouraged to opt for the socially 
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desirable response (Koschack et al., 2010). This approach also reduces reliability as it 
dichotomises a continuous variable (Gabriel and Violato, 2010). This led to a skewed 
distribution, with 43% of participants reporting perfect adherence behaviour (Morisky et 
al., 1986b), when this is an unrealistic target for most patients. Morisky et al. also 
validated the scale according only to therapeutic outcome, which is a poor indicator of 
adherence behaviour. There are further questions surrounding the psychometrics of this 
scale. The internal reliability of the scale is reported as ‘relatively high’ with a Cronbach’s 
alpha of 0.61, when the conventional cut off for acceptable internal reliability is an alpha 
of above 0.7 or 0.8 (Bland and Altman, 1997, Oppenheim, 1992). Koschack et al. (2010) 
found particularly poor internal consistency for the Morisky scale with Cronbach’s alpha 
only 0.25. 
The Morisky adherence scale has been updated with the addition of four additional items 
(Morisky et al., 2008), however the assessment of this scale retained a number of 
significant problems. The primary criterion for validity was the assessment of the size of 
the correlation between the new eight item and the previous four item version of the 
same questionnaire. Although the wording of all items was changed, it remained very 
similar to that used in the original scale and so covariance between the two scales is very 
likely. Therapeutic outcome was again used to assess validity. Finally, the sample in the 
update retained many of the problems that impacted upon generalisability in the prior 
study with 77% being black, 51% not having attended college and 26% being married, and 
54% having an income below $5,000.  
Kim et al. (2000) developed the “Hill-Bone” scale by adapting the Morisky scale into a new 
adherence measure specific to hypertension by including more items pertaining to 
lifestyle modifications. Kripalani et al. (2009) then adapted the “Hill-Bone” scale to 
develop the “Adherence to Refills and Medications Scale” (ARMS) in order to make it 
generalisable to other chronic conditions and to simplify the wording for patients with 
low literacy. This was done via cognitive interviewing with 10 patients, and by assessing 
the literacy of the scale. It was found that the scale had reasonable internal consistency 
(α = 0.81). The scale had an average reading level that would be suitable for a reader with 
an 8th grade reading level in the US (age 13-14) which is above the capacity of the average 
adult in the UK (Williams, 2003). Methodologically the ARMS scale has a number of 
strengths. The scale was compared to multiple measures of adherence and measures of 
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outcome. However, correlations with refill adherence were relatively low, and evidence 
for an association with outcome was weak. Further, sampling problems were again 
evident with 91% of the sample in the study African American and 45% having inadequate 
literacy. 
 
1.3.2.9.2 Svarstad et al. “Brief Medication Questionnaire” (1999) 
Svarstad et al. reported that seven of the eight questionnaires developed before the Brief 
Medication Questionnaire had a sensitivity of below 60%. Ben et al. (2012) compared the 
Brief Medication Questionnaire to the Morisky scale and found sensitivity and specificity 
of 77% and 58% for the Brief Medication Questionnaire as opposed to 61% and 36% for 
the Morisky scale. Svarstad also claimed that the questions used in other questionnaires 
were often vague or insensitive. Respondents were rarely asked to recall events over a 
specific time period or else were asked to recall behaviour over an unrealistically long 
period of time. For the purpose of validation adherence was measured using a MEMS cap 
which is an advance over the therapeutic outcome used by Morisky. The scale attempts 
to identify different types of nonadherent behaviour, such as sporadic forgetting versus 
repeated and persistent nonadherence. Despite these theoretical strengths, there are 
significant weaknesses in the development of the questionnaire. Ambiguousness was not 
eliminated from the questionnaire. The item “Do your medications bother you in any 
way” is intended to assess patient concerns about medications regarding their side 
effects or long term risks. However, there are a number of ways the question could be 
interpreted which do not deal with beliefs about the impact of the medicines upon their 
body. However the main weaknesses of this study lie in the small sample size they were 
able to obtain, and the short prospective follow up period. Most results presented are 
based on 20 participants that were observed using MEMS for a period of one month. This 
provided the authors with a sample that had a limited amount of variability in adherence 
behaviour and this made it impossible to assess sections on their questionnaire which 
examined practical barriers to adherence such as accessing a new supply, opening bottles, 
or reading labels. Consequently these items have not been validated. Another 
consequence is the risk of sampling bias which is not acknowledged by the authors. They 
report that their section for screening aspects of the drug regimen that may impact on 
adherence had a sensitivity of 80% while their beliefs about medicines section had a 
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sensitivity of 100%. However, these sensitivities are based on observations from only five 
nonadherent participants. The results are not presented as a pilot or feasibility study and 
no further validation of this questionnaire has taken place. The scale has also been said to 
be difficult to score at the point of care (Lavsa et al., 2011). 
 
1.3.2.9.3 Chesney et al “Adult Aids Clinical Trial Group Adherence Instrument” (AACTG) 
(2000) 
The AACTG was developed specifically for HIV rather than chronic illnesses in general; 
however it is covered here because of its widespread use. In common with most 
adherence questionnaires the AACTG lacks any theoretical underpinning and the content 
is based upon a limited review of the literature, with only three cited works. The scale is 
not validated against any other adherence measure, and all but two of the scales used for 
construct validity were non-validated tools developed by the authors. Offering 
participants a list of reasons for skipping a dose could provide useful information for 
intervention, although incorporating an “other” option might have improved the scale. 
Their sample was also predominantly middle class and white which limits generalizability. 
 
1.3.2.9.4 George et al. “Beliefs and Behaviour Questionnaire” (BBQ), (2006) 
The items on the BBQ were generated based on a series of 28 in-depth interviews which 
were thematically analysed using the model of adherence behaviour proposed by Becker 
and Maiman (1975). The questionnaire was validated against the Medication Adherence 
Rating Scale (MARS Cummings et al., 1982). However, no reference for the validity of this 
comparison scale is provided because there is no paper which describes the construction 
and validity of the MARS tool. Further, correlations between the MARS and BBQ on items 
that directly assessed behaviours associated with adherence and nonadherence were 
small (Spearman’s Rho = 0.09, and 0.40 respectively). The items on nonadherence also 
demonstrated poor internal consistency with α = 0.59. The value is presented as 
acceptable because Cronbach’s Alpha represents the lower bound of reliability and so 
“high values of alpha are informative and reassuring while low values are ambiguous” 
(George et al., 2006, p. 57). While this argument is true it does not sufficiently explain the 
reasons they were unable to achieve a more reassuring value for Alpha. 
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1.3.2.9.5 Hahn et al. “ASK-20 Adherence Barrier Survey” (2008) 
The aim of ASK-20 was to develop a scale for clinical use that would identify specific 
barriers to adherence for patients in chronic illness. It sought to build on the Morisky and 
Brief Medication Questionnaire scales. The Morisky scale was perceived to screen 
adherence but not identify causes of nonadherence, while the Brief Medication 
Questionnaire was perceived to assess beliefs about medicines but not practical barriers. 
Items were generated from a literature review, but the methods for this are not 
described. The content validity piloting of the scale is comprehensive with a large number 
of patients and medical practitioners consulted. However, the study suffers from having 
the items included based heavily on subjective assessments of worth. Further, the 
authors chose a 12 factor solution because it fit their a priori assumptions best, however 
the information required to assess the suitability of this solution versus others is not 
presented. The origin of a 12 factor solution is also not fully described and is at odds with 
the initial statement that 16 topic areas were being assessed. Further questions about the 
validity of the scale are raised by relying on a web sample where patients were asked to 
provide their own diagnosis with no confirmation as to the accuracy of this provided by a 
physician. The internet deployment also specified that participants had to answer every 
question on the scale which meant that useful information regarding how acceptable 
participants found individual items could not be gathered as only complete case analysis 
was possible. 
 
1.3.2.9.6 McHorney (2009) and McHorney et al. (2009) “The Adherence Estimator” 
The adherence estimator measures concerns about taking medicines, the perceived 
necessity of taking medicines, and the affordability of medicines to assign patients as 
being at high, medium or low level risk of nonadherence. The scale is brief and easy to 
score having just three items. It was also validated on much larger samples than any other 
adherence tool. However there are some issues with the development of this 
questionnaire. A number of predictors seemed to perform better than medication 
affordability in identifying nonadherers. These include patient knowledge, proneness to 
side effects, trust in physician, participation in consultations, and perceived value of 
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supplementary medication. The consequence of this is that information that might be 
useful in predicting adherence is left out of the eventual scale. Coupled with the high rate 
of error associated with single item tests of a variable (Epstein, 1979, Shaughnessy et al., 
2009) this results in a situation where the maximum and minimum possible adherence 
refill scores were found for participants at all levels of risk in the validation trial, and a 
specificity of just 49%. 
 
1.3.2.9.7 Indirect self-reports of adherence 
An alternative to directly measuring adherence is to measure beliefs that have been 
shown to correlate with adherence. Avoiding direct questioning can reduce self-
presentation biases and because medication taking is not directly assessed recall biases 
are no longer an issue. Two examples of this approach are the ‘Satisfaction with 
Information about Medicine Scale (SIMS)’ (Horne et al., 2001) and the ‘Beliefs about 
Medication Questionnaire (BMQ)’ (Horne et al., 1999).Questionnaires of this type can be 
used to assess patients’ perspectives of aspects of their care which may affect outcomes, 
including their adherence to medication. For example, the SIMS seeks to explore how the 
patient feels about the quality of information provision regarding their medication, while 
the BMQ explores how far patients perceptions about medicine in general and their own 
prescribed medication in particular may impact upon medication usage. 
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1.4 Typology of nonadherence 
There are many ways that nonadherent behaviour can be expressed, and an even greater 
number of causes of such behaviour. Nonetheless, nonadherence can be categorised as 
primary or secondary. Nonadherence can then be further split into unintentional and 
intentional nonadherence. 
 
1.4.1 Primary nonadherence 
Patients are described as displaying primary nonadherence when they fail to fill their 
prescription. It can be thought of as the most severe form of nonadherence as the patient 
fails to follow any of their prescribed regime (Jackevicius et al., 2008). However, primary 
nonadherence has not been extensively studied. In part this is due to the difficulty of 
knowing what prescriptions are dispensed by practitioners when these are not filled by 
patients; it is much easier to track medication use after a prescription has been filled 
(Williams et al., 2007b). There are many possible causes of primary nonadherence. Many 
prescriptions can be more affordably purchased by patients over-the-counter (Jones and 
Britten, 1998) and difficulty affording or justifying the cost of prescriptions is an often 
cited cause of primary nonadherence (Wamala et al., 2007, Beardon et al., 1993, Jones 
and Britten, 1998, Stavropoulou, 2011, Kennedy and Morgan, 2006). Lack of concordance 
has been cited as a factor in primary nonadherence (Storm et al., 2008). How much 
patients respect the prescriber may also have some impact. Beardon et al. (1993) found 
higher primary nonadherence rates when patients had consultations with trainee versus 
more experienced doctors. Primary nonadherence is also more likely for medications 
perceived to be less essential to patients. For example, non-cardiac versus cardiac 
medication (Jackevicius et al., 2008), patients with mild asthmatic symptoms versus those 
with severe or frequent symptoms (Williams et al., 2007b) and contraceptive 
prescriptions (Beardon et al., 1993). However, Storm et al. (2008) found that the 
adherence rates were not different for emergency versus non-emergency patients in a 
dermatology clinic, and the only difference was in the haste prescriptions were filled. 
Younger age has also tended to be shown to be associated with lower primary adherence 
(Williams et al., 2007b, Beardon et al., 1993), although this may be partly accounted for 
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by younger females receiving prescriptions for contraceptives. Younger patients are also 
more likely to present with less serious disease states (Beardon et al., 1993). 
 
1.4.2 Secondary Nonadherence 
Secondary nonadherence refers to the patient deviating from the prescribed medication 
regimen once in possession of the medication. The extent of secondary nonadherence 
can range from a patient not taking any of their medicine, to missing only a single dose, or 
not taking their medication on time (Osterberg and Blaschke, 2005). Consequently 
‘secondary nonadherence’ covers a wide range of behaviours with an extensive number 
of possible causes, causing some authors to question whether the term adherence has 
any real relevance at all (e.g. Steiner and Earnest, 2000). Because adherence covers a 
range of possible behaviours it is difficult to identify a standard set of causes. One way to 
simplify this task has been to split adherence into unintentional or accidental 
nonadherence and intentional nonadherence. 
 
1.4.3 Unintentional nonadherence 
Unintentional nonadherence refers to occasions where patients are incapable of adhering 
to their medicine regimen. The most commonly cited reasons for unintentional 
nonadherence are forgetting to take doses, misunderstanding or misreading the 
instructions, or physical impairments preventing access to the medication (Horne, 2001). 
Gordis (1979) argues that the term ‘medication error’ is more appropriate to prevent 
stigmatising patients as nonadherent or noncompliant when they are unable to comply. 
Nonetheless, unintentional nonadherence is a significant problem. When participants in 
studies are asked to give reasons for their nonadherence, factors such as forgetting, being 
too busy, or experiencing a change in their daily routines are those most frequently cited 
implying unintentional factors responsible for a significant proportion of nonadherent 
behaviour (Atkins and Fallowfield, 2006). 
One proposed cause of unintentional nonadherence is complexity of the medicine 
regimen. The larger the number of pills to be taken, and the more rigid the conditions 
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under which they must be taken, the more potential there is for a patient to make a 
mistake, the more likely they are to forget some aspect of their treatment, and the 
greater an adjustment they must make to their normal routines (Horne et al., 2005). It 
has been found that there is an inverse relationship between adherence and complexity 
of the medication regimen (Claxton et al., 2001, Connor et al., 2004). van Dulmen et al. 
(2007) performed a review of the systematic reviews into interventions to increase 
adherence to medication and found that medicine regimens demanding fewer doses are 
associated with better adherence than those requiring more frequent doses. Developing 
medicines with longer dosing intervals, combining different medicines into a single dose, 
and which have fewer conditions for effective action may help to reduce nonadherence of 
this type (Connor et al., 2004). 
Providing patients accurate and consistent information which can be both understood 
and remembered is integral to a patient’s ability to comply with their medicine (Ley, 
1988). However, beyond the basic requirement of allowing patients to know how to take 
their medicine, information provision has not been found to be a strong predictor of 
adherence behaviour. Peterson et al. (2003) conducted a meta-analysis that found that 
behavioural interventions to improve adherence, such as providing blister packs or 
reminder notes, offer small but reliable improvements to adherence while educational 
interventions had a far less reliable positive impact. Furthermore, studies have often 
failed to be able to ascribe the direction of causality in this relationship. It cannot be 
easily ascertained whether nonadherent patients are less interested in their treatment 
and so seek less information, or whether that those with less information become more 
nonadherent (Horne et al., 2005). 
The costs of medication may also be barrier to secondary adherence. The poor are 
disproportionately affected by adherence barriers (World Health Organisation, 2003). In 
chronic illness many patients will have repeat prescriptions and this will often come at a 
significant direct cost to patients. Patients may also expect further indirect costs from 
having to travel to and from hospitals or pharmacies to collect their medicines. 
Schafheutle (2003) argues that the cost of medication remains a problem in the UK, which 
uses a flat prescription charge rather than the co-payments and insurance systems 
adopted elsewhere. While 85% of medications are provided free of charge, around half 
the population are not exempt from paying the prescription charge (Bradley et al., 1998). 
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Schafheutle et al. (2002) identified patients not filling prescriptions or purchasing cheaper 
alternatives, patients also took less of their medication than prescribed to make it last 
longer due to their inability to afford their prescriptions. 
Forgetting to take medicine is the most heavily cited cause of unintentional 
nonadherence by practitioners, researchers and patients themselves. Estimates of the 
extent to which forgetting impacts nonadherence are biased by patients reporting that 
they forgot to take medication when they chose not to take them, believing this a more 
socially desirable way to allow their doctors to know they have not taken all of their 
medicine (Atkins and Fallowfield, 2006). Nonetheless, forgetting to take a dose would 
appear to be the most common single cause of nonadherence, accounting for 
approximately 30% of non-adherent cases (Osterberg and Blaschke, 2005). Haynes et al. 
(2008) find that while a number of interventions can improve adherence and boost recall, 
such as telephoning patients or offering medicines counselling, the effect is rarely large, 
tends to lack longevity, and rarely has a significant impact on treatment outcome.  
 
1.4.4 Intentional nonadherence 
The focus upon unintentional nonadherence reflects the perception of patients as passive 
recipients of health advice, when they are more properly perceived as active decision 
makers (Horne, 2000). However there is still a wide literature which seeks to identify 
what factors influence the decision to not take medicines. It is commonly assumed that 
behaviours are based upon individuals’ beliefs about those behaviours, and there are a 
number of theories for how the relationship between beliefs and behaviour can be 
modelled (Lehane and McCarthy, 2007). 
 
1.4.4.1 Health Belief Model 
A common explanatory framework for adherence behaviour is the Health Belief Model 
(HBM). The HBM assumes that patients make a rational choice about whether to engage 
in a specific behaviour (Chisolm et al., 2010). These rational decisions are based upon 
patients weighing up the costs and benefits of a health intervention based upon the 
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perceived threat of the health concern, versus the perceived effectiveness of the medical 
intervention (Munro et al., 2007). The perceived threats are based upon an assessment of 
how susceptible to illness the patient is, and how severe the consequences of illness will 
be; while the perceived effectiveness of intervention is based upon the perceived benefits 
of the intervention versus the barriers that are in place to obtaining those benefits (Janz 
and Becker, 1984).  
Evidence for the efficacy of using the HBM to predict adherence via meta-analysis has 
indicated that there are significant but small relationships between variables in the model 
and adherence behaviours (Harrison et al., 1992). Moreover, estimates of the variance 
accounted for by the HBM are also typically around 20% for the full model (Olsen et al., 
2008) and range between 0.01% – 9% for individual constructs (Harrison et al., 1992). Due 
to the small magnitude of relationships between HBM constructs and adherence 
individual studies have often failed to identify the existence of these relationships. 
Instead situational factors such as social support or ability to perform behaviour are 
found to have greater influence upon adherence. For example, Cummings et al. (1982) 
explored the size of the relationship between variables in the HBM and medication 
adherence in 116 haemodialysis patients. The study identified a positive relationship 
between all variables in the HBM and adherence as measured via serum phosphorus and 
potassium levels recorded in medical charts. However, the only relationship reaching 
statistical significance was that between lower perceived efficacy for adherence and 
actual measured adherence. It was proposed that the influence of health beliefs was 
largely overwhelmed by variance in situational factors that impact upon decision making. 
On these grounds, the HBM has been criticised for being too simple. It does not allow the 
variables in the model to interact with one another, and it is assumed that threat and 
effectiveness beliefs directly affect health behaviours (Munro et al., 2007). The model is 
not considered to be comprehensive, neglecting the role of social influence and 
overstating the role of rationality in decision making; many activities are engaged in 
habitually, not consciously deliberated each time (Munro et al., 2007). Additionally, one 
study found that HBM constructs were correlated with adherence during treatment but 
not before treatment was initiated (Taylor, 1979). This suggests that health beliefs 
develop alongside experience with treatment rather than determine treatment 
behaviours themselves. It has also been observed that once adherence ceases to occur 
there are no observable changes in health beliefs  (Becker et al., 1978) which undermines 
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the causal attributions specified in the model. For these reason it is argued that the HBM 
is a better model for one off behaviours such as health screening than for long term 
adherence to therapy (Horne, 2000). 
 
1.4.4.2 Theory of Reasoned Action 
Some weaknesses in the HBM are accounted for in the Theory of Reason Action (TRA, 
Fishbein and Ajzen, 1975). The TRA shared the cost benefits assessment of the HBM and 
proposed that this assessment determines an individual’s attitude toward engaging in a 
specific behaviour. However, the TRA has two additional elements to improve predictive 
power. The TRA accounts for the HBM’s problem of having beliefs about specific 
behaviours directly relate to the enactment of that behaviour. In the TRA, attitudes 
impact upon the intention to engage in behaviour rather than upon behaviour directly. 
This helps to account for the often small observed relationship between attitudes about a 
behaviour and the overt performance of that behaviour (Fishbein and Ajzen, 1975). This is 
done by accounting for the role of social norms, which are seen as an additional influence 
upon intentions to perform behaviours. Social norms are thought to consist of the 
perception of what significant others think about a behaviour, and the amount of 
motivation to conform with the norms of those significant others (Fishbein and Ajzen, 
1975). 
Utilisation of the TRA has been rare in adherence research and when utilised has been 
found to more strongly predict behaviours other than medication adherence. Syrjälä et al. 
(2002) used the TRA to predict tooth brushing and adherence to medication in 149 
diabetic patients and found that attitudes but not subjective norms were significantly 
related to self-reported adherence to diabetes medication. In contrast subjective norms 
and attitudes were both highly indicative of whether or not tooth brushing was adhered 
to. Miller et al. (1992) used path analysis with 56 newly diagnosed patients with 
hypertension and although the TRA was able to predict adherence to smoking cessation 
and prescribed diet, no significant relationships between variables in the TRA and 
adherence medication was identified. Despite these weaknesses the TRA may still 
represent an advance over the HBM. Ried and Christensen (1988) directly compared the 
explanatory power of the HBM and the TRA in predicting self-reported adherence to 
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medication for urinary tract infections. They recruited 113 participants from both a 
university health centre and pharmacies represented by a single Health Maintenance 
Organisation presenting with a prescription for trimethoprim 160 mg/sulfamethoxazole 
800 mg. Participants were interviewed via telephone 10 days after the prescription was 
dispensed. Reid and Christensen found that HBM variables could only explain 10% of the 
variance in adherence to the antibiotic regimen, however combining the HBM with the 
TRA was able to explain 29% of variance in the same behaviour. However despite this 
additional explanatory power, the TRA is limited by its ability to explain only volitional 
behaviour (Fishbein and Ajzen, 1975) and may not predict adherence behaviour as well as 
it does other behaviour. To account for the fact that the enactment of behaviour is not 
always under an individual’s control once an intention has been formed, the TRA was 
extended into the Theory of Planned Behaviour (TPB, Ajzen, 1991). 
 
1.4.4.3 Theory of Planned Behaviour 
The TPB builds upon the TRA by incorporating the concept of self-efficacy from social 
learning theory. Social learning theory stipulates that behaviour is based upon past 
experiences and observation of others, which influences beliefs about the outcome of 
specific behaviours (Bandura, 1991, Munro et al., 2007). Moreover, past experience and 
observation also impacts upon an individual’s perception of how capable they are of 
carrying out a specific behaviour, which has been termed “self-efficacy” (Bandura, 1991, 
Bandura, 1994). The TPB incorporates self-efficacy under the variable “perceived 
behavioural control”. Perceived behavioural control is composed of self-efficacy and 
controllability which is the extent to which performance of the task is under the volitional 
control of the individual (Ajzen, 2002). Perceived behavioural control is thought to impact 
upon the intention to perform behaviour in the same way as social norms and attitudes. 
However, it is also said to directly impact upon behaviour and help to bridge the gap 
between intention and overt behaviour (Ajzen, 2001, Ajzen, 2002). 
Like the TRA, the TPB has rarely been utilised in the medication adherence literature and 
the evidence that does exist does not provide strong support for its utilisation as a 
theoretical framework to guide the development of an adherence questionnaire. One 
review (Burns, 2009) identified only two prior articles that have directly applied the TPB 
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to medication taking. Farmer et al. (2006) utilised the MARS adherence questionnaire as 
part of a self-report questionnaire which aimed to measure the correlations between TPB 
constructs and adherence intentions and behaviour. The questionnaire was posted to 
patients with diabetes aged over 40 taking oral hypoglycaemic medication but not insulin. 
Their analysis showed that for their 121 respondents beliefs about medicines were 
correlated with adherence intentions and behaviours, but evidence for correlations with 
social norms and perceived control variables with outcomes were more limited. Russell et 
al. (2003) utilised the TPB as a framework in a series of 16 qualitative interviews with 
adult renal transplant recipients and found that patients form attitudes based upon the 
comparative utility and disutility of competing behavioural options, that family support 
was a key facilitator of adherence, and that steps were taken by patients to enhance 
perceived behavioural control. However, as a qualitative study utilising the TPB as a 
framework no direct inferences regarding the ability to the TPB to predict actual 
behaviour can be derived from this study. An additional study omitted by the Burns 
review found that the TPB predicted 41% of the variance in intention to adhere to 
immunosuppressant therapy in renal transplant patients. However, intentions regarding 
adherence explained only 10% of the variance in adherence behaviour (Chisholm et al., 
2007). In contrast 23% of behaviour could be explained by past adherence behaviour 
again reinforcing the role of situational factors over beliefs about medicines alone in 
predicting adherence behaviours. 
Despite a lack of applications directly to adherence, the TPB has been used extensively 
elsewhere. A meta-analysis of the TPB incorporating 185 studies found broad support for 
the capability of the theory to predict behaviour and intentions with variance accounted 
for of 27% and 39% respectively (Armitage and Conner, 2001). Similarly, a meta-analysis 
of prior meta-analyses of the TPB indicated that the TPB could account for between 35% 
to 50% of variation in intentions and 26% to 35% of variance in actual behaviours (Sutton, 
2007). However, these studies also identified areas of weakness in the theory, in 
particular the weakness of the relationships identified between social norms and 
intentions in many papers. However, the lack of influence of social norms may be a facet 
of the culture in which most studies are carried out rather than a weakness of theory. The 
literature relating adherence to the TPB encompasses studies exclusively conducted in 
western industrialised nations in the US and Europe which comprise of more individualist 
cultures. Individualist cultures are characterised by societies in which individuals are 
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expected to look after themselves and their immediate families. Conversely collectivist 
cultures are typified by societies in which there exist strong cohesive in groups which 
exchange protection for unthinking loyalty (Hofstede, 1997). The role of social norms has 
been identified as being more powerful in more collectivist than individualist cultures 
(Aleassa et al., 2011). Regardless of the appropriateness or otherwise of the social norms 
variable, the TPB has been criticised for not taking sufficient account of affective 
influences on decision making and assuming behaviour is rationally determined (Mullen 
et al., 1987). It is also assumed that cognitive processes determine behaviour, and does 
not allow for behaviour to affect cognitive processes (Weinstein, 2007). The brain must 
interpret behaviour as well as cause it, and it often interprets behaviour in such a way as 
to reduce cognitive dissonance (Weinstein, 2007). An additional concern is that the TPB 
does not offer formal guidance upon the design of interventions but only targets which 
beliefs are thought to be of importance (Bratby, 2008). For this reason an extensive 
review of behaviour change interventions designed using the TPB found that most studies 
had not fully incorporated the theory into their design and were mostly standard 
educational interventions with little or no measurable change in behaviour being the 
most common outcome (Hardeman et al., 2002). Because the TPB does not offer a clear 
theoretical guide for designing interventions and does not have a firm empirical track 
record for predicting adherence behaviour it may not be a strong candidate on which to 
base any attempt to predict adherence. 
 
1.4.4.4 The self-regulatory model of adherence 
The SRM attempts to produce a framework for adherence which marries the findings 
from modelling approaches such as the HBM and TPB with cognitive and affective 
processes (Leventhal et al., 1992). The theory suggests illness is understood by patients 
producing a framework of their illness based upon its cause, its effects, how long it lasts, 
and what can be done to cure or control it  (Reynolds, 2003, Weinman et al., 1996). Like 
the HBM the model accounts for rational decision making, and like the TPB influences 
upon perceptions are permitted to come from the individual and their wider socio-
cultural context. However, the theory gives a far more prevalent role to affective 
processes via the “parallel response framework”(Leventhal et al., 1992). The parallel 
response framework proposes a largely separate cognitive and affective response to 
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stimuli, with both proposing partially independent coping strategies. Coping strategies are 
then appraised based upon their outcomes, which have a direct influence upon the 
stimuli that are put forward for reappraisal. While the two systems are proposed as 
separate, they are allowed to interact. The inclusion of affective processing is a major 
advance over previous models of health behaviour because it provides an explanation for 
irrational responses to illness, such as patients not taking medicines they know will help 
in the long term (Horne, 2000). 
The SRM is a far more comprehensive model of adherence than the current alternatives, 
but is unwieldy for facilitating the design of interventions (Munro et al., 2007). The 
strength of the SRM is that it puts forth an argument for complex interventions which 
incorporate education to moderate cognitive decision making, skill provision to facilitate 
coping, and affective support to manage patients expectations and coping strategies for 
the difficulty and duration of treatment (Reynolds, 2003). However, a review of studies 
purportedly utilising the SRM for self-monitoring of therapy identified that few studies 
actually use the constructs of the SRM to guide their design but instead focus broadly on 
illness or medication beliefs (Breland et al., 2013). One study that did utilise the SRM to 
design a simple intervention was  the use of text messages targeted to combat specific 
illness beliefs thought to undermine adherence (Petrie et al., 2012). Patients with asthma 
that self-identified as non-adherent between 16 – 45 years of age (n = 216) were 
recruited via flyers dispensed with asthma preventer medication alongside e-mails sent to 
members of a marketing website. This study demonstrated that this simple SRM based 
intervention might help to maintain adherence, with mean self-reported adherence 
remaining broadly similar to baseline in the intervention group. Baseline adherence was 
56.5% and averaged 57.8% over the course of the study. In comparison, a control group 
that received no text messages experienced a drop in adherence over the nine months 
follow up with baseline adherence estimated to be 54% and averaging 43.2% over the full 
study period. However, these conclusions are compromised by a very high dropout rate 
(32%), which is not controlled for statistically. Such a high attrition rate raises doubts 
about the acceptability of the intervention. Moreover, adherence was not improved by 
the intervention, which may indicate the text messages served as reminders and not as 
belief modifiers. Therefore it is impossible even in this relatively simple case to be able to 
ascribe with confidence the effect upon adherence to the health beliefs proposed by the 
SRM. Furthermore, meta-analysis of 15 studies utilising the SRM found that only 
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perceptions regarding whether the illness can be controlled or cured was associated with 
adherence and other self-care behaviours (r = 0.12). Correlations for beliefs about 
consequences, identity, and timeline ranged from -0.01 to 0.01 (Hagger and Orbell, 2003). 
As a consequence there is not currently a strong empirical argument for utilising the SRM 
as a basis for the design of a questionnaire to identify patients at risk of non-adherence 
despite its appeal as a coherent and comprehensive theoretical model. 
 
1.4.4.5 The proximal-distal model of adherence 
The weaknesses of behavioural models to inform the design of a tool to predict 
adherence can be illustrated using the proximal-distal model of adherence which is 
presented in figure 1.1. The model proposes that the more specific a skill, belief, or 
experience is for adherence then the greater the association between the two variables 
will be, and with more distal causes of adherence feeding into the more proximal 
(McHorney, 2009). This model was utilised in the design of the Adherence Estimator 
questionnaire (see section 1.2.3.9.6). However, if this questionnaire identified a patient as 
being at risk of nonadherence it is not clear what a clinician could do to intervene because 
there are no indications of the causes of the beliefs that put patients at risk of 
nonadherence in the tool or in the model. The only specification given in the model is that 
weaker correlates of adherence partially contribute to the stronger correlates of 
adherence. These associations are also assumed to be causal, when evidence for the 
model is based entirely upon correlational research. A criticism common to all models 
apart from the SRM (Weinstein, 2007). A structural equation modelling study has been 
performed to determine whether more distal causes of adherence are associated with 
more proximal causes of adherence(McHorney et al., 2012). This study utilised an online 
sample of 1072 chronic disease patients and did demonstrate links between patient 
characteristics and distal adherence beliefs, and distal beliefs with proximal adherence 
beliefs. However, this paper does not explore the relationships between beliefs and 
actual adherence behaviour so the predictive power of the model is unclear. On these 
grounds it is difficult to see how the theory can inform the design of an intervention to 
improve adherence or provide an underlying theory upon which to design a 
questionnaire. 
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Figure 1.1 The proximal-distal model of adherence. Adapted from McHorney (2009) 
 
A clinically useful tool for adherence needs to measure beliefs about medicines and 
illness, as well as specific barriers to enacting behaviour, in order to accurately predict 
whether or not a patient will be adherent to their medication. It also needs to measure 
the variables that determine those beliefs and barriers so that clinicians are able to 
identify specific targets for intervention tailored for individual patients. There has been a 
vast amount of speculation as to what variables might be associated with adherence to 
medication but no consensus (Lehane and McCarthy, 2007, Arbuthnott and Sharpe, 
2009). 
 
1.5 Summary and statement of aims 
Given the prevalence of nonadherence and its health and financial implications, it is 
essential that practitioners are able to identify which patients are at risk of 
nonadherence, and identify the causes of nonadherence for individual patients so that 
adjustments can be made to optimise treatment acceptability and outcomes. However, 
current methods of measurement are suboptimal. In particular physicians’ own estimates 
of nonadherence are particularly inaccurate. Moreover there is no current single 
questionnaire which synthesises the various proposed correlates of adherence behaviour 
into a single brief instrument. 
 
Adherence 
Treatment 
related beliefs 
Disease related 
beliefs and 
skills 
Generic 
psychosocial 
beliefs, states, 
and skills 
Demographics 
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1.6 Aims and objectives of the thesis 
The aim of this thesis is to develop a new tool which will predict the likelihood of 
nonadherence to medication and help clinicians to identify patient specific interventions 
to mitigate specific risk factors for nonadherence. The questionnaire will do this by 
avoiding direct questioning of adherence, and instead measuring correlates of adherence 
which have been empirically shown so be related to the behaviour. 
The objectives are to: 
Chapter 2 
 Identify variables objectively shown via meta-analysis to correlate with 
nonadherence to medication 
Chapter 3 
 Perform a literature review of best practice in questionnaire design to develop a 
new tool to predict nonadherence to medication 
Chapter 4 
 Perform a feasibility study of the proposed research to appraise the new 
adherence tool, and perform preliminary psychometric assessments 
Chapter 5 
 Perform a qualitative assessment with clinicians and patients to determine the 
clinical utility and acceptability of the new tool; and to provide a comprehensive 
assessment of its validity 
Chapter 6 
 Assess the performance of the new questionnaire by synthesising the results of 
chapters 4 and 5 and discuss the contribution of the thesis to the wider adherence 
literature 
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Chapter 2 – Identification of the indicators of adherence 
 
2.1 Introduction 
Over 200 correlates and indicators of adherence behaviour have been studied in the 
literature (Lehane and McCarthy, 2007, Arbuthnott and Sharpe, 2009). Focussing on 
indicators with a demonstrable relationship to adherence contributes to brevity and thus 
increased acceptability of the resulting adherence questionnaire (Marshall, 2005). Thus a 
literature review of the indicators of adherence was undertaken to identify those with 
sufficient evidence to support inclusion in the new questionnaire. 
 
2.1.1 Narrative Reviews of the adherence literature 
There are a number of narrative reviews of the adherence literature (Vlasnik et al., 2005, 
Sawyer and Aroni, 2003, Kettler et al., 2002, Lakatos, 2009, Lehane and McCarthy, 2007, 
Horne, 2006, Osterberg and Blaschke, 2005, Vermeire et al., 2001). However, the broad 
scope of these reviews restricts the depth of the coverage provided for specific issues, 
such as identifying indicators of adherence behaviour. Vermeire (2001), Horne (2006) and 
Lehane and McCarthy (2007) provide a more thorough consideration of possible 
indicators however these articles remain susceptible to a number of known biases that 
can impact upon the selection and presentation of evidence in narrative reviews. 
The biases associated with narrative reviews are summarised below. “Preference bias” 
describes the propensity for authors to design an investigation so that their preferred 
outcome is likely to be found (Wilholt, 2009). For example, authors may omit poor quality 
studies that counter the authors proposed view, but include studies that support this 
view (Stanley, 2001). “Availability bias” refers to the ease with which associations are 
brought to mind being used as a heuristic to ascertain their likelihood (Shanteau, 1989, 
Tversky and Kahneman, 1973). “Cognitive Dissonance” refers to discomfort that is felt 
when information inconsistent with what we already believe is presented (Festinger, 
1957). “Selective exposure” refers to seeking information congruent with what is already 
believed and avoiding contrary evidence to avoid cognitive dissonance (Hart et al., 2009, 
Wason, 1960). “Confirmation bias” refers to the tendency to both seek and misperceive 
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or misremember incongruent information in a manner that supports prior beliefs (Oswald 
and Grosjean, 2004, Smith et al., 2008, Smith et al., 2007). The inevitable introduction of 
these biases mean that narrative reviews cannot be replicated, and their results cannot 
be independently verified (Easley et al., 2000, Hemingway and Brereton, 2009).  
 
2.1.2 Systematic Review and meta-analysis 
 
2.1.2.1 Fundamentals of systematic review and meta-analysis 
The aim is to produce an objective list of the most relevant and highest quality literature 
from a comprehensive list of primary sources in order to answer a specific research 
question (Higgins and Green, 2006, Akers et al., 2009). The procedures adopted enforce 
transparency and rigour via an explicit and reproducible method (Hemingway and 
Brereton, 2009). The process by which articles are identified, included or excluded in the 
review, processed, and conclusions drawn are all presented alongside summaries of data. 
This ensures that all conclusions must be grounded in the data identified, and limits the 
extent to which the prior beliefs and assumptions of a researcher can influence 
interpretations of that data. 
Where possible, mathematically combining the results of different studies into a single 
effect size via meta-analysis (Hunter and Schmidt, 2004) offers additional power to find 
real but rare events or effects (Green et al., 2006). Furthermore, the larger sample size 
allows for a more accurate approximation of the population effect size (Sutton et al., 
2000). However, it is rare that there is a single invariant population effect size that all 
samples measure in research involving humans (Schmidt et al., 2009). The use of different 
definitions, variables, cut-offs, and scales when measuring phenomena can introduce 
further between study differences beyond random error (Higgins and Green, 2006). It is 
therefore often more appropriate to adopt a random effects model which does not 
assume an identical population effect size, as opposed to a fixed effects model which 
does (Hunter and Schmidt, 2000, Raudenbush, 2009). 
Systematic reviews can take teams of specialists months or years to complete. When time 
is at a premium alternative options are to complete a Rapid Evidence Assessment (REA, 
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Akers et al., 2009) or scoping review (Hetrick et al., 2010, Levac et al., 2010). REA’s are 
designed to take two to six months to complete, and prioritise achieving a broad 
overview of the available literature over an in depth analysis of a single hypothesis (REA 
Methods, 2009). The aim in an REA or scoping study is to achieve conceptual breadth of 
available studies rather than to identify all available studies. 
 
2.1.2.2 Prior attempts to meta-analyse the adherence literature 
Despite these difficulties there have been attempts to meta-analyse the adherence 
literature. Atkinson and Petrozzino (2009) tried to reduce between study differences by 
including only studies regarding HIV and excluding all studies that did not measure the 
relationships between indicator variables and adherence in terms of odds ratios or hazard 
ratios. Focussing on only a single disease, however, significantly reduces generalisability 
because adherence rates differ between different diseases (DiMatteo, 2004c, Claxton et 
al., 2001). Furthermore, including studies which use only two of the available effect size 
measures excludes a large number of relevant studies. 
DiMatteo et al. have conducted a series of meta-analyses into specific indicators of 
adherence (DiMatteo et al., 2000, DiMatteo et al., 2002, DiMatteo, 2004b, DiMatteo, 
2004c, DiMatteo et al., 2007). However, these analyses confound their results by 
incorporating adherence to medicines, diet, and exercise into a single estimate of effect 
despite also finding that adherence rates differ between these different types of therapy 
(DiMatteo, 2004c). Therefore the estimated relationships are unlikely to be accurate for 
medication adherence alone. 
Drotar and Bonner (2009), Karamanidou et al. (2008) and Jindel et al. (2003) used the 
approach of comparing the number of statistically significant results for or against a 
relationship between an indicator and adherence. However, this method has poor 
statistical rigour (Stanley, 2001, Borenstein et al., 2009, Bushman and Wang, 2009, 
Greenland, 1987). Furthermore, a tally of p-values does not aggregate the individual 
samples as meta-analysis should; consequently there is no increase in power or ability to 
detect small but true effects. Publication bias, where studies are more likely to be 
published if they find a significant result, and outcome bias, where significant results are 
more likely to be reported within studies, may also skew conclusions (Palmer, 2000, Egger 
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et al., 1997, Gøtzsche, 1987, Nieminen et al., 2007). Together these biases make it more 
likely that vote counting procedures will suggest that variables are associated with 
adherence when the strength of evidence is weak. 
 
2.1.2.3 Additional biases in Systematic Reviews and Meta-analysis 
Systematic reviews limit, but do not remove bias (Egger et al., 1997). Song et al. (2010) 
published a comprehensive review of all the dissemination biases that may impact upon 
the review process. 
 
2.1.2.3.2 Time lag bias 
“Time lag bias” occurs where significant results take longer to be published than non-
significant results (Song et al., 2010). It is recommended that systematic reviews are 
regularly updated to ensure effect sizes remain accurate and that risk of publication bias 
is assessed whenever a review is undertaken (Higgins and Green, 2006). Stern and Simes 
(1997) also recommend limiting studies to those started before a certain date to allow all 
studies undertaken during a specific time frame an opportunity to be published. 
 
2.1.2.3.3 Grey literature bias 
“Grey literature bias” refers to the tendency for unpublished or non-peer reviewed 
articles and those published by non-commercial organisations to have lower effect sizes 
than peer reviewed journal articles (Song et al., 2010). There is rarely a difference in the 
scientific quality of published versus unpublished or non-peer reviewed studies (Conn et 
al., 2003). The higher effect size in peer reviewed articles reflects the preferences of 
journals to publish findings with a larger impact. Including grey literature can reduce bias 
in an analysis but because unpublished articles are difficult to retrieve, time constraints 
can often render this impossible.  
 
2.1.2.3.4 Database indexing bias 
“Database indexing bias” refers to the fact that different electronic databases have 
different content and often systematically differ from each other (Song et al., 2010). 
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Systematic reviews should therefore search more than one database (Higgins and Green, 
2006, Critical Reviews Advisory Group, 1996, Akers et al., 2009). 
 
2.1.2.3.5 Data-extraction bias 
“Data-extraction bias” refers to differentially extracting information from, or applying 
exclusion or quality assessment criteria differently to, studies that support the authors 
own views (Petticrew and Roberts, 2006). Similarly, authors may be biased for or against 
specific authors or institutions. Blinding reviewers by blanking out author information can 
help reduce this bias, and it is recommended that more than one author be involved in 
data extraction to limit individual author bias (Critical Reviews Advisory Group, 1996, 
Higgins and Green, 2006, Handoll and Smith, 2004, Akers et al., 2009). It is also possible to 
validate the extraction process by having the data extraction checked by another person, 
or by another independent reviewer performing the same data extraction for 
comparison. 
 
2.1.2.4 Control of bias in systematic reviews 
A number of techniques are available to limit or control for bias in meta-analyses. Duval 
and Tweedie’s (2000) Trim and Fill method is used to correct effect size estimates for 
papers missing due to publication bias. The ‘fail safe’ number can provide an estimate of 
the robustness of the meta-analysis findings by calculating the number of studies of no 
effect that would need to be identified before the findings of the meta-analysis were 
nullified (Palmer, 2000). It is also possible to estimate whether or not bias is present in 
studies via regression (Egger et al., 1997). However, these techniques require access to 
specialist software. 
Including low quality studies in a systematic review can introduce bias (Chalmers et al., 
1981) and so it can be advantageous to assess study quality (Akers et al., 2009). However, 
standardised checklists of study quality have been criticised for being arbitrary and failing 
to take sufficient account of the context in which research takes place (Juni et al., 1999, 
Greenland, 1994). An alternative to checklists is to use meta-regression with coded 
indices for different methodological criteria to determine the level of influence 
methodological factors had upon results (Greenland, 1994, Stanley, 2001, Shapiro, 1994, 
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Stroup et al., 2000). However, in a scoping study where the aim is to collate and 
summarise areas of research it is not always appropriate or feasible to exclude or rank 
studies according to quality (Hetrick et al., 2010). However it can be useful to collect and 
quantify some measures of study quality to provide context to results. 
2.1.3 The need for meta-analysis 
Despite the difficulties associated with meta-analysis, this approach offers the best 
method available for evaluating relative strength of evidence for indicators of adherence 
objectively. By sacrificing sensitivity for higher specificity, a large number of indicators can 
be compared in a relatively short time. The costs of this approach in terms of 
comprehensiveness can be weighed against the value of achieving comprehensive 
conceptual breadth within a feasible timeframe. 
 
2.1.4 The scope of the proposed meta-analysis 
The nature of the relationships between adherence and indicator variables is not uniform 
across all populations. Patients on hospital wards, in prisons, on military bases, and in 
care homes might have their medication regimens enforced upon them (DiMatteo, 
2004c). Children may also face different constraints and freedoms regarding their 
medication taking than independent adults (DiMatteo, 2004a, DiMatteo, 2004c, Wrubel 
et al., 2005, Landier, 2011). In addition, patients on a medication regime targeted towards 
treating a mental illness may be expected to face separate and specific challenges to their 
adherence to those faced by the mentally healthy population (Yen et al., 2005). 
Furthermore, there may be a greater need for coercive practices when dealing with 
mentally ill patients (Jaeger and Rossler, 2010). Consequently these populations were 
excluded from the analysis. It has also been argued that the inclusion of small studies 
with sample sizes below 100 has been found to introduce bias into meta-analysis (Nüesch 
et al., 2010). However a greater concern can be a possible lack of statistical power. Turner 
et al. (2013) examined existing Cochrane reviews and re-examined the data excluding 
underpowered studies. They identified that where adequately powered studies were 
available, excluding studies of smaller sample sizes can provide more accurate estimates 
of effect size with less heterogeneity. However, they also identified that the vast majority 
of studies are underpowered, with 70% of meta-analyses including only underpowered 
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studies, and 34% of meta-analyses themselves being underpowered. Given the relatively 
shallow search strategy adopted it was determined that a lack of power was a greater 
concern than was rising heterogeneity and so studies with small sample sizes are not 
excluded. However, studies with sample sizes below 10 were excluded in order to narrow 
the search away from articles extremely unlikely to include quantifiable data such as 
qualitative investigations and case studies (DiMatteo, 2004c). 
 
 
2.1.5 Objectives 
The objectives of the systematic review were to: 
 Identify the correlates of adherence to medicines identified in the literature. 
 Estimate the size of relationships between identified indicators of adherence via 
meta-analysis. 
 Use estimates of effect size to evaluate the strength of evidence for a relationship 
between identified indicators and adherence. 
 Evaluate the extent of heterogeneity in effect size estimates to determine the 
reliability of the identified relationship between an indicator and adherence 
(Sutton et al., 2000).  
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2.2 Methods 
 
2.2.1 Population 
 Adult patients (aged 18 or over). Samples with a small minority (< 5%) of patients 
under this age were not excluded.  
 Diagnosed with a chronic illness (condition typically lasting longer than 6 months). 
 Prescribed medicinal therapy.  
 
2.2.2 Exclusion Criteria 
 Patients with institutional controls over medicine taking (such as prisoners, drug 
or alcohol dependent patients, and military personnel). 
 Medication regimes designed to treat mental illness. Non-institutionalised 
patients diagnosed with a mental illness or substance dependency in addition to 
other chronic conditions were not excluded. Such patients would be found in a 
normal population of chronic disease sufferers, and so it would be inappropriate 
to discount data from these sources.  
 Studies of sample sizes below 10, to avoid case studies (DiMatteo, 2004c). 
 Non-English language studies. 
 Investigations on non-human samples. 
 
2.2.3 Outcomes 
 Effect size measures for the magnitude of association between adherence and 
another variable. 
 Estimates of heterogeneity in the effect size estimate for the magnitude of 
association between adherence and another variable. 
 
2.2.4 Study design 
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2.2.4.1 Search criteria 
The aim of scoping reviews is to cover the conceptual breadth of a topic, and not to 
achieve the full depth of literature coverage expected in a systematic review (Gough et 
al., 2012). Therefore in order to balance the competing requirements of depth of 
coverage with plausible research aims the search was limited to studies that dealt 
explicitly with indicators and correlates of medication adherence by limiting the search to 
articles that included such terms in their titles (see point 2 below). Additionally, the 
search focussed upon patients that were nonadherent to their medicines rather than 
those that had ceased to take them altogether. For this reason the term “persistence” 
was not included in the search. However given the lack of consistency in the use of terms 
it is acknowledged that this may result in relevant articles not being included in the search 
(Vrijens et al., 2012). The search was conducted on 26.04.2010. The full search protocol 
was: 
 The databases Medline, Embase and PsychInfo were searched using the following 
terms in the title, abstract, subject headings, heading word, or original title: 
o  “patient complian* or patient adheren* or patient nonadheren* or 
patient noncomplian* or patient non-adheren* or patient non-complian* 
or patient non adheren* or patient non complian*” and “medic*”  
 To limit search results to those that dealt explicitly with indicators and correlates 
of medication adherence, the following terms were specified in the title field of 
articles.  
o “predic* or influ* or determ* or caus* or correla*or associat*”. 
 No limits were placed upon publication date. 
 
Retrieved studies were saved to a dedicated Endnote Library to identify any duplicated 
citations. Titles and abstracts of the remaining articles were then examined for relevance. 
Full texts of potentially relevant articles were then acquired before being assessed against 
the inclusion and exclusion criteria. Where full texts were not available, authors were 
contacted with a request for the article. Due to a lack of funding, articles which could not 
be retrieved in this manner were excluded from the analysis. All data was extracted, 
coded and analysed by a single researcher. However, a practice run of 10 randomly 
selected studies was performed with the results discussed with the principle supervisor 
and a research collaborator who was a specialist in meta-analysis. This stage was 
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performed in order to modify the extraction sheet and procedures in order to ensure they 
would meet study aims. 
 
2.2.4.2 Effect size extraction 
All data were extracted only from published material. For purposes of this analysis, the 
original study author’s own definitions of adherence were used.  Adherence rates were 
also recorded where available. 
Where authors reported univariate and multivariate effect sizes, the univariate effect size 
was preferred. This limited the impact of different multivariate models impacting upon 
effect size estimates (Atkinson and Petrozzino, 2009). 
Effect sizes were recorded as either Pearson’s correlation coefficients (r) or as Odds 
Ratios (OR). Pearson’s r was the preferred metric. Adherence behaviour occurs on a 
continuum, and r represents the relationship between continuous variables in a robust 
way. The Odds Ratio was employed when the indicator of adherence was a categorical 
variable or when a majority of studies in the analysis had used the OR. Metrics were 
converted by Comprehensive Meta-Analysis (Borenstein et al., 2010). 
Where effect sizes were not reported directly as OR or as r, they were calculated via 
contingency tables, reports of mean differences, or the results of statistical tests. Where 
authors presented significance levels rather than exact p-values, the significance level was 
recorded and treated as if it were the exact p for the purposes of analysis (DiMatteo, 
2004c). This is a conservative method which underestimates the true significance level, 
but reduces the probability of a Type 1 error (Borenstein et al., 2009). To account for 
significance values and effect sizes that were not reported or reported only as not 
significant, sensitivity analysis was performed. The analysis was run once where non-
significant or unreported results were omitted and a second time with all unreported or 
non-significant values assumed to be r = 0. If this second analysis changed the statistical 
significance of the association, the new effect size and significance test were reported 
(Hönekopp and Watson, 2011, DiMatteo et al., 2007, DeCoster, 2009). 
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2.2.4.3 Statistical analysis 
 
2.2.4.3.1 Effect size estimation 
Each indicator identified in the literature was coded to link together identical and similar 
indicators for analysis, and to separate dissimilar indicators (Sharpe, 1997). Indicators 
were assigned codes as they emerged. Indicators within each category were then sorted 
so that only indicators sufficiently similar to each other were combined. Because HIV 
requires high adherence to a regimen more complicated than for most other illnesses 
(Atkinson and Petrozzino, 2009), subgroup analysis was performed with HIV studies also 
examined in isolation. These are reported only where a difference was found in effect size 
estimates. Meta-analyses were not performed when less than three identified studies 
could have an effect size calculated for synthesis, or when indicator variables were too 
variable for combination. In this case whether or not any direction of effect could be 
discerned from individual study results is reported. 
Random effects meta-analysis was employed with all effect size estimates presented 
alongside confidence intervals and p-values. 
Where studies reported multiple measures for the same outcome, data were 
amalgamated by using the mean scores for this outcome. This prevented bias from 
including information from the same sample more than once (Gleser and Olkin, 2009). 
Amalgamation was not considered appropriate where the differences in outcome 
between measures were large. When this occurred the study sample was excluded to 
prevent author preference biasing results. 
All effect sizes are presented so that OR’s greater than 1 and positive values for r indicate 
a variable is associated with greater adherence. 
 
2.2.4.3.2 Heterogeneity analysis and Meta-regression variable coding 
The I2 statistic was used to quantify the extent of heterogeneity in analyses. This variable 
expresses the percentage of variation in a meta-analysis which can be attributed to 
differences between studies as opposed to random error around a single effect size 
(Borenstein et al., 2009).  
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2.2.4.3.3 Descriptors of studies  
 
Data were recorded to describe the population of studies in terms of year and place of 
publication, type of study design, how and whether adherence was defined in the study, 
how and if adherence was dichotomised, the method of adherence measurement, 
whether self-reported adherence utilised an existing measure or not, the duration of 
adherence measurement, and the disease studied. These findings are summarised in 
appendix A. None of these indicators were utilised  for ranking or rating of study quality. 
This data is collected and presented only to characterise the type of evidence available in 
terms of study designs utilised. This helps to place presented results in the context of the 
methods employed (Hetrick et al., 2010). For example, a lack of experimental studies and 
RCTs makes attributions of causality inappropriate in the identified body of research. 
 
2.2.4.3.4 Expanded results 
An expanded table of results providing more detail into the outcomes of analysis is 
presented in appendix B for studies analysed via the correlation coefficient and appendix 
C for studies analysed via the odds ratio. In addition to the results presented in the main 
text, these appendices presents median, minimum, and maximum effect sizes within 
meta-analyses for all variables, a significance test to identify whether heterogeneity is 
statistically significant or not within the analysis, and estimates of standard error and tau 
for comparison of within and between study error. Appendix D lists the studies included 
in each meta-analysis along with individual effect size estimate and presents a 
bibliography for these studies.  
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2.3 Results 
Figure 2.1 summarises the flow of article inclusion and exclusion. A total of 97 articles 
could not be obtained, and 317 articles failed to fulfil inclusion criteria or else met 
exclusion criteria. A total of 198 articles met all inclusion criteria (10.44%). The reasons 
for exclusion during full text review are indicated in figure 2.1. Other than a lack of 
relevance and inability to acquire a full text, the primary cause of exclusion was articles 
providing insufficient data to calculate an effect size. Of the 198 articles which had data 
extracted, 53 contained indicators which could not be combined with those from other 
studies and so analyses are based upon a final sample of 145 studies. Included studies 
had a median (Quartiles) sample size of 288 (121, 708) with a minimum sample size of 28 
and a maximum of 1,888,682. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Flow of articles included in review 
 
For all articles that dichotomised adherence as a proportion of medicines taken (k = 124), 
the median (Quartiles) per cent of patients rated as adherent was 67.28% (52.5%, 
80.85%), with a range of 10% to 98.53%. 
Articles identified in search 
(n = 2482) 
Articles identified for 
screening (n = 1878) 
Articles identified for full 
text review (n = 620) 
Articles identified for data 
extraction (n = 198) 
Duplicate or duel 
publications (n = 604) 
Irrelevant articles  
(n = 1258) 
No predictors of adherence/adherence not an outcome (n 
= 57), effect size could not be calculated (n = 64), review 
articles with no new data (n = 37), could not acquire 
articles (n = 97), not relevant population (n = 32), study 
not relevant (n = 66), adherence to non-medication 
regimens (n = 24), Qualitative studies (n = 7), Mentally ill, 
paediatric, drug/alcohol dependent or acute illness 
sample (n = 36), physician rated adherence only (n = 2), 
protocol only paper (n = 1), not in English language (n = 1) 
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2.3.1 Patient Demographics 
The results of meta-analyses exploring the evidence for links between adherence and 
categorical demographic variables are presented in table 2.1 where the results were 
analysed using the odds ratio. Therefore factors which such as age or income which are 
better presented as correlations are not included in the table. In general there was no 
evidence for associations between patient demographics and adherence behaviour. 
Furthermore, all analyses displayed high heterogeneity. However, being employed was 
found to be associated with improved adherence to medication.  
 
Indicator k n OR Lower 
CI 
Upper 
CI 
p I
2 
Sex (Female vs. male) 68 2167404 0.988 0.933 1.045 0.665 84.059 
Education (as level of education 
increases) 
48 48321 1.144 0.942 1.389 0.176 87.224 
Education (college education vs. 
none) 
25 42361 1.150 0.861 1.537 0.345 89.579 
Employment (yes vs. no) 15 5661 1.315 1.006 1.719 0.045 72.422 
Health insurance (Yes vs. No) 7 3118 1.080 0.693 1.685 0.734 64.313 
Items in bold show a statistically significant association with adherence at α = 0.05. 
Items in italics show a statistically significant association at α = 0.1. 
k refers to the number of studies in the meta-analysis 
n refers to the pooled sample size.  
Table 2.1 Relationship to adherence between demographic characteristics 
 
A weak positive correlation was associated between age and adherence, k = 83, n = 
2,079,337, r (95% CI) = 0.057 (0.037, 0.078), R2 = 0.003, p < 0.001, I2 = 98.485. There was 
no indication that income had any relationship with adherence, k= 19, n = 7657, r (95% CI) 
= 0.006 (-0.051, 0.063), R2< 0.001, p = 0.835, I2 = 69.057. Classification of samples into 
high or low sociodemographic groupings was rare (k = 3) and the methods of those 
studies too variable to draw conclusions. Only three studies examined the effects of 
having children on adherence, and they indicated that having children was associated 
with improved adherence (Moralejo et al., 2006, Corless et al., 2005), and that having 
more children correlated with improved adherence (Corless et al., 2005, Golin et al., 
2002). Sexuality was investigated by three studies in HIV regimens. All were small samples 
with a combined n of 343, and there was a lack of evidence for any effect, OR (95% CI) = 
1.404 (0.538, 3.662), p = 0.488, I2 = 59.578. 
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2.3.2 Patient Race 
The relationships between race and adherence are represented in table 2.2. Despite large 
sample sizes and a tendency for white participants to have higher adherence, this effect 
was not statistically significant at α = 0.05. However, comparisons of white patients to 
non-white patients as a whole, and to ethnic minorities that were neither black nor 
Hispanic did achieve significance at α = 0.1. Black patients were shown to be less 
adherent than other ethnic minority patients. 
 
Indicator k n OR Lower 
CI 
Upper 
CI 
p I
2
 
Black / Other races 6 40263 0.601 0.464 0.777 <0.001 42.771 
White / black 13 1954297 1.432 0.956 2.143 0.081 99.118 
White / Hispanic 6 1892707 1.121 0.789 1.593 0.522 80.418 
White / non-white 12 6901 1.376 0.942 2.008 0.098 81.371 
White / other 9 1947200 1.204 0.831 1.745 0.327 98.901 
Items in bold show a statistically significant association with adherence at α = 0.05. 
Items in italics show a statistically significant association at α = 0.1. 
k refers to the number of studies in the meta-analysis 
n refers to the pooled sample size.  
Table 2.2 Relationship between adherence and race 
 
2.3.3 Adherence to non-medication regimens 
It was not possible to meta-analyse adherence to appointments or to exercise because 
too few studies were identified. Any identified associations were weak (Stanton, 1987, 
Bane et al., 2006, Trivedi et al., 2008). Four studies explored the relationship between 
adherence to medications and to diet (n = 1881) and those that were more adherent to 
diet regimens were also more adherent to their medication regimens, r (95% CI) = 0.187 
(0.034, 0.332), R2 = 0.035, p = 0.017, I2 = 86.473. 
 
2.3.4 Medication regimen 
Table 2.3 represents the results of meta-analyses utilising ORs which explored 
relationships between adherence and characteristics of patients medication regimen. 
Differences in medication regimen were not related to adherence. One exception to this 
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was a higher number of unique medications for HIV patients. Longer duration of a 
medication regimen was associated with lower adherence, k = 12, n = 20806, r (95% CI) = 
-0.062 (-0.116, -0.007), R2 = 0.003, p = 0.027, I2 = 97.344. The number of pills taken 
throughout the day was not associated with adherence, k = 11, n = 4482, r (95% CI) = 
0.034 (-0.033, 0.100), R2 = 0.001, p = 0.318, I2 = 59.524. It was not possible to combine 
studies comparing weekly to daily regimens because effect sizes could not be calculated 
for studies that were sufficiently similar to combine, nor could any direction of effect be 
discerned. Patients that had experienced a change in medication regimen may have lower 
adherence (Parruti et al., 2006, Lam et al., 2007, Deschamps et al., 2004), but it was not 
possible to calculate an effect size for these studies.  
 
Indicator k n OR Lower 
CI 
Upper 
CI 
p I
2
 
Number of co-medications 4 24204 1.002 0.790 1.271 0.987 91.885 
Fewer different types of pills per day  14 180468 0.984 0.695 1.395 0.929 99.5 
Fewer different types of pills per 
day for HIV 
5 1504 1.888 1.300 2.740 0.001 44.103 
Fewer different types of pills per day 
for non-HIV 
9 178964 0.738 0.485 1.122 0.155 99.686 
Complexity of regimen (e.g. 
monotherapy vs. combination /pills 
per dose) 
8 4435 0.857 0.508 1.444 0.562 88.71 
Items in bold show a statistically significant association with adherence at α = 0.05. 
Items in italics show a statistically significant association at α = 0.1. 
k refers to the number of studies in the meta-analysis 
n refers to the pooled sample size.  
Table 2.3 Relationship between adherence and medication regimen factors 
 
2.3.5 Use of memory aids 
A total of 6 studies (n = 2419) examined the use of memory aids. These were associated 
with higher levels of adherence, OR (95% CI) = 1.971 (1.463, 2.656), p < 0.001, I2 = 35.597. 
 
2.3.6 Barriers to adherence 
Where studies explored practical or perceived barriers to adherence without further 
specification, it was found that patients that reported a greater number of barriers were 
less adherent than those facing fewer obstacles, k = 8, n = 2941, r (95% CI) = -0.253 (-
0.356, -0.142), R2 = 0.064, p < 0.001, I2 = 84.489. Patients reporting good access to 
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medical care were more likely to be adherent, k = 4, n = 912, OR (95% CI) = 2.323 (1.659, 
3.253), p < 0.001, I2< 0.001. Ease of access to medication was also associated with better 
adherence, k = 3, n = 688, OR (95% CI) = 2.333 (1.445, 3.765) p = 0.001, I2< 0.001. 
 
2.3.7 Costs of treatment 
There were 10 studies (n = 55,800) that investigated the effects of cost of medicines upon 
adherence. A significant difference whereby higher costs were associated with lower 
adherence was identified, OR (95% CI) = 0.760 (0.654, 0.884), p < 0.001, I2 = 92.529. There 
was no significant relationship found between the total cost of medical treatment and 
adherence, k =4, n = 23,013 OR (95% CI) = 1.250 (0.826, 1.891), p = 0.292, I2 = 90.279. 
 
2.3.8 Comorbidity 
All analyses exploring the relationship between comorbidity and adherence are shown in 
table 2.4. The presence of hypertension was found to have a small but statistically 
significant relationship with adherence. Three studies also examined five respiratory 
conditions (Ho et al., 2008, Diette et al., 1999, Balkrishnan and Christensen, 2000), 
however these studies were not sufficiently similar to combine. There were no clear 
indications of the direction of any effect. 
 
Indicator k n OR Lower 
CI 
Upper 
CI 
p I
2
 
Comorbidity 19 2047198 0.987 0.821 1.186 0.885 98.530 
Dyslipidaemia 3 19852 1.027 0.762 1.384 0.861 84.105 
Liver Disease 3 6015 0.758 0.343 1.675 0.493 43.740 
Hypertension 6 91860 1.081 1.002 1.165 0.045 72.301 
Other cardiovascular conditions 6 89450 1.119 0.965 1.297 0.136 89.496 
Diabetes 10 74563 0.988 0.930 1.050 0.692 53.442 
Stroke 4 43097 1.072 0.960 1.196 0.215 55.578 
Myocardial infarction 4 48287 1.058 0.959 1.167 0.264 34.747 
Heart Failure 5 79940 1.106 0.993 1.232 0.067 67.986 
Items in bold show a statistically significant association with adherence at α = 0.05. 
Items in italics show a statistically significant association at α = 0.1. 
k refers to the number of studies in the meta-analysis 
n refers to the pooled sample size.  
Table 2.4 Relationships between adherence and comorbidity 
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2.3.9 Disease severity and outcomes 
The relationship between indicators of disease severity and outcome with adherence as 
measured via ORs are presented in table 2.5. In most cases any relationship between 
disease severity and outcomes with adherence was weak and not statistically significant. 
However, HIV patients were more likely to be hospitalised when adherence was low. The 
correlation between symptom severity and adherence was not statistically significant, k = 
15, n = 8460, r (95% CI) = -0.019 (-0.046, 0.008), p = 0.163, I2 = 73.726. The duration a 
patient had presented with a particular illness was not significantly associated with 
adherence, k = 21, n = 15608, r (95% CI) = -0.008 (-0.052, 0.037), p = 0.731, I2 = 66.788. 
 
Indicator k n OR Lower 
CI 
Upper 
CI 
p I
2
 
CD4 Count 15 9775 0.980 0.820 1.171 0.822 76.470 
HIV RNA 15 9811 1.072 0.839 1.369 0.578 83.159 
HIV Status (More severe/AIDS vs. 
less severe/no AIDS) 
11 2768 1.028 0.760 1.390 0.860 51.645 
Systolic BP 5 2025 0.949 0.640 1.408 0.795 76.937 
Diastolic BP 5 2025 1.137 0.738 1.751 0.561 80.687 
Fewer/No symptoms 6 6016 1.400 0.915 2.144 0.121 87.157 
No GP/Outpatient visit 11 180297 0.919 0.825 1.023 0.123 94.425 
Fewer/No Hospitalisation 13 84332 1.090 0.921 1.289 0.317 94.361 
Fewer/No Hospitalisation - HIV 4 1099 1.861 1.383 2.504 <0.001 12.670 
Fewer/No Hospitalisation - non-HIV 9 83233 0.956 0.802 1.140 0.619 95.569 
Fewer/No Emergency department 
visits 
4 40056 1.032 0.811 1.313 0.796 95.243 
Items in bold show a statistically significant association with adherence at α = 0.05. 
Items in italics show a statistically significant association at α = 0.1. 
k refers to the number of studies in the meta-analysis 
n refers to the pooled sample size.  
Table 2.5 Relationship between adherence and measures of disease severity and 
outcome 
 
2.3.10 Quality of life and patient wellbeing 
Table 2.6 presents the estimates of association between measures of quality of life and 
adherence to medication. Higher patient quality of life was associated with better 
adherence. However, sub-group analyses showed that the statistical significance of these 
effects was primarily due to the strength of these relationships in HIV patients. General 
measures of patient mental wellbeing were not associated with adherence behaviour. 
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Additionally, all but two studies in this sample were cross sectional making causal 
inferences impossible. 
 
Indicator k n OR Lower 
CI 
Upper 
CI 
p I
2
 
General QOL measures 15 5379 0.102 0.043 0.161 0.001 65.53 
General QOL measures, HIV only 6 1129 0.178 0.115 0.240 <0.001 <0.001 
General QOL measures, non-HIV 
only 
9 4250 0.061 -0.017 0.139 0.127 72.278 
Physical functioning 18 15175 0.075 0.007 0.142 0.030 81.106 
Physical functioning, HIV only. 8 1721 0.175 0.034 0.310 0.015 85.172 
Physical functioning, non-HIV only. 10 13454 0.012 -0.052 0.075 0.175 67.134 
Mental wellbeing 7 1942 0.056 -0.014 0.126 0.115 50.743 
Items in bold show a statistically significant association with adherence at α = 0.05. 
Items in italics show a statistically significant association at α = 0.1. 
k refers to the number of studies in the meta-analysis 
n refers to the pooled sample size.  
Table 2.6 Relationships between adherence and measures of patient quality of life 
 
2.3.11 Side effects of treatment 
Side effects of treatment were found to be negatively associated with treatment 
adherence. Presence of side effects versus their perceived absence was shown to predict 
lower adherence, k = 11, n = 4161, OR (95% CI) = 0.402 (0.193, 0.837), p = 0.015, I2 = 
95.231. The number of side effects experienced was associated with lower adherence, k = 
5, n = 1394, r (95% CI) = -0.168 (-0.290, -0.040), p = 0.010, I2 = 86.355. The severity of 
experienced side effects was also associated with lower adherence, k = 5, n = 3672, r (95% 
CI) = -0.222 (-0.261, -0.182), p < 0.001, I2 = 2.329. 
 
2.3.12 Health beliefs 
It was not possible to meta-analyse outcome expectations because the measures were 
too inconsistent. Perceived susceptibility to disease was not found to be a significant 
indicator, k = 4, n = 988, r (95% CI) = -0.004 (-0.232, 0.225), p = 0.975, I2 = 89.265. Higher 
self-efficacy was associated with higher adherence, k =21, n = 9047, r (95% CI) = 0.273 
(0.202, 0.342), R2 = 0.075, p < 0.001, I2 = 83.854. 
 
69 
 
2.3.13 Patient beliefs regarding their medication 
Correlations between patient’s beliefs about medicines and adherence are presented in 
table 2.7. Positive beliefs were associated with greater adherence. However, the evidence 
was far less strong regarding any effect of negative beliefs regarding medication. 
 
Indicator k n r Lower 
CI 
Upper 
CI 
p R
2 
I
2
 
Satisfaction with medicines 5 1872 0.245 0.118 0.364 <0.001 0.060 82.975 
Positive belief regarding 
medicine 
6 3207 0.153 0.100 0.205 <0.001 0.023 39.898 
BMQ Necessity 4 622 0.286 0.136 0.423 <0.001 0.082 69.812 
BMQ Concerns 3 622 -0.041 -0.152 0.072 0.481 0.002 46.197 
Items in bold show a statistically significant association with adherence at α = 0.05. 
Items in italics show a statistically significant association at α = 0.1. 
k refers to the number of studies in the meta-analysis 
n refers to the pooled sample size.  
BMQ refers to the Beliefs about Medicines Questionnaire (Horne et al., 1999). 
Table 2.7 Relationship between adherence and patient beliefs about medication 
 
Belief in the effectiveness of medicine was associated with better adherence, k = 6, n = 
1607, OR (95% CI) = 2.244 (1.121, 4.492) p = 0.022, I2 = 80.295. Studies using scales other 
than the Beliefs about Medicines Questionnaire (Horne et al., 1999) to measure patient 
concerns about medication were too varied in design to combine, and also varied in 
terms of outcome so no indications for direction of effect could be determined (Carr et 
al., 2006, Bardel et al., 2007, Mann et al., 2007, Mann et al., 2009). Two studies examined 
the role of the BMQ General harms scale and the BMQ General overuse scale, and greater 
concerns were associated with lowered adherence (Menckeberg et al., 2008, Gauchet et 
al., 2007). A further two studies examined the role of the perceived importance of 
medication on adherence behaviour (Bardel et al., 2007, Mann et al., 2007) and both 
found a positive association. 
 
2.3.14 Patient knowledge and education 
Patients having better knowledge of their medication, illness and their general health 
literacy are all associated with improved medication adherence. Knowledge of medication 
was assessed by 10 studies (n = 6208) with a correlation of r (95% CI) = 0.084 (0.080, 
0.261), R2 = 0.007, p < 0.001, I2 = 80.362, while knowledge of a patients illness was 
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assessed by eight studies (n = 2945) with an OR (95% CI) of 2.486 (1.551, 3.983) p < 0.001, 
I2 = 86.850. Health literacy was assessed by four studies (n = 2062) finding a positive 
relationship with adherence with r (95% CI) = 0.193 (0.069, 0.311), R2 = 0.037, p = 0.002, I2 
= 74.525. 
 
2.3.15 Risky health behaviours 
The relationships between patients’ engagement in risky health behaviours are presented 
in table 2.8. Patients engaging in risky health behaviours were more likely to be 
nonadherent. Studies investigating the use of complementary medicines were not similar 
and so were not meta-analysed. Evidence for any association between adherence and 
complementary medicine was not consistent in the individual studies (Ng et al., 2004, 
Murri et al., 2009, Liu et al., 2007). Similarly, it was not possible to combine studies 
investigating the impact of Body Mass Index (BMI) upon adherence. However, where the 
direction of the association between BMI could be discerned and calculated, the 
indications were toward larger BMI being associated with lower adherence (Shah et al., 
2007, Janson et al., 2008). Only two studies examined the relationship between 
adherence and exercise, and both suggested that more exercise was associated with 
lower adherence (Shah et al., 2007, Irvine et al., 1999). 
 
Indicator k n OR Lower 
CI 
Upper 
CI 
p I
2
 
Smoking Yes/More vs. No/Less) 15 151636 0.708 0.630 0.796 <0.001 42.910 
Alcohol use 11 4449 0.657 0.534 0.809 <0.001 <0.001 
Problem alcohol use 7 10351 0.471 0.352 0.629 <0.001 21.130 
Drug use 11 2862 0.516 0.401 0.665 <0.001 41.318 
Items in bold show a statistically significant association with adherence at α = 0.05. 
Items in italics show a statistically significant association at α = 0.1. 
k refers to the number of studies in the meta-analysis 
n refers to the pooled sample size.  
Table 2.8 Relationship between adherence and health behaviours 
 
2.3.16 Relationship with medication provider 
The associations between measures of patient-provider relationship and adherence are 
presented in table 2.9. Having a good relationship with healthcare providers predicts 
higher adherence. Furthermore, receiving care from a family physician or GP is associated 
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with higher adherence than is care received from other medical personnel, k = 5, n = 
25153, OR (95% CI) = 0.820 (0.730, 0.922), p = 0.001, I2 = 43.408. 
 
Indicator k n r Lower 
CI 
Upper 
CI 
p R
2 
I
2
 
Satisfaction with care 9 3336 0.131 0.045 0.216 0.003 0.017 85.445 
Trust in physician 8 7263 0.164 0.117 0.210 <0.001 0.027 68.152 
Good communication / 
Relationship with Physician 
13 8592 0.100 0.057 0.142 <0.001 0.010 53.401 
Items in bold show a statistically significant association with adherence at α = 0.05. 
Items in italics show a statistically significant association at α = 0.1. 
k refers to the number of studies in the meta-analysis 
n refers to the pooled sample size.  
Table 2.9 Relationships between adherence and provider relationship factors 
 
2.3.17 Social support 
Social support was directly measured by 22 studies (n = 6641) with more social support 
associated with higher medication adherence, r (95% CI) = 0.138, (0.080, 0.195), R2 = 
0.019, p < 0.001, I2 = 75.349. The value of the subjective norms of patients significant 
others was investigated by four studies and five samples, however an effect size could not 
be calculated. Nonetheless, all five samples indicated that the support of significant 
others improved adherence (Holstad et al., 2006, Brus et al., 1999, Barclay et al., 2007, 
Bane et al., 2006). The benefit of being married or living with a long term partner was 
assessed by 19 studies (n = 9799) and adherence was higher in patients with such a 
relationship, OR (95% CI) = 1.267 (1.077, 1.491) p = 0.004, I2 = 59.026. Patients that 
received help taking their medicines was investigated by five studies (n = 2682) and was 
found to produce a statistically significant boost to adherence, OR (95% CI) = 1.752 
(1.159, 2.649), p = 0.008, I2 = 47.713. 
 
2.3.18 Patient affect 
The relationships between measures of mental distress and adherence are presented in 
table 2.10. Hostility was not found to be associated with adherence behaviour. Hope may 
help patients adhere to their medications, but the evidence is scant with only two studies 
investigating this (Van Servellen et al., 2002, Treadaway et al., 2009). 
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Indicator k n r Lower 
CI 
Upper 
CI 
p R
2 
I
2
 
Anxiety 11 1375 -0.163 -0.250 -0.073 <0.001 0.027 59.343 
Stress 12 3423 -0.162 -0.229 -0.094 0.001 0.026 80.008 
Distress 6 885 -0.167 -0.246 -0.086 <0.001 0.028 48.881 
Hostility 3 671 -0.158 -0.415 0.121 0.266 0.025 91.592 
Items in bold show a statistically significant association with adherence at α = 0.05. 
Items in italics show a statistically significant association at α = 0.1. 
k refers to the number of studies in the meta-analysis 
n refers to the pooled sample size.  
Table 2.10 Relationship between adherence and patient affect 
 
2.3.19 Patient mental health 
Mental health summary scores, with higher scores suggesting better mental health, 
correlated positively with improved adherence behaviour, k = 6, n = 4154, r (95% CI) = 
0.153 (0.102, 0.204), R2 = 0.023, p < 0.001, I2 = 50.741. Furthermore, patients with a past 
or current psychiatric diagnosis were significantly less adherent than those without such a 
diagnosis, k = 8, n = 16849, OR (95% CI) = 0.531, (0.356, 0.791), p = 0.002, I2 = 76.590. 
Depression was a significant risk factor for nonadherence, k =39, n = 95192, r (95% CI) = -
0.100, (-0.127, -0.073), R2 = 0.010, p < 0.001, I2 = 76.664. Anxiety disorders were 
investigated by three studies (Tucker et al., 2003, Woods et al., 2009, Cluley and 
Cochrane, 2001) which could not be combined, but all indicated a negative relationship to 
adherence. Similarly, only one study (n = 5548) looked into the effect of psychosis (Ye et 
al., 2007). Adherence was found to be lower when psychosis was present (54.70% vs. 
64.50%) but this difference was not statistically significant (p = 0.135). 
 
2.3.20 Cognitive ability 
While measures of general cognitive ability were too varied to combine, it could be 
determined that the onset of dementia or cognitive decline in old age was associated 
with lowered adherence, k = 8, n = 49596, OR (95% CI) = 0.839 (0.741, 0.949), p = 0.005, 
I2< 0.001. Strength of memory in the general population was also associated with better 
adherence, k = 4, n = 441, r (95% CI) = 0.181 (0.006, 0.345) R2 = 0.033, p = 0.043, I2 = 
65.992.  
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2.3.21 Personality variables 
A wide variety of personality measures are used in the literature which resulted in very 
few variables having a sufficient number of studies available for meta-analysis. In 
particular it was noted that only two studies were identified which employed the Big 5 or 
OCEAN model of adherence with one of these Evangelista et al. (2001), only utilising the 
Neuroticism dimention indicating greater neurotisism was associated with lower 
adherence in their sample of 82 patients with heart failure. Christensen and Smith (1995) 
utilised all five dimesions of the OCEAN model but only identified a positive relationship 
between greater conscientiousness and adherence in a sample of 72 renal transplant 
patients. Only variables examining the importance of locus of control, and of coping style 
could be combined. There were five studies and six samples that examined the 
relationship between adherence and an internal locus of control, however only three of 
these studies could have an effect size calculated for them to indicate a non-significant 
positive correlation between the two variables, n = 485, r (95% CI) = 0.131 (-0.071, 0.323), 
R2 = 0.017, p = 0.203, I2 = 77.246. The three samples that could not be combined also 
indicate a positive relationship between the two variables (Barclay et al., 2007, 
Molassiotis et al., 2002). A chance locus of control measure could not be synthesised. 
Barclay et al. (2007) identified a statistically significant relationship with poor adherence 
and a chance locus of control (t = 1.96, p = 0.05). Lynam et al. (2009), and Frazier et al. 
(1994) also identified negative associations between a greater chance locus of control and 
lower adherence (r = -0.11 and r = -0.15 respectively). Two measures from one sample in 
Lynam at al. (2009) and one from Frazier et al. (1994) examined the role of powerful 
others locus of control and found no evidence of any effect, with r’s ranging from -0.03 to 
0.06. 
The benefits of adopting an active coping style was investigated by four studies (n = 536) 
but no strong evidence of an effect was found, r (95% CI) = -0.032 (-0.134, 0.071), R2 = 
0.001, p = 0.071, I2 = 62.510. Adoption of avoidant coping strategies was examined by 
just two studies (Frazier et al., 1994, Deschamps et al., 2004) and both indicated that such 
strategies were associated with lower adherence. 
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2.4 Discussion 
 
2.4.1 Indicators of adherence to medication 
 
In common with previous reviews of the literature, the proportion of patients adhering to 
their medication varied greatly between studies (DiMatteo, 2004c, Vermeire et al., 2001). 
However the overall estimate of approximately one third of patients not taking 
medications as prescribed underlines the importance of being able to identify and offer 
appropriate interventions to this large group of patients. The study has also identified 
which indicators of adherence can be objectively shown to be related to adherence. 
 
2.4.1.1 The role of health and healthcare 
Measures of disease severity were not associated with adherence which agrees with 
findings of DiMatteo et al. (2007). It was also demonstrated that most outcomes were not 
highly correlated with adherence. This finding is in partial agreement with DiMatteo et al. 
(2002). Although this study reported a 26% benefit to outcomes from adherence, the 
identified benefits were larger for non-medication regimens, and also in ‘soft’ non-
disease specific patient orientated outcomes such as experience of pain, weight gain or 
hospitalization, than in ‘hard’ disease specific outcomes such as blood pressure, 
cholesterol levels, or CD4 counts. One explanation for the lack of association between 
adherence and outcome is the variable dichotomisation of adherence when the 
therapeutic effect of adherence above or below specific values is unknown. Patients may 
be being asked to take more medicines than is required for therapeutic benefit. 
Consequently, prescribers should approach each individual patient as a therapeutic 
experiment and modify regimens to find the optimal dose for individual patients, rather 
than assume the average effect from randomised controlled trials will necessarily apply 
(Healy, 2004). 
Patients’ access to medical care and to medicines has been shown to impact upon 
adherence. This validates efforts to introduce schemes that enhance patient access to 
care. These include pharmacist domiciliary visiting (Bhattacharya et al., 2008), NHS walk-
in centres (Jackson et al., 2005), and the NHS direct helpline (Knowles et al., 2002, 
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O'Cathain et al., 2005). Furthermore, access to care in UK pharmacies has been criticised, 
and could benefit from regulation which ensures pharmacies are located in such a way as 
to ensure access for remote communities (Lluch and Kanavos, 2010). Personal barriers to 
medication taking were also shown to predict up to 6% of adherence behaviour.  
Intervening to identify and remove individual patient’s barriers could therefore enhance 
adherence (Krousel-Wood et al., 2009, Horne, 2006). Interventions may include reducing 
regimen complexity (Catz et al., 2000), the use of memory aids (Fogarty et al., 2002), and 
discussing the affordability of medicines and the availability of schemes that may help 
patients to afford them (Schafheutle et al., 2002). While the overall cost of healthcare 
was not found to predict adherence, the cost of medicine was an indicator. The 
affordability of medicine to those on a low income in the NHS is important to ensure the 
patient has access to required medication. 
Complexity of the drug regimen was not a significant predictor of adherence. Iskedjian et 
al. (2002) and Bangalore et al. (2007) did find increased regimen complexity to be 
associated with lower medication adherence in prior meta-analyses with a similar number 
of studies identified here (k = 8, and k = 9 respectively). Failure to replicate these results 
may be due to varied cut points being used to indicate higher or lower complexity with 
this being less controlled for in the current study with different measures of complexity 
more broadly grouped so as to maintain statistical power. The relationship between 
adherence and regimen complexity may not be linear (Patel and David, 2004, 
Demyttenaere, 2003), which would also lower the likelihood of the current analyses 
identifying a relationship.  
It was demonstrated that the longer a patient is prescribed a regimen then the more 
likely they are to become nonadherent. It is common for the proportion of patients 
categorised as adherent to fall sharply in the first 6 months, with a more gradual decline 
after this period (Chapman et al., 2005, Chapman, 2004). Encouraging adherence during 
this critical early period of adjustment may prove important and the reasons why patients 
become less likely to become nonadherent after 6 months explored. 
The current analysis did not find that comorbidity was a reliable indicator of adherence. 
Prior research has found that patients with more than one condition experience  more 
side effects and dislike having to take multiple medicines (Williams et al., 2008). However, 
Schüz et al. (2011) also performed a longitudinal study that did not find a significant 
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association between the number of illnesses or prescribed medications and adherence in 
an older population. Comorbidty may only impact adherence when patients have a high 
disease or medication burden.  
Comorbidity is also an important indicator of adherence when patients have concurrent 
or prior mental health issues, or for those displaying symptoms of cognitive decline and 
dementia. The studies included in the review strongly indicate that patients with mental 
health difficulties are less likely to be able to adhere to their medication. Patients with 
comorbid mental health difficulties should be considered at greater risk of nonadherence 
(Demyttenaere, 2003). However, even in mentally health patients’ tests of memory were 
suggested to be indicative of ability to adhere to medication. This corroborates prior 
research which has found patients executive functioning and prospective memory to be 
associated with medication adherence (Zartman, 2006, McNally et al., 2010, Insel et al., 
2006). Therefore the importance of cognitive abilities even in mentally healthy 
populations should not be discounted.  
 
2.4.1.2 Patient experience, beliefs, and knowledge about medicines 
Patients experiencing side effects from their medicines are less adherent to them. This 
can be seen as a rational response of patients to preserve their quality of life (Gay et al., 
2011, Johnson et al., 2005). Qualitative studies show that many patients do not like taking 
medicines as they are seen as toxic or unnatural (Britten, 1994, Benson and Britten, 
2002), and an inability to cope with adverse effects have been cited as the primary reason 
for nonadherence by patients in focus groups (Golub et al., 2006). Such beliefs, coupled 
with experience of side effects, will encourage patients to become nonadherent either by 
reducing their doses or stopping altogether. Factor analysis of doctors’ prescribing 
decisions shows that they do consider side effects of various competing drugs when 
prescribing (Monteiro et al., 2010). However, individual risk factors in patients are often 
overlooked (Scheiman and Hindley, 2010). Appropriate and minimal prescribing to 
optimise patient benefit and minimise the costs of medication taking should be sought, 
with medication reviews using validated criteria to identify inappropriate or over 
prescribing implemented to reduce potential harm to patients (e.g. STOPP and START 
criteria, O'Mahony et al., 2010). 
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Moreover it was demonstrated that actual negative experiences were consistently 
associated with nonadherence while concerns about medicines were not. An economic 
framework can be used to investigate these trade-offs (Elliott et al., 2008). Adherence is 
lower in asymptomatic conditions (DiMatteo et al., 2002), possibly because patients may 
believe they are only ill when symptoms flair up (Svensson et al., 2000). Here medicines 
may induce side effects whilst not offering any obvious health improvement to the 
patient, increasing the likelihood of a rational but potentially harmful decision to not 
adhere to medicine (Iskedjian et al., 2002). Patients positive beliefs in the necessity of 
medicines were shown to be associated with adherece and this may help to offset some 
of the negative impact of side effects from medicine. 
Patient knowledge of their medicines and illness, as well as health literacy, were shown to 
be associated with greater adherence. Reviews appraising the impact of increasing 
patient knowledge upon adherence indicate that such interventions are of benefit, but 
are not sufficient (Haynes et al., 1996, Weinman, 1990). Patients seek information about 
their medicines, and application of simple tools to measure patient satisfaction with 
information received may prevent lack of knowledge damaging patient adherence (Horne 
et al., 2001). 
 
2.4.1.3 Key relationships 
In support of previous literature, patient relationships with healthcare providers and 
prescribers was identified as important for promoting adherence (Bultman and Svarstad, 
2000). The personal qualities of physician may be a key determinant of adherence 
(Sencan et al., 2011). Prior reviews of the literature have found that open, friendly, and 
collaborative consultations are associated with better adherence (Banning, 2008, 
Arbuthnott and Sharpe, 2009). What constitutes a good consultation will be sensitive to 
context and individual, and what is good practice with one patient may alienate another 
(Penn et al., 2011). Consequently, practitioners need to be sensitive to the needs and 
barriers of individuals in order to enhance adherence (Broers et al., 2005, Ong et al., 
1995, DiMatteo, 2003). 
The current investigation has also emphasised the importance of a patient’s support 
network outside of the healthcare setting, including the benefits of being married or in a 
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long term relationship. This is in agreement with a prior meta-analysis (DiMatteo, 2004b).  
Improving a patient’s social support is difficult. While patient disclosure of illness has 
been shown to improve adherence, it has also been linked to patients facing social stigma 
and isolation (Burstein et al., 2011). Careful analysis of how and when it is of benefit to 
patients to disclose their illness offers potential for maximising gains and limiting risks 
(Chaudoir et al., 2011). 
 
2.4.1.4 Individual differences and adherence 
Stress, anxiety, and distress were all found to explain largely the same amount of 
variability in the adherence relationship, and the different constructs will co-vary to some 
degree. The variables are also likely to co-vary with the relationship between adherence 
and depression (Mineka et al., 1998). Although causality is difficult to determine, negative 
affect in patients should be treated as both an indicator of adherence and a target for 
interventions. Intervening to combat negative emotional states in subclinical samples can 
prevent the onset of more severe psychiatric comorbidity (Lovibond and Lovibond, 1995). 
The negative relationship between medication adherence and anxiety found here 
contradicts a previous meta-analysis of this issue (DiMatteo et al., 2000). However, 
DiMatteo et al.(2000) did not sperate adherence to medication regimens and other 
therapeutic behaviours such as diet and exercise and the correlations closest to zero in 
their analysis were for non-medication regimens. 
There was a scaricity of studies available for exploring any association between 
personality and adherence. Horne argues against the use of personality variable to inform 
adherence research because personality is not amenable to change and so is of limited 
use for informing the design of interventions (Horne, 2001), and because correlations 
between adherence and personality tend to be small (Horne, 2000). Correlations between 
personality variables and most behaviours tend to be small, however they benefit from 
being consistent across an individual’s lifespan (Nettle, 2007). Furthermore, Christensen 
argues that much of the debate surrounding the personality literature in adherence stems 
from failing to acknowledge the importance of context and interaction effects with other 
variables (Christensen, 2000). This does not mean that personality traits are not 
potentially useful indicators. Patients of different personalities may respond to medical 
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interventions differently and this should be investigated, particularly in reference to 
communication with prescribers. Therefore it is argued that specific review of the 
influence of personality, and in particular the OCEAN model of personality, is warrented. 
A large study investigating the relationship between the OCEAN model dimentions and 
personality in 749 Swedish chronic disease patients has already suggested that studies 
with adequate power to cope with the anticipated small relationships expected in 
personality research can successfully identify such relationships (Axelsson et al., 2011). In 
particular this study found that it is the interation of personality traits that are most 
important. For example, while conscientiousness is usually associated with greater 
adherence, where higher conscientiousness is coupled with high neuroticism lower 
adherence was identified. However, further research exploring the causes and 
implications of these relationships is necessary before they can be utilised to help predict 
adherence. 
An internal locus of control is associated with the belief that an individual’s actions impact 
upon outcomes, and evidence suggets that such beliefs are associated with greater 
adherence to medicines. Conversely, patients with a chance locus of control, indicating a 
more fatalistic outlook, may be negatively associated with adherence. A lack of belief in 
the power of personal actions could contribute to lowered motivation to adhere to a 
medication regimen (Lynam et al., 2009, Frazier et al., 1994, McDonald-Miszczak et al., 
2000). Lynam et al and Frazier et al. also failed to find any effect for the influence of the 
powerful others locus of control. It may be expected that any effect of this trait may be 
expected to be mediated by the positions of that individual’s social group. 
Active coping styles tend to be found amongst patients with a belief in the importance of 
their actions, while passive coping strategies are analogous to the fatalistic chance locus 
of control. Evidence was scarce for any effect of an active coping style. This may be 
because prior research has indicated that it is not the prevailing coping style of the 
patients in isolation that is important, but how appropriate that style is to a particular 
patient’s circumstances (Christensen, 2000, Wiebe and Christensen, 1996). The two 
available studies suggest avoidant coping styles may be associated with lower adherence 
(Frazier et al., 1994, Deschamps et al., 2004), but there is a need for more research on 
this issue that addresses the problem of interaction effects. 
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2.4.1.5 Patient demographics 
In common with prior research, few patient demographics were related to adherence 
(Horne, 2000, Falagas et al., 2008), despite some assertions to the contrary (Bezie et al., 
2006).  
Older patients have a tendency towards superior adherence supporting previous research 
(Kripalani et al., 2010, Atkins and Fallowfield, 2006). The reasons why patients of a 
younger age may be less adherent has not yet been fully elucidated. Older patients may 
be more experienced with taking medicine (Kripalani et al., 2010), more concerned with 
or cautious about their health (Leventhal and Crouch, 1997), may be more accepting of 
illness and thus more capable of normalising medication taking (McDonald-Miszczak et 
al., 2000, Gooberman-Hill et al., 2003, Kondryn et al., 2011, Kondryn et al., 2009). 
Alternatively older patients may be more conscientious (Soto et al., 2010) which has been 
shown to be correlated with adherence (O'Cleirigh et al., 2007) and engagement in other 
health behaviours (Terracciano et al., 2008). 
The current results do identify differences between races in adherence behaviour. White 
patients were more adherent than other races, and black patients were less adherent 
than other races. Almost all studies that used race as an indicator were based in the USA, 
with only four exceptions limiting how far findings should be generalised to other nations. 
The causes of racial difference in adherence are most likely environmental factors. Gerber 
et al. (2010) indicate covariance between race and greater depression, lowered social 
support, lower health literacy, and poorer relationships with providers. Each of these 
factors has been identified as a correlate of adherence in this analysis. The difference 
between races is apparently larger for white-black than for white-Hispanic. Comparing 
the experience of the three races directly could identify the barriers patients of different 
races have adhering to medicine. 
Being employed was found to be a significant indicator of higher adherence; however, 
there is very little discussion as to why this should be the case in the extant literature. 
Employment may offer greater structure to the day facilitating the taking of medication. 
Employed patients may also be experiencing less severe disease than those unable to 
work, and it has been demonstrated that adherence is lower for the most severely ill 
patients (DiMatteo et al., 2007). 
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2.4.2 Limitations of the collected literature and implications for findings 
The majority of articles collected were published in the last 5 years. This reflects that 
where it was impossible to source articles via current library subscriptions, it was easier to 
contact authors of more recent articles and they may be more willing to share recent 
publications. It also reflects more thorough cataloguing of recent articles in electronic 
databases. Similarly a wide number of disease states were studied, and each may 
influence patient behaviour differently. A number of different definitions of adherence 
were employed, with a majority of studies not providing any definition at all, and a 
number of different cut points for the percentage of pills required to be taken for a 
patient to be categorised as adherent were used. Furthermore, a number of different 
measures were used for both adherence and indicators of adherence, and measures were 
taken over a wide variety of time periods. These differences between study methods and 
sample populations will contribute to heterogeneity in the presented results and should 
be born in mind. The vast majority of presented studies were also observational, and the 
majority of these were cross-sectional. This makes causal inferences difficult to ascribe, 
and it may be the case that the relationship between indicators may not be 
unidirectional. 
 
2.4.3 Limitations of analysis and implications for future research 
The series of meta-analyses and evidence syntheses presented are wide ranging in scope, 
generated a number of hypotheses for further work, and revealed areas where the 
evidence base is currently weak. However, the wide scope of the project forced a more 
shallow review of individual indicators than would be possible with a series of individual 
systematic reviews. In particular the search string failed to identify a significant 
proportion of the literature exploring health beliefs and beliefs about medications which 
limits the conclusions that could be drawn upon these topics. However, the relative utility 
of these beliefs was reviewed in chapter 1. In the absence of such reviews for most 
indicators of adherence, the results presented provide the most comprehensive 
assessment of the strength of evidence for the many indicators of adherence currently 
available. 
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Heterogeneity in analyses was often very high, a factor present in other meta-analyses of 
the adherence literature (Shi et al., 2010, Demonceau et al., 2013). Included literature 
were primarily observational studies from a wide variety of different nations using 
different tools in patients of varied disease states, whilst the quality of included studies 
was not controlled for. All of these factors may have contributed to the high 
heterogeneity identified and introduced some risk of bias (Simpson et al., 2006, Sutton et 
al., 2000, Yang et al., 2010, Egger et al., 1998). Use of the robust random effects model 
helped to limit the impact of heterogeneity but the precision of estimates will be reduced 
as a consequence of these factors. 
 
2.4.4 Conclusion 
This analysis has identified where the strength of evidence for a relationship between 
indicators and adherence is strongest, such as the experience of side effects, patient 
affect, mental health, and the relationships between patients, practitioners, and social 
support considered more broadly. The analyses further indicate which areas require 
greater research before any firm conclusions can be drawn, such as personality, the 
complexity of regimen, and the importance of patient concerns about medicine. A final 
consideration is that the R2 estimates were for most variables very low, highlighting that 
adherence is a complicated behaviour and interventions which target only a single facet 
are unlikely to be successful (Haynes et al., 2008, Haynes et al., 1996). Further, despite 
the large number of indicators examined in this analysis, much of the variation in 
adherence behaviour remains unexplained. It is clear that despite decades of research, 
much remains unknown regarding why patients do or do not take their medications as 
prescribed.
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Chapter 3 –Questionnaire development 
 
3.1 Introduction 
The meta-analyses of chapter 2 were used to identify variables that have been empirically 
shown to be associated with adherence. This chapter describes the process of developing 
a questionnaire to measure these variables in order estimate how at risk a patient is for 
nonadherence to medication whilst utilising the best evidence available to optimise 
reliability, validity, and acceptability.  
 
3.1.1 Reliability  
Kerlinger (1973) identifies three key facets of reliability; reproducibility of results on 
multiple administrations, accuracy of captured information, and the amount of error 
found in measurement. In any effort to measure an attribute numerous sources of error 
may be present such as the mood or health of a participant upon a given day, the manner 
a questionnaire is delivered, the instructions given to participants, or the weather 
(Nunnally, 1978). Similarly, questions which can be interpreted in different ways might 
elicit different responses from different participants or from the same participant on 
different occasions (de Vaus, 1995). Steps to reduce the impact of error includes the use 
of standard instructions which can be understood by all participants, piloting questions to 
ensure their meaning is clear and the way to respond is properly understood, or ordering 
questions so as to not confuse participants. 
 
3.1.2 Validity 
There are three primary categories of validity: content validity, criterion validity and 
construct validity (Kerlinger, 1973, Nunnally, 1978, Cronbach and Meehl, 1955). 
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3.1.2.1 Content validity 
Face validity is determined by discussing the items generated for the questionnaire with 
individuals representative of the target population to ensure items are appropriate, 
inoffensive, and mean the same thing to participants as they do to the researchers 
(Rosenthal and Rosnow, 2008, Oppenheim, 1992, Hardesty and Bearden, 2004, Alumran 
et al., 2012). Content validity is then established by ensuring questionnaire items are 
comprehensive and representative of the construct under consideration via consultation 
with experts in a research field (Oppenheim, 1992, Huang et al., 2006, Beckstead, 2009, 
Cronbach and Meehl, 1955, Kerlinger, 1973). 
 
3.1.2.2 Criterion validity 
Criterion validity refers to comparing a new questionnaire to one or more external 
variables believed to measure the attribute under study (Kerlinger, 1973). Criterion 
validity is often split into predictive validity and concurrent validity. Predictive validity is 
ability to predict behaviour external to the measurement itself (Nunnally, 1978). For 
example, a questionnaire which purports to measure willingness to take medication 
should predict how medication is actually taken. When phenomena cannot be measured 
directly or no good measure of the phenomena exist concurrent validity may be 
established instead, which involves correlating scores on a new questionnaire with 
validated measures on the same topic (Oppenheim, 1992, Nunnally, 1978). 
 
3.1.2.3 Construct validity 
Construct validity refers to how well a test measures the theoretical construct it is 
assumed to measure (Oppenheim, 1992, Shaughnessy et al., 2009). Looking at patterns of 
convergence and divergence is one way to assess construct validity (Kerlinger, 1973). 
Most commonly this is performed via factor analysis which identifies which items on a 
questionnaire correlate most strongly with each other and so are most likely to be 
measuring a single underlying construct. Factor analysis is most properly employed to 
confirm patterns of convergence and divergence that were predicted from theory, but 
analyses may be exploratory to help inform the development of theory (Nunnally, 1978). 
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3.1.3 Questionnaire construction 
Item wording, item ordering, how participants are asked to respond to items plus 
questionnaire design and layout can influence questionnaire validity and reliability. 
 
3.1.3.1 Question wording 
The key principals involved in the formation of a questionnaire item are:  
 To avoid jargon, leading questions, and ambiguity or multiple meanings 
(Oppenheim, 1992, Williams, 2003, Meadows, 2003, Murray, 1999, McColl et al., 
2001, de Vaus, 1995) 
 To ensure a conversational tone to build rapport with the participant (Edwards, 
2010). 
 To minimise the cognitive burden required of participants (Groves et al., 2004).  
Murray (1999) recommends that items should be comprehensible for those at the lower 
end of the educational background of the target population and not the average level to 
ensure most respondents will be able to comprehend questionnaire items. Edwards 
(2010) recommends the use of a metric such as the Flesch reading ease score to test for 
readability. The average reading age in the UK is approximately 12 years (Williams, 2003) 
and so questions and instructions should be comprehensible at this reading level at a 
maximum. Adhering to these principles helps to maintain acceptability to participants and 
the accuracy of responses. 
 
3.1.3.2 Question ordering 
It is widely agreed that easy and interesting questions should be placed early in the 
questionnaire while more difficult and sensitive questions should be later, and items on a 
single topic should as far as possible be grouped together (Oppenheim, 1992, Murray, 
1999, Rattray and Jones, 2007, Meadows, 2003, McColl et al., 2001, Edwards, 2010). In 
contrast there is less agreement regarding the optimal positioning of demographic 
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questions. It has been argued that demographic questions ease participants into a 
questionnaire (Murray, 1999), but others argue that demographic questions can be 
boring or threatening and should be placed at the end of a questionnaire (Sudman and 
Bradburn, 1982, Oppenheim, 1992, de Vaus, 1995, Stone, 1993). However, it is argued 
that ordering is less important in postal questionnaires where many participants read the 
entire questionnaire prior to completion (McColl et al., 2001). 
 
3.1.3.3 Participant responses 
There are two basic types of questionnaire item: those that aim to elicit participants’ 
attitudes to specific concepts or current feelings, and questions which seek factual 
information. 
 
3.1.3.3.1 Attitude items 
There are a number of possible ways in which participant attitude can be measured. 
Some of the most powerful scales are those based upon Thurstone’s law of comparative 
judgement (Thurstone, 1927). The utility of this type of scale is that each of the items 
used to gauge attitude are designed to be equally spread across a bipolar attitude 
dimension. Having items that are equally spread across an attitude dimension allows for a 
greater approximation of normality permitting the use of more powerful statistical 
analyses. However, items on a Thurstone scale are all dichotomous, which means that a 
large number of items are required to measure each attitude or belief. A second attitude 
measurement technique is the Guttman or scalogram scale (Oppenheim, 1992). 
Scalogram analysis employs a series of agree-disagree statements of increasing extremity 
to order participants by attitude. The underlying assumption is that participants that 
agree to items higher in the scale will also agree to all items lower in the scale, and will 
not agree with statements higher in the scale than their first item of disagreement 
(Rattray and Jones, 2007). However, this ranking is ordinal, which limits the use of 
powerful statistical methods. Further, the binary response set requires a number of 
questions per attitude to determine participants’ ranking on the attitude spectrum 
reliably (Schooler, 1968). 
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Likert scaling is the most popular attitude measuring technique, and they offer an 
approximation of a Thurstone scales whilst being less laborious to produce (Oppenheim, 
1992). Participants rate where they lie on an attitude dimension for a number of related 
items. Likert scaling has been shown to have the best correlations with actual behaviour 
of the various attitude measurement techniques (Foddy, 1993). Furthermore, having a 
greater number of response options per item increases the sensitivity of individual items 
in terms of placing participants’ attitudes accurately upon a dimension. This accuracy can 
be increased by having a greater number of response options or by having a greater 
number of items addressing the attitude of interest.  
A controversy in the use of Likert scales is whether or not to include a mid-point on the 
scale which can represent the lack of an opinion, or ambivalence. Some authors argue 
that including a mid-point allows participants to tick the middle box rather than invest the 
effort required to make a decision (McColl et al., 2001, Edwards, 2010). There is also 
evidence that participants interpret the mid-point as the ‘typical’ response and use it as a 
reference for their own position (Tourangeau et al., 2004, Schwarz, 1990). Others claim 
that providing a mid-point can reflect genuine ambivalence on the part of participants 
(Murray, 1999, Wandzilak et al., 1987, Schuman and Presser, 1996). Rattary and Jones 
(2007) argue that excluding the mid-point irritates participants and may increase non-
response. Furthermore, omitting the mid-point can force participants to make a 
meaningless choice when participants are uncertain which can affect the conclusions 
made from a study (Bishop et al., 1982). Consequently, forcing participants that genuinely 
have no opinion or lack the information required to make a sensible choice to make a 
choice could lead to erroneous conclusions (Sudman and Bradburn, 1982). 
Visual analogue scales contrast to the “discrete” scales discussed above by asking 
participants to place how they feel on a 10cm line (Williams, 2003, Reips and Funke, 
2008). The line may or may not be separated into Likert style sections which guide 
participants as to where on the line different strengths of attitude lie. This true 
continuous measurement better allows the proper use of parametric statistics. However, 
on a Visual Analogue Scale each score must be measured manually to see how far along 
the continuum it is which takes far longer than checking which of five boxes has been 
ticked. As a consequence, visual analogue scales are laborious to measure without 
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computer assistance (Reips and Funke, 2008) and thus inappropriate for use beyond the 
research setting. 
 
3.1.3.3.2 Factual items 
The design of questions seeking accurate and honest responses to factual questions 
follows many of the guidelines already described. The questions should be short, simple 
to understand, unambiguous, and easy for participants to process. The additional 
requirements are to not over burden participants’ long term memory and to ensure 
multiple choice questions are as comprehensive as possible (Oppenheim, 1992). 
 
3.1.3.4 Presentation of the Questionnaire 
The design and layout of a questionnaire is an important aspect of development 
(Oppenheim, 1992). Smith (1995) demonstrated how small errors in design led to 
misleading conclusions for a number of studies. For example, boxes that were out of line 
with their responses were considered confusing by participants and ignored, as were 
questions that were too cramped together. Despite the demonstrated importance of 
design McColl et al. (2001) note that very little empirical evidence is available to guide 
questionnaire design.  
 
3.1.3.4.1 Use of space 
The need for white space has been emphasised as it makes questionnaires seem less 
intimidating, confusing, and difficult (Sudman and Bradburn, 1982). McColl et al. (2001) 
cite evidence by Layne and Thompson (1981) indicating that a cluttered one page 
questionnaire garnered a lower response rate than the same content appearing over 
three pages. Subar et al. (2001) also showed that a questionnaire that was designed to 
optimise the cognitive ease of completion attained a similar response rate to a far shorter 
questionnaire. Whilst maximising white space between sections and questions is 
advantageous, questions should ideally not be spread over two pages. This has been 
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shown to make questionnaires more difficult for participants to complete (Murray, 1999, 
Meadows, 2003). 
 
3.1.3.4.2 Typeface 
It is advised that a minimum of a 10-point font is used (McColl et al., 2001) or a 12-point 
font where participants may be of older age (Edwards, 2010). Guidance regarding the 
type of font to be used is scarce. However, it is recommended that typeface should have 
a distinct separation between characters. For example, ‘rn’ may be mistaken for ‘m’ in 
some typefaces (McColl et al., 2001). Although it is claimed that sans serif fonts are better 
for readers with dyslexia (e.g. British Dyslexia Association, UXMovement, Hobo-web, 
Evett and Brown, 2005), no literature supporting this claim was identified. 
 
3.1.3.4.3 Use of colour 
The use of colour in questionnaires has not been widely researched (Edwards, 2010, 
Edwards et al., 2002, McColl et al., 2001). Edwards et al. (2002) identified one study which 
found that the use of coloured ink improved response rates. A further eight studies 
indicated non-white questionnaires may produce slightly higher response rates. However 
this effect did not reach statistical significance. Prior opinion stresses the importance of 
being consistent in presentation (Groves et al., 2004) and including an eye catching front 
cover to arouse interest (Sudman and Bradburn, 1982). 
 
3.1.4 Principles guiding questionnaire development 
The aim is to produce a questionnaire that will be easy for participants to complete, for 
practitioners and researchers to assess, and which accurately predicts which patients are 
more likely to be nonadherent to their medications. As far as was possible existing 
measures were used in favour of developing new items. This decision was made for two 
reasons. The first was to reduce the time required to develop the questionnaire (Boynton 
and Greenhalgh, 2004, Williams, 2003). The second was that using existing scales allows 
for the direct comparison of scores on the questionnaire to those found in other studies 
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(Boynton and Greenhalgh, 2004, Edwards, 2010). Using scales familiar to practitioners 
and researchers should also help with interpretation of scores. To improve acceptability, 
where available scales came in long and short versions the shorter version was preferred. 
It has been demonstrated that practitioners prefer short questionnaires because they 
save time when making decisions (Spitzer et al., 1999). It was considered that the 
increased measurement error from a shorter scale was an acceptable trade off to 
maximise the acceptability and clinical utility of the questionnaires (Edwards, 2010). 
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3.2 Methods 
 
3.2.1 Indicator selection 
The meta-analyses of chapter 2 were performed to provide an objective assessment of 
what indicators of adherence should be measured in the questionnaire. The first criterion 
for inclusion was a statistically significant result from meta-analysis. The second was a 
larger than negligible effect size estimate from meta-analysis. Negligible effect sizes were 
defined as those with a correlation between r = -0.05 to 0.05 or Odds Ratios between OR 
= 0.80 – 1.20, as these values approximate to effect sizes of Cohen’s d ≈ 0.1. Calculations 
to establish equivalence in effect sizes were performed using the formulae detailed by 
Borenstein et al. (2009) and Durlak (2009).  
 
3.2.2 Identification of existing questionnaire items 
A literature review was conducted to identify and evaluate existing questionnaires. 
Questionnaires were identified via the studies in the meta-analyses of Chapter 2 and by 
searching the PubMed, Web of Knowledge, and ScienceDirect databases. Any 
questionnaires that were identified also had their references explored to identify 
additional questionnaires. The ‘cited by’ lists available in some electronic databases such 
as Web of Knowledge were also examined to see if questionnaires had been updated, or 
if new questionnaires had been developed on the same topics. In addition, specific 
searches for review articles were also conducted as a way to quickly identify a number of 
scales in a specific topic area. Keyword searches were also conducted in both Google and 
Google Scholar for each topic area. Each identified scale was then checked for suitability 
according to length, appropriateness to the current population, evidence for reliability, 
validity, and acceptability, and whether the questionnaire was available to be used either 
via permission from the copyright holder or because they were in the public domain. 
Whether work was in the public domain or not the original authors of questionnaires 
were contacted wherever possible to seek approval for including their work in the PALS or 
WAMS. Approval was also obtained prior to making any adjustments to existing 
questionnaires. 
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3.2.3 Face validity 
Testing of face validity was performed using a convenience sample of friends and lay 
colleagues of the research team. The aim was to ask people of different ages, educational 
levels, and nationalities to read the questionnaire and to make comments upon it. 
Volunteers were contacted both in person and by e-mail. Where volunteers were able to 
be spoken to in person, this was embellished by talking with them about each of the 
questions, what they thought they meant and if there were any response options that 
should be made available to them. Five volunteers took part exclusively by e-mail, and 
four discussed the questionnaires in person. The four participants that took part in person 
discussed multiple drafts of the questionnaire up to and including the final draft. E-mail 
participants were contacted once at the end of September 2009, and again at the end of 
October 2009 with three respondents in the first instance and two respondents in the 
second. Participants were presented with the following instructions: 
“If you could I would like you to tell me: 
1. How long did it take you to complete each questionnaire? 
2. Did the questions make sense to you? 
3. Are they the sort of things you would expect to be asked, or be happy to answer in 
the situations described above? 
4. Could you understand what each of the questions was asking you to do? 
5. Could you understand how you should respond to each of the questions? 
6. Did you find any of the questions to be too personal or inappropriate? Would you 
be uncomfortable answering any of them bearing in mind the questions may be 
seen by researchers and by medical staff? 
7. Did you spot any mistakes? For example, typos, repeated words, incorrect 
punctuation, or poor grammar that may have escaped our eyes? 
Finally, because we're looking for a range of people from different backgrounds and of 
different ages, if you are comfortable doing so it would be very useful for us to be able to 
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get this information from your parents or other older family members. But neither you 
nor they should not feel under any pressure to do this.” 
Face validity was to be further expanded upon in a full qualitative appraisal following 
preliminary assessment of the questionnaire in a genuine clinical sample in order to have 
any refined questionnaire based upon the experiences of participants that have actually 
completed the questionnaire in a real world setting (see chapter 5). 
 
3.2.4 Content validity 
Content validity was provided by a consultant hospital pharmacist with an interest in 
adherence, and a GP based in a surgery near York. They were invited to comment upon 
question appropriateness, response appropriateness, questionnaire length, potential 
utility of the scale, and comprehensiveness of the tools. This is a relatively superficial 
assessment of content validity, but as with face validity a more complete assessment was 
planned with clinical staff that had utilised the designed questionnaire in order to 
optimise clinical utility (see chapter 5). 
 
3.2.5 Reading comprehension 
The comprehension of questionnaire instructions and items was assessed during face and 
content validity testing. This was augmented by collecting Flesch-Kinkaid grade levels for 
each section on the questionnaire (Kripalani et al., 2009). 
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3.3 Results and discussion 
 
3.3.1 Summary of questionnaire content 
Content validity assessment suggested that clinical utility and could be improved if the  
questionnaire was split into two. One questionnaire would comprise indicators that 
change only slowly over time, while another would comprise indicators which may 
change more readily. The intention was that the former questionnaire would only need to 
be completed rarely; once every few years or when welcoming a new patient to a clinic. 
The second questionnaire would be used more routinely in patient follow up to assess 
how the patient is coping with their medicines in the current context of their life 
situation. This division would reduce the burden of questionnaire completion on 
healthcare professionals by ensuring that only information that genuinely required 
regular monitoring was regularly collected. An additional benefit would be that patients 
would be required to complete two shorter questionnaires rather than one long 
questionnaire which should improve acceptability to patients (Chipperfield and Steel, 
2011). It was decided that the questionnaire which measures more static indicators of 
adherence would be called the Patient And Lifestyle Scale (PALS – Appendix E). The 
questionnaire which measures more transient indicators of adherence was called the 
Wellbeing And Medications Scale (WAMS - Appendix F). 
 
 
3.3.2 Indicator selection 
Indicators which met the inclusion criteria are detailed alongside indicator of the relevant 
items on the PALS and WAMS scales and the location of the discussion regarding the 
development of these items within this chapter in table 3.1.  
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Indicator Chapter 
section 
PALS 
item(s)* 
WAMS 
item(s) 
Sex# 3.3.3.1 1 NA 
Employment 3.3.3.1 2 NA 
Marital status 3.3.3.6 3 NA 
Age 3.3.3.1 4 NA 
Health literacy 3.3.3.2 5 NA 
Beliefs about medicine 3.3.3.3 6-13 NA 
Mental health 3.3.3.4 14 NA 
Alcohol consumption 3.3.3.4 15 NA 
Smoking habits 3.3.3.4 16 NA 
Stress 3.3.3.5 NA 1-4 
Depression 3.3.3.5 14 5-6 
Anxiety 3.3.3.5 NA 7-9 
Side effects of medication 3.3.3.6 NA 10-11 
Positive beliefs about medicines 3.3.3.6 NA 12-14 
Self-efficacy 3.3.3.6 NA 15-17 
Social support 3.3.3.6 NA 17-20 
Access to medications 3.3.3.6 NA 21 
Relationship to provider 3.3.3.7 NA 22-30 
* PALS questionnaire also includes items 6-13 which comprise the BMQ General Beliefs sub-scale. This scale 
was not selected because of a large evidence base in the meta-analysis but because the established 
strength of the BMQ scale. See section 3.4.5 below. 
#Item not statistically associated with adherence, but included as a filler question to aid flow of 
questionnaire. 
Table 3.1 Indicators included in the final questionnaires 
 
3.3.3 Question item identification and generation 
 
3.3.3.1 Demographics 
Few demographic indicators were associated with adherence to medications. The 
exceptions were age and current employment. Current employment can be assessed with 
a simple yes versus no question. However, a complication would be patients that do not 
easily fit this dichotomy such as those that are retired or students. Face validity testing 
highlighted that the option of being a student was not on initial drafts of the scale and so 
was added to the questionnaire. To satisfy the need for these response options with a 
lack of evidence surrounding them, patients who identify as being either retired or a 
student will not have their employment status contribute to a prediction of adherence. 
Age has been demonstrated to be associated to adherence; however it could not be 
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determined accurately how large this relationship is. Consequently age will not be used to 
predict adherence until a more precise estimate of this variable on the weighting of 
adherence prediction can be achieved. Age, as well as sex, will be assessed in the 
questionnaire but will act only as filler questions. This should aid the flow of the 
questionnaire as well as providing an expected and non-threatening introduction to the 
scale (Williams, 2003).  
Early drafts of the questionnaire complied with the majority of the literature which 
argues for placing demographic information near the end of the questionnaire. However, 
after face validity testing it became clear that some participants were confused to find 
this information near the end of the questionnaire rather than at the beginning. 
Consequently the decision was made to split the demographic information into two 
sections. The less sensitive information such as the patient’s age, sex, and occupational 
status was moved to the start of the questionnaire and the more sensitive questions 
regarding patient’s mental health, smoking and drinking habits remained at the end of 
the questionnaire. It was deemed that these questions were sufficiently different to the 
basic demographic information to make their separation seem natural to participants. 
The demographic section of PALS is illustrated in figure 3.1. 
 
 
Figure 3.1 An illustration of the demographics section of the PALS questionnaire 
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3.3.3.2 Health Literacy 
Health literacy is defined as “the degree to which individuals have the capacity to obtain, 
process, and understand basic health information and services needed to make 
appropriate health decisions” (Committee on Health Literacy, 2004). Health literacy is an 
important concept that has been associated with patient outcomes (Wallace, 2010). 
Pleasant and McKinney (2011) argue that most health literacy scales have not undergone 
rigorous psychometric testing and that new tools are urgently required. Nonetheless, 
existing health literacy tools were reviewed. 
NHS Wales (Puntoni and Aylward, 2010) published a report which identified three 
measures assessing health literacy: the Rapid Assessment of Adult Literacy in Medicine 
(REALM-S, Davis et al., 1993), the Test of Functional Health Literacy in Adults (TOFHLA, 
Parker et al., 1995), and the Newest Vital Sign (NVS, Weiss et al., 2005). However, the NVS 
was deemed inappropriate for current needs because it asks patients questions about a 
nutrition label, and it was thought that this would lack face validity. The NVS is also not 
yet validated in the UK (Puntoni and Aylward, 2010). The REALM-S requires an interview 
and so is not appropriate to current needs, while the TOFHLA is too long for current use 
with over 40 questions. A new tool to screen health literacy with only three items has 
recently been developed (McNaughton et al., 2011). However, at present the exact 
contents of this tool are not in the public domain, and it is not yet validated as a self-
report measure. Chew et al. found that single questions regarding health literacy can 
provide adequate screening (Chew et al., 2004, Morris et al., 2006). Consequently, their 
best performing question that was most relevant to the current population was adapted. 
“How often do you need to have someone help you when you read instructions, 
pamphlets or other written material from your doctor or pharmacy” (Morris et al., 2006) 
was adapted to “How often do you have someone help you to understand medical 
information?” with the additional clarification moved to the introduction of the health 
literacy section of the questionnaire. This section of the PALS is illustrated in figure 3.2. 
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Figure 3.2 An illustration of the health literacy section of the PALS questionnaire 
 
3.3.3.3 Patients beliefs about medicines in general 
The BMQ general subscale, which examines patients’ concerns about medicines as a 
category rather than considering a specific medicine a patient is taking, was incorporated. 
The meta-analyses did not identify enough studies to properly assess the utility of the 
subscale and so a subjective assessment of its importance to adherence prediction was 
made. The BMQ general has been associated with adherence and patient outcomes in a 
number of studies outside the current meta-analysis (Mårdby et al., 2007, Saks et al., 
2012, Bermingham et al., 2011, Bautista and Jain, 2011, Horne et al., 1999). The 
questionnaire can also give practitioners and researchers valuable information about the 
type of nonadherence a patient is displaying because high scores on the questionnaire are 
associated with unintentional but not intentional nonadherence (Schüz et al., 2011). For 
this reason, it was judged that the evidence defending the use of the scale was adequate 
for it to be incorporated into the tool. The presentation of the BMQ general questionnaire 
is illustrated in figure 3.3. 
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Figure 3.3 An illustration of the presentation of the BMQ general questionnaire on the 
PALS questionnaire 
 
 
3.3.3.4 Mental health and risky health behaviours 
Questions addressing participants’ mental health and engagement in risky health 
behaviours were considered sensitive and so were presented together at the end of the 
PALS questionnaire. The items developed are presented in figure 3.4. 
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3.3.3.4.1 Mental health 
The evidence for the effects of mental illnesses other than depression on adherence was 
scant in the meta-analysis. Nonetheless the direction of the relationship between the two 
variables was clear. However, when identifying mental illness as an indicator of 
nonadherence it was decided to ask about depression and other mental illness separately 
to reflect the different levels of confidence associated with each. This will allow the 
relative contributions of each question to be assessed and prevent the less well known 
association between mental illness and nonadherence confounding the results of the 
question regarding depression. The sensitivity of these questions is acknowledged and so 
to limit the capacity for this item to reduce response rates participants will be offered the 
right to indicate that they prefer to not say whether or not they have had a diagnosis of a 
mental illness. 
 
3.3.3.4.2 Risky health behaviours 
Meta-analysis indicated that patients that engage in healthy lifestyle behaviours were 
also more likely to be adhering to their medication and vice versa. This phenomenon is 
known as the healthy adherer effect (Silverman and Gold, 2011). The factors shown by 
meta-analysis to be associated with lower medication adherence were taking illegal 
drugs, drinking alcohol, and smoking tobacco.  
Questioning patients about illegal drug use poses unique challenges. Patients might be 
unwilling to discuss engaging in illegal activities. Confidentiality can also be hard to assure 
for such patients when any researcher or medical staff may be forced to reveal responses 
under a court order. There are some “dejeopardizing” techniques available to limit the 
impacts of these problems (Lee, 1993). However, these techniques all rely upon making it 
impossible to identify whether an individual’s response is genuine or else which individual 
provided the response. These techniques are appropriate where inferences are made at 
the level of the sample or population, but are useless for a questionnaire intended to 
inform clinical decision making for individual patients. 
There are many questionnaires in existence to elicit information about patients’ smoking 
and drinking habits, and many are produced on an ad-hoc basis (e.g. Magid et al., 2009, 
Reed et al., 2007). Others use a combination of ad-hoc measures and validated tools (e.g. 
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Peters et al., 2011). Peters et al. developed their own measure for smoking and marijuana 
use, but used the Daily Drinking Questionnaire (DDQ, Collins et al., 1985) to gauge 
participants’ drinking habits. However, the compositions of these questionnaires are 
similar. They attempt to assess the frequency of engagement in the activity, and the 
extent to which the behaviour is carried out when engaged in. Consequently the question 
about drinking was split into two separate questions. The first asked how often a patient 
drank alcohol; the second asked how much a patient drank when they drank alcohol. A 
similar approach was adopted for the smoking question. These items were based on the 
approach taken for a health survey for England conducted by the NHS (Craig and Hirani, 
2010). However, face validity piloting indicated that this split made the question 
regarding smoking more difficult. Further, the medical professionals consulted during 
piloting indicated that the questions could be simplified for participants while offering 
useful information to the practitioners via a single question format. Considering the views 
of the face validity sample and the consulted medical practitioners it was decided to 
instead ask respondents to indicate how many comparable units of alcohol they have in a 
week, and how many cigarettes they smoke per day. They will also be given the option to 
indicate that they do not drink alcohol or smoke. 
  
102 
 
 
 
Figure 3.4 An illustration of the item addressing mental illness diagnoses on the PALS 
questionnaire 
3.3.3.5 Mental wellbeing 
 
3.3.3.5.1 Stress 
There are a number of widely used measures of stress. The Holmes and Rahe Social 
Readjustment Rating Scale (1967) tallies the number of stressful life events experienced 
over the past 6 months. The greater the number of stressful life events, then the greater 
the likelihood the individual will become ill. This scale was rejected because with 43 
separate items it was considered too burdensome for patients to complete. A widely used 
scale in the studies in the meta-analyses and elsewhere is the Perceived Stress Scale (PSS, 
Cohen et al., 1983). The scale comes in three versions with 14, 10 and 4 items. Although 
the four item version loses some internal consistency with Cohen’s α dropping from 0.78 
to 0.60 from the 10 to four item version (Johnston et al., 1995), the PSS retains validity by 
having much the same correlation with health related variables as the two larger scales 
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(Leung et al., 2010). Given the space constraints present the four item version of the PSS 
was deemed to be the most appropriate measure of stress available. The PSS-4 is shown 
as presented on the WAMS questionnaire in figure 3.5. 
 
 
Figure 3.5 An illustration of the PSS-4 as presented on the WAMS questionnaire 
 
3.3.3.5.2 Anxiety and depression 
The Profile of Mood States (POMS) questionnaire which was used by some of the 
investigations found via the meta-analyses was rejected for being too long with 65 
separate items in the full scale and 30 items in the short scale (McNair et al., 1989). For 
similar reasons, the Symptom Check List – 90 was rejected for taking up to 15 minutes to 
complete. Furthermore, neither scale was freely available for public use. 
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The three scales most often used in clinical practice are Beck’s Depression Inventory (BDI, 
Beck et al., 1961), the Hospital Anxiety and Depression Scale (HADS, Zigmond and Snaith, 
1983) and the Patient Health Questionnaire (PHQ, Spitzer et al., 1999). The BDI is a 21 
item questionnaire, which has seen extensive usage and possesses a strong psychometric 
profile (Beck et al., 1988). However, Beck’s scale examines both the physical and 
psychological symptoms of depression. This means that when administered to patients 
with a chronic illness the results of the BDI are confounded by symptoms of illness being 
falsely ascribed to depression (Moore et al., 1998). There is a 4 item version of the BDI 
developed for use in primary care which seeks to avoid the potential confound with 
physical symptoms of other diseases (Steer et al., 1999), however, like all versions of the 
BDI it is not available for public use. 
 
The HADS scale is a 14 item instrument with a large body of research to support its 
validity (Bjelland et al., 2002). It was also developed with use in chronically ill patients in 
mind and so avoids the issue of confounding physical symptoms of illness with physical 
symptoms of depression (Herrmann, 1997). However, it is not available for public use. 
The PHQ is available for public use, and was developed for use in primary care and so 
avoids confounding physical and depressive symptoms (Kroenke et al., 2001). A further 
advantage of the PHQ over the HADS lies in its shorter format, taking only three minutes 
to complete versus HADS five minutes. Furthermore, a short 5 item version of the PHQ is 
available to further reduce patient burden (Kunik et al., 2007). This version is composed 
of a two item depression screen (Whooley et al., 1997), and three item anxiety screen. 
The demonstrated clinical usefulness, shortness of the scale, and freedom of usage made 
the PHQ the most appropriate validated tool to incorporate into the new questionnaire. 
However, the 5 item scale was modified slightly. To return the PHQ-5 to a format more 
akin to the PHQ-9 and to detect more current feelings of depression and anxiety the time 
frame patients are asked to consider when indicating how they feel has been returned to 
two weeks rather than a month. Furthermore to attempt to detect a greater range of 
anxiety levels besides that indicating pathology, the response set has been modified from 
a dichotomous ‘yes/no’ response to the  four point scale of the PHQ-9 which concerns 
how often particular emotional states have been expressed from ‘not at all’ to ‘nearly 
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every day’. The PHQ-5 as adapted is utilised as the second part of section 1 on the WAMS 
scale and is presented in figure 3.6. 
 
 
Figure 3.6 An illustration of the PHQ-5 as presented on the WAMS questionnaire 
 
3.3.3.6 Patient adjustment to medications 
A number of indicators identified via meta-analysis as being associated with adherence 
were related to patients’ ability to integrate their medicines into their lives. These 
variables were patients’ experiences of side effects and positive beliefs about medicines, 
self-efficacy for medicines, social support, and the ease with which patients could access 
their medications. The development of these items is discussed below and the section on 
WAMS comprised of these constructs is presented in figure 3.7. 
 
3.3.3.6.1 Patient beliefs about and experiences with medicines 
In line with the work of Horne et al. (1999) it was found that important indicators of 
medication adherence were patients beliefs in the importance of their medicines for 
health maintenance and a positive experience of their medication versus the negative 
impacts of their medicines such as the experience of side-effects. The Beliefs about 
Medicines Questionnaire (BMQ) is one scale which assesses patient’s beliefs about their 
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medicines specifically and their beliefs about medicines as a category generally (Horne 
and Weinman, 1999, Horne et al., 1999). However, the evidence found via meta-analysis 
was only able to identify positive beliefs and experiences with medicines as being an 
indicator of adherence behaviour. Evidence regarding more long term and abstract 
concerns patients have about their medicines was not as strong as that found by Horne et 
al. (1999). The evidence was much stronger for the importance of side-effects (Watson et 
al., 2012). Given that the BMQ specific concerns subscale has only one question about 
side-effects it did not seem appropriate to use this scale. The decision to not use the BMQ 
concerns scale precluded the possibility of using the necessity subscale as the author of 
the scale stipulates that the two must be used in combination. Unique questions were 
consequently developed to assess how necessary and important patients felt their 
medicines were for maintaining their quality of life both now and in the future. In line 
with the results of the meta-analyses the questions concerning patients concerns about 
their medicines focussed upon the somatic experience of side effects and the extent to 
which medications negatively impacted upon their quality of life. Conversely, the 
questions regarding the necessity of medicines also focussed upon the extent to which 
medicines had improved or protected patients’ daily living standards. 
 
3.3.3.6.2 Self-efficacy 
Self-efficacy refers to an individual’s beliefs about their ability to perform successfully and 
can be conceptualised as a person’s perceived  ability to cope with challenges in general 
or with regard to specific tasks (Bandura, 1994). As well as the more direct links between 
self-efficacy and adherence demonstrated by the current meta-analyses, there are also 
links between self-efficacy and health behaviours which may themselves be related to 
adherence such as smoking, eating well, or participating in health screening programs 
(Schwarzer and Fuchs, 1995). Furthermore, self-efficacy has links to both mental 
wellbeing and successful social relationships (Bandura, 1994). It is a fundamental variable 
in many of the socio-cognitive models that have been employed to explain adherence 
behaviour including the Transtheoretical Model (Prochaska et al., 1992), the Theory of 
Planned Behaviour as ‘perceived behavioural control’ (Ajzen, 2002), and the Health Belief 
Model as ‘barriers to taking action’ (Rosenstock, 1966). It is important patients believe 
they can successfully complete or maintain their treatment if they are to become 
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motivated to engage with their therapy. This belief in their ability to succeed must itself 
be maintained for the continued successful implementation of treatment. Consequently, 
self-efficacy could be a key underlying construct for the initiation and maintenance of 
adherence. 
There are a number of self-efficacy scales available, some specific to adherence 
behaviour. However, some of these scales suffer from being specific to one condition or 
overlong, such as the 35 item Self-Efficacy for Diabetes Scale (Grossman et al., 1987). The 
13 item  revised Medication Adherence Self-Efficacy Scale’ (MASES, Fernandez et al., 
2008) has only been validated in hypertensive patients, and so was not considered broad 
enough in scope for inclusion. The best candidate for inclusion was the Medication 
Understanding and use Self-Efficacy Scale (MUSE, Cameron et al., 2010). This is a revised 
version of the Communication and Attitudinal Self-Efficacy Scale (CASE, Wolf et al., 2005). 
The advantages held by the revised scale were a reduced item pool of 8 questions, and 
greater generalisability. The CASE instrument was cancer specific while MUSE was 
developed with primary care chronic illness patients. However, there are two primary 
difficulties with incorporating any existing self-efficacy measure into the current tool. The 
first is that self-efficacy is highly variable between particular tasks. The same person may 
feel they have no difficulty remembering to take their medicines or organising their 
medicines around their day, but feel as though they would find it very difficult to cope 
with the side effects of treatment. The consequence of this is that measures of self-
efficacy must cover a wide range of possible behaviours. However, when a scale is 
designed to assess a wide number of indicators of non-adherence, self-efficacy will be a 
covariate in a great number of these indicators. Consequently, this will produce a number 
of repeated or redundant items and introduce issues of dependency between items 
which will also impact upon discriminant validity. One option to circumvent this problem 
was to incorporate a general self-efficacy scale such as the “Generalized Self-efficacy 
Scale” (Schwarzer and Jerusalem, 1995). However, this would require additional items 
evaluating the self-efficacy of specific behaviours which are not covered in the scale 
(Schwarzer and Jerusalem, 1995). Therefore, it was decided to instead develop questions 
that directly measure self-efficacy where there were not significant overlaps with other 
indicators that are included in the questionnaire. In particular with patient’s ability to 
remember to take their medicine and to cope with the number of medicines they must 
take. 
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3.3.3.6.3 Social support 
There are three key aspects to social support, each of which may have distinct and 
separate relationships to distress alleviation (Barrera, 1986). The first is an individual’s 
social integration which refers to number and density of the interconnectedness between 
an individual’s relationships (Barrera, 1986). The second is perceived social support which 
refers to an individual’s interpretation of the availability and adequacy of their support 
network. The final construct is enacted support which refers to the actual behaviours of 
the support network when called upon. The three types of social support are all 
independently correlated with physical and mental health, but are not necessarily well 
correlated with each other. They may also have distinct causal relationships to health and 
behaviours including adherence (Bloom, 1990). Although it is recommended that the 
ideal social support questionnaire should measure all of these facets (Stansfeld and 
Marmot, 1992), most existing measures address only one of the three constructs. 
Furthermore, these scales tend to be appropriate only to a specific population, and 
generally comprise too many items to be feasible for use in the current tool (Cohen et al., 
2000). More general measures of social support also tend to be overly long for present 
purposes. For example, the Short Form Social Support Questionnaire (SSQ6, Sarason et 
al., 1987) comprises only six questions. However, each question requires the participant 
to recall all the people in their life that can provide a certain type of support, and then 
rate how satisfied they are with this help. Similarly, the Significant Others Scale (SOS, 
Power et al., 1988) requires participants to rate the frequency of two types of emotional 
and two types of practical support for their seven closest relationships. Both of these 
scales would require a significant cognitive burden and ten minutes or more to complete. 
This would not be appropriate within a multi scale questionnaire. Similarly the social 
support scale developed for the Medical Outcomes Survey had 19 items making it too 
long for the current questionnaires (Sherbourne and Stewart, 1991). The 23 item Social 
Support for Transactions scale (Suurmeijer et al., 1995) was also excluded for being too 
long, despite being shown to have validity across a number of European nations. 
It was decided that new items would need to be developed to assess social support. The 
aim was to create a scale covering the major facets of social support whilst remaining 
brief by drawing inspiration from existing scales. In particular the Short Scale of Social 
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Support (SSS, Funch et al., 1986). This scale has 17 items in total but it has shorter 
sections which individually measure family attitudes and behaviours. It was decided to 
remove the specific role of the family in giving support, and to adapt items such as “My 
family will listen to me if I want to discuss my weight problem/pain/illness” to be more 
general in terms of where the support comes from. This helps to make the new items 
more applicable to a wider range of patients and illnesses. 
Four items were developed. The item “I am concerned about how others will react if I tell 
them what medicines I take” assesses whether or not a patients significant others are 
supportive of the patients particular medicine requirements. The item “I have people I 
can talk to about my illness” assesses the availability of support, while “I can count on my 
family and friends to help me deal with my illness” assesses the perceived efficacy of that 
support. It is difficult to assess enacted support directly in a self-report measure, since 
any assertion of help can only be that which is noticed and available to the memory of the 
participant (Barrera, 1986). Consequently, the item “There are people who will help me 
with my medicines if needed” was developed to assess any practical support that patients 
perceive is available to them. This only demands the participant be able to recall that 
people have in the past been generally available to offer help when required. 
The simplest measure of social support identified was whether or not the patient was 
married or in a significant relationship. After face validity testing, it was suggested that 
the question be further split into those that live with their partner, those that live alone, 
and those that live with others to account for a wider variety of housing statuses. 
 
3.3.3.6.4 Access to medications 
One of the most significant barriers patients may face is being able to get their medicine 
supply, either because of cost or obstacles to accessing their supplier (Wamala et al., 
2007). Initial drafts of the questionnaire focussed upon the cost of medicine because this 
was suggested to be a stronger indicator of adherence based upon a greater number of 
studies in the meta-analyses. However, the importance of cost is liable to fluctuate 
heavily between both individuals and healthcare systems. Upon consultation with 
medical staff to discuss content validity of the questionnaire, it was felt that in some 
contexts it might be expected that no patients would have to pay for their medicines and 
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that any question about costs may prove either confusing or else not provide much 
information. Consequently it was decided to produce a question which focussed upon 
patient’s access to their medication, and how difficult it was for them to acquire a new 
supply of their medicine when needed. The question developed was “I find it hard or 
inconvenient to get my supply of medicine”. 
 
 
Figure 3.7 An illustration of the items addressing patient adjustment to medicines as 
presented on the WAMS questionnaire 
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3.3.3.7 Provider relationships 
The current model for chronic condition management is to facilitate patient self-care with 
guidance from the patient’s family doctor, who acts to also facilitate any movement 
between primary and secondary care (Black et al., 2004). Consequently, it was decided 
that the patient-GP relationship would prove most useful for the prediction of adherence. 
A review exists of questionnaires which are designed to be completed by patients to 
evaluate their experiences with their physicians (Evans et al., 2007). However, while this 
study identified six potential questionnaires each was deemed too long for inclusion in 
the current questionnaires, with the shortest scale having 18 items.  Also excluded for 
being too long were the 55 item Patient Satisfaction Questionnaire (Ware Jr et al., 1983, 
Hagedoorn et al., 2003), and the 18 item short form of the Patient Satisfaction 
Questionnaire developed by RAND Health (Marshall et al., 1994). Also rejected was the 
Medical Interview Satisfaction Scale which has 21 items and is focussed heavily on single 
interactions (Meakin and Weinman, 2002). The Patient Involvement in Discussions (PID, 
Makoul et al., 1995) has only four items but was deemed to focus too heavily on the level 
of concordance in patient-physician interactions rather than on the relationship between 
the two parties. Furthermore, despite being heavily cited, this has yet to be formally 
validated against another measure of patient-doctor communication. A number of other 
tools also focus heavily on patient satisfaction with single interactions, rather than 
assessing the patient’s relationship with their physician. Examples include the 
consultation satisfaction questionnaire (Poulton, 1996), and the 11 item Patient 
Satisfaction Scale recommended by the Royal College of General Practitioners during GP 
training (Royal College of General Practitioners). 
A more viable alternative was the Wake Forest Physician Trust Scale (Hall et al., 2002). 
This scale focusses on the level of trust in the physician-patient relationship which was 
shown to be the strongest indicator within the realm of the provider relationship in the 
meta-analyses of chapter 2. Initial drafts of the questionnaire included this scale after 
contact with the authors revealed a short four item version of the scale (Dugan et al., 
2005). However, testing for face validity and acceptability of the questionnaire indicated 
that some felt uncomfortable completing the questions on the scale. Consequently, an 
alternative scale was selected which had greater acceptability. This was the Patient-
Doctor Relationship Questionnaire (PDRQ-9, Van der Feltz-Cornelis et al., 2004). This 
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questionnaire is more comprehensive than the Wake Forest scale and has good internal 
consistency with a Cronbach’s alpha of 0.94. However, there were concerns over the 
ambiguity of some of the items and the response scale. Consequently some adaptations 
were made. The original scale has a five-point response of statements being ‘not at all 
appropriate’, ‘somewhat appropriate’, ‘appropriate’, ‘mostly appropriate’ or ‘totally 
appropriate’. It was felt that it was unclear whether something that was ‘mostly 
appropriate’ was more appropriate than something described only as ‘appropriate’. It 
was considered that couching the response in terms of level of agreement with the 
statements made the response more straightforward for participants. One of the 
questions on this scale was also modified. The original item ‘I feel content with my 
primary care provider’s treatment’ was considered to be ambiguous. Consequently it was 
modified to ‘I feel content with the treatment I receive from my doctor’. This also 
highlights a final change made to this scale. To aid clarity and to keep the focus on the 
patient’s GP’s, the use of the phrase ‘primary care provider’ was replaced with the word 
‘doctor’. The adapted PDRQ-9 is shown as presented on the WAMS in figure 3.8. 
 
3.3.4 Questionnaire design and layout 
Content validity testing indicated a preference on behalf of the medical staff using the 
PALS or WAMS for the questions to be worded such that high scores would always be 
associated with worse adherence for both individual items and subscales. I.e. all 
questions should be either positively or negatively worded. It was felt that this would 
make the scales very easy to interpret in a busy clinical environment. However, face 
validity testing with this question style in place indicated that only having negatively 
worded items made some of the questions hard to interpret. Furthermore, it is claimed 
that mixing both positively and negatively worded questions in a scale minimises the risk 
of participants responding the same way to each of the questions (Rattray and Jones, 
2007). Altering the wording and scoring of existing scales would also negate their current 
validity. Furthermore, it was felt that it was more important to have a questionnaire that 
was easy to complete for participants than it was to have one that was easy to score 
(Murray, 1999). A further concession to this preference was to use a tick-box approach 
over asking participants to circle numbers. It has been found that asking participants to 
circle numbers can affect their perception of the scale (Tourangeau et al., 2004) even if 
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this format makes data entry simpler (McColl et al., 2001). Questions were numbered 
because this has been shown to help guide participants more easily through the 
questionnaire (Murray, 1999). 
 
 
Figure 3.8 An illustration of the PDRQ-9 as presented on the WAMS questionnaire 
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After piloting for face validity no significant issues were found with the design of the 
questionnaire. However, some found the original tick boxes used to be imposing. To 
counteract this, the ink colour was changed from black to a lighter grey and this softened 
the appearance of the boxes adequately. The questionnaires also feature a cover page 
which details the basic instructions and length of the questionnaire. The cover page 
incorporates the University of East Anglia logo and leaves space to include any 
collaborating organisation’s logo (e.g. the NHS). The colour scheme was based around the 
blue of the UEA logo to maintain consistency and to develop a use of colour that would 
be presentable in greyscale. Evidence for serif fonts being more difficult for readers with 
dyslexia is not strong, however, in the absence of evidence to the contrary a sans serif 
typeface was utilised. A 12 point size typeface with a large x height was employed to 
ensure legibility (Edwards, 2010, Bix et al., 2003). It was also ensured that space remained 
to thank participants for their time (Stone, 1993, Sudman and Bradburn, 1982, Meadows, 
2003, Murray, 1999). The front cover of the PALS as utilised in the project described in 
chapter 4 is shown in figure 3.9 to illustrate how the questionnaire can be adapted to 
particular needs. This version of the front cover incorporates the NHS logo, a section for 
participant reference numbers to be recorded, and a description of a self-report of 
adherence added to the PALS used for validation purposes. 
 
3.3.5 Reading comprehension 
The Flesch-Kincaid reading score for all sections of both PALS and WAMS is presented in 
table 3.2. While some sections are above the target level of grade 8, face and content 
validity testing revealed no problems with comprehension of the questions or 
instructions. The high scores may also be an artefact of the topic at hand and the 
requirement to use polysyllabic words such as “medication”. 
 
3.3.6 Questionnaire scoring 
The full scoring guide for both the PALS and WAMS is provided as Appendix G. Many of 
the principles underlying the scoring strategy are based on the Quality of Life in Epilepsy 
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scoring manual (Vickrey et al., 1993), which also requires the combination of multiple 
sections of a questionnaire into a single summary score. 
 
 
Figure 3.9 Front cover of the PALS questionnaire as utilised in the project described in 
chapter 4. 
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Questionnaire Section Flesch-Kincaid Score 
PALS Introduction 7.0 
 1. Demographics 5.8 
 2. Health Literacy 12.0 
 3. BMQ General subscale 7.6 
 4. Mental health and health 
behaviours 
6.4 
 Full scale 9.4 
WAMS Introduction 7.3 
 1. Mental wellbeing 6.2 
 2. PAMS 12.8 
 3. PDRQ-9 7.7 
 Full Scale 10.3 
Table 3.2 Flesch-Kincaid reading grade for questionnaire sections 
 
How the questionnaires would be scored was guided by what the medical practitioners 
consulted stated they would like to derive from the questionnaires. The practitioners 
stated that they wanted a tool that made decision making easy. They wanted to know 
which patients were at risk of nonadherence. Having identified which patients were at 
risk they wanted to know why those patients were at risk. The simplest way to achieve 
this aim is to produce a summary score at the end of the questionnaire which would 
indicate which patients were likely to be at risk of nonadherence. Providing a summary 
score for each subscale in the questionnaire allows for a similarly simple estimate to be 
made for the relative position of each participant for each indicator of adherence. To 
further ease the clarity of the decision-making process, it was decided to convert all raw 
scores on the scale into a percentage. It was felt that using a percentage value would 
make it easier for those using the scales to conceptualise scores. Although this aids 
understanding, it should be noted that the use of the percentage mark is purely arbitrary. 
In addition to user-friendliness, a second factor determining how the scales would be 
scored was the limitations of the meta-analytic procedures that were employed in 
designing the tools. The meta-analyses described in chapter 2 helped determine which 
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indicators of adherence were important. However, they were not very successful in terms 
of providing accurate point estimates for the true relationship between individual 
indicators and adherence. Consequently, any attempt to weight individual items of 
subscale impact upon the results would be highly dubious. Instead, it will be assumed that 
all indicators have an equal impact upon adherence. Once data from a sufficiently large 
sample have been collected using the final questionnaire, regression analyses could be 
employed to weight the subscales according to their beta-weights. 
In order to give items equal weight, scores were based on the number of possible 
responses. A 5 point Likert scale was divided into scores of 0, 25, 50, 75, and 100 to 
represent the available points. A four point scale was allocated values of 0, 33, 67, and 
100, while dichotomous variables take values of 0 and 100. Two questions where the 
format did not quite fit this operation were the items concerning drinking and smoking 
where participants fill in an empty box and do not select from a range of alternatives. 
Here the scaling is revealed only to the individual responsible for data entry. To inform 
the cut points to be used the current advice from the NHS was employed. The NHS 
choices website (NHS, 2011) stated at the time of development that the upper limit of 
alcohol intake for a man should be 4 units no more than 5 times a week. This would give a 
maximum of 20 units per week. This was used as the upper limit and above this the 
maximum a score of 100% would be given. A total of 6 categories were used for this scale. 
Not drinking was scored as 0, 1-5 drinks was scored as 20%, 6-10 drinks was scored as 
40%, 11-15 drinks as 60%, 16-20 drinks as 80%, and 21+ drinks as 100%. A similar 
approach was used for smoking. The NHS does not offer guidelines on an upper limit of 
acceptable smoking, however, there is a dichotomy made between light and heavy 
smokers. Heavy smokers are defined as those that smoke more than 20 cigarettes a day 
(NHS Clinical Knowledge Summaries, 2011). Smoking was split at the same cut points as 
alcohol to make data processing simpler. I.e. Not smoking was scored as 0, 1-5 cigarettes 
was scored as 20%, 6-10 cigarettes was scored as 40%, 11-15 cigarettes as 60%, 16-20 
cigarettes as 80%, and 21+ cigarettes as 100%. 
To prevent subscales with more items having a higher weighting on outcome each 
subscale has the sum of the scores on the scale divided by the number of responses on 
that scale while omitting any items that are left blank or as ‘prefer not to say’. I.e. if all 
items on the PSS-4 are completed the sum of the scores for the four items would be 
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divided by four, and by three if a participant had omitted one item. This ensures that each 
scale is given equal weighting in the questionnaire by taking an average score across the 
answered questions.  
To calculate summary scores for the PALS, WAMS and total scores on both scales the 
scores for each subscales should be summed, and then divided by the number of 
subscales completed either on the WAMS, PALS, or both together. This will give a final 
score out of 100 to allow for the comparison of individuals on either the two tools 
separately or in combination by taking an average score across subscales.  
 
3.3.7 Conclusion 
This chapter has detailed the efforts taken to ensure the questionnaire developed has the 
greatest chance of identifying patients as being at risk of nonadherence to their 
medicines. It has shown how the results of the meta-analyses in chapter 2 were utilised to 
identify the constructs that were required in the final questionnaire. It has indicated how 
these constructs had been measured using short pre-validated scales where possible. 
Where this was not possible new scales were developed which aimed to balance accuracy 
of measurement with patient acceptability and the brevity required by healthcare 
practitioners. This process resulted in preparation of two separate questionnaires. One 
questionnaire which measures slow changing and static indicators of adherence (PALS), 
and one which measure more changeable indicators of adherence (WAMS). Chapter 4 
details the quantitative assessment of these new tools based upon a sample of patients 
with hypertension.  
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Chapter 4 – Piloting with preliminary psychometric evaluation of 
the PALS and WAMS questionnaires 
 
4.1 Introduction 
Chapter 3 charted the development of two new questionnaires to predict adherence to 
medication. The Patient And Lifestyle Scale (PALS) which measures stable risk factors for 
nonadherence, and the Wellbeing And Medications Scale (WAMS) which measures risk 
factors that may change over a short time. The questionnaires were pre-tested on lay 
members of the public and shown to medical professionals to ensure face and content 
validity in chapter 3. This chapter is a feasibility study to appraise the proposed methods 
for assessing the psychometric properties of the PALS and WAMS whilst performing a 
preliminary assessment of those psychometric properties. 
 
4.1.1 The importance of piloting questionnaires 
Piloting of new questionnaires ensures that flaws in research and questionnaire design 
are identified before a large number of people complete the questionnaire (de Vaus, 
1995). This is particularly important for questionnaires designed for clinical populations to 
prevent wasting practitioner and patient time.  
Pilot studies are defined as a small version of a final study which seeks to ensure all 
aspects of the study work in harmony with one another. In contrast a feasibility study is 
performed to assess whether or not a study design is fit for purpose, and to estimate 
parameters needed to design the main study. These include measures of central tendency 
and spread for measures or outcomes, attrition rates, response rates, and the number of 
eligible participants (Arain et al., 2010, NETSCC, 2013, Thabane et al., 2010). Because the 
PALS and WAMS are in an early stage of development with no quantitative information 
about their acceptability, utility, or accuracy it was determined that it would be most 
useful to characterise the current investigation as a feasibility study. 
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4.1.2 Statistical inference in feasibility studies 
The small sample sizes generally associated with feasibility studies result in p-values 
unlikely to be significant except where effect sizes are very large (Cohen, 1992). Estimates 
of effect size can be inaccurate in small samples due to sampling error and extreme 
effects are also more common (Field, 2009). However, preliminary estimates of the 
relative effect sizes of the items, subsections, PALS scores, WAMS scores, and outcomes 
can be made (Bender and Lange, 2001). de Vaus (1995) identifies further analyses that 
can be performed during a feasibility study on a small number of participants: 
1. Variation – If all respondents give the same answer the item will not add useful 
information. 
2. Meaning – Are there any indications that the respondents have misunderstood 
any questions, and can all responses be interpreted by the researcher? 
3. Scalability – Do all items on a scale contribute to scores on that scale? Items on 
the same scale should correlate with each other. If they do not then they can be 
said to not properly form part of the same scale. 
4. Non-response – If a number of participants skip an item this can be an indication 
that items are not acceptable for some reason. 
 
4.1.3 Objectives 
The objectives of the current study are informed by those presented by van Teijlingen and 
Hundly (2001) for feasibility studies. The objectives are to:  
• Estimate the participant identification and consent rate 
• Assess the acceptability of PALS and WAMS to participants 
• Assess the feasibility of clinical data acquisition 
• Estimate variability in outcomes to help determine the sample size for a definitive study 
• Provide an early indication of the psychometric properties of PALS and WAMS  
• Assess the proposed data analysis techniques 
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4.2 Methods 
 
4.2.1 Setting 
Collection of data from patient participant medical records took place at Elvington 
Medical Practice which has been certified as a research ready practice by the Royal 
College of General Practitioners. This is a rural dispensing GP practice near York in a 
moderately affluent area. The surgery has a list size of approximately 7000 individuals 
(NHS Information Centre, 2011). 
 
4.2.2 Sample selection 
Patients with a diagnosis of hypertension were selected because testing in multiple 
populations would increase the number of variables exogenous to the questionnaire that 
could impact upon outcomes. Hypertension was selected as the condition of choice 
because it is monitored by GP surgeries for the Quality and Outcomes Framework (QOF) 
which means GP surgeries should have comparatively complete and accurate patient 
records (National Institute for Clinical Excellence, 2012), and it is a very common 
condition so should offer a reasonable sample size for pilot testing (Chockalingam et al., 
2006). A final rationale for this choice was that the PALS and WAMS were validated 
against the Morisky adherence scale, and this scale was originally validated in a 
hypertensive population (Morisky et al., 1986a). 
 
4.2.2.1 Participant identification 
All patients on Elvington Medical Practice’s hypertension register who had not attended 
an annual hypertension review within the previous nine months were posted a request to 
attend for review plus the study documentation. 
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4.2.2.2 Inclusion criteria 
 Current prescription for medication for the treatment of hypertension. 
 No record of a hypertension review in the nine months before study 
commencement. 
 
4.2.2.3 Exclusion Criteria 
 Under 18 years of age. 
 Considered by the healthcare team to be unable to provide written informed 
consent. 
 Housebound or considered by the healthcare team to be too physically or 
mentally unwell to undertake the research. 
 Unable to read or speak English fluently. 
 
4.2.3 Sample size 
No formal sample size calculation was performed however, it was estimated that 
approximately 200 patients would be eligible for inclusion. Previous studies employing 
similar methodology obtained response rates between 24% to 60% (Moshkovska et al., 
2011, Lynch et al., 2011, Neame and Hammond, 2005, Desborough et al., 2008, Quine et 
al., 2012). This would give a final sample size of between 48 and 120 participants. 
 
4.2.4 Outcomes 
To meet the objectives described in the introduction, the following outcomes were 
estimated: 
 Appraisal of research methods: 
- Identification rate  
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- Participation rate 
- Attrition rate 
- Feedback from patients who elected to not participate in the study 
 Preliminary psychometric evaluation of PALS and WAMS 
- Score distributions on questionnaire sub-scales 
- Internal consistency estimates for questionnaire sub-scales  
- Summary score distributions for PALS + WAMS. 
- Summary score distributions for the combined PALS + WAMS 
- Correlations between sub-scales, PALS, WAMS, combined PALS + WAMS, 
blood pressure control, adherence measured using hypertension 
medication refill over the previous 12 months and the Morisky scale 
- Correlations between sub-scales, PALS, WAMS, combined PALS + WAMS, 
blood pressure control, adherence measured using hypertension 
medication refill over the three months subsequent to questionnaire 
postage and the Morisky scale 
 
4.2.5 Study Procedures 
4.2.5.1 Participant consent and confidentiality 
Written, informed consent was sought for completion of the PALS and WAMS, access by a 
researcher to patient medical records to identify their previous two blood pressure 
readings and examination of their history of prescription refills. Participants were 
informed that the medical practice may use the information in PALS to update their 
records regarding smoking and drinking behaviours. Participants were informed that 
practitioners would not see their responses to the WAMS questionnaire and so the 
WAMS was returned by post to the surgery in a different coloured envelope to the PALS 
to prevent inadvertent opening by surgery staff and to reassure patients. 
Participants who did not return a questionnaire were sent a postcard requesting their 
reasons for choosing to not participate (Appendix H). This card was fully anonymous with 
no way to identify individual responders. 
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4.2.5.2 Questionnaire completion 
Participants completed the questionnaires in their own homes, and returned them either 
to Elvington Medical Practice when they attended for their hypertension review or in a 
reply paid envelope. Questionnaires were returned to the medical practice rather than 
researcher for two reasons: 
1. The questionnaires are intended for use in primary care by practitioners and 
therefore returning the questionnaires to the practice offers a more accurate estimate of 
how acceptable the questionnaires are to patients in a clinical setting. There is conflicting 
evidence as to whether or not response rates differ when questionnaires are returned to 
GP practices or researchers (Desborough et al., 2008, Smith et al., 1985).  
2. The data regarding patients’ drinking and smoking habits are routinely collected 
and recorded by the surgery using a variety of strategies. The questionnaire data provided 
an efficient means for this data to be collected by the surgery and so contributed to their 
Quality Outcomes Framework reporting. This contribution acted as an incentive for the 
surgery to take part in the research and provided a realistic evaluation of the response 
rate to requests for potentially sensitive information by GP surgeries. 
 
4.2.5.2.1 PALS completion 
On 23rd August 2012 all eligible patients were posted an invitation to hypertension review 
at the surgery which notified the participant of the study (appendix I), and included a 
copy of the PALS questionnaire (appendix E), the study information sheet (appendix J), 
consent form (appendix K), an interview information sheet (appendix L), an interview 
consent form (appendix M) and a pre-paid envelope. Patients wishing to participate then 
presented completed forms when attending for hypertension review or posted them to 
the surgery. Returned questionnaires were then posted to the research team by the 
surgery. The available population was lower than expected so ethical approval was 
obtained for distribution of the questionnaires to a second cohort of patients that had 
become eligible for inclusion after the study commenced. These were posted on the 25th 
September 2012. The range of scores for all items, subscales and the full PALS scale 
ranges from 0 to 100.  
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4.2.5.2.2 WAMS completion and follow up 
Four weeks after the initial posting, the WAMS questionnaire (appendix F) was sent to all 
respondents completing the PALS for return in a pre-paid envelope. Responders were also 
sent an information sheet reminding them of what they needed to do to take part in the 
study (appendix N). To all non-responders of PALS, a follow up pack was posted. This 
included a follow up information sheet (appendix O), consent form, PALS and WAMS 
questionnaires, the interview information sheet and consent form, and a pre-paid 
envelope for return. Returned questionnaires were collected from the surgery by a 
member of the research team. The range of scores for all items, subscales and the full 
WAMS scale ranges from 0 to 100. 
 
4.2.5.3 Measurement of adherence 
In order to collect information on self-reported adherence the PALS questionnaire 
contained the Morisky adherence scale. As noted in chapter 1, there is at present no gold 
standard self-reported measure of adherence. In the absence of such a measure the 
Morisky adherence scale was utilised to determine the validity of the PALS and WAMS 
questionnaires. While the Morisky adherence scale has a number of limitations including 
questions regarding the sample and criteria upon which it was validated, and reports of 
low internal consistency, it is nonetheless the scale is the most widely used in adherence 
research. To mitigate against these weaknesses the PALS and WAMS are also validated 
against an objective measure of adherence. The Morisky scale has four questions 
appraising whether or not participants engage in nonadherent behaviours (Morisky et al., 
1986a). Thus the scale provides scores ranging from 0-4 with 0 indicating perfect 
adherence and 4 indicating multiple reasons for nonadherence. The four questions on the 
measure are: 
1. Do you ever forget to take your medicines? 
2. Are you careless at times about taking your medicines? 
3. When you feel better do you sometimes stop taking your medicines? 
4. Sometimes if you feel worse when taking your medicines, do you stop taking 
them? 
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To mitigate against the weaknesses of the Morisky scale the PALS and WAMS are also 
validated against an objective measure of adherence. Medical records were accessed to 
determine the rate of medication refills over one year pre and three months post 
questionnaire completion. Patients at Elvington medical practice are provided 
prescriptions at 28 day intervals. Therefore prospective follow up for all patients included 
three refill events for the purposes of calculating nonadherence. Where participants were 
prescribed multiple medications, a day was considered covered by medication only where 
their full medical regimen was available to them. Medication availability was counted 
from the prescription collected prior to commencement of the study, up until the end 
date giving a “Medication Refill Adherence” score or MRA. This method was preferred 
over the Proportion of Days Covered (PDC) or Medication Possession ratio (MPR) because 
the PDC does not take account of excess medication which can lead to an underestimate 
of medication adherence, while the MPR is poorly defined and can be calculated in a 
number of ways (Hess et al., 2006). The MRA score was estimated according to the 
following formula: 
     
                                                 
                                         
 
 
4.2.5.4 Blood pressure measurements 
Medical records were accessed to obtain participants’ previous two blood pressure 
readings. This ensured all participants had one blood pressure reading from the 
prospective follow up period and one from the year retrospectively monitored. 
 
4.2.6 Data Analysis 
The recruitment and dropout rates of participants were calculated alongside 95% 
confidence intervals to provide an estimate of plausible population response rates. 
Subscale, PALS, WAMS, and PALS + WAMS scores were described in terms of medians and 
quartiles or means and standard deviations as appropriate. The analyses presented differ 
for existing subscales and those developed for the PALS and WAMS. For newly developed 
items and subscales internal consistency was described via Cronbach’s alpha, and scales 
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were retested with each item removed from the scale to identify any items that 
negatively impact upon consistency of the scales. Furthermore, inter-item correlations 
were performed for questionnaire subscales. This information is presented in appendix P. 
Measures of correlation were undertaken to examine the relationship between 
questionnaire items, total and subscale scores, adherence behaviour, and patient 
outcomes. For previously validated scales incorporated into the PALS and WAMS only the 
correlations between total subscale scores, PALS, WAMS, PALS+WAMS and the three 
measures of adherence are presented. 
Due to the lack of a gold standard adherence measure (Paterson et al., 2002, Smith et al., 
2010, Vitolins et al., 2000, Wetzels et al., 2006) the new scales were compared to multiple 
measures of adherence to aid triangulation (Paterson et al., 2002). Correlations between 
subjective and objective measures of adherence were corrected such that a negative 
correlation always indicated that higher scores on PALS or WAMS were associated with 
lower adherence. This had the effect of reversing the scoring of the Morisky 
questionnaire, with scores now ranging from 0-4 with 4 indicating perfect adherence. This 
correction was performed by reversing the sign of correlations performed on raw scores 
and so the results presented in appendix Q are the inverse of those reported in the main 
thesis.  Blood pressure was dichotomised as controlled or uncontrolled at 140/90mmHg 
(NHS, 2011). Given that most comparisons involved ordinal data correlations are 
presented as Spearman’s Rho. Rho was also employed where ordinal or skewed data 
were correlated with a dichotomous variable because it was considered that this was 
more appropriate than the use of the point biserial coefficient, given that the non-
dichotomous variable was ordinal (Nunnally, 1978). Where two dichotomous outcomes 
were compared the Phi coefficient was employed (Rosenthal and Rosnow, 2008). As a 
further concession to the small sample size acceptable adherence was defined as 100% 
adherence via medication refills and not the more commonly used 80%. Results are 
discussed in terms of their theoretical plausibility and the strength of evidence gathered 
in this study and the existing literature and not in terms of their statistical significance 
(Bender and Lange, 2001).  
To further explore data and ensure interesting facets of the data were not hidden in 
summary statistics, the relationship between continuous subscale scores and adherence 
measures were examined using scatter plots, and ordinal or categorical subscale scores 
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and adherence measures were examined with boxplots. These are presented in appendix 
Q. 
Area Under the Curve analyses were performed to assess the predictive validity of the 
questionnaires. However, the small sample sizes obtained lacked the power to make any 
such analysis sufficiently accurate (Hanley and McNeil, 1982). As a consequence these 
analyses are not reported, but are presented in appendix R. 
Factor analysis was planned to estimate discriminant validity, however this would be 
inappropriate in a small sample. As a consequence, an alternative method of assessing 
construct validity was employed through analysing only bivariate relationships. Bivariate 
correlations between all subscales were produced. Correlations between individual 
subscales and estimates of adherence should be stronger than with other subscales in the 
PALS and WAMS. The correlations with adherence indicate that the variable makes a 
meaningful contribution to an estimate of adherence. The lack of correlation with other 
subscales in the PALS and WAMS indicates that there is not excessive collinearity 
between variables (Campbell and Fiske, 1959).  
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4.3 Results 
 
4.3.1 Response rates and procedure evaluation 
Initial screening identified 74 participants listed as having hypertension which was much 
lower than anticipated. This reduction occurred because an administrative delay in the 
approval of Research Governance shifted the start date of the study from before to after 
the Quality and Outcomes Framework data submission deadline for Elvington. The 
majority of outstanding reviews for patients with hypertension had therefore been 
completed prior to study initiation. Furthermore, while screening participants for 
exclusion criteria, 17 (22.97%) were identified as incorrectly labelled with hypertension in 
the surgery records. Figure 4.1 illustrates the sample size at each stage of recruitment and 
analysis. Of the 13 participants that completed the PALS, two opted to not complete the 
WAMS giving an attrition rate (95% CIs) of 15.38% (0.01%, 34.99%). 
Of 56 patients that did not respond to the research invitation, 15 (26.79%) returned a 
postcard which detailed their reasons for not taking part. These are highlighted in Figure 
4.2. Participants were given a free text box in which to include any additional reasons for 
non-participation which are presented in table 4.1. One of the non-responding patients 
also inadvertently returned a non-response form for a different study run by the 
University of York. 
Of those returning questionnaires, nine (69 ± 25.14%) returned the PALS by post rather 
than in person at the surgery while 11 (78.57 ± 21.49%) returned the WAMS by post. All 
13 participants who completed the PALS scale also completed the Morisky adherence 
scale. Morisky scores cannot be compared with WAMS for those participants that chose 
to complete that scale but not the PALS. Therefore comparisons between PALS and 
Morisky is for n = 13 participants, while for WAMS and the combined PALS and WAMS 
scale and Morisky it is n = 11. Retrospective refill data was available for eight participants, 
with one of the 11 participants that completed both scales not sufficiently completing the 
consent form, and two other participants refusing to allow their medical records be 
examined should the research be audited by the ethics committee. Consequently their 
data was not accessed. Blood pressure measurements were only available for seven 
participants. When accessing medical records it was discovered that one participant in 
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the sample was taking medication appropriate for hypertension but not because of 
hypertension. As a consequence they were excluded from this analysis. 
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Figure 4.1 Flow diagram of study recruitment and participation 
Identified as meeting 
inclusion criteria via 
automatic search n = 74 
Eligible for inclusion  
n = 57 
Incorrectly labelled as 
hypertensive in surgery 
records n = 17 
Second search for 
eligible participants 
n = 16 
Invited to participate 
n = 73 
Invite returned by post 
company n = 1 
Participated n = 16 
Did not participate  
n = 56 
Completed non-
response postcard  
n = 15 
Completed PALS 
 n = 13 
Completed PALS and 
WAMS n = 11 
Completed WAMS  
n = 14 
Medical records 
accessed n = 8 
Blood pressure 
measured n = 7 
Identified as not having 
hypertension n = 1 
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Figure 4.2 Reasons for non-response to the questionnaire submitted by participants  
 
4.3.2 Participant demographics 
The demographics of the sample can only be described for patients that completed the 
PALS questionnaire (n = 13). These participants had a mean (sd) age of 62.31 (9.68) years 
and are further described in table 4.2. The median (minimum, maximum) period of time 
between study commencement and previous blood pressure measurement was 351 (301, 
400) days. Of seven participants, five (71.43 ± 33.47%) had controlled blood pressure pre 
questionnaire completion. The median (minimum, maximum) period of time between 
study commencement and the post questionnaire blood pressure measurement was 18 
(12, 89) days. Of seven participants, five (71.43 ± 33.47%) had controlled blood pressure, 
with two participants becoming controlled since the previous measurement and two 
becoming uncontrolled. 
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Response 
category 
Response 
number 
Reason given 
Time or  2 “Lack of time” 
organisation 4 “I put it on one side and forgot about it”  
 6 “I'm sorry, the forms got mislaid” 
 
7 “On Jan 4th I begin a world cruise and will not be 
back in England until the end of April 2013. 
Because of my long absence I did not think that my 
input would help your very worthwhile study” 
 15 “The pack was misplaced” 
Total responses: 5  
Errors or 
confusion 
1 “Something wrong, I agree to take part with 
Elvington's ideas” 
 3 “Am not on medication for hypertension” 
 13 “I did not receive this literature” 
Total responses: 3  
Dissatisfaction or 
anger with 
research 
8 “Felt that GP has all our records and the survey 
was wasting NHS money! Sorry.” 
12 “I don’t want to continuously be pestered by 
questionnaires” 
 14 “I DID NOT WANT TO TAKE PART!” 
Total responses: 3  
Table 4.1 Participant volunteered reasons for non-participation 
 
Characteristic  Frequency 
(N = 13) 
Per cent Lower CI Upper CI 
Sex Male 8 61.5 35.1 88.0 
Employment Employed 7 53.9 26.8 81.0 
 Unemployed 1 7.7 0 22.2 
 Retired 4 30.8 5.7 55.9 
 Missing 1* 7.7 0 22.2 
Housing status Lives with partner 8 61.5 35.1 88.0 
 Lives alone 2 15.4 0 35.0 
 Lives with others 2 15.4 0 35.0 
 Missing 1 7.7 0 22.2 
Drinks alcohol Yes 13 100   
Smokes tobacco No 12 92.3 77.8 100 
 Missing 1 7.7 0 22.2 
*Participant wrote on the form that they were disabled. 
Table 4.2 Participant demographics 
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4.3.2 Medication adherence 
In this sample, Morisky had a Cronbach’s alpha of 0.60. The median (quartiles) score on 
the Morisky adherence measure was 0 (0, 1.5) with seven participants (53.8 ± 27.10%) 
reporting perfect adherence. Three participants reported one reason for adherence, two 
reported two reasons for nonadherence and only one participant reported three reasons 
for nonadherence. Reasons for nonadherence given via Morisky are presented in figure 
4.3. According to participant medication refills, five participants (62.5 ± 33.55%) were 
100% adherent in the year prior to study commencement, and three participants (37.5 ± 
33.55%) were 100% adherent in the three months after study commencement. 
Distributions of participants’ refill adherence over the study period are shown in figure 
4.4. Seven of eight participants who self-identified as adherent via the Morisky scale were 
100% adherent with both prospective and retrospective refills (87.5 ± 22.92%). 
Participants who were adherent in the year before the study start date remained 
adherent in the three months follow up on six of eight occasions (75 ± 30.01%). 
Evidence for a correlation between adherence and blood pressure was stronger for 
measurements of refill adherence retrospectively and prospectively in the year before 
study commencement (Rho = -0.656, p = 0.109, Rho = -0.523, p = 0.228 respectively) than 
for current blood pressure (Rho = 0.164, p = 0.725, Rho = 0.087, p = 0.852). This was also 
true for Morisky with Rho = 0.529, p = 0.222 for blood pressure in the past year and no 
correlation identified with current adherence (Rho = 0, p = 1). 
 
4.3.2 Description of full scales 
The distribution of the scores on the PALS, WAMS, and all subsections are presented in 
Appendix S. The PALS scale was approximately normally distributed with a mean (sd) 
score of 26.19 (11.64). The WAMS scale was positively skewed and had a median 
(quartiles) score of 21.35 (16.90, 43.62). Combining PALS and WAMS into a single 
summary score also produced a positively skewed distribution with a median (quartiles) 
score of 24.10 (20.30, 26.99). 
  
135 
 
 
Figure 4.3 Reasons for nonadherence to the medications identified by the Morisky 
adherence tool 
 
  
Figure 4.4 Distribution of participant refill rates during the study period 
 
 
0 1 2 3 4 5 6 7
Do you ever forget to take your
medicines?
Are you careless at times about taking
your medicines?
When you feel better do you sometimes
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4.3.3 Predictive validity of the PALS, WAMS and combined scales 
The correlations between questionnaire summary scores and measures of adherence and 
blood pressure are presented in table 4.3. The questionnaires have a stronger 
relationship with self-reported and prospective refill adherence than they do with 
retrospective refill adherence. Similarly the scales are more strongly correlated with 
current blood pressure than previous blood pressure. 
 
Questionnaire Validity measure 
 Morisky (n = 
13 PALS, 11 
WAMS/ 
combined)
* 
Retrospective 
Refill (n = 8) 
Prospective 
Refill (n = 8) 
Retrospective 
Blood Pressure 
(n =7) 
Prospective 
Blood Pressure 
(n = 7) 
 Rho p Rho p Rho p Rho p Rho p 
PALS -0.241 0.427 0.146 0.729 -0.518 0.188 0.158 0.735 -0.474 0.282 
WAMS -0.520 0.101 0.146 0.729 -0.300 0.470 0.316 0.490 0.316 0.490 
Combined -0.391 0.234 0.122 0.774 -0.464 0.267 0.158 0.735 -0.158 0.735 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
Table 4.3 Correlations between questionnaire summary scores and outcomes for 
adherence and blood pressure 
 
4.3.4 Sub-scale and item analyses 
 
4.3.4.1 Demographics 
One participant did not tick any of the available boxes to indicate their employment 
status but instead wrote in that they were disabled. Only one participant indicated that 
they were unemployed making comparison between unemployed and employed 
participants impossible. Instead this participant was combined with four retired 
participants and one participant identified as disabled to create a separate comparison 
between those working (n =7) and those not working or unable to work (n =6). 
Participants that indicated that they lived with others but not a romantic partner were 
treated as missing data, because no evidence for a relationship between this living 
arrangement and adherence was identified in chapter 2. An additional participant also 
omitted this question reducing the sample size from 13 to 10 for this variable. One 
participant indicated that they both lived with a spouse and with others. This participant 
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was treated in the analyses as if they had indicated that they live with their romantic 
partner. 
 
4.3.4.1.1 Demographics and medication adherence 
The correlations between participant demographics and measures of medication 
adherence are presented in table 4.4. There was a moderate correlation between being 
male and self-reported nonadherence. There was no strong evidence for a correlation 
between employment and adherence. There was a large correlation between not living 
with a romantic partner and retrospective and prospective adherence. However, these 
correlations are heavily influenced by a lack of variability in that only two participants in 
the sample live alone and both have 100% refill adherence both retrospectively and 
prospectively.  There was also a large correlation indicating older participants were more 
likely to have greater prospective refill adherence. 
 
Demographic Measure of adherence 
 Morisky (n = 13)
 
Retrospective 
Refill (n = 8) 
Prospective refill 
(n = 8) 
 Rho p Rho p Rho p 
Sex 0.463 0.111 0.173 0.682 0.194 0.646 
Employment
 
0.249 0.413 0.224 0.595 0.125 0.768 
Housing status (n = 10) 0.398 0.254 0.656 0.109 0.587 0.126 
Age 0.275 0.364 0.220 0.601 0.546 0.162 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
Table 4.4 Correlations between three measures of adherence and participant 
demographics 
 
4.3.4.1.2 Demographics and blood pressure 
There was also no evidence for a correlation between previous blood pressure control 
and sex (Phi = 0.091, p = 0.809). All three female participants had controlled blood 
pressure during the prospective collection period which resulted in a moderate non-
statistically significant relationship between the two variables (Phi = 0.548, p = 0.147). 
There was no indication of a relationship between employment and past controlled blood 
pressure or current controlled blood pressure (for both Phi = -0.091, p = 0.809). There 
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was no evidence for a correlation between housing status and past or current blood 
pressure control (for both Phi = -0.250, p = 0.540). Increased age was statistically 
significantly associated with having uncontrolled blood pressure prior to questionnaire 
completion (Rho = -0.791, p = 0.034) but there was no evidence for a correlation with 
current blood pressure control (Rho = -0.400, p = 0.374). 
 
4.3.4.1.3 Demographics and PALS, WAMS and combined summary scores 
Table 4.5 presents the correlations between demographic variables and scale summary 
scores. There was a small non-statistically significant relationship indicating males scored 
more highly on the PALS and PALS + WAMS score. No relationship was identified between 
sex and scores on WAMS. Being employed was moderately correlated with a lower score 
on PALS. Living with a romantic partner was correlated with higher scores on PALS, 
WAMS, and to a lesser extent the combined PALS + WAMS total indicating a greater risk 
for nonadherence. There was a moderate correlation between age and the combined 
PALS + WAMS score. 
 
Demographic Scale Summary Score 
 PALS (n = 13) WAMS (n = 11) Combined (n = 
11) 
 Rho p Rho p Rho p 
Sex -0.254 0.403 0 1 -0.258 0.443 
Employment
 
0.330 0.270 -0.173 0.611 0.115 0.735 
Housing status (n = 10) 0.611 0.061 0.725 0.001 0.311 0.416 
Age 0.116 0.706 -0.137 0.689 -0.401 0.222 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
Table 4.5 Correlations between PALS, WAMS and combined scale scores and participant 
demographics 
 
4.3.4.2 Health literacy 
The sample displayed a range of ability with regard to health literacy (Appendix S). There 
was a moderate and statistically significant relationship indicating that lower health 
literacy was associated with lower self-reported adherence (Rho = -0.615, p = 0.025). 
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There were also statistically significant relationships indicating that lower literacy was 
associated with lower refill adherence both retrospectively (Rho = -0.872, p = 0.005) and 
prospectively (Rho = -0.860, p = 0.006). There was weak evidence to suggest blood 
pressure may be less likely to be controlled when health literacy is good (Rho = 0.683, p = 
0.091). However, this was not evident for current blood pressure (Rho = -0.400, p = 
0.374). The item did not correlate with scores on PALS (Rho = 0.242, p = 0.425), WAMS 
(Rho = 0.275, p = 0.413), or the combined scales (Rho = 0.034, p = 0.921). 
 
 
4.3.4.3 BMQ Overuse scale 
One participant omitted the item “Doctors prescribe too many medicines”. The scale did 
not correlate with self-reported adherence (Rho = -0.086, p = 0.780) or retrospective 
adherence (Rho = -0.075, p = 0.859). The correlation identified for prospective adherence 
was moderate but not statistically significant (Rho = -0.394, p = 0.334). There was no 
indication that the BMQ Overuse scale was correlated with blood pressure retrospectively 
(Rho = -0.242, p = 0.602) or prospectively (Rho = -0.081, p = 0.684).BMQ Overuse scores 
was also not statistically significantly related to PALS summary scores (Rho = 0.376, p = 
0.205), WAMS summary scores (Rho = -0.203, p = 0.580) or the combined PALS + WAMS 
summary scores (Rho = 0.295, p = 0.379).  
 
4.3.4.4 BMQ General Harm scale 
One participant indicated that they found two items on the scale difficult to answer by 
underlining the word “Most” in “Most medicines are addictive” and “All” in “All medicines 
are poisons”. The BMQ General Harm scale was not statistically significantly associated 
with adherence as measures by Morisky (Rho = 0.147, p = 0.632), retrospective 
medication refills (Rho = -0.264, p = 0.527), or prospective medication refills (Rho = -
0.394, p = 0.334). There was no evidence to suggest a correlation between BMQ General 
Harm scores and past blood pressure measurements (Rho = 0, p = 1), or current blood 
pressure (Rho = 0.164, p = 0.725). The BMQ General Harm scale was also not associated 
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with summary scores for PALS (Rho = 0.165, p = 0.590), WAMS (Rho = -0.210, p = 0.536), 
or the PALS + WAMS (Rho = 0.219, p = 0.517). 
 
4.3.4.5 Mental Health 
The sample contained two patients diagnosed with depression, and one participant wrote 
that they “possibly” have depression next to this option. It was assumed that this 
participant had not been diagnosed and so they were treated as not having a mental 
health diagnosis. No participants indicated having a diagnosis for any other mental illness. 
One participant did not respond to this question. Consequently analyses are based on the 
12 participants that responded to the depression question. 
There was no evidence found to indicate that the two patients with depression scored 
any differently on self-reported nonadherence (Rho = -0.070, p – 0.829), nor was there 
any indication that depression affected retrospective refill rates (Rho = 0.258, p = 0.537) 
or prospective refill rates (Rho = 0.289, p = 0.488). There was no identified association 
between a depression diagnosis and past or current blood pressure control (Rho = -0.300, 
p = 0.427, and Rho = 0.400, p = 0.290 respectively). There was no correlation between 
having depression and total scores for PALS (Rho = 0.389, p = 0.211), WAMS (Rho = 0.149, 
p = 0.662) or the combined total (Rho = 0.075, p =0.828). 
 
4.3.4.6 Health behaviours – Smoking and drinking. 
No participants indicated that they smoked, and so no analyses could be run on this 
variable. The amount of alcohol drunk per week was positively skewed, with most 
participants drinking a little or not at all, but with three participants (23.08%) drinking 
more than the NHS recommended maximum (appendix S). A moderate relationship 
between drinking and self-reported adherence was found (Rho = -0.433, p = 0.139), but 
the evidence was weak for a relationship between retrospective refill adherence (Rho = -
0.050, p = 0.906) or prospective refill adherence (Rho = -0.280, p = 0.503). While there 
was no identified correlation between drinking and past blood pressure control (Rho = 
0.406, p = 0.366) there was evidence to suggest that the more participants drank then the 
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greater the likelihood of not having controlled blood pressure in the present (Rho = -
0.813, p = 0.026). There was no indication that the amount participants drank per week 
correlated with scores on PALS (Rho =0.243, p = 0.424), WAMS (Rho = 0.270, p = 0.422) or 
the combined total (Rho = 0.163, p = 0.632). 
 
4.3.4.7 Perceived Stress Scale (PSS-4) 
Scores on the PSS-4 correlated fairly strongly with self-reported (Rho = -0.720, p = 0.012) 
and prospective adherence (Rho = -0.878, p = 0.004), but there was little evidence for a 
correlation with retrospective adherence (Rho = -0.245, p = 0.558). Evidence was not 
found to suggest that stress was associated with blood pressure control in the past year 
(Rho = 0.558, p = 0.193) or currently (Rho = -0.319, p = 0.485). The PSS-4 also correlated 
with total PALS (0.616, p = 0.044), WAMS (Rho = 0.760, p = 0.002), and combined scale 
scores (Rho = 0.639, p = 0.034). 
 
4.3.4.8 PHQ Depression items 
There was reasonable evidence to suggest the scale correlated with self-reported 
nonadherence (Rho = -0.671, p = 0.024). Evidence for a correlation with refill adherence 
was weaker, particularly for retrospective refill adherence (Rho = 0.208, p = 0.208). 
Prospective refill adherence displayed a moderate but not statistically significant 
correlation (Rho = -0.375, p = 0.360). There was no evidence to suggest a correlation 
between blood pressure control from participants previous (Rho = 0.394, p = 0.381) or 
current (Rho = -0.197, p = 0.672) blood pressure readings. The PHQ depression scale 
items were significantly correlated with scores on WAMS (Rho = 0.846, p = 0.001) and the 
combined PALS + WAMS (Rho = 0.748, p = 0.008), but there was no evidence the items 
were correlated with scores on PALS (Rho = 0.484, p = 0.131). 
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4.3.4.9 PHQ Anxiety items 
There was evidence for a correlation between anxiety and self-reported nonadherence 
(Rho = -0.695, p = 0.018), but not for a relationship with retrospective or prospective refill 
adherence (Rho = 0.127, p = 0.765 and Rho = -0.425, p = 0.294 respectively). There was no 
evidence to suggest that anxiety scores were related to previous or current blood 
pressure readings (Rho = 0.529, p = 0.222 and Rho = -0.176, p = 0.705 respectively). PHQ – 
Anxiety items showed evidence for a correlation between summary scores for WAMS 
(Rho = 0.877, p < 0.001) and the PALS + WAMS (Rho = 0.621, p = 0.041). However, there 
was no evidence of a relationship between PHQ Anxiety items and PALS scores (Rho = 
0.249, p = 0.461). 
 
4.3.4.10 Medication Concerns scale 
One participant did not respond to any item on the Patient Adjustment to Medication 
(PAMS) scale which comprises patient concerns about medicines, beliefs in medication 
necessity, self-efficacy for medicines, social support, and access to medications. 
Consequently the sample size is reduced by one in the following section until the end of 
4.3.4.14. This reduction does not affect the refill rate calculations as the participant 
omitting this section did not give consent for their medical records to be accessed. 
The two items that comprise the medications concerns scale had only modest inter-item 
reliability (Cronbach’s α = 0.621). The scale was normally distributed (Appendix S) with a 
mean (sd) of 50.00 (26.02). Correlations between the medications concerns scale and 
measures of adherence are presented in table 4.6. Scores on this scale were not found to 
be related to self-reported adherence or refill behaviour. However, there was some 
evidence that the highest scorers were also more likely to self-report non-adherence 
which may indicate a non-linear relationship between concerns and adherence (Appendix 
Q). There was no evidence found to correlate medication concerns with past blood 
pressure (Rho = 0, p = 1). Evidence for a correlation with current blood pressure was not 
strong (Rho = 0.497, p = 0.256).  Scale scores were related to total WAMS scores but were 
not related to PALS or combined scores. All correlations between the medication 
concerns scale and summary scores are presented in table 4.7. 
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Medication Concerns Item Measure of adherence 
 Morisky (n = 10) Retrospective 
Refill (n = 8) 
Prospective refill 
(n = 8) 
 Rho p Rho p Rho p 
I think my medicines are giving me side 
effects 
-0.389 0.266 0.088 0.836 -0.070 0.869 
If my medicines are making me feel worse 
than my illness, I think it makes sense to stop 
taking it for a while 
-0.075 0.838 0.570 0.140 0.170 0.688 
Medication Concerns -0.245 0.496 0.214 0.611 0.183 0.665 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
Table 4.6 Correlations between three measures of adherence and the medication 
concerns scale 
 
Medication Concerns Item Scale Summary Score 
 PALS (n = 10) WAMS (n = 13) Combined (n = 
10) 
 Rho p Rho p Rho p 
I think my medicines are giving me side 
effects 
-0.277 0.439 0.529 0.063 -0.094 0.795 
If my medicines are making me feel worse 
than my illness, I think it makes sense to stop 
taking it for a while 
-0.119 0.744 0.614 0.018 0.163 0.654 
Medication Concerns -0.179 0.621 0.616 0.025 0 1 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
Table 4.7 Correlations between PALS, WAMS and combined scale scores and the 
medication concerns scale 
 
4.3.4.11 Medication Necessity scale 
In addition to the participant that omitted the entire PAMS scale, an additional 
participant omitted the item “I think my medicines help to keep me feeling as healthy as 
possible” reducing the sample size to 12 for this question. The three items in this scale 
displayed good internal reliability with a Cronbach’s α of 0.890. The scale was normally 
distributed (appendix S) with a mean (sd) of 25.00 (18.94). Correlations between items on 
the medication necessity scale and measures of adherence are presented in table 4.8. 
There was no evidence that medicine concerns were associated with refill adherence in 
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this sample. However, as with medication concerns there was an indication that those 
that see their medicines as least necessary were more likely to self-report being non-
adherent which may indicate a non-linear relationship between necessity and adherence 
(Appendix Q). No strong evidence was found to indicate that medication concerns are 
correlated with controlled blood pressure retrospectively (Rho = -0.479, p = 0.277) or 
prospectively (Rho = 0.558, p = 0.193). Correlations between scale summary scores and 
items on the medication necessity scale are presented in table 4.9.  Scores on the 
necessity scale were significantly related to scores on WAMS but not with PALS or the 
combined scales. 
 
Medication Necessity Item Measure of adherence 
 Morisky (n = 10) Retrospective 
Refill (n = 8) 
Prospective refill 
(n = 8) 
 Rho p Rho p Rho p 
I think my medicines make me feel better 
than I would without them 
-0.208 0.563 0.510 0.196 0.102 0.809 
I think my illness would be worse without my 
medicines 
-0.440 0.193 0.224 0.595 0.125 0.768 
I think my medicines help to keep me feeling 
as healthy as possible 
-0.449 0.193 0.200 0.634 0 1 
Medication Necessity -0.319 0.369 0.383 0.349 0.097 0.820 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
Table 4.8 Correlations between three measures of adherence and the Medication 
Necessity scale 
 
Medication Necessity Item Scale Summary Score 
 PALS (n = 10) WAMS (n = 13) Combined (n = 
10) 
 Rho p Rho p Rho p 
I think my medicines make me feel better 
than I would without them 
0.065 0.858 0.575 0.040 0.521 0.123 
I think my illness would be worse without my 
medicines 
-0.121 0.740 0.609 0.027 0.107 0.768 
I think my medicines help to keep me feeling 
as healthy as possible 
-0.097 0.790 0.575 0.050* 0.065 0.859 
Medication Necessity -0.012 0.973 0.649 0.016 0.275 0.441 
* N = 12 for this item 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
Table 4.9 Correlations between PALS, WAMS and combined scale scores and the 
Medication Necessity scale 
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4.3.4.12 Self-Efficacy scale 
The two items on the self-efficacy scale did not correlate well with each other (Rho = 
0.314, p = 0.296) and so have very poor inter-item reliability (Chronbach’s α = 0.299). The 
scale was positively skewed, but with a relatively wide distributions of scores (appendix 
S). Correlations between items on the self-efficacy scale and adherence measures are 
presented in table 4.10. There was reasonable evidence to suggest that the items on the 
scale were related to self-reported adherence and prospective refill adherence. The 
evidence was weak with regard to any relationship to retrospective refill adherence. Self-
efficacy did not appear to be correlated with blood pressure control in the past year (Rho 
= 0.080, p = 0.865) or currently (Rho = 0.160, p = 0.733). The correlations between self-
efficacy items and scale summary scores are presented in table 4.11. There was evidence 
to suggest that scores on the scale were related to overall WAMS scores, but this was 
stronger for the item regarding remembering to take medicine than for the item 
regarding coping with medication. There was little evidence to suggest the scale was 
associated with scores on PALS or combined total scores. 
 
Self-Efficacy Item Measure of adherence 
 Morisky (n = 10) Retrospective 
Refill (n = 8) 
Prospective refill 
(n = 8) 
 Rho p Rho p Rho p 
I find it hard to remember to take all of my 
medicines each day 
-0.796 0.006 -0.555 0.153 -0.751 0.032 
I think I can cope with the number of 
medicines I am prescribed at the moment 
-0.579 0.079 -0.256 0.540 -0.459 0.253 
Self-Efficacy -0.695 0.018 -0.259 0.535 -0.607 0.110 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
Table 4.10 Correlations between three measures of adherence and the Self-Efficacy 
scale 
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Self-Efficacy Item Scale Summary Score 
 PALS (n = 10) WAMS (n = 13) Combined (n = 
10) 
 Rho p Rho p Rho p 
I find it hard to remember to take all of my 
medicines each day 
0.363 0.302 0.618 0.024 0.363 0.302 
I think I can cope with the number of 
medicines I am prescribed at the moment 
0.317 0.372 0.388 0.190 0.414 0.235 
Self-Efficacy 0.454 0.188 0.565 0.044 0.541 0.107 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
Table 4.11 Correlations between PALS, WAMS and combined scale scores and the Self-
Efficacy scale 
 
4.3.4.13 Social Support 
One participant wrote on their questionnaire that they were unsure of what the phrase 
“help me” referred to in the item “There are people that will help me with my 
medications if needed”. The four items concerning social support had a Cronbach’s α of 
0.695. Removing the item “I am concerned about how others will react if I tell them what 
medicines I take” would improve the inter-item reliability to 0.849. As a consequence the 
analyses were run with and without this item included in the scale, but since it made no 
major difference to the results, the results incorporating the full four item full scale are 
presented here. The scale was approximately normally distributed (Appendix S) with a 
mean (sd) of 30.29 (20.06). The correlations between items on the social support scale 
and measures of adherence are shown in table 4.12. There was no strong evidence to 
suggest a relationship between scores on the scale and measures of adherence. 
Correlations between social support and blood pressure were identical to those found 
between self-efficacy and blood pressure with Rho = -0.080, p = 0.865 for previous blood 
pressure and Rho = 0.160, p = 0.733 for current blood pressure. Correlations between 
items on the social support scale and scale summary scores are presented in table 4.13. 
There was evidence to suggest a correlation between higher scores on the social support 
scale and higher scores elsewhere on WAMS. This was not found for PALS or combined 
scale scores. 
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Social Support Item Measure of adherence 
 Morisky (n = 10) Retrospective 
Refill (n = 8) 
Prospective refill 
(n = 8) 
 Rho p Rho p Rho p 
I am concerned about how others will react if 
I tell them what medicines I take 
-0.263 0.462 0.144 0.734 0.044 0.918 
There are people who will help me with my 
medicines if needed 
-0.548 0.101 -0.118 0.781 0.512 0.195 
I have people I can talk to about my illness -0.046 0.899 0.553 0.155 0.177 0.675 
I can count on my family and friends to help 
me deal with my illness 
-0.012 0.973 0.493 0.214 0.016 0.970 
Social Support -0.183 0.614 0.491 0.217 0.110 0.796 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
Table 4.12 Correlations between three measures of adherence and the Social Support 
scale 
 
Social Support Item Scale Summary Score 
 PALS (n = 10) WAMS (n = 13) Combined (n = 
10) 
 Rho p Rho p Rho p 
I am concerned about how others will react if 
I tell them what medicines I take 
-0.007 0.986 0.411 0.162 0.243 0.499 
There are people who will help me with my 
medicines if needed 
0.610 0.061 0.684 0.010 0.400 0.252 
I have people I can talk to about my illness 0.395 0.259 0.652 0.016 0.395 0.259 
I can count on my family and friends to help 
me deal with my illness 
0.390 0.266 0.599 0.031 0.629 0.051 
Social Support 0.422 0.224 0.752 0.003 0.563 0.090 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
Table 4.13 Correlations between PALS, WAMS and combined scale scores and the Social 
Support scale 
 
4.3.4.14 Access to Medications 
The item assessing patient’s ease of access to a new supply of medicines indicated that 
most participants have little or no difficulty with this (Appendix S). The item was 
statistically significantly correlated with self-reported adherence (n = 10, Rho = 0.739, p = 
0.015) but not with retrospective refill (Rho = -0.264, p = 0.528) or prospective refill 
adherence (Rho = -0.471, p = 0.238). No evidence was found to link blood pressure 
control to access to medications in the past year (Rho = 0.088, p = 0.851) or currently 
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(Rho = 0.529, p = 0.222). There was evidence to suggest the scale was associated with 
overall WAMS scores (n = 13, Rho = 0.785, p = 0.001) but not PALS (n = 10, Rho = 0, p = 1) 
or the combined totals (n = 10, Rho = 0.098, p = 0.788).  
 
4.3.4.15 Patient-Doctor Relationship Questionnaire (PDRQ-9) 
One participant wrote on their questionnaire that their responses on this scale depended 
upon which doctor they were thinking about. Scores on individual items and 
consequently the final scale were skewed with few participants criticising their doctor 
(Appendix S). Evidence was weak for a correlation between self-reported nonadherence 
and higher scores on the PDRQ-9 (Rho = -0.490, p =0.126), but no evidence was found for 
a relationship between the PDRQ-9 and retrospective or prospective refill adherence (Rho 
= -0.02, p = 0.977 and Rho = -0.206, p = 0.625 respectively). There may be an indication of 
a non-linear relationship where the relationship between self-reported nonadherence 
and doctor relationships become more important when relationships are especially poor 
(Appendix Q). There was no relationship identified between the relationship participants 
had with their doctor and past or current blood pressure control (Rho = 0.316, p = 0.490 
and Rho = 0.474, p = 0.282 respectively). There was little evidence to suggest scores on 
the PDRQ-9 items were correlated with total scores on the PALS (Rho = -0.142, p = 0.678), 
WAMS (Rho = 0.498, p = 0.070), or combined scales (Rho = -0.009, p = 0.979). 
 
4.3.5 Discriminant validity 
As described in section 4.2.6 discriminant validity was assessed by comparing the 
bivariate relationships between subscales with estimates of adherence and each other. 
Correlations between individual subscales should be stronger with estimates of 
adherence than with any other subscale if it is to be concluded that the subscale is 
contributing unique variance over and above that provided by other subscales. A full table 
highlighting the correlations between all subscales can be found in Appendix T. Whether 
or not a person lived with a long term partner correlated more strongly with retrospective 
refill data than any other measure other than social support, for which it is a proxy. This 
suggests this variable contributes unique variance to an estimate of risk of nonadherence. 
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Health literacy correlated more strongly with all three measures of adherence than it did 
with any other subscale suggesting adequate discriminant validity. The BMQ Overuse 
scale correlated more strongly with prospective refill rates than any other measure on the 
scale other than the BMQ General Harm scale which suggests significant overlap between 
the contributions to an estimate of nonadherence provided by the two BMQ scales. The 
PSS-4 correlated more strongly with prospective refill rates than any other measure, but 
correlated more strongly with the PHQ Depression and Anxiety subscales than the 
Morisky or retrospective refill measures of adherence. Similarly, the PHQ-Depression 
subscale correlated most strongly with the Morisky measure of adherence. However the 
PHQ-Depression scale correlated more strongly with PHQ Anxiety scale and the PSS-4 
than with retrospective or prospective adherence. This suggests significant overlap in the 
variance explained by the three mental wellbeing scales. Access to medications correlated 
more strongly with self-reported adherence than with any other variables. No other 
scales demonstrated sufficient discriminant validity according to the criteria of Campbell 
and Fiske (1959).  
When the scales considered are restricted to those with a Rho > 0.5 with at least one 
measure of adherence as an arbitrary indication of having sufficient convergent validity, 
then all scales other than depression have a greater correlation with at least one measure 
of adherence than they do with any other scale. Table 4.14 illustrates these correlations. 
 
PALS/WAMS Subscale Measure of adherence - Rho 
 Housing 
Status 
Health 
literacy 
PSS-4 PHQ-D PHQ-A Self-
Efficacy 
Morisky Retro-
spective 
Refill 
Pro-
spective 
Refill 
Housing 
Status 
1 -0.467 0.106 0.283 0.184 0.321 0.398 0.656 0.394 
Health 
literacy 
- 1 0.493 0.112 0.066 0.491 -0.615 -0.872 -0.860 
PSS-4 - - 1 0.813 0.760 0.534 -0.720 -0.245 0.878 
PHQ-D - - 
 
1 0.865 0.343 -0.671 0.208 -0.375 
PHQ-A - - - - 1 0.307 -0.684 0.127 -0.425 
Self-
Efficacy 
- - - - - 1 -0.627 -0.259 -0.607 
* Items in bold identify the strongest correlation for a subscale; items in italics indicate a correlation with 
adherence stronger than with any other subscale. 
Table 4.14 Discriminant validity of the subscales comprising the PALS and WAMS tools 
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4.4 Discussion 
 
4.4.1 Main findings 
 
4.4.1.1 Development of the research method 
Targeting patients with hypertension appears to have been appropriate as triangulation 
of adherence, and clinical outcome data has been achieved. The available population was, 
however, smaller than expected at the start of the study. This was largely due to the host 
surgery actively inviting patients for hypertension review immediately prior to study 
implementation. Furthermore, over a fifth of the patients listed as having hypertension in 
the surgery’s database did not have hypertension. This substantially impaired the ability 
of the designed study to meet a number of the studies aims. In particular the sample size 
was inappropriate for psychometric testing and so all conclusions must be discussed with 
the strength of evidence available in this study borne in mind. If a larger multisite study 
were to take place ethical approval could be sought for a clinically trained member of the 
research team to assess whether or not a participant is eligible and appropriate for 
inclusion across all sites to ensure consistency and to minimise the impact of record 
errors and variations in interpretation of the inclusion criteria across different surgeries. 
Items within the questionnaires may have affected response rates which would also 
partially account for participation in this study approximating the lower bound estimated 
prior to study initiation. It was expected that some participants might object to questions 
regarding their mental health, smoking, drinking and relationship with their provider. 
Asking sensitive questions can impact upon both item and total response rates (Dillman 
et al., 1993). Ideally the acceptability of these sections would be assessed via the use of 
alternate forms of the questionnaire. This would allow a direct comparison of how much 
each section impacted upon acceptability to be made. However, there were too many 
comparisons for this to be feasible. Instead it was decided to include the sensitive items 
and measure total acceptability of the questionnaire, with a qualitative assessment of the 
acceptability of these sections with patients and practitioners that had experience with 
the questionnaires (chapter 5). Responses from non-participants indicate that at least 
some participants were uncomfortable with the questions they were being asked, 
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sending the questionnaires back to the surgery, and with staff at the surgery seeing their 
responses. Removing or rewording these sections in collaboration with the relevant 
population may improve acceptability.  
The responses provided by non-responders to the survey also indicate that some 
participants may have been over-burdened with requests to participate in research. The 
questionnaire was split into two sections, PALS and WAMS, in order to reduce respondent 
burden (Chipperfield and Steel, 2011). However, this may be counterproductive when 
respondent burden comes from the number of questionnaires administered rather than 
the length of a single questionnaire. Although only two participants that completed the 
PALS did not go on to complete the WAMS this represented 15% of the current sample. 
Response rates from a single questionnaire versus a split PALS and WAMS could assess 
whether or not respondent fatigue affected scores or acceptability. An alternative 
approach to avoid over-burdening participants is to exclude participants that have taken 
part in research in the last year. However with a small available population it was 
considered unwise to further restrict the potential sample.  
Participant non-response postcards indicated additional procedural problems. 
Streamlining the process to make it easier for participants to take part, and modifying the 
instructions to enhance ease of understanding may be achieved through lay review of 
study documents and procedures. Some participants indicated that they did not take part 
in the study because they did not want to take part in the interviews. The instructions 
stated that participation in the main study did not obligate participation in interviews; 
however some participants may not be comfortable taking part in only one element. An 
alternative design might have been to inform participants that interviews are taking place 
at the end of the study and if they were interested in taking part they could tick a box on 
the consent form. Information could then be sent out separately only to those that were 
interested. Some participants also felt that the research was not interesting or that the 
questionnaire was too long. This reinforces the importance of keeping respondent burden 
to a minimum so as to minimise the costs of taking part (Chipperfield and Steel, 2011). It 
was also clear that a number of participants forgot about the questionnaire or else lost 
the forms. A more thorough follow up procedure may limit the impact of participant 
forgetfulness (Edwards et al., 2002). 
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A final factor that lowered the sample size was that some participants refused permission 
for their data to be audited by the ethics committee or for researchers to access their 
medical records. The ethics committee’s standard wording for this section of the consent 
form was used. Previous literature has indicated that patients and practitioners consider 
medical records to be highly private (Goodwin et al., 2002, Shaw et al., 2011). However a 
qualitative study exploring the specific problem of researcher access to medical records 
would be valuable. 
A final methodological consideration was the return of questionnaires by post versus in 
person. Most participants returned their questionnaire by post, but a significant 
proportion decided to return questionnaires by hand. This was true even for the WAMS 
which contained instructions only on how to return the questionnaire by post. This 
indicates that participants appreciate a number of alternative methods for questionnaire 
return that best suit their needs. Offering a number of different modes of administration 
might also improve response rates and acceptability. 
 
4.4.1.2 The central role of mental health and wellbeing 
In line with work based upon the findings of chapter 2 (Watson et al., 2011), a 
relationship between stress and mental wellbeing and adherence was demonstrated in 
this study. It is not clear whether stress impacts directly upon adherence, whether it 
influences other mediating variables, or what the direction of causality is between 
adherence and distress. Nonetheless mental distress is an indicator of nonadherence and 
should be dealt with when recognised to prevent worsening mental health (Lovibond and 
Lovibond, 1995) which may have a detrimental impact upon both adherence and clinical 
outcome (DiMatteo et al., 2000). 
 
4.4.1.3 The role of beliefs about medicines 
The importance of patient beliefs about medicines in adherence has been emphasised in 
the literature and has received some endorsement in this study. The medication necessity 
scale had a moderate association with self-reported adherence, and there was an 
indication that patients reporting multiple types of nonadherence were less likely to rate 
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their medicines as necessary. Evidence for a correlation between patients’ concerns 
about their medicines and adherence was weak in this study as it has been in others (Carr 
et al., 2006, Bardel et al., 2007, Mann et al., 2007, Mann et al., 2009). However, there was 
an indication that patients reporting multiple types of nonadherence had the highest 
concern about medicines scores. 
In contrast to previous studies (Horne et al., 1999, Mahler et al., 2012, Mårdby et al., 
2007, Saks et al., 2012), evidence for a correlation between the BMQ General subscales 
and adherence was weak in this study. However, correlations between the BMQ General 
subscale and adherence have tended to be low. Mahler et al. (2012) found all correlations 
between BMQ subscales and adherence to be below a Rho of 0.3. In the validation study 
for the BMQ correlations between the General Harm and Overuse scale were even lower 
(Rho = -0.19 and Rho = -0.06 respectively). It is unlikely that a sample of the size available 
for this study would identify a relationship between adherence and the BMQ general 
scales. 
 
4.4.1.4 Health literacy and adherence 
The item assessing health literacy correlated with all three measures of adherence. A 
recent systematic review failed to find consistent evidence for the importance of health 
literacy in adherence (Loke et al., 2012). However, the conclusion of this review was that 
there was a lack of robust studies rather than that there is no association between health 
literacy and adherence. Moreover, no meta-analyses could be performed to properly 
quantify the estimated relationships between health literacy and adherence in the studies 
they identified. Consequently whether or not health literacy is associated with medication 
adherence remains an open question which should be explored further. 
 
4.4.2 Prediction of nonadherence 
The PALS and WAMS are designed to predict which patients are likely to be at risk of 
being nonadherent to medicines. The PALS and WAMS have been shown to have 
moderate to large correlations with self-reported adherence and prospective adherence 
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over three months. Although not statistically significant due to the small sample size, 
these correlations indicate that the questionnaires may perform well at predicting 
adherence over the short term. Correlations with longer term retrospective adherence 
were lower. This reflects that the strongest indicators of adherence are those most 
proximal to the behaviour (McHorney, 2009), and these are more changeable and context 
specific. However, the questionnaires aim to go beyond achieving a strong correlation 
with adherence and identify specific causes of nonadherence and targets for intervention. 
Therefore items with a small correlation with adherence may still be useful for 
practitioners so long as they are correlated with more proximal causes of nonadherence 
and present a clinically useful target for intervention. The clinical utility of questionnaire 
sections is appraised in chapter 5. 
 
4.4.3 Correlation with patient outcomes 
The study identified that measures of adherence and blood pressure correlated more 
strongly with past rather than current blood pressure. The relationship between 
medication adherence and patient outcome is unclear, with some analyses finding a 
stronger relationship between the two variables than others (DiMatteo et al., 2002, 
Simpson et al., 2006). For less serious disease adherence to medication can be associated 
with worse health outcomes (DiMatteo et al., 2007). The current sample had the most 
severely ill patients screened out which might explain the lack of association between 
adherence and current outcome. An alternative explanation is that participation in the 
study introduced reactivity effects and adherence improved for participants before 
current blood pressure was taken. The number of patients displaying perfect adherence 
increased by two after the study began. Reduced variation in outcome in a small sample 
could explain the lack of relationship identified. 
It was hypothesised that the PALS and WAMS might have a stronger correlation with 
patient outcome than traditional adherence measures because it contains sub-scales that 
might also correlate with patient outcomes such as mental wellbeing and health literacy. 
However few correlations were identified. One possible cause for the lack of identified 
relationships is that only seven participants could have their blood pressure measured. 
This provides extremely low power for any analysis. Despite this lack of power, age, 
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drinking alcohol and health literacy were associated with uncontrolled blood pressure. 
The relationship between age and blood pressure is well established and age is the 
primary indicator for hypertension (Baksi et al., 2009). There is also a documented 
independent effect of drinking on blood pressure (Klatsky et al., 1977). Drinking is 
acknowledged as one of the most important causes of resistant hypertension alongside 
nonadherence to therapy (Mancia et al., 2007). It has also been demonstrated via meta-
analysis that reducing alcohol intake directly reduces blood pressure (Xin et al., 2001). In 
contrast health literacy has not been associated reliably with blood pressure control in 
the past (Pignone et al., 2005, DeWalt and Hink, 2009) nor was the evidence for a 
relationship strong in the current investigation. Given the strength of evidence available 
and the lack of an underpinning theoretical argument to support the direction of the 
effect it is impossible to rule out chance and sampling error as the cause of the negative 
correlation found between health literacy and controlled blood pressure. 
 
4.4.4 Interpretation of subscale performance 
 
4.4.4.1 Recommendations for PALS 
 
4.4.4.1.1 Patient demographics: “About you” 
Absence of a relationship between sex and adherence was expected as none was 
identified via meta-analysis. The meta-analysis did identify a small relationship between 
age and nonadherence however the current sample was far too small to show a 
significant effect. There is no reason to suggest changing or removing these items from 
the questionnaires at this stage. One participant had to write in that they were disabled 
and so did not fit into any of the pre-specified criteria for the item regarding employment. 
Adding this option alongside an “other, please specify” box could solve this problem. 
Housing status did not correlate strongly with adherence, but only two participants did 
not live with their romantic partner restricting the power to detect any association 
between the variables. The item should be tested in a larger sample. This item may also 
be too ambiguous as currently worded. One participant indicated that they live with 
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others and their romantic partner, and if an individual lives with their spouse and their 
children it would not be clear how they should respond. The item should be modified 
whilst still maintaining the focus on spousal support which has been shown to be the 
strongest form of social support available (Johnson, 1983). This could be done by asking 
only whether or not the patient lives with a long term romantic partner. 
 
4.4.4.1.2 Health literacy: “Written information” 
The health literacy item correlated well with all measures of adherence. However, the 
item did not correlate strongly with summary scores for the PALS and WAMS. However 
many items on PALS had poor correlations with adherence. The lack of correlation with 
WAMS scores may be due to the high covariance between high scoring items on the 
WAMS such as depression, anxiety, and stress. The discriminant validity analysis indicated 
that health literacy correlated moderately with the PSS-4 correlations but less strongly 
with the PHQ anxiety and depression scales. This might indicate that health literacy 
explains a significant amount of unique variation in adherence behaviour otherwise not 
assessed in the WAMS. Therefore this item should be retained in future versions of the 
scale. 
 
4.4.4.1.3 BMQ General subscale: “Your beliefs about medicines” 
Correlations between the items on the BMQ and adherence were low in this and other 
studies and are likely to have weak predictive power (Mahler et al., 2012, Horne et al., 
1999). However, the BMQ general scale offers insight to the general beliefs patients have 
about treatment. While such beliefs are difficult to change and therefore not generally a 
suitable target for interventions, distal beliefs can inform practitioners of the perspectives 
of their patients and facilitate consultations (Porteous et al., 2010). 
 
4.4.4.1.4 Mental health and risky behaviours: “Your mental health and behaviour” 
Only two participants in this sample were diagnosed with depression, and no other 
mental illness was present. This lack of variation makes proper assessment of the 
importance of this variable impossible to determine in this sample. Nonetheless, the 
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importance of mental wellbeing was reinforced in this study via the PSS-4 and PHQ tools. 
However, there will be significant overlap between a diagnosis for depression and scores 
on the PHQ and PSS which might suggest this item will add little unique information. 
Additional problems were identified by participants writing freehand on the 
questionnaire. One wrote that they were “possibly” depressed indicating that they were 
worried that their concerns would be overlooked because they lacked a formal diagnosis. 
Another emphasised the word “past” in the phrase “I have a current or past diagnosis for 
depression” which may indicates that they do not want to be judged according to 
historical events. Given these issues omitting the item on diagnosis of a mental health 
problem is recommended. 
No participants reported smoking in this sample. There is a strong link between smoking 
and hypertension (Virdis et al., 2010) and it is unlikely that a sample with no smokers is 
representative of the surgery’s hypertension population. A wider range of alcohol 
consumption behaviours was reported. However, it remains possible that a number of 
heavier drinkers elected to not participate rather than send this sensitive information to 
the doctor. There is evidence to suggest that both patients (Simmons et al., 2009, Ulbricht 
et al., 2011) and doctors (Noordman et al., 2010, Mules et al., 2012) are uncomfortable 
discussing lifestyle behaviours with each other. Consequently the accuracy of this 
information in patients’ medical records is poor (Thiru et al., 2003). However, both 
smoking and drinking were shown to be correlated with adherence in chapter 2, and this 
study has also demonstrated a relationship between alcohol consumption and blood 
pressure. Given these arguments the reasons why participants may have been unwilling 
to complete these items should be explored (chapter 5) and a decision on whether to 
include smoking and drinking information withheld until after this stage. 
 
 
4.4.4.2 Recommendations for WAMS 
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4.4.4.2.1 Patient affect: “Mental wellbeing and happiness” 
The items in the mental wellbeing section may correlate highly with each other. The 
amount of collinearity can be assessed in a study with a larger sample size. If collinearity 
is excessive options would be to include only the scale which adds most information, or 
else is most acceptable to participants. Another option is be to employ factor analysis 
with rotation to identify whether or not three independent factors emerge representing 
stress, anxiety, and depression. If one factor were to emerge, indicating the tests are 
measuring a single underlying variable, then the items which loaded most heavily upon 
this factor could be used to form a new short measure of mental distress. 
 
4.4.4.2.2 Patient concerns about medicines 
The medication concerns scale had modest inter-item reliability. This would suggest an 
expansion of this scale might be necessary (Nunnally, 1978).  Further modifications are 
recommended. The conditional from the item “If my medicines are making me feel worse 
than my illness, I think it makes sense to stop taking it for a while” should be removed. 
The current wording makes this question impossible to answer for participants that have 
not experienced their medicine making them feel worse than their illness. The item is also 
a fairly direct question about adherence. The PALS and WAMS aimed to avoid direct 
assessment of adherence to avoid social desirability biases. This item might be replaced 
by questions that collect information about experiences taking their medicines less 
directly. For example “I think my medicines make me feel worse than my illness”. 
 
4.4.4.2.3 Perceived necessity of medications 
The medication necessity scale had good internal consistency, and there was an 
indication that in a larger sample a statistically significant relationship with self-reported 
adherence may have been identified. Given the strength of evidence for the importance 
of medication necessity in prior literature (Byer and Myers, 2000, Gauchet et al., 2007, 
Menckeberg et al., 2008, Bardel et al., 2007, Schneider et al., 2004, Horne and Weinman, 
1999, Horne et al., 1999) and the otherwise desirable psychometric properties of the 
scale it should be retained in its present form for trial in a larger sample which can more 
accurately estimate the importance of the scale in predicting adherence. 
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4.4.4.2.4 Self-efficacy for medicines 
There was some evidence to suggest the items on the self-efficacy scale were related to 
adherence, however there was no strong indication that the items were related to each 
other. Item 15, “I find it hard to remember to take my medicines each day”, may be too 
direct an assessment of adherence and may not properly assess self-efficacy. A revision 
such as “I am confident I can take all of my medicines each day” might remove these 
problems. It might also be useful to expand the self-efficacy scale in order to improve the 
internal consistency of the scale. 
 
4.4.4.2.5 Social support 
The social support scale did not have a strong relationship with adherence with the 
exception of the item “There are people who will help me with my medicines if needed” 
which had a Rho > 0.5 with both self-reported and prospective refill adherence. This was 
also the only item on the questionnaire that directly assessed social support with regard 
to medicines and not the illness. Revising the items “I have people I can talk to about my 
illness” and “I can count on my friends and family to help me deal with my illness” to 
items that focus upon the relationship participants have with their medicines and not 
their illness is recommended. Despite this weakness the scale was internally consistent 
with the exception of the item “I am concerned about how others will react if I tell them 
what medicines I take”. This item might refer more to social stigma associated with the 
participant’s illness and not the support they receive. This item did not correlate well with 
adherence independently of the other items in the social support scale and so should be 
removed. 
 
4.4.4.2.6 Access to medications 
The item assessing the impact of access to a new supply of medications was associated 
with self-reported adherence, and total scores on the WAMS scale. The item may also 
serve as an important indicator to a medical professional that a participant has a specific 
problem that needs to be addressed. The item should be retained in any future scale.  
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4.4.4.2.7 Provider relationship: “About your doctor” 
One participant wrote on the questionnaire that their answers would vary depending 
upon the particular doctor they were seeing indicating that respondents may be unclear 
as to how to answer the questionnaire as currently worded. One solution could be to 
change the wording of the questionnaire to be more explicit that the scale seeks 
information about the practitioner that is most involved with their care for a particular 
course of medications. Responses on the scale also indicated that almost all participants 
considered themselves to have a good relationship with their doctor. This lack of variation 
will have contributed to the very high internal consistency of the scale. The high scores 
might reflect that the patients that did not think highly of their doctor did not respond, 
which might have in part accounted for the low response rate. Despite this, a number of 
items on the scale did correlate with self-reported adherence in particular. The scale 
should be removed from the study if it can be demonstrated that its inclusion has a 
significant impact upon response rates. 
 
4.4.5 Limitations of the adherence measures used 
All available measures of adherence have demonstrable flaws (Vitolins et al., 2000). While 
the weaknesses of the methods employed are acknowledged it is also considered that 
they were optimal given the constraints in place for this study. The Morisky scale has 
numerous flaws including a low internal consistency (Morisky et al., 1986a), which was 
also identified in this sample. Similarly there are known flaws with the use of refill rates, 
with the strongest criticism being that it is not a direct measure of medication taking 
behaviour. Pill counts or electronic monitoring of medication taking provide a more direct 
estimate of medication taking but the resources were not in place to utilise such an 
approach. Moreover, the use of refill rates significantly reduces the likelihood of reactivity 
effects artificially increasing adherence rates in the sample, particularly when follow up is 
over a short period (Vitolins et al., 2000). As a consequence, in the absence of a superior 
existing scale for the self-report of non-adherence it was determined that the best option 
was to utilise the Morisky scale and use refill rates as an objective measure of adherence. 
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4.4.6 Conclusion 
Several opportunities to improve the design of the PALS and WAMS questionnaires and 
their psychometric testing have been identified. The research methodology is further 
explored qualitatively in chapter 5. Despite the small sample size, some indications for the 
relative utility of different sections on the PALS and WAMS are identified. However, it is 
clear that refinements in design are necessary in order to optimise response rate. Further, 
tentative evidence has been found for the relationship between mental wellbeing, patient 
medication beliefs, and health literacy in adherence.  
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Chapter 5 – Qualitative appraisal of the PALS and WAMS 
 
5.1 Introduction 
 
5.1.1 Study Rationale 
Chapter 4 detailed the quantitative assessment of the PALS and WAMS questionnaires by 
estimating the ability of the new questionnaires to predict prospective and retrospective 
adherence. In the absence of a widely accepted gold standard measure to validate 
against, achieving a non-zero correlation with another imperfect measure of adherence is 
insufficient evidence of validity. Qualitative techniques provide insight into the meaning 
behind question responses and so may illuminate how the indicators of adherence are 
related to each other and adherence. Further, exploring participant understanding of 
items can highlight where questions need to be reworded to correct for ambiguity 
(Morgan, 1997, Morgan, 1996, Huston and Hobson, 2008, Krueger and Casey, 2000). 
Moreover, it has not yet been appraised how useful medical professionals will find PALS 
and WAMS or whether or not they would be able to use the responses to inform decision 
making with patients. To provide insight into these questions a qualitative study is 
necessary. 
 
5.1.2 Aims and Objective 
The aims of this qualitative section of the project were to: 
1. Assess the validity of participant responses to the PALS and WAMS 
2. Improve the design and content of the PALS and WAMS 
3. Improve the design of the quantitative study of the PALS and WAMS for future 
testing of the questionnaires 
The objectives are to: 
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 Examine the agreement and contradiction between participants attitudes and 
behaviours as expressed via interview versus those expressed via postal 
questionnaire 
 Explore participant feelings about taking part in the research 
 Identify strategies to increase questionnaire response rates 
 Explore participant understanding of items and instructions in the questionnaires 
 Explore participant understanding of instructions for taking part in the research 
 Explore whether practitioners consider subsections of the questionnaires useful 
and relevant for intervening to improve medication adherence  
 Identify better ways of conducting research with GP practices so as to minimise 
cost and time disruptions 
 
5.1.3 Method selection  
Focus groups can be employed after the development of an initial corpus of questions to 
help develop questions that are worded in a way that is meaningful to the target group 
(Alquati Bisol et al., 2008). The advantage of a focus group over traditional face validity 
piloting is the ability for a compromise to be reached regarding wording that is 
appropriate to representatives of the target population during the group, rather than the 
researcher having to amalgamate disparate views after a number of individual sessions. 
Participants in a focus group tend to talk in a manner appropriate to the norms of the 
group rather than in a way that expresses private views (Morgan, 1997, Wight, 1994). This 
makes focus groups useful for understanding how a peer group understands a topic by 
analysing naturalistic talk between peers (Wilkinson, 2008, Michell, 1999, Wilkinson, 
2004). Further, disagreements in a group can lead to further elaboration of accounts, 
particularly when group members are known to each other (Wilkinson, 2004). However, 
minority positions or the views of those with less power in a group may be crowded out 
or suppressed (Michell, 1999). Moreover, the group interaction can lead to the changing 
of held views and so using focus groups to establish current views is not recommended 
(Barbour, 2008). When individual accounts of behaviour are desired, one-to-one 
interviews are the preferred choice because focus groups can quickly become disjointed 
and informative narratives lost (Barbour, 2008). 
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Focus groups can also be useful for bringing together a group which has multiple 
objectives. For example, O’Donnell et al. (2007) utilised focus groups of GPs in the UK and 
the US after they had used a new method of comparing diagnoses between UK and US 
doctors in order to appraise the tool and the proposed research methodology. The 
method allowed for assessment of comprehensibility of the individual questions and 
identification of ways to facilitate conducting research with physicians based upon their 
experiences in the study simultaneously. 
A common method of qualitative validation of questionnaires is cognitive interviewing 
(Ericsson and Simon, 1993, Hernandez et al., 2011). There are two versions of cognitive 
interview, “think aloud” and “verbal probing” (Willis, 1999, Willis, 2005). “Think aloud” 
involves asking participants to verbalise their thought processes as they go through each 
item in order to gain insight into what the question might mean to participants and 
identify any problems that may arise when participants are asked to respond to each 
item. “Verbal probing” involves direct questioning of participants to gather this 
information. The process is very time consuming so often very few interviews are 
conducted which can lead to inappropriate generalisations being made about the 
adequacy of an item based upon an opinion or thought process that may be very rare 
(Dillman et al., 2009). 
An alternative to cognitive interviewing is the use of semi-structured interviews. 
Mallinson (2002) used individual interviews to appraise the SF-36 Health Status 
Questionnaire instead of cognitive interviewing to avoid changing how participants would 
normally complete the questionnaire. Their analysis identified a number of problems with 
the questions in the SF-36. The problems identified in the scale included asking about 
multiple behaviours in a single question, asking questions about distance in absolute 
terms such as how many miles they can walk which mean little to respondents, and 
asking about a number of behaviours which may not be important or relevant to 
participants with no option to opt out. A key finding of this study was the importance of 
relativism. Participants respond to questions based upon the context of their lives. If a 
respondent indicates that they are “stressed” this may reflect how well the participant 
feels they are coping compared to others in their own situation rather than provide a 
population level ranking of stress. Such an assessment might reflect very different 
absolute levels of stress in populations with a different illness, age, or prognosis. Including 
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qualitative validation of questionnaire responses can therefore provide a rich 
understanding of what responses actually mean and thus appraise validity at a deeper 
level of meaning than correlation with external measures (Mason, 2002, Fern, 2001). 
This study would require the use of both focus groups and semi-structured interviews in 
order to meet the dual aims of identifying the needs of practitioners for the 
questionnaires, and corroborating questionnaire responses with individual testimony. 
 
5.1.4 Focus groups 
 
5.1.4.1 Sampling strategy and selection of group members 
Sample selection should ensure that information which is representative of the biases and 
perspectives inherent in the target population is gathered (Morgan, 1997). The goal is to 
identify “information rich sources” that can provide depth of information on a topic 
(Krueger and Casey, 2000). Segmenting all participants into individual groups that are 
similar ensures that the research project covers the relevant population while minimising 
the difficulty of conducting individual groups (Fern, 2001, Krueger and Casey, 2000, 
Morgan, 1997). The number of groups required to answer a research question therefore 
varies between studies, with one important factor being the diversity of the population 
under study (Morgan, 1997, Krueger and Casey, 2000). 
The present study is interested in research active practitioners who have a need to assess 
adherence in their patients. Ideally a number of practitioners practicing in different socio-
demographic areas and both the primary and secondary care setting would be consulted 
to ensure as wide as possible acceptability for the tool. However, at this early stage in the 
development of the questionnaire it is more appropriate to focus on the population most 
frequently reviewing patient adherence; it would be inappropriate to use the time of a 
large number of health practitioners. 
The PALS and WAMS questionnaires were designed with the assumption that in the UK, 
care for chronic illness is primarily the responsibility of the patient’s GP (Black et al., 
2004). However, it is not uncommon for nurses to take an active role in management of 
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chronic conditions (Bonsall and Cheater, 2008). Including GPs and nurses in the same 
focus group lowers group homogeneity and introduces differences in social ranking. This 
can make it more difficult for the researcher to identify differences between the views of 
the two groups as group processes tend to lead toward consensus (Finch and Lewis, 
2003). However, the PALS and WAMS may be used in multidisciplinary teams and so it 
was considered that having the nurses in the same group might encourage the GPs to 
consider viewpoints other than their own and enable a compromise between the needs 
of two groups to be reached (Barbour, 2008). 
Conducting research with pre-existing groups can make participants more willing to 
challenge views that are expressed during a focus group (Rabiee, 2004). However, shared 
assumptions may not be expressed which can lead to biases in the data that remain 
unknown to the researcher if they cannot be elicited (Finch and Lewis, 2003, Morgan, 
1997). Moreover, in a pre-existing group dominance hierarchies will be set before the 
group begins and so it is difficult for a moderator to influence these in a one off 
discussion (Finch and Lewis, 2003). 
 
5.1.4.2 Location and Environment of focus groups 
The location and internal ambiance of the room can impact upon data generated during a 
focus group (Fern, 2001). For pre-existing groups using a location at which the group 
normally meets reduces the likelihood of participants not attending and helps the group 
feel more comfortable and willing to share (Finch and Lewis, 2003). Provision of 
refreshments before the group discussion can help to put participants at ease, become 
acquainted, and provide the researcher with an opportunity to identify participants who 
might require encouragement to take part or else need to be limited from dominating the 
discussion (Krueger and Casey, 2000). Participants can then be positioned in the focus 
group seating so that more reticent participants are closer to the moderator to encourage 
their discussion and the more dominating members opposite the researcher so their 
contributions can be more readily managed (Morgan, 1997).  
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5.4.1.3 Management of the group and moderating style 
Having an experienced moderator with interviewing and people management skills is 
important for creating the atmosphere and type of talk required to generate the type of 
data that a particular study desires (Wilkinson, 2008). Moderating can be either flexible or 
directive (Fern, 2001, Morgan, 1997, Finch and Lewis, 2003). Flexible groups allow the 
participants to take more control of the conversation with the moderator making less 
frequent interjections. Directive groups are required when the topics to be discussed are 
relatively fixed. Flexible groups allow the topics of greater interest and importance to the 
group to be identified and prioritised within the discussion, but can lead to some relevant 
topics either being passed over or omitted from the discussion. A directed approach 
allows the moderator to ensure all relevant topics are covered (Morgan, 1997). 
 
5.1.5 Individual interviews 
 
5.1.5.1 Sampling strategy  
In common with focus group research, the aim in interview research is to create a 
purposive sample which is capable of fully illustrating the phenomena of interest (Ritchie 
et al., 2003a). Theoretical sampling is one robust method for achieving this within a 
grounded theory approach (Mason, 2002). Theoretical sampling is an iterative process 
where cases that might disconfirm the proposed process or explanations for phenomena 
are sought. Sampling continues until a reasonable explanation of the phenomena of 
interest can be generated and substantial data for amending the proposed theory is not 
obtained from further interviews (Mason, 2002, Charmaz, 2008). 
Heterogeneous sampling seeks to achieve the same aims as theoretical sampling but is 
less intensive (Ritchie et al., 2003a). Heterogeneous sampling seeks a diverse range of 
participants to maximise the likelihood of having disconfirming cases when sampling is 
not iterative, and is useful for identifying themes that cut across a diverse population. 
Homogenous sampling samples a number of similar cases and is useful for exploring 
specific phenomena in depth. Extreme case sampling can be used to explore rare or 
unusual cases. Intensity sampling is similar to extreme case sampling but focuses on cases 
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especially representative of the phenomenon of interest rather than unusual ones. 
Typical case sampling focusses on average cases. Stratified sampling merges different 
approaches by seeking different groups of relatively homogenous membership in order to 
contrast the different groups more fully. 
 
5.1.5.2 Location and Environment of the interviews 
The location of interviews can produce different types of data. For example, participants 
interviewed in their place of work tend to respond as employees in accordance with 
company policy, feel less empowered, and worry more about giving “the right answers” 
compared with participants interviewed in their homes. Anderson and Jones (2009) found 
that when children were interviewed in their classrooms they see adults as authority 
figures and were more relaxed and open when interviews were conducted in the school 
storage cupboard. The location of the interview should be one participants are 
comfortable with and one in which the feel empowered. Giving participants the option to 
choose where interviews are conducted is one way to achieve this (Anderson and Jones, 
2009, Elwood and Martin, 2000). 
 
5.1.5.3 Interviewing conduct 
The context and conduct of the interview is a key determinant of what is said. Knowledge 
is therefore constructed during the interview not extracted from it (Holstein and 
Gubrium, 2004). Talking about specific experiences can help ensure that data more 
accurately reflect how participants think, feel and act in the context of interest (Mason, 
2002). Probing responses to explore the reasons provided can also reveal contradictions 
in reasoning or the cause of any context-dependent differences in behaviour and attitude. 
Conducting an interview that fulfils these criteria requires an interviewer to listen, 
process what is being said, identify how or whether it fits with the research aims, ensure 
coverage of the intended material and that interesting data are followed up (Legard et al., 
2003). 
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5.1.6 Validity of analyses 
Investigating the same topic in different ways gives access to different levels of meaning 
(Mason, 2002). Triangulation of data from different methodologies (e.g. survey and 
interview) and perspectives (e.g. patients and practitioners) can provide a more thorough 
understanding of how questionnaires are perceived and can utilised most effectively. 
However, responses from focus groups, interviews, or surveys cannot be added together 
to produce an “overall truth” (Silverman, 2005). Deviations between responses in 
interview versus questionnaire might be expected in a different context where ideas are 
considered in a new light, or the meaning of questions reconsidered after further 
deliberation. Consequently corroboration between survey and interview responses allows 
an evaluation of how well the questions elicit the experiences and perceptions of 
participants in a meaningful way. 
A further requirement for validity in qualitative research is a transparent process of 
analysis demonstrating the development of analyses from initial thought to the final 
presented themes (Yardley, 2008). Comparison of analysis decisions between more than 
one researcher and participant feedback further enhance validity (Yardley, 2008). 
A final method to improve upon the validity of any analysis is constant comparative 
analysis (Mason, 2002, Yardley, 2008, Lewis and Ritchie, 2003). Researchers should seek 
to identify, present, and explain evidence that seems to disconfirm the current theory 
(Mason, 2002). 
 
5.1.7 Qualitative data analysis 
Qualitative data analysis can attempt to access different levels of meaning which can 
inform what type of analysis is employed (Mason, 2002). A useful starting point can be to 
revisit the study’s epistemological position (Braun and Clarke, 2006). Essentialist 
epistemologies assume a straightforward relationship between meaning and language. In 
contrast more constructionist epistemologies tend to see the meanings themselves as 
socially produced and reproduced. Therefore studies which employ the former views may 
focus more upon what is said while studies with the latter assumption may be more 
interested in analysing why what was said was said (Braun and Clarke, 2006). A second 
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decision to make is whether the study seeks a rich description of the full data set or else a 
detailed account of an individual phenomena (Braun and Clarke, 2006). A related 
question is whether or not to engage in “content” or “ethnographic” analysis (Silverman, 
2005). Procedures that are closer to the content approach seek to systematically cover all 
data to identify what topics are mentioned and how often. Ethnographic approaches are 
more interpretive and therefore more selective in terms of what data are analysed. 
Ethnographic approaches address how and why topics are discussed. An allied question is 
whether analysis is at the semantic or latent level (Braun and Clarke, 2006). Semantic 
analyses move from a purely descriptive account to interpreting the meaning behind 
what is said, but analyses are firmly based upon the actual words of participants. Latent 
analyses seek to identify underlying ideas and assumptions that give rise to what 
participants have said. A final question posed by Braun and Clarke (2006) is whether 
analysis are inductive, or theoretical. Inductive analyses are “bottom up” with theory is 
generated from the data. Theoretical analyses have prior assumptions about what the 
underlying will be. As a result the aim in this kind of analysis is to assess how well the data 
fit the theory. However, even in a theoretical analysis it is expected that the data will 
challenge prior theory and some “bottom up” analysis will take place. 
Where study aims require constructionist, interpretive, and latent analysis the most 
appropriate methods are observer participation, or phenomenological analysis (Mason, 
2002, Smith and Osborn, 2008, Silverman, 2005). Thematic, content, and framework 
analysis approaches are more appropriate when studies require essentialist, descriptive, 
and semantic analyses. Content analysis is more appropriate where results are highly 
descriptive and less interpretation of meaning is required (Silverman, 2005). Thematic 
analysis should be preferred when some interpretation is required and analyses are 
predominantly inductive (Braun and Clarke, 2006). Framework analysis is most 
appropriate when analyses are mostly descriptive and theoretically based, but some 
inductive and interpretive analysis is required (Ritchie and Spencer, 1994, Ritchie et al., 
2003c, Rabiee, 2004). 
The components of a valid qualitative analysis centre on transparency in the decisions 
made with regard to choice of method, sampling, and analysis. The assumptions made by 
the researcher at each stage should be made explicit and be open to external scrutiny. 
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5.2. Methods 
 
5.2.1 Practitioner focus group study procedures 
 
5.2.1.1 Participant identification and sample selection 
All practitioners at Elvington medical practice were invited by the local collaborator to 
attend one focus group as part of the regular weekly lunchtime meeting. Written, 
informed consent was sought from practitioners for focus group participation and audio 
recording. Upon being invited to participate all practitioners were given electronic and 
physical copies of the two questionnaires to look over before the focus group session 
took place. 
 
5.2.1.2 Setting 
The focus group was conducted in a meeting room at Elvington medical practice. 
 
5.2.1.3 Interview conduct 
The focus group was moderated by the principal investigator and the primary supervisor 
acted as assistant moderator. 
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5.2.2 Participant interview study procedures 
 
5.2.2.1 Participant identification 
All participants who were invited to take part in the trial described in chapter 4 were 
concurrently asked to provide consent to take part in an interview. Consequently, the 
identification, inclusion and exclusion criteria are identical to those specified in Chapter 4. 
 
5.2.2.2 Sample selection 
Heterogeneous purposive sampling was utilised  to ensure a comprehensive range of 
views and to allow for disconfirming cases to be included (Ritchie et al., 2003b). 
Participant selection was to maximise variability in terms of adherence to medication, 
employment, beliefs about medicines, mental wellbeing, social support, relationship with 
practitioners, and sex. 
 
5.2.2.3 Participant consent 
Written, informed consent was sought from participants for interviews to be audio 
recorded and discussions held about the participant experience of study involvement and 
to explore perception and understanding of the adherence questionnaires. Participants 
that consented to take part but were not selected for interview, or else consented to take 
part but not to have the audio of the interview recorded were sent a letter informing 
them that they would not be required for the study. 
 
5.2.2.4 Setting 
Participants were given a choice of being interviewed in their own home or at Elvington 
Medical Practice. 
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5.2.2.5 Interview conduct 
Interviews were directive in that the interviewer steered discussion towards topics that 
appeared upon the questionnaire, and discussing the process of taking part in the 
research. However, interviewee’s were given freedom to introduce new topics, change 
the order in which topics were introduced, or stray from the current topic in order for 
participant priorities or topics missing from the questionnaire or interview guide to be 
elucidated (Morgan, 1997). 
 
5.2.3 Plan of analysis for the practitioner focus group and participant 
interviews 
Data analysis was based upon Framework analysis as described by Ritchie and Spencer 
(1994), Ritchie et al. (2003c), and Rabiee (2004). 
 
5.2.3.1 Topic Guide development 
Topic guides were developed for the practitioner focus group and patient interviews 
(Appendix U, and Appendix V respectively). The focus group was more directed than the 
interviews in order to ensure all relevant topics were covered within the allotted hour. 
This is reflected in a more prescriptive topic guide, which follows a comparatively rigid 
order. In contrast, the interview topic guide had few specifically worded prompts (Arthur 
and Nazroo, 2003). More sensitive questions are also located toward the end of 
interviews. This placement allows for a rapport to be built between interviewer and 
interviewee before these topics are broached (Smith and Osborn, 2008). It also allows for 
these topics to be introduced by the interviewee at a time they are comfortable bringing 
them up without the interviewer having to force the topics into the conversation (Arthur 
and Nazroo, 2003). 
The aims of the focus group topic schedule were to begin with a discussion regarding the 
use of questionnaires in regular practice, to consider good and bad features of tools in 
general and then the specific tools. The questions placed at the end were about how best 
to engage practitioners and GP practices in research were asked as these questions were 
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considered less fundamental to the study aims. In contrast, exploring the experience of 
taking part in research was the first item on the interview schedule. It was thought that as 
a non-personal topic this would be the least sensitive topic to be discussed.  
 
5.2.3.2 Development of an initial framework 
Initial frameworks were developed from the results of the meta-analyses described in 
chapter 2 and qualitative studies of influences upon adherence (Benson and Britten, 
2002, Marshall et al., 2012, Britten, 1994). The interview framework therefore resembled 
the sections identified on the questionnaire. The addition of themes taken from 
qualitative studies allowed for comparison of items which may correlate with adherence 
but may not be the primary drivers of adherence. Fewer directly applicable studies were 
identified to inform the design of the focus group framework. However, the work of 
O’Donnell et al. (2007) which also examined practitioner assessments of a newly 
developed tool and how best to include practitioners in research was influential. The 
initial framework developed for the practitioner focus group is shown in table 5.1. The 
initial framework for the patient interviews is shown in table 5.2. 
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Theme Subtheme 
1. Perception of questionnaire 
tools 
 
1.1 Influence on decision making 
1.2 Impact upon consultations (time, rapport, structure) 
1.3 Influence on relationship with the patient (understanding and 
knowledge of patient) 
2. Design of questionnaire tools  
2.1 Wording 
2.2 Length 
2.3 Scoring and interpretation 
3. Ethical considerations  
3.1 Dealing with sensitive questions 
3.2 Managing difficult responses (e.g. mental illness screening and dislike 
of practitioners) 
4. Patient adherence  
4.1 Identification 
4.2 Causes 
4.3 Management 
5. Participation in research 
(O'Donnell et al., 2007) 
 
5.1 Incentives 
5.2 Barriers 
5.3 Logistics 
*Themes in italics taken from research articles (cited) 
Table 5.1 Initial thematic framework for the practitioner focus group 
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Theme Subtheme 
1. Patient factors  
1.1 Demographic 
1.2 Normalising of medicine/illness 
1.3 Stress and anxiety (Marshall et al., 2012) 
2. Perception of medicines  
2.1 Aspects of the drug regimen 
2.2 Perceptions of side effects 
2.3 Positive aspects of the medicine (Benson and Britten, 2002) 
2.4 Reservations about medicines (Benson and Britten, 2002) 
3. Perception of illness  
3.1 Causes of illness/exacerbating factors 
3.2 Perception and impact of symptoms 
3.3 Impact and role of any comorbid conditions 
3.4 Perception of general health and wellbeing 
4. Access to health care  
4.1 Obtaining a new supply 
4.2 Paying for medication 
4.3 Getting a consultation 
4.4 Dealing with problems 
4.5 Literacy and understanding 
5. Social factors  
5.1 Practical help 
5.2 Emotional support 
5.3 Role of romantic partners 
5.4 Giving and receiving advice 
6. Relationship with health care 
providers 
 
6.1 Relationship to individuals 
6.2 Relationship to the surgery 
6.3 Trust 
6.4 Time 
6.5 Empathy 
7. Participation in research  
7.1 Perceived benefits of participation 
7.2 Perceived risks of participation 
7.3 Barriers to participation 
8. Recurrent themes/meta 
classifications (Ritchie et al., 
2003a) 
 
8.1 Trust – In researcher, practitioner, drug companies and support group 
8.2 Normalisation – of medicine and illness 
8.3 Motivations – to take pills, to participate, to see doctor 
*Themes in italics taken from research articles (cited) 
Table 5.2 Initial thematic framework for the participant interviews 
 
5.2.3.3 Data familiarisation 
To aid in data familiarisation, the focus group and interviews were transcribed verbatim 
by the principal investigator (Gorecki et al., 2012, Braun and Clarke, 2006, Wilkinson, 
2008, Lewis and Ritchie, 2003). Non-verbal cues and speech patterns that might be 
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considered important for interpretation by the principal investigator or assistant 
moderator in the practitioner focus group were also included (Charmaz, 2008). 
 
5.2.3.4 Indexing the data 
For participant interviews, indexing was initiated on a transcript felt to be rich in data by 
the principal investigator. Where data did not fit adequately within an existing theme 
Rabiee (2004) was followed: 
The theme was modified to better fit or a new theme was developed. Where the data 
were not considered useful for achieving the study aims it was not coded. The revised 
framework was then used to index a second transcript and further changes were made as 
required. The revised framework was then reapplied to the first transcript to ensure the 
data fit the new framework. When all the data considered relevant to the study aims 
could be coded the process was repeated for the third transcript and so on until a 
framework was developed that was capable of classifying all relevant data present in all 
transcripts. 
For the practitioner focus group the initial framework was adapted to fit the data 
according to the same principles outlined above. Indexing was carried out independently 
by two researchers (SW with either MA or DB) with disagreements resolved via 
discussion. 
 
5.2.3.5 Synthesising and charting the data 
Data were grouped by participant and charted using NVivo VS. 10 software. For both 
interview and focus group data this permitted the analysis of frequency, and intensity 
with which ideas were expressed to be analysed (Rabiee, 2004). Themes that did not 
contain sufficient meaningful data were discarded, and their contents either moved to 
alternative themes or else removed from analysis. Where overlaps between different 
themes were identified the possible reasons for these were explored (Ritchie et al., 
2003c). Synthesis of data was performed by one researcher (SW) with a second (DB) 
applying the revised frameworks to transcripts independently to ensure robustness. 
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Issues identified during checking were referred to the first researcher (SW) who re-
examined the developed framework for subsequent checking. This procedure was 
followed iteratively until both researchers were satisfied that the developed thematic 
framework was sufficient to summarise the findings of the study. 
 
5.2.3.6 Data description and interpretation 
The final stage of analysis was to present and interpret the responses of participants in 
the context of the present study. Where possible, underlying explanations for the views 
presented were proposed (Ritchie et al., 2003c). Inferences will be based upon the 
recurring conjunction of ideas or else by comparing the accounts of participants that do 
not make an observation with those that do (Ritchie et al., 2003c). Additional 
explanations will be sought via comparison with the existing literature. As with previous 
stages all analyses were performed with input from multiple researchers to ensure the 
presented analyses are trustworthy. The interpretations offered by SW were checked 
with reference to the source material by DB, and additional independent reviewing by FP 
highlighted any areas where assumptions were being made in reporting or where the 
interpretations offered were not suitably transparent. 
 
5.2.3.7 Validity assurance 
Survey, focus group, and interview data were triangulated so that inconsistencies in 
participant testimony could be highlighted for discussion whilst ensuring that the 
interpretations offered for participants’ testimony were internally consistent with the 
multiple sources of evidence gathered (Mason, 2002). Additionally, regular meetings  
were held as described above between the primary researcher and supervisors to ensure 
that interpretations were grounded in the data and not the presupposed ideas of an 
individual researcher (Yardley, 2008, Mason, 2002). The trustworthiness of the results 
was further ensured by maintaining intermediate copies of data files and thematic 
frameworks as the work progressed (Yardley, 2008). 
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5.3 Results 
 
5.3.1 Practitioner Focus group 
 
5.3.1.1 Focus group composition and management 
Seven practitioners consented to participate in the focus group. At the beginning of the 
session practitioners were asked whether or not they had looked over the questionnaires 
prior to the session. They had not and so physical copies of the questionnaires were 
distributed and practitioners looked over these whilst the investigators prepared the 
session and equipment. Practitioners were also encouraged to refer to these during the 
session. The sample comprised of two nurses and five GPs including a trainee GP and a 
partner in the practice (table 5.3). 
 
Participant Code Role in Surgery Sex 
1 Practice Nurse Female 
2 Partner Male 
3 GP Registrar Male 
4 GP Female 
5 Practice Nurse Female 
6 GP Female 
7 GP Female 
SW Moderator Male 
DB Assistant Moderator Female 
Table 5.3 Focus Group participant demographics 
 
There was no evidence that the nurses tended to defer to the doctors. Although P1 was 
the least active participant in the discussion, P5 was one of the most active. The greater 
seniority of P2 as a partner in the practice did impact upon group discussions; his 
perceived rank permitted him to give views counter to the group consensus and this often 
opened up new ideas to debate. However, his rank also led to his views rarely being 
challenged. On the one occasion where his views were challenged he conceded the point. 
The willingness of participant (P4) to challenge him may indicate that deference was 
based more upon respect than hierarchy. The willingness of the junior GP (P3) to express 
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sometimes contrary opinions also bears witness to this claim. With the exception of P2 all 
participants appeared to have equal status. 
 
5.3.1.2 Construction of themes from the practitioner focus group 
Whilst coding, new themes were developed that could not be represented with the initial 
framework presented in table 5.1. This resulted in two additional primary themes and the 
number of subthemes increased from 14 to 22. This expanded framework is presented in 
Appendix W. After overlaps and links between different themes were identified and 
examined, it was judged that data could be adequately described and interpreted using 
seven themes but a condensed set of 10 subthemes. Table 5.4 illustrates the final set of 
themes and subthemes. 
 
Theme Subtheme 
1. Perception of questionnaire tools 
 1.1 Influence of questionnaires upon the process 
and outcomes of consultations 
 1.2 Motivations for use of tools 
2. Design of questionnaire tools 
 2.1 Ease of use and administration 
3. Areas for improvement in current tools 
 3.1 Omissions 
 3.2 Ambiguities 
 3.3 Ethical considerations 
4. Patient adherence 
 4.1 Causes 
 4.2 Management of non-adherence 
5. Participation in research 
 5.1 Incentives 
 5.2 Barriers 
6. Perception of patients 
7. Practitioner Professional autonomy 
Table 5.4 Final framework of practitioner focus group themes 
 
5.3.1.2.1 Perception of questionnaire tools. 
Participants were concerned that introducing questionnaires during a consultation could 
stop the flow of the conversation. The view that paper forms can act as a barrier between 
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patients and practitioners was expressed by a majority of GPs (P2, P3, P4 and P7). The 
following quote in response to a question asking about the impact of questionnaires on 
the timing of consultations demonstrates the stresses the use of questionnaires during a 
consultation can impose on GPs: 
“It’s just another pressure, our consultation times are between ten and twelve 
minutes and I think it’s already pressured and sometimes you can ask the patient 
to fill it in while you’re there but that is time consuming, you could ask them to 
bring it back I guess, but with the PHQs the pressures to get it done at the first 
assessment.” (P2) 
This GP expresses the discomfort he experiences with trying to balance the need to give 
time to a patient, his own obligations to complete a time consuming questionnaire, and 
the additional pressure of trying to keep the consultation within a reasonable total time. 
P7 was also concerned that relying on questionnaires to guide consultations might lead to 
practitioners not asking questions that might be on the questionnaire in a context 
appropriate manner, or else not asking questions that are not on the questionnaire. 
However, it was stated by P2, P5, and P7 that patients completing questionnaires before 
the consultation could allow for better discussions. One nurse (P5) stated that rather than 
being a block to communication is was possible to use questionnaires to generate a more 
effective consultation: 
“…sometimes with questionnaires its better using or reading them in advance as 
well so you can, rather than use it as a barrier, there’s a piece of paper as a barrier, 
you can use the questions as prompts to speak to the patient afterwards or when 
they come  in the consultation” (P5) 
P2 and P4 said the potential utility of questionnaires was maximised when patients are 
unknown to the doctors, or when it was known that patients were nonadherent and the 
aim of the consultation was to address specific problems. This view was also expressed by 
P4 who had been the most critical of questionnaires up to this point in the discussion, 
finding them “intrusive” even when completed before the consultation. However, the 
assumption that the doctors knew their regular patients well enough to derive no benefit 
from questionnaires was questioned by P2 who mentioned the capacity for patients to 
surprise doctors or to change their beliefs based upon their background or new 
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information e.g. from newspapers. He suggests that the BMQ general subscale could 
provide valuable information to inform a consultation and the type of patient education 
necessary. P7 also stated that an additional benefit of the questionnaire might be the 
opportunity for patients to express views that they may feel uncomfortable mentioning in 
person. The dissent of the authoritative P2 appeared to be the point in conversation at 
which it became acceptable to question the capabilities of practitioners to get all of the 
relevant information from patients. 
The practitioners were sceptical of the probability of patients returning questionnaires. 
However, P2 stated that having to complete a questionnaire for the Quality and 
Outcomes Framework (QOF) can serve as a motivator for the surgery to dispense 
questionnaires and encourage patients to respond. The practitioners had individual 
strategies for collecting and uploading data making a trade-off between ensuring a 
response and maximising time in a consultation. One nurse (P5) said that she asks her 
patients to complete questionnaires in the consultation and enters the information into 
the patients’ medical records immediately to ensure the information is captured. Two 
doctors (P2 and P3) said they also used to do this but no longer did because it took up too 
much consultation time. It was widely acknowledged by the group that since information 
on anxiety and depression had to be collected routinely for patients with chronic illness it 
would be economical to incorporate this into a questionnaire that addressed a larger 
number of issues such as PALS or WAMS. The group came to accept the utility of this 
approach after their initial reluctance to collect information on anxiety and depression 
after P2 legitimised considering whether there were benefits to collecting information on 
mental wellbeing. 
 
5.3.1.2.2 Design of Questionnaire tools 
Time was mentioned throughout the discussion as a vital consideration for the 
practitioners. One aspect of this was a desire for questionnaires that are easy to score 
(P2), and with no free text for participants to complete (P1). One participant (P2) twice 
brought up the possibility of utilising technology to both deliver and collect information. 
There was a feeling that a useful questionnaire would make it simple to categorise 
respondents into adherers and non-adherers using a summary score. In particular it was 
felt it would be useful to be able to differentiate patients requiring a simple solution such 
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as the provision of a dosett box from those requiring motivational and behavioural 
interventions to influence intentional non-adherence. There was initial reluctance from 
the practitioners to consider having scores which differentiated patients further regarding 
specific reasons for nonadherence; however, P2 mentioned some ways this could lead to 
greater time economy. This eventually led to group wide agreement that more detailed 
information on the causes of nonadherence would be useful: 
 “Although I could see the problem group, if we can call them that, having 
diametrically opposite reasons for that, like [P1] said some people can’t swallow 
tablets, some can’t get to surgery, em, believe that all medicines are poisonous, 
you know it’s completely different reasons and so you’d approach these completely 
different so if you could categorise those without too many categories, what your 
core reason is then it helps you know how to deal with them…”  (P2) 
The practitioners as a group agreed that they would be happy to score the questionnaire 
as it is currently, although one practitioner (P6) would have preferred there to not be a 
middle option on the Likert scales on the questionnaires. 
 
5.3.1.2.3 Areas for Improvement in the current tools 
The practitioners noted the lack of questions regarding the cost of medicines, whether or 
not patients had a stockpile of medicines at home, and whether patients were having 
difficulties swallowing their pills. The lack of a section concerning cost was of particular 
concern to P4:  
“The other thing this questionnaire doesn’t address is cost of medicines. We 
certainly see patients who are on multiple medications [some umms of agreement 
from P5] who don’t qualify for various benefits and they’ll only take one or two or 
none of the medicines you prescribe, they literally can’t afford them.” (P4) 
Another area of importance unrepresented in the questionnaire was the possibility of 
over adherence and patients self-treating inappropriately: 
 “…we’re reviewing all of our patients on thyroxine because of [unintelligible] 
anyway I found two patients that have been buying additional thyroxin on the 
internet.“ (P6) 
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Another perceived omission was related to access to medications. Two practitioners (P3 
and P7) were concerned that the ‘occupation question’ did not take into account working 
hours which can make it difficult for some patients to collect their medicines. A final 
omission of the tool was the capacity for it to be completed by someone other than the 
patient themselves. One practitioner (P3) noted that often patients don’t necessarily have 
much awareness of what medicines they are taking or why and it is their partner that 
ensures adherence. 
The practitioners found some aspects of the questionnaire to be ambiguous: 
“21 on the, “I find it hard to get my supply of medicine” on section 2, the bottom of 
section 2. I don’t know if you’re just getting at the sort of place that they go to 
wherever they pick it up or the frequency with which they have to pick it up?” (P2) 
 “So that’s perhaps not as clear as it could be?” (SW) 
“Yeah, “do you find it frustrating to collect it monthly or about twice, six times a 
year” or whatever. That could be an issue. We are supposed to, as a quality 
measure, supply monthly quantities. Which implies someone on a long term 
treatment has to visit the surgery or the chemist twelve times a year and I wonder 
sometimes if that was me, how frustrating that would be. Would it actually be a 
barrier to being reliable and compliant?”  (P2) 
These practitioners express frustration that they are unable to exercise their judgement 
regarding whether or not to allow patients to collect more than a month’s supply or not, 
particularly when they think this may reduce patient adherence. 
A second area of ambiguity concerned which doctor would be implicated if a patient 
indicated that they had a poor relationship with their doctor. Patient’s often do not see 
the same doctor. Moreover, patients often see a practice nurse for routine check-ups. 
Consequently it was said that the questionnaire could be improved by disambiguating 
which doctor was referred to on the PDRQ-9, and by better representing nurse 
involvement. 
The most critical problems perceived with the questionnaires were those that dealt with 
possible ethical failings: 
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“With the mental health scoring system, you’re doing a two week window aren’t 
you with the depression anxiety screening tool, aren’t you endangering the fact 
you’re going to get a lot of positives with the two week window that aren’t 
actually, you wouldn’t ever give them officially depression or anxiety?” (P3) 
 … 
“That puts you in a can of worms. You don’t do anything about it and next week 
they kill themselves. It doesn’t look good.” (P6) 
  
There is a perceived risk that having a two week window for screening anxiety and 
depression may identify a number of healthy participants as potentially having mental 
illness. This will result in wasted time for practitioners. An additional concern was the 
culpability that might be placed upon the practice if they failed to follow up on a patient 
that scored highly on this scale. However, P2 later points out that they are required to 
collect this information anyway. 
Some GPs (P3, P4 and P7) also said that the section assessing the doctor-patient 
relationship may make some patients uncomfortable. It was said that a “prefer not to 
say” option might ameliorate these concerns. An additional problem was how 
practitioners might respond to this information: 
“What about information in the relationship you have with the patient or the 
patient has with you? Would you necessarily want to know if they don’t like you 
very much? Would that impact on your relationship with the patient?” (SW) 
 [long pause] 
 “If I think it’s useful.” (P5) 
“Difficult when people say they see different doctors. You don’t know which doctor 
they mean when they make a comment then. You don’t always see, I mean, most 
people try and see the same doctor most of the time but that doesn’t happen for 
all sorts of reasons.” (P4) 
The long pause at the beginning of this exchange suggested discomfort on the part of the 
practitioners answering this question. The initial response of P5 does not directly address 
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the question and the response of P4 could be interpreted as defensive. The section is 
perceived by the practitioners as potentially threatening to both patients and themselves. 
 
5.3.1.2.4 Patient adherence 
The practitioners as a group acknowledged the importance of patient beliefs about 
medicines upon adherence. P2 initiated a discussion regarding the importance of 
understanding the patient’s perspective and potential biases towards their medication. 
He argues that applying a single uniform strategy to all patients will not necessarily lead 
to adherence: 
“I think these sorts of things are highlighted in a modern medical curriculum which 
is far more based upon patients expectations and ideas, not just about the 
condition they’ve got …if they haven’t gained that understanding where the 
patients coming from with that perspective we’re not going to progress with 
treatment full stop.” (P2) 
An educational approach to help patients balance the costs and benefits of medicine was 
also highlighted as a method by which adherence could be encouraged by P5. 
The cost of treatment and access to medicines were also considered as potential causes 
of nonadherence. P4 stated that there was not always a solution that could be 
implemented by practitioners to remedy some access problems including the limitations 
of rural transport and not being able to prescribe more than one month’s medication at a 
time. Therefore collecting this information would not necessarily be useful from a clinical 
perspective. 
 
5.3.1.2.5 Participation in research 
P2 and P7 emphasised that they would like to see some potential for benefit of 
participation in research for their patient population. P4 advised that it was best to 
approach a partner in the surgery because they could unilaterally introduce basic 
research, and where research was more complicated they would still have the greater say 
in the decision. The potential for a personal incentive was brought up jokingly by P2: 
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 “Any other thoughts on how to get you excited, interested or?” (SW) 
 “Early retirement possibly?” (P2) 
 [laugher] 
Following this exchange P4 and P1 joined in with jokes about receiving personal 
incentives, but when directly asked if they would prefer researchers to offer more 
personal gifts P4 quickly shut down the suggestion with the support of the group. This 
indicated that the group saw personal incentives as improper and not an approach that 
should be employed. 
The importance of time was again mentioned in terms of providing a barrier to 
participation in research by P2, P7 and P4. Staff time was considered a valuable resource 
and there was a desire for researchers to implement systems that would minimise time 
burdens and to compensate surgeries monetarily for the cost of staff time, postage or 
other analogous costs. 
 
5.3.1.2.6 Perception of patients 
An issue not mentioned frequently by any individual but brought up separately by P2, P3, 
and P7 was the issue of trusting patients to return questionnaires. In all cases the lack of 
trust was based upon experience of having difficulty getting responses from patients. As a 
potential solution the doctors note that they currently send two follow up letters to 
patients if no response is obtained and after that they receive a phone call. 
 
5.3.1.2.7 Professional Autonomy 
An underlying theme that reoccurred during many discussions was distaste for anything 
that impinged upon the autonomy of the GPs in the group. Reluctance towards 
questionnaire tools was heavily influenced by a perception that they get in the way of the 
assumed superiority of doctors to identify problems and find solutions for patients within 
consultations. There was a similar hostility towards the inability to dispense medicines in 
larger quantities to patients. The group was only willing to consider that questionnaires 
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might assist the doctors in making a decision or getting to know a patient after their most 
senior member (P2) opened up that possibility. 
 
5.3.2 Participant Interviews 
 
5.3.2.1 Profile of participants and their interviews 
Only six participants consented for interview so all were invited. However, one participant 
withdrew from the project. This left a convenience sample of five participants. Table 5.5 
presents the demographic characteristics of the sample alongside their scores on the 
PALS and WAMS questionnaire, measures of medication adherence, and medical 
outcome. 
 
Participant 
ID 
Sex Age PALS 
Score 
WAMS 
Score 
Morisky* Retrospective 
Refill Rate (% 
collected) 
Prospective 
Refill Rate (% 
collected) 
Blood 
pressure 
controlled 
PA Female 68 30.9 19.3 0 100 100 Yes 
PB Male 59 32.1 8.6 1 43.3 69.6 No 
PC Male 71 22.7 15.3 0 100 100 Yes 
PD Male 84 21.5 19.1 1 63.3 100 NA
# 
PE Female 49 22.1 23.8 1 81.4 97.8 Yes 
*Morisky scores range from 0-4 with higher scores indicating a greater number of reasons for non-
adherence. 
#
 Participant was taking medication that reduces blood pressure, but was not diagnosed with hypertension. 
Table 5.5 Interview participant demographics, adherence and blood pressure outcomes 
 
Two participants had no indications of nonadherence (PA and PC), two participants were 
intermittently nonadherent (PD and PE), and one participant consistently nonadherent 
(PB). The consistently nonadherent participant was the only individual in the sample that 
did not have controlled blood pressure. Participants in the sample tended to be more 
nervous and eager to please the interviewer, or else more defensive when interviewed in 
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their own home. A brief profile of each participant and interview is contained within 
appendix Y. 
 
5.3.2.2 Construction of themes from participant interviews 
During the process of analysis the theme “Patient factors” was removed. There was 
insufficient evidence for any relevance of demographic factors. The “stress and anxiety” 
subtheme was moved into the “Perception of illness” theme because discussion was 
primarily in relation to the relationship between stress and the symptoms of 
hypertension. The remaining elements of the theme “Patient factors” were subthemes 
that were brought up by participants in a number of contexts and so are considered 
recurrent themes and have been moved accordingly (Ritchie et al., 2003b). The 
framework prior to synthesis is presented in appendix X. The final framework is presented 
in table 5.6. 
 
5.3.2.2.1 Perception of medicines 
Both of the participants with perfect adherence (PA and PC) stressed the importance of 
routine in their lives. These two participants also did not express that they found having 
to take medicines an imposition on their life. In contrast PB, PD and PE did. The next most 
adherent participant, PD, had no problem taking his morning medicines because “you 
have a routine”, but was more likely to forget his medicine in the evening because 
“You’re not thinking about medicines” and he found taking them at a certain time of day 
“restrictive”. PB and PE seemed to actively resist incorporating medicines into their lives. 
PB did not like being dependent upon medicines, whether for a headache or 
hypertension. PE said she wants to have her medicines “whenever I choose to take it”. 
She does not want an external power such as her medicines or doctor decide when she 
will do things. 
Participants considered the positive and negative aspects of their medications. PA and PC 
seemed to have regular reminders for the benefits of taking their medicines. PA has 
friends that have had strokes and she said she wants to avoid a stroke herself. For PC the 
reminder was calling his medicines his “stay alive pills”. In contrast PD and do not 
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emphasise the good health they enjoy because of their medicines but instead stress the 
more negative view that they would be worse without them: 
“Well the only positive, if you want to call it a positive, is that I know that without 
it I can’t do what, things I like doing, and probably without it my health would 
deteriorate. So it’s an indirect positive isn’t it if that makes sense.” (PB) 
PB expresses the freedom provided by taking his medicines as an “indirect” benefit of his 
medicines. He has a negative view of his medicines impinging upon his independence 
which he tolerates only because they confer a net benefit to that independence via the 
alleviation of symptoms. 
A contrast can be made between PB and PC in the way they talk about the potential 
unknown side effects of medicines. PC talks about thalidomide as an example of when 
drug companies and doctors got it wrong and prescribed medicines that did lasting harm. 
But he has faith that doctors and drug manufacturers get it right most of the time 
because “some bright guys have had a look at it.” For PB the assumption was that medical 
advice changes all the time and he was concerned that in ten years the drugs he takes 
now may have been found to have a detrimental effect. 
PA, PD and PE all stated that they would not stop their medicine without the permission 
of a doctor, with PA considering this “immoral”. PA and PD said they would stop taking 
medicines that made them feel ill until they could see a doctor. However, PE described an 
experience where she kept taking her medicine until she could see a doctor even when it 
was making her feel ill and causing her hair to fall out. PC argued it acceptable to stop 
taking a medicine that makes you feel ill and that he would mention it at a routine visit to 
the doctor but not make a special appointment. 
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Theme Subtheme 
1. Perception of medicines 
 1.1 Aspects of the drug regimen 
 1.2 Perception of side effects 
 1.3 Positive aspects of the medicine 
2. Perception of Illness 
 2.1 Role of stress as an exacerbating factor 
 2.2 Perception and impact of symptoms 
3. Access to healthcare 
 3.1 Obtaining a new supply 
 3.2 Paying for medication 
 3.3 Getting a consultation 
 3.4 Literacy and understanding 
4. Social Factors 
 4.1 Practical help 
 4.2 Emotional Support 
 4.3 Role of romantic partners 
 4.4 Giving and receiving advice 
5. Relationship with health care providers 
 5.1 Doctor-Patient relationship  
 5.2 Trust 
 5.3 Time 
 5.4 Empathy and rapport 
6. Participation in research 
 6.1 Perceived benefits of participation 
 6.2 Perceived threats from participation 
 6.3 Understanding questions and instructions 
7. Recurrent themes 
 7.1 Normalisation 
 7.2 Emotive responses versus rationalisations 
 7.3 Social desirability 
 7.4 Desire for independence v4 
 7.5 Desire for information 
Table 5.6 Final framework of participant interview themes 
 
 
5.3.2.2.2 Perception of illness 
The role of stress as an exacerbating and causal factor in hypertension was expressed by 
participants PB, PC, and PE. For all three participants stress was considered a potential 
cause of their hypertension. PB and PE both said that stress exacerbates their symptoms. 
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PB and PE also use the experience of symptoms as a reminder to take their medication. 
PA and PC do not experience symptoms of hypertension. 
 
5.3.2.2.3 Access to healthcare 
The highly adherent PA had not taken her pills at all in the week of the interview because 
a road closure had made getting to the surgery very difficult. PB has to travel to a 
different village to collect his medicines and this is something he “just has to get used to”. 
Collecting medicines was a greater irritant for PE because she does not have a local 
pharmacy and considers traveling to the surgery every month to collect her prescription 
an unreasonable expense of time and money. She did not understand why medicines 
could not be posted to her or why they could not dispense more than a month’s 
medication. Some participants expressed difficulty in getting a consultation. PE is 
frustrated that there is a local surgery branch that is rarely open to her. PB was frustrated 
because he needs to travel a lot for work so getting an appointment would require taking 
a day off. 
The cost of medicines was seen as a potential barrier to adherence by participants. PA 
and PD do not have to pay for medicines but expressed concern for the potential for cost 
to be prohibitive for others. PB does not have a problem affording his medicines. PE was 
irritated by having to pay for medicine. She felt that as someone that has paid taxes she 
should be rewarded for that with free medication. 
Participants PB and PC had no difficulty understanding written instructions. Participant PE 
did not discuss literacy. PA and PD expressed that they sometimes found patient 
information leaflets difficult to understand. PA found the language in them too technical 
and wished they’d “call salt salt”. PD expressed that he did not seek clarification if he 
didn’t understand the information sheet. 
 
5.3.2.2.4 Social factors 
Participants did not discuss receiving much practical help regarding their adherence. 
However, PA did talk about being concerned about getting her medicines if she did 
become ill because she is far from the surgery and her neighbour that used to help her in 
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this situation had moved away. She also talked about her own experiences giving help to 
an individual that had large stockpiles of medicines at home. 
The most adherent participants, PA and PC, discussed how they remain socially active. PC 
said his group of friends provide a direct coping mechanism for illness and the process of 
aging. He talks about how whenever anyone is having a problem with illness or their 
medicines someone else in the group has probably had the problem before and can offer 
advice. He mentions multiple times about the groups use of humour to remove the 
anxiety from health problems. For PA engaging in varied social activities seems to be 
about maintaining a healthy lifestyle rather than a way of coping with new health 
problems. If others bring up medicines she’ll talk about them but she would rather “take 
them and forget about them” than discuss them at length with others. In contrast PB talks 
about only being open with his wife, sister, best friend and preferred doctor, PD relies 
only upon his wife for support, and PE makes no mention of any support she receives 
outside of work.  
All three married participants emphasised the importance of their spouses in coping with 
their illnesses. For PB his wife made a number of crucial interventions, first making him go 
to the doctor to get diagnosed with hypertension, and second making him go to the 
doctor after having a brain haemorrhage. PB and PD shared a reluctance to seek support 
from those outside of their marriage. PC, who did receive support from a wider circle of 
friends, still considered his wife to be the single most important source of support. 
Participants PE and PC expressed how useful they found sharing their own experiences 
with others. PE seems to get satisfaction from directing people at work to the doctor if 
they have been feeling ill in ways that she recognises as similar to her experiences with 
hypertension. She finds it “cathartic” to help people in this way. This was important for PC 
too. He is particularly keen to talk to people about stress after his own experience of a 
“breakdown”. 
 
5.3.2.2.5 Relationship to health care providers 
Participants had good relationships with at least one GP at the surgery. Particularly 
important aspects of the doctor-patient relationship were perceived to be trust, not 
feeling rushed during consultations, and the empathy displayed by their doctor. PA 
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discussed the changing role of the doctor. She prefers that doctors more approachable 
now, but misses having a relationship with a single doctor. PB and PE reported mostly 
seeing one doctor they felt they had a particularly good affinity with. The other three 
participants had preferred doctors but were willing to see any of the doctors. Some 
participants completed the PDRQ-9 considering the surgery as a whole (PA, PD) and some 
considering a specific doctor (PB, PE). 
Participants PA and PD said that honesty from practitioners is essential. They wanted 
doctors to tell them what is wrong, what action they propose and why. For PD it was 
especially important that he felt like he had “a right to veto” any decision about his 
healthcare. PA, PB and PD all expressed the view that they were unlikely to remain 
registered with a GP surgery they did not like. PB also stated that if he didn’t like his 
doctor he wouldn’t have completed the questionnaire and PC said the PDRQ-9 might 
worry some patients.  
Trust in practitioners was very high in this sample. The participants’ trust in practitioners 
contrasted with their lack of trust in drug companies, with all five participants describing 
the primary purpose of patient information leaflets as “covering the back” of the drug 
companies in case someone were to get side effects. The participants also trusted the 
doctor over other information sources to know whether what they experienced was a 
side effect or not. PE expressed this most strongly: 
“…I put my trust in the doctor. I think well if he says I’ve got to be on this then I 
trust his instincts to be right, I think he’s the one that’s qualified to know whether 
I’m feeling bad or not as the case may be so I leave all the trust with him.” (PE) 
Here PE goes as far as to say the doctor is better qualified than she is to determine 
whether or not she feels bad. PD assumed his doctor will know he is experiencing side 
effects such as impotency without him having to tell them. Doctors were also trusted by 
participants over friends (PA), and the internet (PC and PE).  
 
5.3.2.2.6 Participation in research 
A common reason for participation was a desire to help the surgery or a particular doctor 
(PB, PD and PE). The desire to help was also present for PA who participated partly 
because it was a student project. PD commented that the research was interesting to 
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him, which was why he took part despite getting a lot of questionnaires. The opportunity 
to take part in research that might help others was important for PC. PB also liked the 
idea of helping others but admitted his motive was more selfish in terms of hoping it 
would be possible to stop taking medicine. A desire to contribute to improving the NHS 
was a motivation for PA and PD, particularly PA who considers the waste of medicines to 
be a waste of money that could be spent elsewhere. 
For participant PC a key reason for taking part was that the process of taking part in the 
study and completing the questionnaire looked easy. PA and PB also said that it did not 
take long to complete the questionnaires. PA and PD commented that they did not find 
completion of questions that did not apply to them intrusive or a waste of time. PE said 
the questions were “very very straightforward” and “you’d have to be an idiot not to be 
able to answer them”. 
However, some problems regarding the interpretation of questions and instructions were 
identified. PB has longstanding concerns about side effects that do not become known 
until a drug has been used for a long time, and so he was unsure about how to answer the 
questions on side effects because he thought it was likely that he may have side effects 
he doesn’t know about. A second problem was that while PD had no problems with the 
individual questions, he and his wife completed it together as a single person. This means 
that the responses represent a compromise of views and not his individual opinions. PE 
struggled to answer the question about her average weekly alcohol intake because she 
said her drinking habits vary from having almost no alcohol one week to three bottles of 
wine the next. PC said the BMQ items were difficult to answer because they were too 
sweeping. I.e. “Most medicines are addictive” and “All medicines are poisons” were 
interpreted as ‘yes’ ‘no’ answers which he did not have the relevant expertise to answer. 
Some sections of the questionnaire were perceived as threatening. PC thought some 
might be “frightened off” by the questions on the PDRQ-9, particularly if completed face 
to face. PA expressed a preference for completing the smoking and drinking questions in 
person rather than on a questionnaire, and PC thought that people might omit or lie on 
this section. PC was the only participant to have any other concerns. He thought that the 
option to “prefer not to say” should be the first option available to participants as when 
placed at the end of the question it would feel like a “yes” rather than a refusal to 
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respond. PC also agreed with P3 from the practitioner focus group that 2 weeks would be 
an insufficient period of time to identify people having difficulties with mental health. 
 
5.3.2.2.7 Recurrent themes 
One theme that underpinned much of the interviews were patients’ ability to “normalise” 
or accept their change in every day circumstances as a result of being prescribed 
medication or receiving a diagnosis. The participants who accepted hypertension and 
taking medicines most readily (PA and PC) were also the most adherent. Participants PB 
and PE were least adherent and most actively resisted accepting medicines as part of 
everyday life: 
“…because I remember I was only like 41 I think when I started on blood pressure 
tablets and I kept thinking I was far too young to be on blood pressure tablets, so 
yeah I was toying with that quite a lot in the early days, but no not now. It’s 
something you have to adapt to very easily and you know it’s the difference 
between you live or die, so it’s a case of you just take it.” (PE) 
Here PE expresses her initial reluctance to be diagnosed with hypertension and be 
required to take tablets, but then expresses that she quickly adapted because of the 
perceived necessity of her medication. Participant PD becomes frustrated at having to 
take medicines about once per month. PB expressed similar feelings saying that taking 
medicines doesn’t bother him “ninety per cent of the time”. In contrast, PA she says you 
“just take them and forget about them”. The process of normalisation goes beyond just 
medication adherence, with PC using his group of friends to adapt to illness. He talks 
about having to get used to getting older and accepting that you are no longer 
“fireproof”. Another expression of this tendency is PD’s normalisation of his side effects. 
His medicines make him dizzy every day and he has become accustomed to the loss of 
sexual function even though this was initially troubling. 
A related tendency was for participants to respond emotionally in the first instance then 
to engage in an active decision making process. Few participants responded favourably to 
having to take medicines in the first instance, but considered the advantages and decided 
to take their medicines. PA and PC had methods of supporting a regular reappraisal of the 
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benefits of taking medicine via knowing people that had experienced strokes, discussing 
experiences with friends, or calling medicines “stay alive pills”. 
A theme that was present in the interviews of PA, PD, PE and especially PB was a desire to 
maintain independence. For PA, PD and PE this was expressed in terms of doctors 
explaining fully what they were advising and why. PE refuses to set alarm clocks or keep 
medicines next to the bedside because she does not want to feel restricted by her 
medicines even though she suggests that these techniques might help her to remember 
her medicines. The independence theme largely defined the interview with PB. He aims 
to balance the benefits from his medicines with not feeling he is dependent upon them. 
Despite this PB continues to take propranolol even though both he and his doctor 
consider this to have a nominal effect and to be primarily only for reassurance. 
The desire for information was a common theme; PA, PD, and PE wanted their doctors to 
fully explain the reasons for any recommendations. PA said that information exchange 
was a way to build rapport between doctor and patient. Participants also sought 
information about their illness from other sources, such as their friends, patient 
information leaflets, and the internet. However, none of these sources were trusted to 
the same extent as the doctor. 
A final theme that could impact upon the interpretation of data from both questionnaire 
and interview was the differing extents to which participants tried to present themselves 
in a socially desirable light. In most of the interviews instances of this were fleeting and 
unlikely to have impacted heavily upon the results. For example, PA felt compelled to go 
and fetch a glass to show how much alcohol she drank to assure the interviewer that she 
did not drink to excess. For PB there might be a suggestion that he felt uncomfortable 
talking about his nonadherence because he claimed in the interview to be “98%” 
adherent when this would appear impossible from his medication refills. The desire to be 
seen as helpful was a persistent theme in the interview with PE both when discussing her 
participation in the research and when discussing how she enjoys referring co-workers to 
the doctor when they describe symptoms similar to her own. 
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5.3.2.3 Triangulating participant survey and interview data 
Participant demographic data collected via PALS is assumed to be correct, except in the 
case of PE who had split up with her partner between completing the survey and 
conducting the interview. All other sections of PALS and WAMS have their responses 
cross referenced with interview testimony. 
 
5.3.2.3.1 Health literacy 
Participant PA indicated that she sometimes struggled to understand medical terminology 
in interview, but indicated that she never needed to ask for help on the PALS. PB also 
indicated that he had no difficulty understanding patient information leaflets contained 
with his medication in interview, but indicated that he often had to ask for help reading 
medical information on PALS. The difficulty PD reported in understanding literature was 
detected on the health literacy screen. No other participants mentioned any difficulties 
and none were reported on the PALS. 
 
5.3.2.3.2 BMQ-General subscale 
The BMQ general subscale validates PA’s opinion that skipping medicines is immoral, 
where she strongly disagrees that people should stop their treatment every now and 
again. However, she otherwise portrays a largely negative view of medicines. However, 
four responses indicate “uncertain” rather than actual negative views. Uncertainty was 
also expressed by PB.  Otherwise participant responses on the BMQ accurately 
represented the generally positive views expressed by PC, PD and PE and the more 
negative views of PB. 
 
5.3.2.3.3 Mental health and behaviour 
Only PC reported ever having had a past diagnosis of mental illness, which was 
corroborated during interview. No participants gave any indications during interview that 
the volume of alcohol consumed reported upon the PALS was inaccurate. 
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5.3.2.3.4 Morisky Adherence Scale 
Participants PB, PD and PE did report forgetting to take medicines in interview and this 
was identified by Morisky. PA and PC identified as perfectly adherent on Morisky. Pc 
confirmed he always takes his medicines. PA did report sometimes skipping evening 
doses but this was rare and in the context of her perfect refill rate adherence this not 
being identified by Morisky seems reasonable. 
 
5.3.2.3.5 Mental wellbeing and happiness 
PA and PC did not describe experiences of stress during interview or on the PSS-4 or PHQ-
5. The stress described at work as well as the breakup of her marriage was reflected in 
the responses on the PSS-4 and PHQ-5 provided by PE. However, PD expressed some 
concern about the health of his wife and the severity of his condition during interview 
which was not reflected on the PSS-4. PD also stated during interview that he felt these 
items did not apply to him. However he ticked “never” for all items, when for two items 
this indicated a greater amount of stress. PB indicated that he experiences stress during 
interview, though the only item which indicates a significant amount of difficulty on the 
PSS-4 or PHQ-9 for this participant was the question “In the last month, how often have 
you felt things were going your way” to which PB replied “never”. 
 
5.3.2.3.6 Patient concerns about medications 
Participants PC, and PD were adequately represented by the concerns scale. Participant 
PE contradicts herself by saying she has no side effects in interview, but indicated that she 
was uncertain on the questionnaire. Participant PA indicated that she was uncertain if she 
should stop taking medicine when she has side effects. From interview this uncertainty 
may be caused because she thinks it is only sensible to stop if you intend to see the 
doctor to solve the problem. Participant PB indicated that he disagreed that he was 
experiencing side effects, but during interview expressed concerns about the long term 
effects of medicines.  
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5.3.2.3.7 Medication necessity 
All participants indicated that they found their medications to be necessary via WAMS. 
These sentiments were expressed during interview. 
 
5.3.2.3.8 Self-efficacy 
The scale accounted for the occasional forgetting by participants and that they all 
expressed an ability to cope with taking their medicines during interview. Only PA gave 
counter intuitive responses in this scale by indicating that she could not cope with her 
medicines when no such difficulties were reported during interview, and she has very 
high adherence. 
 
5.3.2.3.9 Social support 
All participants indicated that they had good social support via WAMS, and this was also 
indicated during interviews. The exception may be PE who made no mention of social 
contacts outside of the workplace but her survey results are confounded by the breakup 
of her marriage. However, while PB and PD receive social support from a very small 
network in comparison to PA and PC. The size of the social support network is not well 
accounted for on the current questionnaire. PA indicated that she is concerned how 
others will react if they knew what medicines she took. This concern was not clearly 
articulated during interview, although she did say she preferred to not talk about her 
medicines. 
 
5.3.2.3.10 Access to medications 
The difficulty PE had getting her medicine was reported on the WAMS. However, the 
occasional difficulties PA had obtaining her medicines were not identified, though this 
may be due to the rarity of those events. The minor difficulties expressed by the 
remaining participants in collecting medicines were represented on the questionnaire. 
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5.3.2.3.11 Provider relationship 
All participants indicated that they had a good relationship with at least their preferred 
doctor at the surgery and this was reflected on the WAMS. PC scores “agree” for all items 
on the PDRQ-9 and this may reflect his opinion that the quality of the doctors at the 
surgery is variable but generally good, and so he has avoided extreme scores. PE 
expressed her mixed opinion of the doctors in the surgery by indicating “uncertain” for 
the first item on the scale, with a note to say “Depends on which doctor” and then 
marked her scores so as to indicate the remainder of her responses were applicable to 
her preferred doctor only. 
 
5.3.2.3.12 Triangulation summary 
Overall the PALS and WAMS accurately reflected the perceptions of participants as 
expressed during interview. However, the PSS may not be sufficiently comprehensive, 
and participants understanding of side effects and how these should be managed may be 
more nuanced than can be detected upon a questionnaire. These findings stress that 
while the PALS and WAMS may be useful for identifying areas of concern for patient 
adherence they should be used to guide but not replace physician consultations. 
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5.4 Discussion 
 
5.4.1 Incorporating questionnaires into clinical practice 
The findings of this study indicate that doctors and patients see value in a questionnaire 
that can be used to improve adherence, and that participant views were predominantly 
accurately represented by the questionnaire. However, there was reticence on the part of 
doctors to incorporate questionnaires into routine practice. Questionnaires are perceived 
to stunt consultations, be time consuming, and be inferior to professional judgement. The 
best methods to combat these perceptions were to have a method of delivery pre-
consultation that required minimal staff time in the practice and which allowed a 
questionnaire to guide a consultation rather than dominate it. Scoring and interpretation 
should be simple to indicate clear solutions. Items which address patient forgetting, 
dysphasia, stockpiling, and prescription augmentation via OTC medicines or the internet 
were seen as important problems that could easily be fixed if practitioners were aware of 
them. However, only forgetting is currently assessed on the current questionnaire. 
Mandatory collection of data for QOF assessment was a key motivation for practitioners 
to complete questionnaires. This validates the strategy of incorporating items already 
required for QOF assessment in order to increase uptake of the questionnaire and to 
make collection of this data simpler for GP surgeries. 
 
5.4.2 Beliefs about medicines and adherence 
The beliefs measured on the BMQ general scale were seen as relevant and useful for 
informing a consultation with a patient. Benson and Britten (2002) conducted a 
qualitative study of nonadherence to anti-hypertensive medicines and identified general 
negative beliefs about medicines as being important. However, they did not have the 
capability in their study to compare participant testimony with actual adherence 
behaviour or with responses on a questionnaire. In this sample it was shown that the 
general negative beliefs about medicines expressed by PA did not result in nonadherence. 
However, her interview and responses on WAMS indicated few concerns with her 
antihypertensive medicines specifically. Adherence to medications can fluctuate within 
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individuals depending upon medication (Krigsman et al., 2007). This indicates that more 
direct beliefs about specific medicines are more important for predicting adherence than 
general beliefs (McHorney, 2009, McHorney et al., 2012). The experiences of PA support 
these prior findings.  
A finding that has been identified in the qualitative and quantitative literature is the 
importance of perceptions about the costs and benefits of taking medicines (e.g. Benson 
and Britten, 2002, Horne et al., 1999, McHorney, 2009, Pound et al., 2005). The current 
sample demonstrated that most participants would rather not take their medicines but 
had decided that taking them was sufficiently important to overcome this dislike. This 
decision took place rapidly after the initial prescription was made, and occurred for all 
participants whether they were adherent or not. However, it has been suggested that 
adherent patients are more likely to take their medications for granted, and that only 
patients that are opposed to taking medicine need to continue to consider the costs and 
benefits of their medicine (Britten, 1994). This study replicated this finding but has been 
able to demonstrate that patients that incorporate medicines into their daily routine did 
have higher adherence than those that continue to resist having to take medicines. 
Therefore, an initial assessment of necessities and concerns may be essential for the 
initiation of adherence but continued deliberation of the costs and benefits may have a 
detrimental impact. 
As well as taking their medicines for granted, the two most adherent participants 
received frequent reminders about the benefits of adherence. Participant PA had 
frequent exposure to the negative effects of stroke, and PC talked positively about his 
pills frequently with friends. These experiences may serve to motivate continued 
adherence via easing the recall of the benefits of hypertension medications (Tversky and 
Kahneman, 1973, Chen and Chaiken, 1999). The interaction between affective and 
heuristic cognition versus deliberate thought should be explored more thoroughly in 
future studies of adherence. 
 
5.4.3 Stress, adherence and hypertension 
The experience of symptoms and stress were very closely associated for the less adherent 
participants PB and PE, with both participants using the experience of symptoms as a 
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reminder to take medication. This belief has been shown to be widely held despite the 
relationship between the experience of stress and raised blood pressure being weak 
(Marshall et al., 2012). This could lead to patients taking hypertension medication to 
alleviate stress instead of addressing the underlying stressor which could have a direct 
detrimental impact upon physical health and generate predispositions toward unhealthy 
behaviours (Steptoe, 1991). An additional concern with patients associating their illness 
with felt symptoms is that research in asthma has indicated that the belief that a disease 
is only present when symptoms are felt is associated with lower adherence (Halm et al., 
2006). Thus relying on symptom expression to maintain adherence could lower patient 
outcomes. 
 
5.4.4 Patient information 
The importance of information provision to patients was also highlighted. Individual 
patients have differing requirements for how much information they desire, and meeting 
those requirements may improve adherence (Weinman, 1990, Horne et al., 2001). 
Provision of information was the primary means by which the practitioners in this sample 
sought to improve adherence. Despite this, there are currently no items on the 
questionnaire which assess how well patients feel they have adequate information to 
make an informed choice about taking their medicine. 
 
5.4.5 Questionnaire refinement  
Both the practitioners and one participant had concerns about using a two week window 
to assess anxiety and depression. It was perceived that this would produce false positives 
which could waste practitioner time. However, while the PHQ-5 uses a month long 
screening period, the PHQ-9 recommended by the NHS for QOF uses a two week window 
(NHS Information Centre, 2012). A two week duration of symptoms is also required for a 
diagnosis of depression according to the DSM-IV (American Psychiatric Association, 2000). 
One way to ameliorate the controversy and facilitate using QOF questionnaires to 
improve questionnaire uptake would be to incorporate the full PHQ-9. This may appear 
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more familiar to doctors, and the extra items will reduce the likelihood of false positives 
by making extreme scores less likely. 
Only the item “In the last month, how often have you felt things were going your way” on 
the PSS-4 was able to represent the stress described by PB. This might reflect the 
importance of feeling in control to this participant. The other three items on the PSS all 
address participant’s ability to control or deal with problems they face. PB may respond 
that he is in control because he perceives of himself as someone that is in control, but it is 
only when asked whether that perceived control is producing positive results that the 
experience of stress is identified. 
The PDRQ-9 measured aspects of the doctor-patient relationship considered important by 
participants, however, both practitioners and patients were uncomfortable with this 
section of WAMS. There was also a mix of responding styles between patients with some 
rating an individual doctor and some the surgery overall. The scale as modified also does 
not sufficiently take into account the role of nurses in chronic illness management. This 
discomfort on the part of participants may partially explain the low response rate for the 
questionnaire. Participants also said that they would not stay at a doctor they did not like, 
and some chose to respond based upon an individual doctor they did like if they did not 
approve of all GPs at the surgery. The ambiguities in interpretation, the potential effect 
upon response rate, and the discomfort with the information expressed by practitioners 
suggest this scale should be omitted from future version of WAMS. 
The items addressing smoking and drinking were perceived as likely to reduce response 
rates and produce false or inaccurate information. However, smoking and drinking 
behaviours are reliable indicators of adherence and also serve as a motivation for the 
uptake of the questionnaire in primary care because they are required for QOF 
assessment. Therefore, comparing the response rate of WAMS with the section removed 
and with a “prefer not to say” option is advocated. 
Participants had difficulty interpreting some questions on the BMQ-General scale. 
Participants used the “uncertain” option frequently and one participant stated they did 
not consider themselves qualified to answer the questions. However, the practitioners 
stressed that this section would be useful for informing consultations with patients. 
Consequently negotiating rewording with the authors of the scale to improve the wording 
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of items or else developing a new scale which seeks to assess similar content is 
recommended. 
The section on access to medicines could be expanded. Cost of medicines was identified 
as a potential cause of non-adherence by both practitioners and patients. Participant PE 
also indicated that willingness to pay may be a separate factor to ability to pay. It was 
suggested that difficulty in getting access to a new supply of medicines should be 
considered separately to difficulty with the frequency of requiring a new supply of 
medicines. However, there was also reluctance on the part of the practitioners to identify 
problems that they could not solve. Expanding the access section beyond cost may not be 
productive, and individual access problems can be discussed in consultation. 
Routine was shown to be extremely important to participants. It could be useful to add 
items regarding whether participants have a routine and whether or not they find taking 
medicines restricts their freedom. 
Participant PA indicated that the current item regarding health literacy may confound 
social support and health literacy. This participant lived alone and this might have been a 
factor in their stating that they “never” have help reading health materials when during 
interview she stated she finds PILs difficult to read. 
The item “If my medicines are making me feel worse than my illness, I think it makes 
sense to stop taking it for a while” is ambiguous. This question as phrased does not make 
it clear whether or not a patient should agree or disagree to this statement if they think 
they should stop if medicines feel worse but only if they then plan to seek a consultation 
to discuss this with their doctor. 
Participants PB and PC expressed concerns regarding the long term effects of medicines. 
The concerns scale could be expanded to consider these beliefs as well as the felt 
experience of side effects. 
Having both positively and negatively worded items caused confusion for some 
participants. PD said during interview that the section on stress did not apply to him, but 
scored maximally at risk for nonadherence for the negatively worded items on the PSS-4 
which might indicate that he had ticked the wrong box. Similarly PA is very adherent and 
gave no indications during interview of struggling with her medicines but ticked the box 
to indicate that she could not cope with the number of medicines she has to take on 
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WAMS. The most likely explanation is that the switch from positive to negative wording 
confused her. Outside of pre-validated scales, it might be advantageous to reword 
questions to be all positively or negatively worded to reduce the probability of 
respondents making errors of this kind. 
 
5.4.6 Opportunities for further study 
The role of social network size on adherence requires further study. All participants 
received emotional support from at least one other individual, or from colleagues at 
work. One proposed mechanism for  this relationship is that higher social engagement 
increases self-efficacy (Berkman et al., 2000). Regular social activity, particularly in the 
elderly has been shown to increase self-efficacy and promote engagement in healthy 
activities. The comments from the adherent patients within this study suggest plausible 
mechanisms for this increase in self-efficacy. Participant PC’s friends would often discuss 
their problems in order to reduce how threatening they seemed. The use of humour 
seemed especially important and could be explored further. Participant PA did not like to 
discuss her illness. However, her regular activities may give her an identity other than as a 
“sick person”. A phenomenological study has indicated that not defining yourself by your 
disease can lead to acceptance and improved adherence (Tilden et al., 2005). This 
hypothesis requires further study. 
Practitioners liked the idea of using technology to deliver questionnaires in order to 
improve response rates and automate data collection. The evidence is not strong that the 
use of technology would increase response rates, with e-mailed questionnaires having 
especially low response rates (Sheehan, 2001). However, the difference in response rates 
between mail and e-mail surveys may be reducing (Shih and Fan, 2009), and additional 
options for deployment such as smartphones are being developed (Millar and Dillman, 
2012). The advantages and disadvantages of utilising these technologies require 
continued study. 
The reluctance of participant PB, who had a strong dislike of taking and relying on 
medicines, to stop taking a medication he and his doctor acknowledged was having no 
effect upon his health. This represents a waste of NHS money and an unneeded 
restriction upon the patient’s routine. The endowment effect refers to the tendency for 
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individuals to place greater value on properties that they own than they would ascribe to 
the same property if they did not own it (Thaler, 1980). This loss aversion could explain 
the choice to keep taking medicine even taking medicine is generally resisted. No prior 
studies into this effect have been identified. 
 
5.4.7 Limitations 
The primary limitation of this study was the low consent rate which enforced a 
convenience sampling method. Participants are therefore unlikely to be representative of 
the wider population. Additionally, deliberately selecting a heterogeneous sample to 
ensure conceptual breadth was not possible. However, the sample was heterogeneous in 
terms of adherence, age, social support, and beliefs about medicines. Only mental 
wellbeing and relationship to providers were mostly homogenous in the sample so the 
lack of deliberate sampling may not impact heavily upon the conclusions that were 
reached. However, the sample had very little heterogeneity in social class, and issues of 
access to medicines in terms of cost and transport may be very different to those 
experienced in urban populations. 
When participants were interviewed in their own home they tended to be more prone to 
presenting themselves in a socially desirable light. This effect was particularly pronounced 
in the two female participants. This may be related to the discomfort participants in 
interview feel when interviewed in their own home, and a third, neutral location may 
have reduced the impact of self-presentation biases (Elwood and Martin, 2000). 
Regarding the practitioner focus group a particular limitation was that the practitioners 
had not read the questionnaires before the session as instructed. This meant that the 
flow of the focus group was impacted due to a lack of familiarity with the materials 
required for the session. As a consequence practitioners were required to frequently 
refer to the written material rather than engage freely in discussion about it. In itself that 
the questionnaires were not read is a useful result in terms of highlighting the premium 
healthcare practitioners place upon their time and their reluctance to engage in non-
essential tasks. Nonetheless the session was able to meet the objectives of exploring 
practitioner perceptions of the questionnaires clinical utility, patient acceptability and 
optimising practitioner time for research. 
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5.4.8 Conclusion 
This chapter has built upon the quantitative assessment of the PALS and WAMS in 
chapter 4 and presented additional opportunities to improve the tools for future use. 
Methods for increasing the probability of GPs incorporating the questionnaire into regular 
practice have been identified. Potentially important omissions, confounds, and 
ambiguities in current questions have also been highlighted. Importantly, the qualitative 
treatment has provided a richer understanding of how the indicators identified via meta-
analysis in chapter 2 such as stress and beliefs about medicines interact with patients’ 
experiences of illness and medicines to influence adherence. 
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Chapter 6 – General Discussion 
 
6.1 The necessity of the current work 
Chapter 1 highlighted the need for a new clinically useful measure of nonadherence. 
Physicians predominantly overestimate the probability that their patients are adherent 
and so may fail to attribute treatment failure to nonadherence, an additional and greater 
concern is that physicians may underestimate adherence and so not prescribe potentially 
valuable therapy (Paterson et al., 2000). Existing measures for nonadherence are not 
adequate for improving the accuracy of physician estimates. The scales overestimate 
adherence by asking direct questions about adherence which introduces social 
desirability biases (Guénette et al., 2005, Paterson et al., 2002). Moreover, existing scales 
either lack clinical utility by failing to identify targets for intervention to improve 
nonadherence (Morisky et al., 1986a, McHorney, 2009), or else have significant 
psychometric weaknesses such as sections that have not been validated (Svarstad et al., 
1999), poor internal consistency and criterion validity (George et al., 2006), or have 
ambiguous structure due to an incomprehensive description of test construction (Hahn et 
al., 2008). The stated aim of this thesis was therefore to develop a new tool which could 
predict the likelihood of nonadherence to medication and help clinicians to identify 
patient specific interventions to mitigate risk factors for nonadherence. 
 
6.2 Identified indicators of adherence 
A barrier to achieving the aims of the thesis was that existing models of adherence fail to 
identify the antecedents of the beliefs that contribute to adherence behaviour; and 
knowledge of these is required in order to inform interventions (Weinstein, 2007). 
Moreover the models often explain only a small proportion of adherence behaviour and 
so cannot be said to be comprehensive (Chisolm et al., 2010). In order to develop a new 
questionnaire, the indicators of adherence were therefore identified via a quantitative 
review. By searching for all indicators of adherence with a demonstrable relationship with 
adherence and not only those with the strongest relationships both proximal and more 
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distal variables could be identified. This helps to ensure that the questionnaire was 
comprehensive and able to inform clinical decisions. 
This review revealed that the adherence literature is vast and poorly coordinated. The 
majority of identified studies did not define adherence, over a third did not provide 
information regarding how they divided participants into adherers and nonadherers, and 
most developed their own measure of adherence particular to the individual study. The 
lack of consistency and quality of medication adherence measurement made providing 
any accurate assessment of the size of the relationship between any indicator and 
adherence challenging. There is therefore a desperate need for consistency of definitions, 
methods, and measurement in adherence research (Vermeire et al., 2001, Kyngäs et al., 
2000). In an attempt to foster greater consistency across the adherence literature, the 
discrepancies in definition prevalent in the current literature have been quantified and a 
standardised taxonomy of adherence proposed (Vrijens et al., 2012).  
Despite the lack of coherence in the literature, a number of indicators were reliably 
associated with adherence. These included patients’ engagement in risky health 
behaviours, quality of life and mental wellbeing, beliefs about medicines, self-efficacy, 
barriers to medicine taking and acquisition, social support, the relationship patients have 
with their healthcare providers, and health literacy. It was also considered that these 
variables may be amenable to intervention. Previous reviews have identified that 
education about the benefits of medicine, reducing the difficulty of taking medicines, 
using peer or family support, stress management, and skill building or routine 
management can all help to improve adherence (Demonceau et al., 2013, Haynes et al., 
2008). This suggests that the identified factors could have clinical utility as well as the 
property of being able to identify patients at risk of nonadherence. Therefore it was 
decided that the new adherence questionnaire should measure these variables. 
 
6.3 Incorporating identified indicators into an adherence measure 
Practitioner consultation to optimise clinical utility identified that brevity is of paramount 
importance both to reduce the burden placed upon patients, but also to facilitate rapid 
decision making (Spitzer et al., 1999). The use of existing scales was also perceived as 
likely to improve acceptability to GPs and the use of previously validated scales also 
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streamlines the questionnaire development process. As a consequence, two new 
questionnaires were composed, where possible comprising of existing scales which 
measured the constructs identified as associated with adherence. Splitting the 
questionnaire into two sections was expected to reduce the burden of questionnaire 
administration for both patients and medical personnel and therefore allow the new 
questionnaires to optimise comprehensiveness with pragmatism (Chipperfield and Steel, 
2011).  
 
6.4 Quantitative appraisal of the PALS and WAMS 
Despite a small sample size it was possible to discern some aspects of the questionnaire 
which had associations with adherence. Health literacy was an indicator of both refill and 
self-reported adherence. If health literacy is considered a proxy for a patient’s ability to 
seek and comprehend information about their illness and medicines, then the cause of 
the strong association identified could be related to the study participants having above 
average adherence. It has been demonstrated that patients are more likely to seek 
information that confirm prior hypotheses, and are not generally able to develop 
searches that would also present information for alternative hypotheses (Kayhan, 2013). 
Thus patients with high health literacy may be more able to seek information that 
reinforces their own positive view about medicines. This could account for the more 
variable association between health literacy and adherence identified elsewhere (Loke et 
al., 2012) because for samples which incorporate patients with a more negative view of 
medicines or illness, health literacy may promote identification of information that 
reinforces nonadherence. 
Stress, anxiety and depression were also identified as predicting self-reported and 
prospective adherence. It has been proposed that depression may negatively impact 
upon adherence because belief in the positive efficacy of treatment is diminished 
(DiMatteo et al., 2000). It is plausible that subclinical mental distress has a similar impact 
upon adherence. Measuring how stressed, anxious, or depressed patients are could be 
interpreted as estimating the extent of negative bias introduced into appraisal of 
medicines through the affective stream of the parallel response framework (Leventhal et 
al., 1992). This hypothesis is supported by the finding that that general stress, but not 
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disease specific stress, mediated adolescent adherence to diabetes medication (Farrell et 
al., 2004). Disease specific stress may augment the cognitive perception of the necessity 
for one’s medicine while general stress and a lower quality of life may inhibit the 
perception of benefit from medicine (DiMatteo et al., 2000, Farrell et al., 2004). One of 
the core benefits of medicinal therapy for patients is the restoration of quality of life 
(Erlen and Mellors, 1999), and so optimising patient quality of life would bring the aims of 
practitioners and the aims of patients closer together (Pollock, 2005). Regular monitoring 
and early intervention to prevent deterioration of patient mental health has been 
advocated (Watson et al., 2011). 
 
6.5 Qualitative appraisal of PALS and WAMS 
In chapter 5 a group of practitioners were consulted to appraise the clinical utility of the 
scale. Practitioners stated that they thought the key to improving adherence was to 
educate their patients about the benefits of their medicines. However, all interviewed 
patients stated that they felt that the benefits of their medicines outweighed the costs 
whether they were adherent or not. Recent evidence from a meta-analysis has suggested 
that the benefits of cognitive interventions to improve adherence become smaller as the 
duration of the study increases (Demonceau et al., 2013). Similarly, Haynes et al. (2008) 
found that interventions to increase adherence were more successful for short term 
treatments than for chronic conditions. These findings suggest that cognitive appraisals 
may be more important soon after initiation of a new medicine. This could explain why 
the perceived importance of a medicine has been shown to be critical for primary 
adherence (Jackevicius et al., 2008, Williams et al., 2007b, Beardon et al., 1993), and why 
the rate at which patients become nonadherent is much more rapid in the first six months 
of therapy (Chapman, 2004). Moreover, a study directly comparing the importance of 
habit versus appraisal for long term adherence found habit to be the stronger indicator, 
particularly for long term adherence (Phillips et al., In press). However, all patients will 
continue to hold positive and negative beliefs about medicines, and these beliefs will both 
cause and be caused by behaviour (Weinstein, 2007). Therefore patients with high 
adherence will report that medicine is necessary despite their concerns, while 
nonadherent patients may report side effects and concerns more strongly than a belief in 
the importance of medicine. However, these appraisals may not represent an everyday 
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decision making process so much as one provoked by a researcher, doctor, or in the case 
of one participant, a newspaper. These findings highlight the need for regular monitoring 
of patient perceptions of medicines, but also the necessity of investigating beyond 
patients beliefs about medicines and exploring their ability to incorporate medicines into 
their everyday life. 
The importance of social support in adherence was also highlighted. In particular the key 
role relationship partners play in offering direct practical and emotional support to 
improve adherence which for some individuals they might be the only source of support 
available. However prior research has indicated that a wider network of social support 
offers greater benefits for adherence (DiMatteo, 2004b).The various ways in which social 
support can help improve adherence were described in chapter 5. For one participant 
their support network provided a distraction that prevented them feeling defined by their 
illness, which has been tentatively linked to improved adherence (Tilden et al., 2005). For 
another, the role of the support network was to provide direct reassurance and 
information, and help to maintain an optimistic outlook (Berkman et al., 2000). Thus the 
role of social support for two adherent individuals appeared very different. There has also 
been evidence to suggest social support does not have a universally beneficial effect upon 
adherence. Warner et al. (2013) performed a longitudinal study of the effect of social 
support upon adherence in older individuals and found that general social support had no 
effect upon adherence while medication specific social support had a negative effect 
upon later medication adherence. The study also found evidence that the cause of 
medication specific social support lowering adherence could be explained by social 
conflict. This proposes that unwanted social support that reduces an individual’s sense of 
autonomy may have a negative impact upon adherence. This account would fit with the 
resistance of some participants to receive support from outside their marriage and 
unwillingness to talk to others about their medical condition. However the present 
analyses were not designed to answer this specific question. Focussed qualitative studies 
exploring the ways in which patients utilise social support to manage their medicines and 
illness may identify the ways in which wanted and unwanted social support is sought and 
managed which could help to develop theory which could facilitate the design of group 
interventions involving a wider support network to improve adherence. 
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Interviews with patients also highlighted that modern healthcare is characterised by a 
lack of continuity in care; with patients receiving treatment from multiple GPs and nurses 
as part of chronic illness management. The quality of relationship between patients and 
different healthcare practitioners is also variable. Adherence is related to both the quality 
of the relationship patients have with their practitioners, and congruence between 
patient and practitioners interpretations of illness and treatment (Leventhal et al., 1992, 
Arbuthnott and Sharpe, 2009). Evidence from chapter 5 indicated that the disclosures 
made to practitioners may differ depending upon the quality of the doctor-patient 
relationship. Therefore, in a multi-personnel, multi-disciplinary healthcare framework, 
standardisation of information retrieval via objective measures such as the PALS and 
WAMS could help to ensure quality of care for all patients. 
Participants and practitioners alike discussed the importance of honesty from medical 
practitioners when discussing the impacts of diagnoses and treatments with patients. 
However, there was a perceived reluctance on the part of participants to talk about some 
topic with their doctors. It was thought that some patients might lie to their doctors 
about their smoking and drinking habits, and disclosing information to the GP was one 
reason for non-participation amongst those invited to complete the PALS and WAMS. It is 
suggested patients are uncomfortable talking about unhealthy behaviours because they 
are wary of being stigmatised by their doctors, particularly in older patients (Simmons et 
al., 2009). Moreover doctors are also reluctant to discuss these topics with patients 
(Mules et al., 2012, Noordman et al., 2010). Therefore for doctors to be able to learn 
about behaviours patients may be reluctant to discuss, such as smoking, drinking, or 
nonadherence, they need to be able to foster non-judgemental relationships with their 
patients. In particular the qualitative study found that some participants were only 
comfortable discussing their health with a preferred doctor. Thus participants expressed a 
desire to have a genuine relationship with their medical practitioners based upon trust. 
This is one motive for the concordance initiative (Marinker, 2004). While it has been 
questioned whether all patients desire a concordance model of health care (Kettunen et 
al., 2001, Levinson et al., 2005), fostering relationships with patients where doctors are 
not seen to pass judgement may promote greater disclosure on the part of patients.  
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6.6 Future development of the questionnaire 
An important first step in any future development of the PALS and WAMS is negotiation 
with copyright owners of the utilised scales to extend permissions for use beyond the 
current investigation. This is a particularly pressing concern should future development 
seek to profit financially from any use of the PALS and WAMS. Some questionnaire 
authors may prefer to have their work kept in the public domain while others may prefer 
to retain the right to control when and by whom their questionnaire is utilised, and these 
different positions will need to be consolidated before the scales are utilised further. 
A weakness of the appraisal of the PALS and WAMS was that a sample size suitable for full 
psychometric testing was not obtained. While the intention of chapter 4 was primarily to 
identify potential weaknesses in the research method and ensure feasibility, and while 
other questionnaires have been successfully implemented having been tested on similarly 
small samples (Svarstad et al., 1999), the small sample size obtained severely restricted 
the confidence with which statements regarding the performance of PALS and WAMS 
could be made. Before further refinement of the PALS and WAMS is undertaken there 
therefore needs to be revisions made to the proposed testing methods. 
The first recommendation is to significantly expand the extent of face and content validity 
testing. Chapters 4 and 5 both identified some unease on the part of participants to 
complete sections of the questionnaire, as well as instances in which questions where 
there were possible ambiguities in interpretation. This included items on the BMQ 
general scale and the PDRQ-9. Therefore it would appear worthwhile to engage in 
cognitive interviewing of the full PALS and WAMS scales with both patients and health 
care workers in order to fully explore the different potential meanings of items with 
participants (Ericsson and Simon, 1993, Hernandez et al., 2011, Willis, 1999, Willis, 2005). 
Any required changes to existing scales could be negotiated with existing authors. 
Having determined acceptability and comprehensibility via this step there would be 
considerably less risk in trialling the revised questionnaire on a larger sample size. Testing 
at multiple sites should negate the risk of procedural problems at any one site having an 
overly significant impact upon total sample size while also allowing for greater claims of 
generalisability. Similarly, it could be advantageous to test the PALS and WAMS in 
illnesses beyond hypertension to establish validity across disease states as was performed 
during the validation of the BMQ questionnaires (Horne et al., 1999). This approach is 
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preferred to the use of the internet to achieve a wide sample as utilised by (Hahn et al., 
2008) because it better represents the clinical situation in which the questionnaires 
would be deployed, and it permits the collection of patient outcome data. 
In addition to general recommendations for the future design of the scales, the findings 
of chapters 4 and 5 have also highlighted action that could be applied to specific 
subscales. 
 
6.6.1 Patient demographics: “About you” 
Employment status should be expanded to account for patients unable to work because 
of disability. Similarly, not all possible living arrangements are accounted for and this item 
should be reworded so that it asks only whether or not a patient lives with their romantic 
partner. 
 
6.6.2 Health Literacy: “Written information” 
This item predicted adherence well, however chapter 5 indicated that the current item 
“How often do you ask someone to help you understand medical information?” may be 
difficult to answer if a person has nobody to ask for help. It is also acknowledged that 
given the small sample it remains plausible that health literacy may have different 
relationships with adherence depending upon patient health beliefs and so the factor 
would not remain so strongly predictive if tested in a more diverse sample. However, 
given the strong performance of this question for predicting nonadherence thus far, it is 
recommended that no changes should be made at this stage. 
 
6.6.3 BMQ-General subscale: “Your beliefs about medicines” 
Practitioners thought that the content of the BMQ would be useful with regard to 
planning a consultation with a patient. However, the BMQ should be tested via cognitive 
interviewing to identify how participants understand the items on the scale (Willis, 2005). 
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If significant problems are identified a new set of questions should be developed, or the 
current BMQ reworded with the consent or collaboration of the original authors. 
 
6.6.4 Mental health and risky behaviours: “Your mental health and 
behaviour” 
The item on mental health should be removed. The omission of risk behaviours might 
negatively impact upon the ability of the tool to predict adherence. However, this section 
may have lowered response rate in chapter 4. Consequently the impact of including and 
excluding this section on acceptability and adherence prediction should be directly 
measured. 
 
6.6.5 Patient affect: “Mental wellbeing and happiness” 
The PSS-4 and PHQ were used to measure stress, anxiety, and depression, and the tools 
should both be retained for future iterations of the questionnaire. However, the extent of 
the collinearity between the three constructs should be estimated. The two week window 
for responses on the PHQ also caused some concern for practitioners and one of the 
patients. To remedy these concerns swapping the PHQ-5 for the PHQ-9 as currently 
utilised for QOF is recommended. 
 
6.6.6 Patient Adjustment to Medications Scale: “Adjusting to your 
medicines” 
 
6.6.6.1 Concerns about medicines 
The item “If my medicines are making me feel worse than my illness, I think it makes 
sense to stop taking it for a while” contains a conditional which should be removed. The 
item also asks about whether patients think they should do something, not how they 
actually behave which may lower accuracy (Mason, 2002). The item also asks about 
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adherence in a direct way which the questionnaire aims to avoid. In chapter 4 the 
alternative “I think my medicines make me feel worse than my illness” was suggested. 
Chapter 5 also indicated that the scale should be expanded to include items which 
consider long term concerns about the effects of medicines beyond perceived side 
effects.  
 
6.6.6.2 Medication necessity 
No immediate problems were identified with the medication necessity scale. However, 
based upon the experiences of participants interviewed in chapter 5 the scale could be 
expanded in scope to cover the extent to which medicines are integrated into the 
everyday life of patients, and not just how necessary they are deemed to be. 
 
6.6.6.3 Self-efficacy 
The items on this scale did not appear to be measuring a unitary construct. It was 
suggested that the question “I find it hard to remember to take my medicines each day” 
may be too direct an assessment of unintentional nonadherence and could be made to 
measure self-efficacy by changing the wording to “I am confident I can take all of my 
medicines each day”. However, the practitioners expressed a desire for items on the 
questionnaire which identified unintentional nonadherence behaviours that could be 
fixed with simple interventions. An alternative to expanding the self-efficacy scale is to 
use this section to instead determine whether patients think they find the number of 
medicines they take overwhelming or difficult to remember, in which case a pill box could 
be used to help with adherence (Petersen et al., 2007). Additional items could identify 
difficulties caused by dysphasia, the stockpiling of medicines, or the augmentation of 
prescriptions via OTC or internet purchases.  
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6.6.6.4 Social support 
This item “I am concerned about how others will react if I tell them what medicines I 
take” measures social stigma of illness and not social support and should be removed. 
Chapter 5 indicated that there may be an important role for social network size in 
adherence. The social stigma item could be replaced with a question which gave an 
indication of the number of people in a patient’s social circle. Further the scale should 
focus more upon support received pertinent to taking medication, and not dealing with 
illness. This more direct relationship may improve the ability of the section to predict 
nonadherence. 
 
6.6.6.5 Access to medication 
The single item in the scale predicted adherence successfully. However, practitioners felt 
that there were important aspects of access that were not covered. Practitioners and 
patients were concerned about the cost of medicines. However further expansion of the 
scale beyond cost risks exposing doctors to an expectation that they can change access 
problems beyond their control. 
 
6.6.7 Provider relationship: “About your doctor” 
Scores on the PDRQ-9 were heavily skewed toward indicating a good relationship with 
doctors limiting how much information is provided by this scale. Further, given the 
possible impact upon response rates and the potential difficulties the responses on the 
questionnaire may create for the doctor patient relationship it should be excluded 
outright from future versions of the questionnaire. This does not indicate that the 
patient-practitioner relationship is not considered to be important, the evidence 
presented has reinforced that it is a factor of high importance for medication adherence. 
The recommendation to remove the section only reflects the belief that this 
questionnaire is not the correct forum in which to explore patient-practitioner 
relationships. 
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6.7 Final conclusions 
The objective of the thesis was to develop and pilot a novel clinically useful questionnaire 
which would help clinicians to identify patients at risk of nonadherence and help to 
inform tailored interventions to augment adherence. The result was the production of the 
PALS and WAMS questionnaires. Preliminary psychometric evaluation and qualitative 
validity assessment has indicated that while the PALS and WAMS could make a 
meaningful contribution to clinical management of adherence, further development of 
the questionnaires is required. Some subjects within the PALS and WAMS may be 
considered too sensitive for measurement via a clinical tool, such as smoking, drinking, 
mental health, and assessment of the patient-practitioner relationship. Further, some 
scales required expansion in order to improve internal consistency and clinical decision 
making, such as the self-efficacy scale and assessment of barriers to taking medicines. 
However, in the main both the PALS and WAMS were seen by clinicians and patients as 
potentially useful, and easy to understand. 
  
222 
 
Appendices
Appendix A – Description of studies included in meta-analyses 
 
223 
 
 Number of Studies Per cent of Sample 
Year published   
1981-1990 3 1.52 
1991-2000 18 9.09 
2001-2005 59 29.80 
2005-2010 118 59.60 
Total 198 100 
Study Type   
RCT 6 3.03 
Cross-sectional 95 47.98 
Prospective cohort 46 23.23 
Retrospective cohort 45 22.73 
Before-After 4 2.02 
Case-Control 2 1.01 
Total 198 100 
Definition of adherence   
Haynes (1979) 13 6.57 
WHO (2003) 6 3.03 
Studies own 38 19.19 
Other 5 2.53 
None 136 68.69 
Total 198 100 
Cut point for % pills required to be adherent 
0-79% 7 3.54 
80-89% 42 21.21 
90-94% 14 7.07 
95-99% 18 9.09 
100% 20 10.10 
Unclear/Not stated 70 35.35 
Not dichotomised 27 13.64 
Total 198 100 
Method of adherence measurement 
Direct (E.g. Blood sample) 4 2.02 
Questionnaire 48 9.09 
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Interview 60 30.30 
Refill rate 47 23.74 
Pill Count 12 6.06 
Electronic device 13 6.57 
Multiple 10 5.05 
Unclear/Not stated 4 2.02 
Total 198 100 
Questionnaire/Interview tools used to measure adherence 
Morisky 18 16.98 
AACTG 10 9.43 
Other 13 12.26 
Studies own 65 61.32 
Total 106 100 
Adherence assessment period   
0-1 week 29 14.65 
> 1 week – 1 month 29 14.65 
> 1 month – 6 months 37 18.69 
> 6 months – 1 year 30 15.15 
> 1 Year 21 10.61 
Unclear 52 26.26 
Total 198 100 
Disease State   
HIV 64 32.32 
Hypertension 26 13.13 
Other cardiovascular illness 21 10.61 
Diabetes Type 1 1 0.51 
Diabetes Type 2 13 6.57 
Diabetes (Type not specified) 2 1.01 
Osteoporosis 8 4.04 
Cancers 6 3.03 
Asthma 12 2.53 
Renal illness 5 2.53 
Arthritis 5 2.53 
Tuberculosis 5 2.53 
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Multiple Sclerosis 4 2.02 
Sleep Apnoea 3 1.52 
Glaucoma 2 1.01 
Cerebrovascular disease 1 0.51 
Dermatological conditions 1 0.51 
Inflammatory Bowel Disease 1 0.51 
Migrane 1 0.51 
Parkinson’s 1 0.51 
Epilepsy 1 0.51 
Multiple/Unclear 15 5.56 
Total 198 100 
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Indicator k n Median 
r 
Minimum 
r 
Maximum 
r 
R1 R2 Lower 
C.I. 
Upper 
C.I. 
p Q2 d.f.3 Q-p4 I2 S.E.5 Tau6 
Demographics                 
Increasing age 83 2079337 0·06 -0·21 0·51 0·06 <0·01 0·04 0·08 <0·001 5022·31 82 <0·001 98·37 0·01 0·08 
Income 19 7657 -0·04 -0·31 0·3 0·01 <0·01 -0·05 0·06 0·208 58·17 18 <0·001 69·06 0·01 <0·01 
Adherence behaviours                 
Adherence to diet 4 1881 0·21 0·03 0·37 0·19 0·03 0·03 0·33 0·017 22·18 3 <0·001 86·47 0·02 0·14 
Affect                 
Anxiety 11 1375 -0·20 -0·48 0·16 -0·16 0·03 -0·25 -0·07 <0·001 24·60 10 0·006 59·34 0·01 0·11 
Stress 12 3423 -0·17 -0·4 -0·03 -0·16 0·03 -0·23 -0·09 0·001 55·02 11 <0·001 80·01 0·01 0·10 
Distress 6 885 -0·18 -0·35 -0·07 -0·17 0·03 -0·25 -0·09 <0·001 9·78 5 0·082 48·88 0·01 0·07 
Hostility 3 671 -0·16 -0·35 0·04 -0·16 0·02 -0·42 0·12 0·266 23·79 2 0·001 91·59 0·07 0·24 
Beliefs about medicines                 
Satisfaction with medicines 5 1872 0·29 0·1 0·4 0·25 0·06 0·12 0·36 <0·001 23·50 4 0·001 82·98 0·02 0·13 
Positive belief regarding 
medicine 
6 3207 0·16 0·11 0·32 0·15 0·02 0·10 0·21 <0·001 8·32 5 0·139 39·90 <0·01 0·04 
BMQ Necessity 4 622 0·34 0·11 0·44 0·29 0·08 0·14 0·42 <0·001 9·94 3 0·019 69·81 0·02 0·13 
BMQ Concerns 3 622 -0·02 -0·13 0·05 -0·04 <0·01 -0·15 0·07 0·481 3·72 2 0·156 46·20 0·01 0·07 
Fewer concerns (Including 
BMQ) 
7 2783 0·13 -0·09 0·32 0·09 0·01 -0·04 0·22 0·151 39·374 6 <0·001 84·90 0·02 0·15 
Knowledge                 
Knowledge of medication 10 6208 0·18 -0·03 0·56 0·08 0·01 0·08 0·26 <0·001 45·83 9 <0·001 80·36 0·01 0·13 
Health Literacy 4 2062 0·24 0·07 0·29 0·19 0·04 0·07 0·31 0·002 11·78 3 0·008 74·53 0·01 0·12 
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Regimen                 
Frequency pills per day 11 4482 0·014 -0·4 0·21 0·03 <0·01 -0·03 0·10 0·318 24·71 10 0·006 59·52 0·01 0·08 
Longer time on regimen 12 20806 -0·08 -0·21 0·45 -0·06 <0·01 -0·12 -0·01 0·027 414·17 11 <0·001 97·34 0·01 0·07 
Social Support                 
Social support 22 6641 0·16 -0·2 0·61 0·14 0·02 0·08 0·20 <0·001 109·53 27 <0·001 75·35 0·01 0·13 
Costs                 
Cost of Medicines 10 55800 -0·08 -0·35 0·03 -0·08 0·01 -0·11 -0·04 <0·001 119·45 9 <0·001 92·47 <0·01 0·06 
Total costs of treatment 4 23013 0·09 -0·13 0·18 0·06 <0·01 -0·05 0·16 0·302 30·66 3 <0·001 90·22 0·01 0·10 
Provider Relationship                 
Satisfaction with care 9 3336 0·17 -0·08 0·61 0·13 0·02 0·05 0·22 0·003 54·96 8 <0·001 85·45 0·01 0·11 
Trust in physician 8 7263 0·19 0·1 0·31 0·16 0·03 0·12 0·21 <0·001 21·98 7 0·003 68·15 <0·01 0·05 
Good 
communication/Relationship 
with Physician 
13 8592 0·09 -0·13 0·35 0·10 0·01 0·06 0·14 <0·001 25·75 12 0·012 53·40 <0·01 0·05 
Disease Severity                 
Symptom severity 15 8460 -0·02 -0·25 0·15 -0·02 <0·01 -0·05 0·01 0·163 53·29 14 <0·001 73·73 <0·01 0·03 
Duration of disease 21 15608 -0·01 -0·24 0·27 -0·01 <0·01 -0·05 0·04 0·731 60·22 20 <0·001 66·79 <0·01 0·08 
Side effects                 
Number of side effects 5 1394 -0·16 -0·3 -0·02 -0·17 0·03 -0·29 -0·04 0·010 29·32 4 <0·001 86·36 0·02 0·13 
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Severity of side effects 5 3672 -0·27 -0·31 -0·2 -0·22 0·05 -0·26 -0·18 <0·001 4·11 4 0·392 2·63 <0·01 0·01 
Disease Beliefs                 
Susceptibility to disease 4 988 0·09 -0·07 0·49 <-0·01 <0·01 -0·23 0·23 0·975 27·95 3 <0·001 89·27 0·08 0·22 
Barriers to medication                 
General Barriers 8 2941 -0·28 -0·53 -0·06 -0·25 0·06 -0·36 -0·14 <0·001 45·04 7 <0·001 84·46 0·02 0·14 
Good access to medical care 4 912 0·23 0·02 0·26 0·20 0·04 0·09 0·29 <0·001 4·73 3 0·193 36·53 0·01 0·06 
Good access to medication 3 688 0·15 0·14 0·38 0·20 0·04 0·07 0·32 0·004 3·77 2 0·152 46·94 0·02 0·08 
Mental Health                 
Mental health summary scores 6 4154 0·17 -0·01 0·22 0·15 0·02 0·10 0·20 <0·001 10·15 5 0·071 50·74 <0·01 0·05 
Depression 39 95192 -0·12 -0·56 0·31 -0·10 0·01 -0·13 -0·07 <0·001 162·84 38 <0·001 76·66 <0·01 0·06 
Cognitive ability                 
Good memory 4 441 0·14 -0·01 0·42 0·18 0·03 0·01 0·35 0·043 8·82 3 0·032 65·99 0·03 0·15 
Social cognition                 
Self-efficacy/Perceived 
behavioural control 
21 9047 0·26 -0·02 0·64 0·27 0·07 0·20 0·34 <0·001 123·87 20 <0·001 83·85 0·01 0·15 
Quality of Life/Wellbeing                 
General QOL measures 15 5379 0·12 -0·26 0·25 0·10 0·01 0·04 0·16 0·001 40·62 14 <0·001 65·53 0·01 0·09 
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General QOL measures, HIV 
only 
6 1129 0·20 0·05 -0·26 0·18 0·03 0·12 0·24 <0·001 3·50 4 0·624 <0·01 0·01 <0·01 
General QOL measures, non-
HIV only 
9 4250 0·09 -0·26 0·23 0·06 <0·01 -0·02 0·14 0·127 28·86 8 <0·001 72·28 0·01 0·10 
Physical functioning 18 15175 0·10 -0·27 0·59 0·08 0·01 0·01 0·14 0·030 89·98 17 0·001 81·11 0·01 0·12 
Physical functioning, HIV only. 8 1721 0·14 -0·2 0·59 0·18 0·03 0·03 0·31 0·015 47·21 7 <0·001 85·17 0·03 0·19 
Physical functioning, non-HIV 
only. 
10 13454 0·04 -0·27 0·18 0·01 <0·01 -0·05 0·08 0·175 27·38 8 0·001 67·13 0·01 0·08 
Mental wellbeing 7 1942 0·06 -0·08 0·15 0·06 <0·01 -0·01 0·13 0·115 12·18 6 0·058 50·74 0·01 0·07 
Personality                 
Locus of control                 
Internal LOC 3 485 0·07 -0·01 0·41 0·13 0·02 -0·07 0·32 0·203 8·79 2 0·012 77·25 0·03 0·16 
Coping style                 
Active 4 536 -0·04 -0·31 0·1 -0·03 <0·01 -0·13 0·07 0·554 8·00 3 0·146 62·51 0·01 0·08 
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Indicator k n Median 
OR 
Minimum 
OR 
Maximum 
OR 
OR1 Lower 
C.I. 
Upper 
C.I. 
p Q2 d.f.3 Q-p4 I2 S.E.5 Tau6 
Demographics                
Black vs Other races 6 40263 0.51 0.43 0.96 0.60 0.46 0.78 <0.001 8.74 5 0.120 42.77 0.07 0.20 
White vs black 13 1954297 1.46 0.20 4.38 1.43 0.96 2.14 0.081 1360.30 12 <0.001 99.12 0.55 0.69 
White vs. Hispanic 6 1892707 1.38 0.13 3.43 1.12 0.79 1.59 0.522 25.53 5 <0.001 80.42 0.13 0.35 
White vs non-white 12 6901 1.74 0.30 5.00 1.38 0.94 2.01 0.098 59.05 11 <0.001 81.37 0.22 0.54 
White vs other 9 1947200 1.16 0.18 2.33 1.20 0.83 1.75 0.327 728.02 8 <0.001 98.90 0.28 0.48 
Sex (Female vs male) 68 2167404 1.00 0.36 3.82 0.99 0.93 1.05 0.665 420.30 67 <0.001 84.06 0.02 0.15 
Education (all) 48 48321 1.15 0.19 10.60 1.14 0.94 1.39 0.176 367.87 47 <0.001 87.22 0.15 0.59 
Education (college education vs none) 25 42361 1.18 0.23 10.60 1.15 0.86 1.54 0.345 230.30 24 <0.001 89.58 0.24 0.65 
Employment (yes vs no) 14 5661 1.12 0.41 4.33 1.32 1.01 1.72 0.045 47.14 13 <0.001 72.42 0.11 0.41 
Health insurance (Yes vs No) 7 3118 1.12 0.25 2.40 1.08 0.69 1.69 0.734 16.81 6 <0.001 64.31 0.21 0.47 
Health behaviours                
Smoking Yes/More vs No/Less) 15 151636 0.67 0.32 1.40 0.71 0.63 0.80 <0.001 24.52 14 0.040 42.91 0.02 0.12 
Alcohol use 11 4449 0.77 0.36 0.99 0.66 0.53 0.81 <0.001 7.23 10 0.704 <0.01 0.57 <0.01 
Problem alcohol use 7 10351 0.64 0.30 0.86 0.47 0.35 0.63 <0.001 7.61 6 0.268 21.13 0.09 0.18 
Drug use 11 2862 0.48 0.14 0.92 0.52 0.40 0.67 <0.001 17.04 10 0.073 41.32 0.08 0.26 
Complementary medicine use 3 2334 0.59 0.35 1.26 0.68 0.34 1.34 0.261 23.30 2 <0.001 91.42 0.40 0.56 
Beliefs about medicines                
Effectiveness 6 1607 2.70 0.77 5.18 2.24 1.12 4.49 0.022 25.37 5 <0.001 80.30 0.50 0.73 
Fewer Concerns about medication (independent of 
BMQ) 
4 2161 2.04 0.69 3.40 1.68 0.75 3.79 0.208 29.90 3 <0.001 89.97 0.66 0.75 
Fewer concerns (Including BMQ) 7 2783 1.61 0.69 3.40 1.41 0.88 2.25 0.158 37.43 6 <0.001 83.97 0.26 0.56 
Knowledge                
Knowledge of illness 8 2945 3.04 1.15 7.89 2.49 1.55 3.98 <0.001 53.23 7 <0.001 86.85 0.31 0.59 
Regimen                
Number of co-medications 4 24204 1.05 0.78 1.25 1.00 0.79 1.27 0.987 36.97 3 <0.001 91.89 0.06 0.22 
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Different types of medicines per day for condition 14 180468 1.04 0.16 3.43 0.98 0.70 1.40 0.929 2599.52 13 <0.001 99.50 0.32 0.63 
Fewer different types of medicines per day for HIV 5 1504 1.89 1.12 3.43 1.89 1.30 2.74 0.001 7.16 4 0.128 44.10 0.13 0.28 
Fewer different types of medicines per day for non-
HIV 
9 178964 0.94 0.16 1.34 0.74 0.49 1.12 0.155 2551.13 8 <0.001 99.69 0.32 0.63 
Complexity of regimen 8 4435 0.97 0.30 3.39 0.86 0.51 1.44 0.562 62.00 7 <0.001 88.71 0.35 0.66 
Increasing number of pills per day, require 90% 
pills to be adherent 
4 2293 0.60 0.57 1.32 1.58 1.18 2.13 0.002 2.23 3 0.526 <0.01 0.08 <0.01 
Social Support                
Married/Living together 19 9799 1.30 0.80 2.10 1.27 1.08 1.49 0.004 43.93 18 0.001 59.03 0.04 0.25 
Help taking meds 5 2682 1.73 1.06 3.78 1.75 1.16 2.65 0.008 7.65 4 0.105 47.71 0.15 0.31 
Costs                
Cost of Medicines 10 55800 0.76 0.18 1.10 0.76 0.65 0.88 <0.001 120.47 9 <0.001 92.53 0.04 0.21 
Total costs of treatment 4 23013 1.39 0.63 2.16 1.25 0.83 1.89 0.292 30.86 3 <0.001 90.28 0.17 0.39 
Provider Relationship                
Under GP's care 5 25153 0.83 0.70 1.30 0.82 0.73 0.92 0.001 7.07 4 0.132 43.41 0.01 0.08 
Disease Severity                
CD4 Count 15 9775 0.97 0.33 3.44 0.98 0.82 1.17 0.822 59.50 14 <0.001 76.47 0.06 0.23 
HIV RNA 15 9811 1.04 0.38 3.25 1.07 0.84 1.37 0.578 83.13 14 <0.001 83.16 0.14 0.37 
HIV Status (More severe/AIDS vs less severe/no 
AIDS) 
11 2768 1.17 0.35 3.70 1.03 0.76 1.39 0.860 20.68 10 0.023 51.65 0.11 0.34 
Systolic BP 5 2025 1.11 0.41 1.55 0.95 0.64 1.41 0.795 17.34 4 0.002 76.94 0.15 0.37 
Diastolic BP 5 2025 1.42 0.18 1.80 1.14 0.74 1.75 0.561 20.71 4 <0.001 80.69 0.18 0.42 
Fewer/No symptoms 6 6016 1.33 0.85 3.00 1.40 0.92 2.14 0.121 38.93 5 0.001 87.16 0.21 0.48 
No GP/Outpatient visit 11 180297 1.01 0.38 1.16 0.92 0.83 1.02 0.123 179.38 10 <0.001 94.43 0.02 0.16 
Fewer/No Hospitilisation 13 84332 1.05 0.64 4.05 1.09 0.92 1.29 0.317 212.82 12 <0.001 94.36 0.05 0.26 
Fewer/No Hospitilisation - HIV 4 1099 1.89 1.31 3.69 1.86 1.38 2.50 <0.001 3.44 3 0.329 12.67 0.08 0.11 
Fewer/No Hospitilisation - non-HIV 9 83233 1.00 0.64 4.05 0.96 0.80 1.14 0.619 180.54 8 <0.001 95.57 0.04 0.24 
Fewer/No Emergency department visits 4 40056 1.04 0.68 2.13 1.03 0.81 1.31 0.796 63.07 3 <0.001 95.24 0.06 0.22 
Side effects                
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presence of side effects 11 4161 0.48 0.10 1.19 0.40 0.19 0.84 0.015 209.67 10 <0.001 95.23 0.94 1.17 
Comorbidity                
Comorbidity 19 2047198 1.04 0.51 3.12 0.99 0.82 1.19 0.885 1224.17 18 <0.001 98.53 0.12 0.36 
Dyslipedemia 3 19852 1.07 0.73 1.28 1.03 0.76 1.38 0.861 12.58 2 0.002 84.11 0.07 0.24 
Liver Disease 3 6015 0.63 0.21 1.54 0.76 0.34 1.68 0.493 3.56 2 0.169 43.74 0.53 0.47 
Hypertension 6 91860 1.11 0.90 1.30 1.08 1.00 1.17 0.045 18.05 5 0.003 72.30 0.01 0.08 
Other cardiovascular conditions 6 89450 1.15 0.80 1.57 1.12 0.97 1.30 0.136 47.60 5 <0.001 89.50 0.02 0.17 
Diabetes 10 74563 1.01 0.78 1.24 0.99 0.93 1.05 0.692 19.33 9 0.023 53.44 0.00 0.06 
Stroke 4 43097 1.06 0.97 1.32 1.07 0.96 1.20 0.215 6.75 3 0.080 55.58 0.01 0.08 
Myocardial infarction 4 48287 1.04 0.90 1.22 1.06 0.96 1.17 0.264 4.60 3 0.204 34.75 0.01 0.06 
Heart Failure 5 79940 1.16 0.97 1.34 1.11 0.99 1.23 0.067 12.50 4 0.014 67.99 0.01 0.10 
Barriers to medication                
Good access to medical care 4 912 2.38 1.13 3.20 2.32 1.66 3.25 <0.001 2.71 3 0.439 <0.01 0.10 <0.01 
Good access to medication 3 688 2.17 1.73 4.56 2.33 1.45 3.47 0.001 2.66 2 0.265 24.71 0.18 0.21 
Mental Health                
Presence/History of psychiatric conditions 8 16849 0.57 0.07 1.01 0.53 0.36 0.79 0.002 29.90 7 <0.001 76.59 0.20 0.42 
Cognitive ability                
General cognitive ability                
Dementia/Cognitive decline 8 49596 0.82 0.50 0.95 0.84 0.74 0.95 0.005 4.59 7 0.710 <0.01 0.02 <0.01 
Use of a memory aid                
Use of a memory aid 6 2419 1.86 1.46 4.22 1.97 1.46 2.66 <0.001 7.76 5 0.170 35.60 0.09 0.22 
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This appendix provides additional details regarding the meta-analyses of chapter 2. Author 
names, study publication dates and country of origin, sample sizes and individual point 
estimates for the relationship with adherence are presented. Analyses are presented in the 
order they appear in the thesis. References for all analyses are provided at the end of the 
appendix. 
Section 1 – Demographics 
Sex (female vs male): 
Author Year Country n OR Estimate r Estimate 
Amfilochiou et al. 2009 Greece 98 3.06 0.25 
Balkrishnan and Christensen 2000 USA 1595 0.84 -0.05 
Benner et al. 2004 USA 19422 0.9 -0.03 
Benner et al. 2005 USA 9510 0.96 -0.01 
Benner et al. 2009 USA 5759 0.8 -0.06 
Bosley, Fosbury and Cochrane 1995 UK 72 0.57 -0.15 
Carlucci et al. 2008 Zambia 409 1.01 0 
Chan et al. 2010 USA 14257 0.87 -0.04 
Chapman et al. 2005 USA 8406 0.85 -0.04 
Cluley and Cochrane 2001 UK 66 0.58 -0.15 
Cohen et al. 1998 Australia 1611 1.43 0.1 
Curtis et al. 2009 USA 101038 1.25 0.06 
Darkow et al. 2007 USA 267 0.51 -0.18 
Deschamps et al. 2004 Belgium 43 1.79 0.12 
Diette et al. 1999 USA 4235 1.4 0.09 
Dosse et al. 2009 Brazil 68 1.09 0.02 
Ferguson et al. 2002 USA 149 1.1 0.02 
Frazier, Davis-Ali and Dahl 1994 USA 246 1.8 0.16 
Garcia et al. 2006 Brazil 182 1.16 0.04 
Gardner et al. 2008 USA 325 0.83 -0.03 
Gauchet, Tarquinio and Fischer 2007 France 127 2.26 0.18 
Gazmarian et al. 2006 USA 1549 0.99 0 
Gebo, Keruly and Moore 2003 USA 196 0.6 -0.13 
Gifford et al. 2000 USA 133 0.6 -0.13 
Godin et al. 2005 Canada 376 0.36 -0.27 
Gregoire et al. 2006 Canada 509 1.24 0.06 
Hashmi et al. 2007 Pakistan 438 0.93 -0.02 
Heath et al. 2002 Canada 638 0.62 -0.06 
Ho et al. 2008 USA 13596 0.87 -0.04 
Hovinga et al. 2008 USA 408 1.57 0.12 
Ickovics et al. 2002 USA 93 3.6 0.33 
Irvine et al. 1999 Canada 341 0.74 -0.06 
Janson et al. 2008 USA 113 1.02 0 
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Jindal et al. 2009 USA 32757 1.1 0.03 
Jose et al. 2007 India 506 0.84 -0.04 
Kaissi and Parchman 2009 USA 618 1.27 0.06 
Kaplan et al. 2004 USA 578 1.25 0.06 
Lam, Lu, and Leung 2007 Hong Kong 209 1.74 0.15 
Mesfin et al. 2009 Ethiopia 237 1.33 0.08 
Miura et al. 2000 Japan 325 0.86 -0.04 
Moralejo et al. 2006 Spain 143 0.7 -0.09 
Murri et al. 2009 Italy 296 1.3 0.07 
Nachega et al. 2006 South Africa 6288 1.23 0.05 
Nguyen et al. 2009 USA 235 0.82 -0.06 
Nichol et al. 2009 USA 5943 1.09 0.02 
Nieuwkerk et al. 2001 Netherlands 160 1.4 0.09 
Olthoff et al. 2009 Netherlands 153 1.19 0.05 
Parruti et al. 2006 Italy 171 1.16 0.04 
Pinheiro et al. 2002 Brazil 195 1.67 0.14 
Pinsky et al. 2009 USA 11027 1.08 0.02 
Royal et al. 2009 USA 350 1.62 0.12 
Sarna et al. 2008 India 310 0.8 -0.04 
Schultz et al. 2005 USA 21239 0.67 -0.11 
Shah et al. 2007 USA 708 1 0 
Shea et al. 1992 USA 202 2.22 0.21 
Shuter and Bernstein 2008 USA 64 1.41 0.09 
Treadaway et al. 2009 USA 798 0.94 -0.01 
Trividi et al. 2008 USA 636 0.96 -0.01 
Ulfvarson et al. 2007 Sweden 200 0.74 -0.08 
van den Bemt et al. 2009 Netherlands 228 0.92 -0.02 
Van Servellen et al. 2002 USA 182 0.53 -0.17 
Walker et al. 2006 USA 1,020 0.78 -0.06 
Woods et al. 2009 USA 79 3.82 0.26 
Wu et al. 2008 USA 134 1.89 0.17 
Wu et al. 2010 USA 592 0.78 -0.07 
Yang et al. 2009 USA 1,888,682 0.92 -0.02 
Ye et al. 2007 USA 5548 0.83 -0.05 
Youssef and Moubarak 2002 Egypt 316 0.66 -0.11 
 
Education (More vs less): 
Author Year Country n OR Estimate r estimate 
Bardel, Wallander and Svardsudd 2007 Sweden 1406 0.93 -0.02 
Brus et al. 1999 Netherlands 55 3.59 0.33 
Burge et al. 2005 USA 150 0.58 -0.15 
Carlucci et al. 2008 Zambia 409 1.28 0.07 
Catz et al. 2001 USA 84 0.32 -0.3 
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Evangelista et al. 2001 USA 82 0.19 -0.42 
Garcia et al. 2006 Brazil 182 0.68 -0.1 
Gauchet, Tarquinio and Fischer 2007 France 127 1.18 0.04 
Gazmarian et al. 2006 USA 1549 3.03 0.22 
Gifford et al. 2000 USA 133 0.76 -0.08 
Gordillo et al. 1999 Spain 366 0.47 -0.14 
Gregoire et al. 2006 Canada 509 0.97 -0.01 
Hashmi et al. 2007 Pakistan 438 1.35 0.08 
Heath et al. 2002 Canada 638 0.46 -0.19 
Hovinga et al. 2008 USA 408 1.29 0.06 
Ickovics et al. 2002 USA 93 1.22 0.05 
Irvine et al. 1999 Canada 341 7.56 0.48 
Janson et al. 2008 USA 113 3.04 0.28 
Jindal et al. 2009 USA 32757 0.96 -0.01 
Kalichman et al. 2008 USA 145 10.6 0.54 
Kleeberger et al. 2001 USA 539 0.81 -0.05 
Lam, Lu, and Leung 2007 Hong Kong 209 2 0.17 
Liu et al. 2007 USA 807 6.9 0.47 
Mann et al. 2007 USA 71 0.58 -0.13 
Mizuno et al. 2008 Japan 121 1.39 0.06 
Moralejo et al. 2006 Spain 143 0.34 -0.26 
Murri et al. 2009 Italy 296 2.17 0.21 
Nguyen et al. 2009 USA 235 0.83 -0.05 
Olthoff et al. 2009 Netherlands 153 1.12 0.02 
Pinheiro et al. 2002 Brazil 195 1.62 0.11 
Royal et al. 2009 USA 350 1.24 0.06 
Saounatsou et al. 2001 Greece 40 0.45 -0.21 
Sarna et al. 2008 India 310 0.74 -0.08 
Schneider et al. 2004 USA 554 2.33 0.17 
Shea et al. 1992 USA 202 1.1 0.02 
Shuter and Bernstein 2008 USA 64 1.63 0.1 
Sleath et al. 2009 USA 141 0.75 -0.08 
Treadaway et al. 2009 USA 798 2.61 0.21 
Ulfvarson et al. 2007 Sweden 200 0.95 -0.01 
van den Bemt 2009 Netherlands 228 2.36 0.23 
Van Servellen 2002 USA 182 2.78 0.27 
Wagner et al. 2002 USA 40 0.41 -0.24 
Walker et al. 2006 USA 1,020 0.5 -0.19 
Woods et al. 2009 USA 79 0.23 -0.32 
Wu et al. 2008 USA 134 0.97 -0.01 
Yahaya et al. 2009 Malaysia 52 1.34 0.08 
Youssef and Moubarak 2002 Egypt 316 1.27 0.07 
Zafran et al. 2005 Israel 857 1.19 0.04 
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Education (college vs. no college): 
Author Year Country n OR Estimate r Estimate 
Carlucci et al. 2008 Zambia 409 1.24 0.06 
Gauchet, Tarquinio and Fischer 2007 France 127 1.18 0.04 
Gazmarian et al. 2006 USA 1549 1.29 0.06 
Gifford et al. 2000 USA 133 7.56 0.48 
Golin et al. 2002 USA 117 2.33 0.17 
Gordillo et al. 1999 Spain 366 1.62 0.11 
Gregoire et al. 2006 Canada 509 1.28 0.07 
Hashmi et al. 2007 Pakistan 438 1.12 0.02 
Hovinga et al. 2008 USA 408 0.97 -0.01 
Ickovics et al. 2002 USA 93 0.5 -0.19 
Irvine et al. 1999 Canada 341 0.95 -0.01 
Janson et al. 2008 USA 113 0.47 -0.14 
Jindal et al. 2009 USA 32757 0.46 -0.19 
Kaplan et al. 2004 USA 578 0.45 -0.21 
Kleeberger et al. 2001 USA 539 1.27 0.07 
Liu et al. 2007 USA 807 0.75 -0.08 
Mann et al. 2007 USA 71 0.34 -0.26 
Mizuno et al. 2008 Japan 121 10.6 0.54 
Moralejo et al. 2006 Spain 143 1.39 0.06 
Royal et al. 2009 USA 350 0.68 -0.1 
Sarna et al. 2008 India 310 3.04 0.28 
Shuter and Bernstein 2008 USA 64 0.23 -0.32 
Treadaway et al. 2009 USA 798 1.1 0.02 
Ulfvarson et al. 2007 Sweden 200 1.63 0.1 
Walker et al. 2006 USA 1,020 1.19 0.04 
 
Employment (yes vs no): 
Author Year Country n OR Estimate r Estimate 
Frazier, Davis-Ali and Dahl 1994 USA 246 1.12 0.03 
Gordillo et al. 1999 Spain 366 1.98 0.17 
Heath et al. 2002 Canada 638 2.16 0.21 
Kleeberger et al. 2001 USA 539 1.01 0 
Liu et al. 2007 USA 807 1.12 0.03 
Moralejo et al. 2006 Spain 143 0.66 -0.11 
Nguyen et al. 2009 USA 235 4.33 0.31 
Parruti et al. 2006 Italy 171 1.13 0.03 
Sarna et al. 2008 India 310 2.44 0.18 
Shea et al. 1992 USA 202 0.41 -0.22 
Singh et al. 1996 USA 46 3.29 0.29 
Treadaway et al. 2009 USA 798 1.11 0.03 
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Van Servellen et al. 2002 USA 182 0.8 -0.06 
Zafran et al. 2005 Israel 857 1.95 0.12 
 
Health insurance (yes vs no): 
Author Year Country n OR estimate r Estimate 
Gifford et al. 2000 USA 133 0.25 -0.35 
Gregoire et al. 2006 Canada 509 1.12 0.02 
Kaplan et al. 2004 USA 578 2.4 0.23 
Kleeberger et al. 2001 USA 539 0.85 -0.02 
Liu et al. 2007 USA 807 0.9 -0.03 
Royal 2009 USA 350 1.83 0.09 
Shea et al. 1992 USA 202 1.61 0.11 
 
Age: 
Author Year Country n OR Estimate r Estimate 
Amfilochiou et al. 2009 Greece 98 4.02 0.36 
Barclay et al. 2007 USA 185 4.12 0.32 
Bosley, Fosbury and Cochrane 1995 UK 72 1.6 0.13 
Brus et al. 1999 Netherlands 55 1.34 0.08 
Burge et al. 2005 USA 150 2.02 0.19 
Carr, Thompson and Cooper 2006 UK 533 1 0 
Catz et al. 2001 USA 84 1.04 0.01 
Chan et al. 2010 USA 14257 1.69 0.14 
Chapman et al. 2008 USA 4052 0.92 -0.02 
Cox 2009 USA 378 1.7 0.14 
Darkow et al. 2007 USA 267 1.14 0.04 
deJong et al. 2004 USA 168 0.64 -0.12 
Deschamps et al. 2004 Belgium 43 1.6 0.13 
Diette et al. 1999 USA 4235 1.48 0.09 
Esposito et al. 2009 USA 37408 0.59 -0.14 
Evangelista et al. 2001 USA 82 5.97 0.44 
Frazier, Davis-Ali and Dahl 1994 USA 246 1.94 0.18 
French et al. 2005 USA 590 0.65 -0.12 
Garcia et al. 2006 Brazil 182 1 0 
Gardner et al. 2008 USA 325 1.1 0.03 
Gauchet, Tarquinio and Fischer 2007 France 127 1.51 0.11 
Gazmarian et al. 2006 USA 1549 1.04 0.01 
Golin et al. 2002 USA 117 2.02 0.19 
Gordillo et al. 1999 Spain 366 1.21 0.04 
Gregoire et al. 2006 Canada 509 1.17 0.04 
Hashmi et al. 2007 Pakistan 438 1.64 0.11 
Ho et al. 2008 USA 13596 1.28 0.06 
Hovinga et al. 2008 USA 408 1.11 0.03 
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Ickovics et al. 2002 USA 93 2.1 0.2 
Irvine et al. 1999 Canada 341 1.22 0.04 
Janson et al. 2008 USA 113 1.6 0.11 
Jindal et al. 2009 USA 32757 2.5 0.12 
Jose et al. 2007 India 506 0.81 -0.06 
Kaissi and Parchman 2009 USA 618 1.06 0.02 
Kalichman et al. 2008 USA 145 1 0 
Kiortsis et al. 2000 France 193 2.77 0.22 
Kleeberger et al. 2001 USA 539 1.07 0.02 
Lacasse et al. 2005 Canada 124 1.05 0.01 
Lam, Lu, and Leung 2007 Hong Kong 209 1.63 0.13 
Larizza et al. 2006 Australia 24 8.59 0.51 
Luszczynska, Sarkar, and Knoll 2007 India 104 1.49 0.11 
Mann et al. 2007 USA 71 6.98 0.4 
Mellins et al. 2003 USA 97 1.2 0.05 
Mesfin et al. 2009 Ethiopia 237 0.56 -0.16 
Miura et al. 2000 Japan 325 2.41 0.2 
Moralejo et al. 2006 Spain 143 1.59 0.12 
Murri et al. 2009 Italy 296 1 0 
Nachega et al. 2006 South Africa 6288 1.19 0.03 
Nichol et al. 2009 USA 5943 1.04 0.01 
Nieuwkerk et al. 2001 Netherlands 160 0.45 -0.21 
Olthoff et al. 2009 Netherlands 153 3.32 0.31 
Pamboukian et al. 2008 USA 80 1.8 0.16 
Parruti et al. 2006 Italy 171 0.58 -0.13 
Penning-van Beest 2008 Netherlands 8822 0.97 -0.01 
Pinheiro et al. 2002 Brazil 195 0.77 -0.05 
Pinsky et al. 2009 USA 11027 1.21 0.04 
Rosen et al. 2003 USA 79 3.26 0.31 
Royal et al. 2009 USA 350 2.59 0.24 
Sarna et al. 2008 India 310 0.95 -0.01 
Schneider et al. 2004 USA 554 1.73 0.15 
Schultz et al. 2005 USA 21239 1.58 0.12 
Shah et al. 2007 USA 708 1.53 0.12 
Shaya et al. 2009 USA 568 1.36 0.06 
Shea et al. 1992 USA 202 2.22 0.21 
Shuter and Bernstein 2008 USA 64 0.59 -0.14 
Singh et al. 1996 USA 46 0.58 -0.14 
Sleath et al. 2009 USA 141 0.99 0 
Sullivan et al. 2007 USA 5,887 1.15 0.03 
Treadaway et al. 2009 USA 798 1.46 0.1 
Trividi et al. 2008 USA 636 1.61 0.13 
Tuldra et al. 2000 Netherlands 116 6.16 0.45 
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Ulfvarson et al. 2007 Sweden 200 1.06 0.01 
van den Bemt et al. 2009 Netherlands 228 1.44 0.1 
Van Servellen et al. 2002 USA 182 0.69 -0.1 
Wagner 2002 USA 180 4.65 0.39 
Walker et al. 2006 USA 1,020 1.03 0.01 
Wilson et al. 1986 USA 184 0.69 -0.1 
Woods et al. 2009 USA 79 1.44 0.1 
Wu et al. 2008 USA 134 1.45 0.1 
Wu et al. 2010 USA 592 1.19 0.05 
Yang et al. 2009 USA 1,888,682 2.06 0.13 
Ye et al. 2007 USA 5548 1.23 0.06 
Youssef and Moubarak 2002 Egypt 316 0.77 -0.06 
 
Income: 
Author Year Country n OR Estimate r Estimate 
Barclay et al. 2007 USA 45 3.13 0.3 
Bardel, Wallander and Svardsudd 2007 Sweden 1406 0.8 -0.06 
Frazier, Davis-Ali and Dahl 1994 USA 246 1.94 0.18 
Garcia et al. 2006 Brazil 182 1.12 0.03 
Gebo, Keruly and Moore 2003 USA 196 2.21 0.21 
Gregoire et al. 2006 Canada 509 1.07 0.02 
Hashmi et al. 2007 Pakistan 438 0.96 -0.01 
Hovinga et al. 2008 USA 408 0.69 -0.1 
Ickovics et al. 2002 USA 93 0.48 -0.2 
Janson et al. 2008 USA 113 0.45 -0.18 
Kleeberger et al. 2001 USA 539 1.87 0.16 
Liu et al. 2007 USA 807 0.81 -0.06 
Nguyen et al. 2009 USA 235 1.44 0.1 
Pinheiro et al. 2002 Brazil 195 0.75 -0.06 
Van Servellen et al. 2002 USA 182 0.83 -0.05 
Walker et al. 2006 USA 1,020 1.63 0.12 
Wu et al. 2008 USA 134 0.88 -0.04 
Yahaya et al. 2009 Malaysia 52 0.31 -0.31 
Zafran et al. 2005 Israel 857 0.7 -0.08 
 
Sociodemographic status: 
Author Year Country n OR Estimate r Estimate 
Bosley, Fosbury and Cochrane 1995 UK 72 NA  NA  
Parruti et al. 2006 Italy 171 NA  NA  
Sarna et al. 2008 India 310 NA  NA  
 
Effects of having children: 
Author Year Country n OR Estimate r Estimate 
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Moralejo et al. 2006 Spain 143 NA  NA  
Corless  et al. 2005 USA 165 NA  NA  
Golin et al. 2002 USA 117 NA  NA  
 
Sexuality (homosexual vs heterosexual): 
Author Year Country n OR Estimate r Estimate 
Barclay et al. 2007 USA 45 3.42 0.32 
Gauchet, Tarquinio and Fischer 2007 France 127 0.69 -0.1 
Parruti et al. 2006 Italy 171 1.44 0.09 
 
Section 2 – Race 
Black vs Other races:  
Author Year Country n OR Estimate r estimate 
Gebo, Keruly and Moore 2003 USA 196 0.48 -0.17 
Gifford et al. 2000 USA 133 0.46 -0.2 
Jindal et al. 2009 USA 32757 0.54 -0.15 
Kleeberger et al. 2001 USA 539 0.43 -0.14 
Nachega et al. 2006 South Africa 6288 0.92 -0.01 
Royal et al. 2009 USA 350 0.96 -0.01 
 
White vs black: 
Author Year Country n OR Estimate r estimate 
Deschamps et al. 2004 Belgium 43 1.64 0.09 
Esposito et al. 2009 USA 37408 4.38 0.36 
Ferguson et al. 2002 USA 149 0.61 -0.13 
Gazmarian et al. 2006 USA 1549 1.83 0.11 
Kaplan et al. 2004 USA 578 0.2 -0.4 
Liu et al. 2007 USA 807 0.59 -0.14 
Nachega et al. 2006 South Africa 6288 1.14 0.01 
Nguyen et al. 2009 USA 235 4 0.36 
Nichol et al. 2009 USA 5943 1.52 0.09 
Pinsky et al. 2009 USA 11027 1.42 0.09 
Shaya et al. 2009 USA 568 2.31 0.2 
Walker et al. 2006 USA 1,020 1.4 0.08 
Yang et al. 2009 USA 1,888,682 1.46 0.08 
 
White vs Hispanic: 
Author Year Country n OR Estimate r estimate 
Gazmarian et al. 2006 USA 1549 1.40 0.06 
Kaplan et al. 2004 USA 578 0.13 -0.50 
Liu et al. 2007 USA 807 0.71 -0.09 
Mann et al. 2007 USA 71 3.43 0.31 
Walker et al. 2006 USA 1,020 1.51 0.09 
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Yang et al. 2009 USA 1,888,682 1.37 0.05 
 
White vs. non-white: 
Author Year Country n OR Estimate r estimate 
Diette et al. 1999 USA 4235 2.06 0.14 
Frazier, Davis-Ali and Dahl 1994 USA 246 0.78 -0.07 
Gardner et al. 2008 USA 325 0.95 -0.02 
Hovinga et al. 2008 USA 408 0.69 -0.08 
Janson et al. 2008 USA 113 2.03 0.18 
Moralejo et al. 2006 Spain 143 0.33 -0.13 
Rosenbaum et al. 2005 USA 465 2.39 0.17 
Shuter and Bernstein 2008 USA 64 5 0.41 
Singh et al. 1996 USA 46 2.33 0.22 
Sleath et al. 2009 USA 141 0.3 -0.31 
Trividi et al. 2008 USA 636 2.77 0.27 
Woods et al. 2009 USA 79 1.44 0.1 
 
White vs other: 
Author Year Country n OR Estimate r estimate 
Esposito et al. 2009 USA 37408 2.1 0.18 
Gazmarian et al. 2006 USA 1549 2.33 0.06 
Heath et al. 2002 Canada 638 1.68 0.11 
Kaplan et al. 2004 USA 578 0.18 -0.43 
Liu et al. 2007 USA 807 0.48 -0.2 
Nichol et al. 2009 USA 5943 1.16 0.04 
Pinsky et al. 2009 USA 11027 1.37 0.08 
Shaya et al. 2009 USA 568 1 0 
Yang et al. 2009 USA 1,888,682 0.98 0 
 
Part 3 – Adherence to non-medication regimens 
Exercise: 
Author Year Country n OR Estimate r Estimate 
Trividi et al. 2008 USA 636 NA  NA  
 
Appointments: 
Author Year Country n OR Estimate r Estimate 
Stanton 1987 USA 50 NA  NA  
Bane, Hughes and McElnay 2006 UK 139 NA  NA  
 
Diet: 
Author Year Country n total OR Estimate r Estimate 
Christensen and Smith 1995 USA 72 4.24 0.37 
Appendix D – List of references for meta-analyses 
 
242 
 
Trividi et al. 2008 USA 636 1.34 0.08 
Youssef and Moubarak 2002 Egypt 316 4.92 0.33 
Zafran et al. 2005 Israel 857 1.14 0.03 
 
Part 4 – Medication regimen 
Number of co-medications: 
Author Year Country n OR Estimate r Estimate 
Carr, Thompson and Cooper 2006 UK 533 1.01 0 
Chan et al. 2010 USA 14257 1.1 0.02 
Penning-van Beest 2008 Netherlands 8822 0.78 -0.07 
Wu et al. 2010 USA 592 1.25 0.06 
 
Fewer different types of pills: 
Author Year Country n OR Estimate r Estimate 
Bardel, Wallander and Svardsudd 2007 Sweden 1406 1.34 0.08 
Benner et al. 2004 USA 19422 0.97 -0.01 
Benner et al. 2005 USA 9510 0.94 -0.02 
Benner et al. 2009 USA 5759 0.91 -0.03 
Catz et al. 2001 USA 84 1.39 0.09 
Chapman et al. 2008 USA 4052 0.56 -0.16 
Curtis et al. 2009 USA 101038 0.95 -0.01 
Esposito et al. 2009 USA 37408 0.16 -0.4 
French et al. 2005 USA 590 1.89 0.17 
Golin et al. 2002 USA 117 1.12 0.03 
Jones et al. 2003 USA 174 3.43 0.32 
Kleeberger et al. 2001 USA 539 1.99 0.16 
Sleath et al. 2009 USA 141 0.53 -0.17 
van den Bemt 2009 Netherlands 228 1.34 0.08 
 
Complexity of regimen: 
Author Year Country n OR Estimate r Estimate 
Gauchet, Tarquinio and Fischer 2007 France 127 3.39 0.18 
Gazmarian et al. 2006 USA 1549 1.31 0.07 
Hashmi et al. 2007 Pakistan 438 2.32 0.23 
Lam, Lu, and Leung 2007 Hong Kong 209 0.3 -0.31 
Larizza et al. 2006 Australia 24 1.61 0.13 
Morisky et al. 2008 USA 1367 0.55 -0.16 
Olthoff et al. 2009 Netherlands 153 0.3 -0.23 
Shaya 2009 USA 568 0.62 -0.12 
 
Duration of medication regimen: 
Author Year Country n OR Estimate r Estimate 
Bardel, Wallander and Svardsudd 2007 Sweden 1406 1.07 0.02 
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Benner et al. 2005 USA 9510 0.61 -0.14 
Chapman et al. 2005 USA 8406 0.87 -0.04 
Garcia et al. 2006 Brazil 182 0.5 -0.18 
Golin et al. 2002 USA 117 0.67 -0.11 
Holstad et al. 2006 USA 120 0.46 -0.21 
Miura et al. 2000 Japan 325 0.75 -0.06 
Pinheiro et al. 2002 Brazil 195 0.7 -0.09 
Saounatsou et al. 2001 Greece 40 6.11 0.45 
Sarna et al. 2008 India 310 1.31 0.07 
Tuldra et al. 2000 Netherlands 116 0.59 -0.14 
Woods et al. 2009 USA 79 0.91 -0.03 
 
Pills per day: 
Author Year Country n OR Estimate r Estimate 
Bardel, Wallander and Svardsudd 2007 Sweden 1406 0.71 -0.09 
Cohen et al. 1998 Australia 1611 0.58 -0.15 
Gifford et al. 2000 USA 133 2.22 0.21 
Golin et al. 2002 USA 117 1.29 0.07 
Gregoire et al. 2006 Canada 509 1.5 0.11 
Larizza et al. 2006 Australia 24 0.21 -0.4 
Murri et al. 2009 Italy 296 1.05 0.01 
Parruti et al. 2006 Italy 171 1.32 0.07 
Pinheiro et al. 2002 Brazil 195 0.57 -0.15 
Wu et al. 2008 USA 134 1.18 0.05 
Youssef and Moubarak 2002 Egypt 316 0.62 -0.13 
 
Daily vs weekly regimens: 
Author Year Country n OR Estimate r Estimate 
Curtis et al. 2009 USA 101038 NA  NA  
Carr, Thompson and Cooper 2006 UK 533 NA  NA  
Penning-van Beest 2008 Netherlands 8822 NA  NA  
Downey et al. 2006 USA 10566 NA  NA  
 
Regimen changes: 
Author Year Country n OR Estimate r Estimate 
Deschamps et al. 2004 Belgium 43 NA  NA  
Lam, Lu, and Leung 2007 Hong Kong 209 NA  NA  
Parruti et al. 2006 Italy 171 NA  NA  
 
Part 5 – Memory Aides 
Memory Aides: 
Author Year Country n OR Estimate r Estimate 
Amberbir et al. 2008 Ethiopia 383 3.29 0.31 
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Golin et al. 2002 USA 117 1.78 0.16 
Gregoire et al. 2006 Canada 509 1.46 0.07 
Lam, Lum, and Leung 2007 Hong Kong 209 1.95 0.17 
Walker et al. 2006 USA 1,020 1.57 0.12 
Wang and Wu 2007 China 181 4.22 0.32 
 
Part 6 – Barriers to medication 
General barriers: 
Author Year Country n OR Estimate r Estimate 
Brus et al. 1999 Netherlands 55 0.32 -0.3 
Carr, Thompson and Cooper 2006 UK 533 0.81 -0.06 
Holstad et al. 2006 USA 120 0.27 -0.34 
Kuzuyaet al. 2008 Japan 1772 0.59 -0.14 
Molassiotis et al. 2002 Hong Kong 136 0.14 -0.47 
Sleath et al. 2009 USA 141 0.75 -0.08 
Stanton 1987 USA 50 0.1 -0.53 
Wu et al. 2008 USA 134 0.38 -0.26 
 
Access to medical care: 
Author Year Country n OR Estimate r Estimate 
Mesfin et al. 2009 Ethiopia 237 3.2 0.26 
Moralejo et al. 2006 Spain 143 1.13 0.02 
Royal et al. 2009 USA 350 2.11 0.2 
Van Servellen 2002 USA 182 2.66 0.26 
 
Access to medicines: 
Author Year Country n OR Estimate r Estimate 
Gifford et al. 2000 USA 133 4.56 0.38 
Golin et al. 2002 USA 117 1.73 0.15 
Hashmi et al. 2007 Pakistan 438 2.17 0.14 
 
Part 7 – Costs of treatment 
Cost of medication: 
Author Year Country n OR Estimate r Estimate 
Berger et al. 2009 USA 2023 0.76 -0.08 
Chan et al. 2010 USA 14257 0.71 -0.09 
Diette et al. 1999 USA 4235 1.1 0.03 
Gardner et al. 2008 USA 325 0.46 -0.18 
Hashmi et al. 2007 Pakistan 438 0.6 -0.14 
Nachega et al. 2010 South Africa 6833 0.83 -0.05 
Sarna et al. 2008 India 310 0.18 -0.35 
Schultz et al. 2005 USA 21239 1 0 
Wu et al. 2010 USA 592 0.75 -0.08 
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Ye et al. 2007 USA 5548 0.85 -0.04 
 
Cost of medical treatment: 
Author Year Country n OR Estimate r Estimate 
Gardner et al. 2008 USA 325 2.16 0.18 
Schultz et al. 2005 USA 21239 1.4 0.09 
Wu et al. 2010 USA 592 0.63 -0.13 
Zafran et al. 2005 Israel 857 1.38 0.09 
 
Part 8 – Comorbidity 
Comorbidity measures: 
Author Year Country n OR Estimate r Estimate 
Chan et al. 2010 USA 14257 1.02 0.01 
Corless  et al. 2005 USA 165 2.06 0.2 
Curtis et al. 2009 USA 101038 0.89 -0.03 
Gregoire et al. 2006 Canada 509 1.13 0.03 
Hashmi et al. 2007 Pakistan 438 1.1 0.03 
Mann et al. 2007 USA 71 3.12 0.26 
Pamboukian et al. 2008 USA 80 0.58 -0.15 
Parruti et al. 2006 Italy 171 1.14 0.04 
Pinsky et al. 2009 USA 11027 1.13 0.02 
Schultz et al. 2005 USA 21239 1.43 0.1 
Shah et al. 2007 USA 708 1.15 0.04 
Shaya e al. 2009 USA 568 0.8 -0.06 
Treadaway et al. 2009 USA 798 1.31 0.07 
Wu et al. 2008 USA 134 0.51 -0.18 
Wu et al. 2010 USA 592 0.77 -0.07 
Yang et al. 2009 USA 1,888,682 0.68 -0.1 
Ye et al. 2007 USA 5548 0.82 -0.04 
Youssef and Moubarak 2002 Egypt 316 1.04 0.01 
Zafran et al. 2005 Israel 857 0.67 -0.1 
 
Dysplipedemia: 
Author Year Country n OR Estimate r Estimate 
Ho et al. 2008 USA 13596 1.07 0.01 
Shah et al. 2007 USA 708 0.73 -0.09 
Ye et al. 2007 USA 5548 1.28 0.07 
 
Liver disease: 
Author Year Country n OR Estimate r Estimate 
Murri et al. 2009 Italy 296 0.63 -0.13 
Parruti et al. 2006 Italy 171 1.54 0.11 
Ye et al. 2007 USA 5548 0.21 -0.02 
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Hypertension: 
Author Year Country n OR Estimate r Estimate 
Benner et al. 2004 USA 19422 1.13 0.03 
Benner et al. 2005 USA 9510 1.03 0.01 
Ho et al. 2008 USA 13596 1.1 0.02 
Jindel et al. 2009 USA 32757 1.13 0.03 
Pinsky et al. 2009 USA 11027 1.3 0.06 
Ye et al. 2007 USA 5548 0.9 -0.03 
 
Other cardiovascular conditions: 
Author Year Country n OR Estimate r Estimate 
Benner et al. 2004 USA 19422 1.28 0.07 
Benner et al. 2005 USA 9510 1.16 0.04 
Benner et al. 2009 USA 5759 0.8 -0.06 
Chapman et al. 2005 USA 8406 1.15 0.04 
Ho et al. 2008 USA 13596 0.96 -0.01 
Jindel et al. 2009 USA 32757 1.57 0.06 
 
Diabetes: 
Author Year Country n OR Estimate r Estimate 
Benner et al. 2004 USA 19422 1.02 0.01 
Benner et al. 2005 USA 9510 1.08 0.02 
Benner et al. 2009 USA 5759 1.08 0.02 
Chapman et al. 2005 USA 8406 0.99 0 
Frazier, Davis-Ali and Dahl 1994 USA 246 1.24 0.06 
Ho et al. 2008 USA 13596 1 0 
Irvine et al. 1999 Canada 341 0.78 -0.05 
Pinsky et al. 2009 USA 11027 0.8 -0.06 
Shah et al. 2007 USA 708 1.12 0.02 
Ye et al. 2007 USA 5548 0.84 -0.04 
 
Stroke: 
Author Year Country n OR Estimate r Estimate 
Benner et al. 2004 USA 19422 1.01 0 
Benner et al. 2005 USA 9510 0.97 -0.01 
Benner et al. 2009 USA 5759 1.32 0.08 
Chapman et al. 2005 USA 8406 1.1 0.03 
 
Myocardial Infarction: 
Author Year Country n OR Estimate r Estimate 
Benner et al. 2004 USA 19422 1.22 0.05 
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Benner et al. 2005 USA 9510 1.02 0.01 
Benner et al. 2009 USA 5759 0.9 -0.03 
Ho et al. 2008 USA 13596 1.05 0.01 
 
Heart Failure: 
Author Year Country n OR Estimate r Estimate 
Benner et al. 2004 USA 19422 0.97 -0.01 
Benner et al. 2009 USA 5759 1.34 0.08 
Chapman et al. 2005 USA 8406 1.22 0.05 
Ho et al. 2008 USA 13596 1 0 
Jindel et al. 2009 USA 32757 1.16 0.03 
 
Respiratory conditions: 
Author Year Country n OR Estimate r Estimate 
Balkrishnan and Christensen 2000 USA 1595 NA  NA  
Balkrishnan and Christensen 2000 USA 1595 NA  NA  
Diette et al. 1999 USA 4235 NA  NA  
Diette et al. 1999 USA 4235 NA  NA  
Ho et al. 2008 USA 13596 NA  NA  
 
Part 9 – Disease severity and outcomes 
CD4 Count: 
Author Year Country n OR Estimate r estimate 
Gardner et al. 2008 USA 325 2.04 0.19 
Gebo, Keruly and Moore 2003 USA 196 0.97 -0.01 
Gifford et al. 2000 USA 133 0.33 -0.29 
Golin et al. 2002 USA 117 0.72 -0.09 
Gordillo et al. 1999 Spain 366 0.75 -0.08 
Ickovics et al. 2002 USA 93 2.5 0.24 
Kleeberger et al. 2001 USA 539 0.61 -0.13 
Liu et al. 2007 USA 807 0.89 -0.03 
Mellins et al. 2003 USA 97 1.43 0.1 
Murri et al. 2009 Italy 296 1.01 0 
Nachega et al. 2006 South Africa 6288 0.97 -0.01 
Sarna et al. 2008 India 310 3.44 0.26 
Shuter and Bernstein 2008 USA 64 0.48 -0.2 
Singh et al. 1996 USA 46 1.11 0.03 
Wang et al. 2009 China 98 0.37 -0.26 
 
HIV RNA: 
Author Year Country n OR Estimate r Estimate 
Cruess et al. 2007 USA 116 2.02 0.19 
deJong et al. 2004 USA 168 0.5 -0.19 
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Gauchet, Tarquinio and Fischer 2007 France 127 0.61 -0.14 
Gifford et al. 2000 USA 133 0.41 -0.23 
Golin et al. 2002 USA 117 1.04 0.01 
Heath et al. 2002 Canada 638 3.19 0.25 
Ickovics et al. 2002 USA 93 1.9 0.17 
Jones et al. 2003 USA 174 0.38 -0.26 
Kleeberger et al. 2001 USA 539 1.18 0.05 
Liu et al. 2007 USA 807 1.45 0.1 
Mellins et al. 2003 USA 97 1.09 0.02 
Murri et al. 2009 Italy 296 3.25 0.31 
Nachega et al. 2006 South Africa 6288 1 0 
Nieuwkerk 2001 Netherlands 160 0.7 -0.1 
Townsend et al. 2007 USA 58 0.69 -0.1 
 
HIV Status (AIDS vs Non-AIDS): 
Author Year Country n OR Estimate r Estimate 
Carlucci et al. 2008 Zambia 409 0.75 -0.07 
deJong et al. 2004 USA 168 0.63 -0.12 
Deschamps et al. 2004 Belgium 43 0.84 -0.04 
Gifford et al. 2000 USA 133 0.35 -0.27 
Kleeberger et al. 2001 USA 539 0.74 -0.07 
Liu et al. 2007 USA 807 1.37 0.09 
Nieuwkerk et al. 2001 Netherlands 160 1.43 0.1 
Parruti et al. 2006 Italy 171 1.17 0.04 
Pinheiro et al. 2002 Brazil 195 1.27 0.06 
Shuter and Bernstein 2008 USA 64 2.1 0.19 
Woods et al. 2009 USA 79 3.7 0.3 
 
Systolic BP: 
Author Year Country n OR Estimate r Estimate 
Hashmi et al. 2007 Pakistan 438 1.17 0.03 
Kiortsis et al. 2000 France 193 0.41 -0.19 
Shah et al. 2007 USA 708 1.11 0.03 
Stanton 1987 USA 50 0.43 -0.22 
Trividi et al. 2008 USA 636 1.55 0.12 
 
Diastolic BP: 
Author Year Country n OR Estimate r Estimate 
Hashmi et al. 2007 Pakistan 438 1.17 0.03 
Kiortsis et al. 2000 France 193 0.41 -0.19 
Shah et al. 2007 USA 708 1.11 0.03 
Stanton 1987 USA 50 0.43 -0.22 
Trividi et al. 2008 USA 636 1.55 0.12 
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Fewer/no symptoms vs more/any symptoms: 
Author Year Country n OR Estimate r Estimate 
Diette et al. 1999 USA 4235 0.91 -0.03 
Gregoire et al. 2006 Canada 509 0.91 -0.02 
Hovinga et al. 2008 USA 408 3 0.29 
Kalichman et al. 2008 USA 145 1.75 0.13 
Kleeberger et al. 2001 USA 539 0.85 -0.04 
Wagner 2002 USA 180 2.55 0.25 
 
GP Outpatient visits (fewer vs more): 
Author Year Country n OR Estimate r Estimate 
Benner et al. 2004 USA 19422 1.03 0.01 
Benner et al. 2005 USA 9510 1.04 0.01 
Chan et al. 2010 USA 14257 1.01 0 
Chapman et al. 2005 USA 8406 1.16 0.04 
Curtis et al. 2009 USA 101038 0.9 -0.03 
Diette et al. 1999 USA 4235 0.52 -0.15 
Gardner et al. 2008 USA 325 1.15 0.03 
Kaissi and Parchman 2009 USA 618 1.05 0.01 
Kleeberger et al. 2001 USA 539 0.38 -0.12 
Schultz et al. 2005 USA 21239 0.78 -0.07 
Shah et al. 2007 USA 708 1 0 
 
Hospitalisations (fewer vs more): 
Author Year Country n OR Estimate r Estimate 
Benner et al. 2004 USA 19422 0.98 -0.01 
Benner et al. 2005 USA 9510 1.04 0.01 
Benner et al. 2009 USA 5759 1.18 0.04 
Chan et al. 2010 USA 14257 1 0 
Chapman et al 2005 USA 8406 1.05 0.01 
Diette et al. 1999 USA 4235 0.7 -0.06 
Gardner et al. 2008 USA 325 2.1 0.18 
Gordillo et al. 1999 Spain 366 1.67 0.14 
Miura et al. 2000 Japan 325 0.82 -0.06 
Pamboukian et al. 2008 USA 80 4.05 0.36 
Sarna et al. 2008 India 310 1.31 0.06 
Schultz et al. 2005 USA 21239 0.64 -0.11 
Wang et al. 2009 China 98 3.69 0.3 
 
Emergency department visits (fewer vs more): 
Author Year Country n OR Estimate r Estimate 
Chan et al. 2010 USA 14257 1.18 0.04 
Appendix D – List of references for meta-analyses 
 
250 
 
Diette et al. 1999 USA 4235 0.68 -0.06 
Gardner et al. 2008 USA 325 2.13 0.18 
Schultz et al. 2005 USA 21239 0.9 -0.03 
 
Symptom severity: 
Author Year Country n OR Estimate r Estimate 
Bardel, Wallander and Svardsudd 2007 Sweden 1406 0.94 -0.02 
Brus et al. 1999 Netherlands 55 1.39 0.09 
Carr, Thompson and Cooper 2006 UK 533 1.12 0.03 
Diette et al. 1999 USA 4235 1.21 0.05 
Dobkin, Sita and Sewitch 2006 Canada 121 0.97 -0.01 
Gifford et al. 2000 USA 133 0.65 -0.11 
Holstad et al. 2006 USA 120 0.8 -0.06 
Janson et al. 2008 USA 113 0.7 -0.1 
Liang et al. 2008 Taiwan 92 0.65 -0.12 
Nguyen et al. 2009 USA 235 1.05 0.01 
Reynolds 2004 USA 384 0.39 -0.25 
Sewitch et al. 2004 Canada 127 0.95 -0.01 
Wagner 2002 USA 180 1.73 0.15 
Wu et al. 2010 USA 592 0.76 -0.08 
Wu et al. 2008 USA 134 0.54 -0.17 
 
Duration of disease: 
Author Year Country n OR Estimate r Estimate 
Bosley, Fosbury and Cochrane 1995 UK 72 0.43 -0.23 
Catz et al. 2001 USA 84 0.58 -0.15 
Corless  et al. 2005 USA 165 0.63 -0.13 
French et al. 2005 USA 590 0.4 -0.24 
Golin et al. 2002 USA 117 1.39 0.09 
Gregoire et al. 2006 Canada 509 0.93 -0.02 
Holstad et al. 2006 USA 120 2.77 0.27 
Kalichman et al. 2008 USA 145 1.51 0.1 
Linde et al. 2008 Sweden 174 1.12 0.03 
Mellins et al. 2003 USA 97 0.9 -0.03 
Mizuno et al. 2008 Japan 121 0.73 -0.08 
Nguyen et al. 2009 USA 235 0.5 -0.19 
Olthoff et al. 2009 Netherlands 153 0.86 -0.04 
Pinsky et al. 2009 USA 11027 1.04 0.01 
Sarna et al. 2008 India 310 0.95 -0.01 
Sewitch et al. 2004 Canada 127 1.02 0.01 
Sleath et al. 2009 USA 141 1.19 0.05 
Treadaway et al. 2009 USA 798 1.49 0.11 
van den Bemt 2009 Netherlands 228 2.18 0.21 
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Woods et al. 2009 USA 79 0.56 -0.15 
Youssef and Moubarak 2002 Egypt 316 0.95 -0.01 
 
Part 10 – Quality of life and patient wellbeing 
General QOL scores: 
Author Year Country n OR Estimate r Estimate 
Burge et al. 2005 USA 150 0.38 -0.26 
Cote, Farris and Feeny 2003 Canada 199 1.54 0.12 
deJong et al. 2004 USA 168 1.22 0.05 
Gifford et al. 2000 USA 133 2.52 0.24 
Gregoire et al. 2006 Canada 509 0.86 -0.04 
Holstad et al. 2006 USA 120 2.1 0.2 
Janson et al. 2008 USA 113 1.15 0.03 
Kaplan et al. 2004 USA 578 1.8 0.16 
Moralejo et al. 2006 Spain 143 1.57 0.12 
Nguyen et al. 2009 USA 235 1.94 0.18 
Reynolds 2004 USA 384 2.02 0.19 
Ulfvarson et al. 2007 Sweden 200 2.68 0.23 
van den Bemt 2009 Netherlands 228 1.16 0.04 
Wang and Wu 2007 China 181 3.2 0.25 
Williams et al. 2009 USA 2,038 1.39 0.09 
 
Physical functioning: 
Author Year Country n OR Estimate r Estimate 
Brus et al. 1999 Netherlands 55 1.94 0.18 
Burge et al. 2005 USA 150 0.36 -0.27 
Catz et al. 2001 USA 84 2.55 0.25 
Cote, Farris and Feeny 2003 Canada 100 0.78 -0.07 
Cote, Farris and Feeny 2003 Canada 199 1.45 0.1 
Cote, Farris and Feeny 2003 Canada 365 1.4 0.09 
Golin et al. 2002 USA 117 1.34 0.08 
Hovinga et al. 2008 USA 408 1.18 0.04 
Janson et al. 2008 USA 113 0.83 -0.05 
Luszczynska, Sarkar, and Knoll 2007 India 104 14.17 0.59 
Martinez et al. 2008 Mexico 239 0.66 -0.09 
Molassiotis et al. 2002 Hong Kong 136 0.48 -0.2 
Murri et al. 2009 Italy 296 1.64 0.14 
Pinsky et al. 2009 USA 11027 1.15 0.02 
Reynolds 2004 USA 384 1.73 0.15 
Schneider et al. 2004 USA 554 1.55 0.12 
Singh et al. 1996 USA 46 2.71 0.26 
Treadaway et al. 2009 USA 798 1.49 0.11 
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Mental wellbeing: 
Author Year Country n OR Estimate r Estimate 
Cote, Farris and Feeny 2003 Canada 100 0.82 -0.06 
Cote, Farris and Feeny 2003 Canada 199 1.62 0.13 
Cote, Farris and Feeny 2003 Canada 365 1.23 0.06 
Golin et al. 2002 USA 117 0.78 -0.07 
Lacasse et al. 2005 Canada 124 0.74 -0.08 
Martinez et al. 2008 Mexico 239 1.53 0.09 
Treadaway et al. 2009 USA 798 1.74 0.15 
 
Part 11 – Side effects 
Presence of side effects (any vs none): 
Author Year Country n OR Estimate r Estimate 
Carr, Thompson and Cooper 2006 UK 533 1.19 0.05 
Gauchet, Tarquinio and Fischer 2007 France 127 0.58 -0.13 
Gregoire et al. 2006 Canada 509 1 0 
Hashmi et al. 2007 Pakistan 438 0.48 -0.15 
Ickovics et al. 2002 USA 93 0.17 -0.44 
Kaplan et al. 2004 USA 578 0.33 -0.29 
Lam, Lu, and Leung 2007 Hong Kong 209 0.52 -0.16 
Moralejo et al. 2006 Spain 143 0.45 -0.16 
Pinheiro et al. 2002 Brazil 195 0.58 -0.15 
Walker et al. 2006 USA 1,020 0.1 -0.53 
Youssef and Moubarak 2002 Egypt 316 0.12 -0.21 
 
Number of side effects: 
Author Year Country n OR Estimate r Estimate 
Burge et al. 2005 USA 150 0.41 -0.24 
Trividi et al. 2008 USA 636 0.93 -0.02 
van den Bemt 2009 Netherlands 228 0.56 -0.16 
Vytrisalova et al. 2008 Czech 
Republic 
200 0.55 -0.16 
Wagner 2002 USA 180 0.32 -0.3 
 
Severity of side effects: 
Author Year Country n OR Estimate r Estimate 
Catz et al. 2000 USA 72 0.3 -0.25 
Heath et al. 2002 Canada 638 0.3 -0.31 
Kaplan et al. 2004 USA 578 0.3 -0.31 
Pollack et al. 2010 USA 2074 0.48 -0.2 
Sarna et al. 2008 India 310 0.19 -0.27 
 
Part 12 – Health beliefs 
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Outcome expectations: 
Author Year Country n OR Estimate r Estimate 
Brus et al. 1999 Netherlands 55 NA  NA  
Hashmi et al. 2007 Pakistan 438 NA  NA  
Mann et al. 2007 USA 71 NA  NA  
Pinheiro et al. 2002 Brazil 195 NA  NA  
 
Susceptibility to disease: 
Author Year Country n OR Estimate r Estimate 
Deschamps et al. 2004 Belgium 43 2.37 0.23 
Gregoire et al. 2006 Canada 509 1.69 0.14 
Holstad et al. 2006 USA 120 0.83 -0.05 
Youssef and Moubarak 2002 Egypt 316 0.35 -0.25 
 
Self-efficacy: 
Author Year Country n OR Estimate r Estimate 
Bane, Hughes and McElnay 2006 UK 139 16.31 0.53 
Brus et al. 1999 Netherlands 55 13.23 0.58 
Burge et al. 2005 USA 150 5.83 0.44 
Catz et al. 2000 USA 72 6.31 0.36 
Gifford et al. 2000 USA 133 6.96 0.47 
Godin et al. 2005 Canada 376 1.68 0.14 
Golin et al. 2002 USA 117 1.2 0.05 
Holstad et al. 2006 USA 120 1.73 0.15 
Ickovics et al. 2002 USA 93 2.2 0.21 
Liang et al. 2008 Taiwan 92 2.27 0.22 
Luszczynska, Sarkar, and Knoll 2007 India 104 5.63 0.43 
Lynam et al. 2009 USA 189 2.36 0.23 
Mann et al. 2009 USA 151 2.7 0.26 
Mellins et al. 2003 USA 97 0.93 -0.02 
Molassiotis et al. 2002 Hong Kong 136 4.65 0.39 
Mosen et al. 2007 USA 4108 2.65 0.26 
Pinheiro et al. 2002 Brazil 195 3.47 0.32 
Reynolds et al. 2004 USA 384 2.55 0.25 
Tuldra et al. 2000 Netherlands 116 21 0.64 
Van Servellen 2002 USA 182 1.16 0.04 
Williams et al. 2009 USA 2,038 1.47 0.11 
 
Part 13 – Beliefs about medication 
Satisfaction with medicines: 
Author Year Country n OR Estimate r Estimate 
Carr, Thompson and Cooper 2006 UK 533 1.49 0.1 
Deschamps et al. 2004 Belgium 43 3.12 0.29 
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Garcia et al. 2006 Brazil 182 5.15 0.4 
Treadaway et al. 2009 USA 798 3.51 0.14 
Youssef and Moubarak 2002 Egypt 316 4.27 0.33 
 
Positive beliefs about medicines: 
Author Year Country n OR Estimate r Eestimate 
Gauchet, Tarquinio and Fischer 2007 France 127 3.92 0.32 
Gebo, Keruly and Moore 2003 USA 196 1.96 0.18 
Godin et al. 2005 Canada 376 1.56 0.12 
Holstad et al. 2006 USA 120 2.55 0.25 
Royal et al. 2009 USA 350 2.04 0.15 
Williams et al. 2009 USA 2,038 1.49 0.11 
 
BMQ Necessity: 
Author Year Country n OR Estimate r Estimate 
Byer and Myers 2000 UK 34 5.91 0.44 
Gauchet, Tarquinio and Fischer 2007 France 127 3.26 0.31 
Menckeberg et al. 2008 Netherlands 233 4.05 0.36 
van den Bemt 2009 Netherlands 228 1.49 0.11 
 
BMQ Concerns: 
Author Year Country n OR Estimate r Estimate 
Byer and Myers 2000 UK 34 1 0 
Gauchet, Tarquinio and Fischer 2007 France 127 0.86 -0.04 
Menckeberg et al. 2008 Netherlands 233 0.62 -0.13 
van den Bemt 2009 Netherlands 228 1.2 0.05 
 
Effectiveness of medication: 
Author Year Country n OR Estimate r Estimate 
Gregoire et al. 2006 Canada 509 0.77 -0.07 
Hashmi et al. 2007 Pakistan 438 3.31 0.22 
Moralejo et al. 2006 Spain 143 2.09 0.07 
Murri et al. 2009 Italy 296 1.75 0.15 
Wagner et al. 2002 USA 40 4.05 0.36 
Wang and Wu 2007 China 181 5.18 0.27 
 
Concerns about medicines (Non-BMQ): 
Author Year Country n OR Estimate r Estimate 
Bardel, Wallander and Svardsudd 2007 Sweden 1406 NA  NA  
Carr, Thompson and Cooper 2006 UK 533 NA  NA  
Mann et al. 2007 USA 71 NA  NA  
Mann et al. 2009 USA 151 NA  NA  
Appendix D – List of references for meta-analyses 
 
255 
 
 
BMQ General scale: 
Author Year Country n OR Estimate r Estimate 
Gauchet, Tarquinio and Fischer 2007 France 127 NA  NA  
Menckeberg et al. 2008 Netherlands 233 NA  NA  
 
Perceived importance of medicines: 
Author Year Country n OR Estimate r Estimate 
Bardel, Wallander and Svardsudd 2007 Sweden 1406 NA  NA  
Mann et al. 2007 USA 71 NA  NA  
 
Part 14 – Patient knowledge and education 
Knowledge of medicines: 
Author Year Country n OR Estimate r Estimate 
Burge et al. 2005 USA 150 2.12 0.2 
Jackevicius, Li and Tu 2008 Canada 4591 1.23 0.05 
Miura et al. 2000 Japan 325 2.56 0.25 
Sarna et al. 2008 India 310 1.84 0.17 
Stanton 1987 USA 50 11.52 0.56 
Ulfvarson et al. 2007 Sweden 200 0.91 -0.03 
van den Bemt 2009 Netherlands 228 1.12 0.03 
Wagner 2002 USA 180 2.66 0.26 
Wagner et al. 2002 USA 40 3.88 0.35 
Wu et al. 2008 USA 134 1.27 0.07 
 
Knowledge of illness: 
Author Year Country n OR Estimate r Estimate 
Gifford et al. 2000 USA 133 3.48 0.32 
Miura et al. 2000 Japan 325 1.81 0.16 
Moralejo et al. 2006 Spain 143 4.03 0.2 
Morisky et al. 2008 USA 1367 1.15 0.04 
Murri et al. 2009 Italy 296 2.6 0.25 
Wang and Wu 2007 China 181 7.89 0.48 
Wilson 1986 USA 184 4.44 0.38 
Youssef and Moubarak 2002 Egypt 316 1.22 0.05 
 
Health literacy: 
Author Year Country n OR Estimate r Estimate 
DeMasi et al. 2001 USA and 
Puerto Rico 
194 2.36 0.23 
Gazmarian et al. 2006 USA 1549 1.3 0.07 
Jones et al. 2003 USA 174 2.55 0.25 
Kalichman et al. 2008 USA 145 2.99 0.29 
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Part 15: Risky health Behaviours 
Smoking (more vs less/none): 
Author Year Country n OR Estimate r Estimate 
Bardel, Wallander and Svardsudd 2007 Sweden 1406 0.94 -0.02 
Boulet et al. 2008 Canada 107 0.32 -0.24 
Curtis et al. 2009 USA 101038 0.67 -0.11 
Gebo, Keruly and Moore 2003 USA 196 0.82 -0.05 
Ho et al. 2008 USA 13596 0.77 -0.06 
Irvine et al. 1999 Canada 341 0.83 -0.05 
Janson et al. 2008 USA 113 1.4 0.08 
Jindel et al. 2009 USA 32757 0.63 -0.05 
Kiortsis et al. 2000 France 193 0.46 -0.17 
Kleeberger et al. 2001 USA 539 0.75 -0.07 
Murri et al. 2009 Italy 296 0.41 -0.24 
Pamboukian et al. 2008 USA 80 0.53 -0.17 
Shah et al. 2007 USA 708 0.89 -0.02 
Shea et al. 1992 USA 202 0.4 -0.21 
Shuter and Bernstein 2008 USA 64 0.44 -0.14 
 
Alcohol use (more vs less/none): 
Author Year Country n OR Estimate r Estimate 
Braithwaite et al. 2005 USA 2702 0.67 -0.11 
Catz et al. 2001 USA 84 0.36 -0.27 
Catz et al. 2000 USA 72 0.89 -0.02 
deJong et al. 2004 USA 168 0.51 -0.18 
Gebo, Keruly and Moore 2003 USA 196 0.77 -0.07 
Ickovics et al. 2002 USA 93 0.91 -0.03 
Kalichman et al. 2008 USA 145 0.81 -0.05 
Kiortsis et al. 2000 France 193 0.99 0 
Molassiotis et al. 2002 Hong Kong 136 0.48 -0.2 
Royal 2009 USA 350 0.78 -0.04 
Sarna et al. 2008 India 310 0.5 -0.14 
 
Problem alcohol use: 
Author Year Country n OR Estimate r Estimate 
Braithwaite et al. 2005 USA 2702 0.3 -0.26 
Conen et al. 2009 Switzerland 6323 0.4 -0.24 
Kleeberger et al. 2001 USA 539 0.64 -0.06 
Parruti et al. 2006 Italy 171 0.82 -0.04 
Royal et al. 2009 USA 350 0.65 -0.1 
Shea et al. 1992 USA 202 0.35 -0.19 
Shuter and Bernstein 2008 USA 64 0.86 -0.04 
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Illegal drug use: 
Author Year Country n OR Estimate r Estimate 
Barclay et al. 2007 USA 140 0.48 -0.2 
deJong et al. 2004 USA 168 0.29 -0.19 
Gebo, Keruly and Moore 2003 USA 196 0.36 -0.26 
Jones et al. 2003 USA 174 0.39 -0.25 
Kleeberger et al. 2001 USA 539 0.92 -0.02 
Liu et al. 2007 USA 807 0.57 -0.15 
Mellins et al. 2003 USA 97 0.14 -0.48 
Moralejo et al. 2006 Spain 143 0.65 -0.09 
Royal 2009 USA 350 0.72 -0.09 
Shea et al. 1992 USA 202 0.58 -0.1 
Singh et al. 1996 USA 46 0.18 -0.41 
 
Complementary medicine use: 
Author Year Country n OR Estimate r Estimate 
Liu et al. 2007 USA 807 NA  NA  
Murri et al. 2009 Italy 296 NA  NA  
Ng, Tan and Kua 2004 Singapore 1231 NA  NA  
 
BMI: 
Author Year Country n OR Estimate r Estimate 
Bardel, Wallander and Svardsudd 2007 Sweden 1406 NA  NA  
Carlucci et al. 2008 Zambia 409 NA  NA  
Janson et al. 2008 USA 113 NA  NA  
Shah et al. 2007 USA 708 NA  NA  
 
Exercise: 
Author Year Country n OR Estimate r Estimate 
Irvine et al. 1999 Canada 341 NA  NA  
Shah et al. 2007 USA 708 NA  NA  
 
Part 16 – Relationship with medication provider 
Satisfaction with care: 
Author Year Country n OR Estimate r Estimate 
Burge et al. 2005 USA 150 2.11 0.2 
Golin et al. 2002 USA 117 1.08 0.02 
Gregoire et al. 2006 Canada 509 0.73 -0.08 
Hashmi et al. 2007 Pakistan 438 3.19 0.21 
Larizza et al. 2006 Australia 24 16.2 0.61 
Morisky et al. 2008 USA 1367 1.07 0.02 
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Schneider et al. 2004 USA 554 1.87 0.17 
Sewitch et al. 2004 Canada 127 1.8 0.16 
Stanton 1987 USA 50 2.69 0.26 
 
Trust in physician: 
Author Year Country n OR Estimate r Estimate 
Bardel, Wallander and Svardsudd 2007 Sweden 1406 1.43 0.1 
Diette et al. 1999 USA 4235 1.57 0.11 
Gauchet, Tarquinio and Fischer 2007 France 127 3.26 0.31 
Golin et al. 2002 USA 117 2.1 0.2 
Hovinga et al. 2008 USA 408 2.46 0.22 
Nguyen et al. 2009 USA 235 3.13 0.3 
Schneider et al. 2004 USA 554 1.8 0.16 
Wang and Wu 2007 China 181 4.93 0.18 
 
Good communication/Relationship with provider: 
Author Year Country n OR Estimate r Estimate 
Catz et al. 2001 USA 84 2.88 0.28 
Diette et al. 1999 USA 4235 1.42 0.09 
Hashmi et al. 2007 Pakistan 438 1.52 0.11 
Holstad et al. 2006 USA 120 1.39 0.09 
Hovinga et al. 2008 USA 408 1.04 0.01 
Moralejo et al. 2006 Spain 143 2.09 0.07 
Schneider et al. 2004 USA 554 1.87 0.17 
Sewitch et al. 2004 Canada 127 1.8 0.16 
Stanton 1987 USA 50 3.92 0.35 
Van Servellen 2002 USA 182 0.62 -0.13 
Williams et al. 2009 USA 2,038 1.31 0.08 
Woods et al. 2009 USA 79 2.06 0.19 
Wu et al. 2008 USA 134 1.15 0.04 
 
GP care (Yes vs no): 
Author Year Country n OR Estimate r Estimate 
Chan et al. 2010 USA 14257 0.78 -0.05 
Gregoire et al. 2006 Canada 509 1.08 0.01 
Penning-van Beest 2008 Netherlands 8822 0.83 -0.05 
Shah et al. 2007 USA 708 0.7 -0.1 
Zafran et al. 2005 Israel 857 1.3 0.05 
 
Part 17 – Social support 
Social support: 
Author Year Country n OR Estimate r Estimate 
Amberbir et al. 2008 Ethiopia 383 1.82 0.16 
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Brus et al. 1999 Netherlands 55 2.1 0.2 
Catz et al. 2001 USA 84 1.58 0.13 
Corless  et al. 2005 USA 165 1.77 0.16 
DeMasi et al. 2001 USA and 
Puerto Rico 
194 1.04 0.01 
Dobkin, Sita and Sewitch 2006 Canada 121 2.17 0.21 
Frazier, Davis-Ali and Dahl 1994 USA 246 1.04 0.01 
Gifford et al. 2000 USA 133 3.94 0.35 
Golin et al. 2002 USA 117 0.67 -0.11 
Gordillo et al. 1999 Spain 366 2.03 0.17 
Gregoire et al. 2006 Canada 509 0.83 -0.05 
Hashmi et al. 2007 Pakistan 438 1.83 0.16 
Johnell 2005 Sweden 1288 2.2 0.21 
Larizza et al. 2006 Australia 24 16.2 0.61 
Luszczynska, Sarkar, and Knoll 2007 India 104 4.87 0.4 
Molloy et al. A 2008 UK 195 1.23 0.05 
Molloy et al. B 2008 UK 262 4.58 0.38 
Reynolds et al. 2004 USA 384 1.12 0.03 
Van Servellen 2002 USA 182 1.67 0.14 
Wagner 2002 USA 180 0.48 -0.2 
Wilson et al. 1986 USA 184 1.73 0.15 
Wu et al. 2008 USA 134 2.16 0.21 
 
Social norms: 
Author Year Country n OR Estimate r Estimate 
Bane, Hughes and McElnay 2006 UK 139 NA  NA  
Barclay et al. 2007 USA 140 NA  NA  
Barclay et al. 2007 USA 45 NA  NA  
Brus et al. 1999 Netherlands 55 NA  NA  
Holstad et al. 2006 USA 120 NA  NA  
 
Long term relationship (Yes vs no): 
Author Year Country n OR Estimate r Estimate 
Bardel, Wallander and Svardsudd 2007 Sweden 1406 0.8 -0.06 
Deschamps et al. 2004 Belgium 43 2 0.18 
Frazier, Davis-Ali and Dahl 1994 USA 246 2.1 0.2 
Gauchet, Tarquinio and Fischer 2007 France 127 1.31 0.06 
Gazmarian et al. 2006 USA 1549 0.95 -0.02 
Hashmi et al. 2007 Pakistan 438 1.2 0.03 
Hovinga et al. 2008 USA 408 1.3 0.07 
Irvine et al. 1999 Canada 341 1.39 0.08 
Kaplan et al. 2004 USA 578 2.1 0.2 
Nguyen et al. 2009 USA 235 1.44 0.1 
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Parruti et al. 2006 Italy 171 1.84 0.16 
Shea et al. 1992 USA 202 0.88 -0.03 
Treadaway et al. 2009 USA 798 0.87 -0.03 
Trividi et al. 2008 USA 636 2.02 0.19 
Ulfvarson et al. 2007 Sweden 200 1.22 0.05 
van den Bemt 2009 Netherlands 228 1.7 0.11 
Walker et al. 2006 USA 1,020 1.28 0.06 
Youssef and Moubarak 2002 Egypt 316 1.12 0.03 
Zafran et al. 2005 Israel 857 1.21 0.05 
 
Receive help taking medicines (Yes VS No): 
Author Year Country n OR Estimate r Estimate 
Berger , Hudmon and Liang 2004 USA 516 1.06 0.02 
Gifford et al. 2000 USA 133 3.78 0.34 
Holstad et al. 2006 USA 120 1.73 0.15 
Kuzuya et al. 2008 Japan 1772 2.03 0.14 
Sleath et al. 2009 USA 141 1.52 0.11 
 
Part 18 – Patient affect 
Anxiety: 
Author Year Country n OR Estimate r Estimate 
Bosley, Fosbury and Cochrane 1995 UK 72 0.04 -0.48 
Catz et al. 2001 USA 84 0.39 -0.25 
Cruess et al. 2007 USA 116 1.8 0.16 
Deschamps et al. 2004 Belgium 43 0.89 -0.03 
Frazier, Davis-Ali and Dahl 1994 USA 246 0.33 -0.29 
Moralejo et al. 2006 Spain 143 0.66 -0.08 
Singh et al. 1996 USA 46 0.46 -0.2 
Van Servellen 2002 USA 182 0.44 -0.22 
Wagner 2002 USA 180 0.51 -0.18 
Wilson et al. 1986 USA 184 0.78 -0.07 
Woods et al. 2009 USA 79 0.33 -0.28 
 
Stress: 
Author Year Country n OR Estimate r Estimate 
Catz et al. 2001 USA 84 0.36 -0.27 
Frazier, Davis-Ali and Dahl 1994 USA 246 0.36 -0.27 
French et al. 2005 USA 590 0.59 -0.14 
Gifford et al. 2000 USA 133 0.6 -0.13 
Golin et al. 2002 USA 117 0.83 -0.05 
Ickovics et al. 2002 USA 93 0.53 -0.17 
Mellins et al. 2003 USA 97 0.78 -0.07 
Morisky et al. 2008 USA 1367 0.91 -0.03 
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O'Cleirigh, Ironson and Smits 2007 USA 116 0.21 -0.4 
Royal et al. 2009 USA 350 0.37 -0.2 
Singh et al. 1996 USA 46 0.43 -0.22 
Wilson et al. 1986 USA 184 0.56 -0.16 
 
Distress: 
Author Year Country n OR Estimate r Estimate 
Dobkin, Sita and Sewitch 2006 Canada 121 0.65 -0.12 
Irvine et al. 1999 Canada 341 0.75 -0.07 
O'Cleirigh, Ironson and Smits 2007 USA 116 0.26 -0.35 
Singh et al. 1996 USA 46 0.39 -0.24 
Van Servellen 2002 USA 182 0.44 -0.22 
Woods et al. 2009 USA 79 0.57 -0.15 
 
Hostility: 
Author Year Country n OR Estimate r Estimate 
Catz et al. 2001 USA 84 0.56 -0.16 
Frazier, Davis-Ali and Dahl 1994 USA 246 0.26 -0.35 
Irvine et al. 1999 Canada 341 1.21 0.04 
 
Hope: 
Author Year Country n OR Estimate r Estimate 
Treadaway et al. 2009 USA 798 NA  NA  
Van Servellen 2002 USA 182 NA  NA  
 
Part 19 – Patient mental health 
Mental health summary scores: 
Author Year Country n OR estimate r Estimate 
Hovinga et al. 2008 USA 408 1.98 0.18 
Murri et al. 2009 Italy 296 0.98 -0.01 
Royal et al. 2009 USA 350 3.03 0.22 
Schneider et al. 2004 USA 554 2.1 0.2 
Trividi et al. 2008 USA 636 1.8 0.16 
Tucker et al. 2003 USA 1,910 1.47 0.11 
 
Psychiatric diagnosis: 
Author Year Country n OR Estimate r Estimate 
Chan et al. 2010 USA 14257 1.01 0 
Cluley and Cochrane 2001 UK 66 0.57 -0.12 
Cruess et al. 2007 USA 116 0.6 -0.14 
deJong et al. 2004 USA 168 0.35 -0.27 
Mellins et al. 2003 USA 97 0.07 -0.59 
Parruti et al. 2006 Italy 171 0.57 -0.14 
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Shuter and Bernstein 2008 USA 64 0.33 -0.24 
Tucker et al. 2003 USA 1,910 0.58 -0.12 
 
Depression: 
Author Year Country n OR Estimate r Estimate 
Amberbir et al. 2008 Ethiopia 383 0.47 -0.2 
Benner et al. 2004 USA 19422 1 0 
Benner et al. 2009 USA 5759 0.94 -0.02 
Bosley, Fosbury and Cochrane 1995 UK 72 1.51 0.1 
Catz et al. 2001 USA 84 0.58 -0.15 
Catz et al. 2000 USA 72 0.25 -0.28 
Chapman et al 2005 USA 8406 0.83 -0.05 
Cluley and Cochrane 2001 UK 66 0.05 -0.56 
Corless  et al. 2005 USA 165 0.35 -0.28 
Cruess et al. 2007 USA 116 0.42 -0.23 
Frazier, Davis-Ali and Dahl 1994 USA 246 0.53 -0.17 
Gifford et al. 2000 USA 133 1.25 0.06 
Gonzalez et al. 2008 USA 208 0.93 -0.02 
Gordillo et al. 1999 Spain 366 0.56 -0.16 
Hashmi et al. 2007 Pakistan 438 0.82 -0.05 
Ho et al. 2008 USA 13596 0.81 -0.05 
Hovinga et al. 2008 USA 408 0.33 -0.21 
Ickovics et al. 2002 USA 93 0.56 -0.16 
Irvine et al. 1999 Canada 341 0.97 -0.01 
Janson et al. 2008 USA 113 0.84 -0.04 
Jindel et al. 2009 USA 32757 0.63 -0.1 
Kalichman et al. 2008 USA 145 0.86 -0.04 
Kleeberger et al. 2001 USA 539 0.84 -0.04 
Liu et al. 2007 USA 807 0.82 -0.05 
Molassiotis et al. 2002 Hong Kong 136 0.5 -0.19 
Moralejo et al. 2006 Spain 143 0.74 -0.06 
Reynolds et al. 2004 USA 384 0.28 -0.33 
Royal et al. 2009 USA 350 0.33 -0.22 
Sarna et al. 2008 India 310 0.31 -0.3 
Shuter and Bernstein 2008 USA 64 0.5 -0.19 
Singh et al. 1996 USA 46 0.6 -0.14 
Tellez-Zenteno and Cardiel 2002 Mexico 189 3.36 0.31 
Treadaway et al. 2009 USA 798 0.63 -0.12 
Tucker et al. 2003 USA 1,910 0.89 -0.01 
Van Servellen et al. 2002 USA 182 0.56 -0.16 
Wilson et al. 1986 USA 184 0.6 -0.14 
Woods et al. 2009 USA 79 0.95 -0.02 
Wu et al. 2008 USA 134 0.38 -0.26 
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Ye et al.  2007 USA 5548 0.57 -0.04 
 
Anxiety disorders: 
Author Year Country n OR Estimate r Estimate 
Cluley and Cochrane 2001 UK 66 NA  NA  
Tucker et al. 2003 USA 1,910 NA  NA  
Woods et al. 2009 USA 79 NA  NA  
 
Psychosis: 
Author Year Country n OR Estimate r Estimate 
Ye et al.  2007 USA 5548 NA  NA  
 
Part 20 – Cognitive ability 
Measures of cognition: 
Author Year Country n OR Estimate r Estimate 
Hovinga et al. 2008 USA 408 NA  NA  
Rosen et al. 2003 USA 79 NA  NA  
Wagner 2002 USA 180 NA  NA  
Woods et al. 2009 USA 79 NA  NA  
 
Dementia/cognitive decline: 
Author Year Country n OR Estimate r Estimate 
Benner et al. 2004 USA 19422 0.72 -0.09 
Benner et al. 2009 USA 5759 0.95 -0.01 
Chapman et al. 2005 USA 8406 0.89 -0.03 
Cruess et al. 2007 USA 116 0.5 -0.19 
Gazmarian et al. 2006 USA 1549 0.76 -0.06 
Ho et al. 2008 USA 13596 0.93 -0.01 
Kleeberger et al. 2001 USA 539 0.83 -0.03 
Lam, Lu, and Leung 2007 Hong Kong 209 0.81 -0.06 
 
Strength of memory: 
Author Year Country n OR Estimate r Estimate 
Bane, Hughes and McElnay 2006 UK 139 0.97 -0.01 
Molassiotis et al. 2002 Hong Kong 136 1.94 0.18 
Woods et al. 2009 USA 79 1.47 0.1 
Woods et al. 2008 USA 87 5.23 0.42 
 
Part 21 – Personality variables 
OCEAN model: 
Author Year Country n OR Estimate r Estimate 
Evangelista et al. 2001 USA 82 NA  NA  
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Christensen and Smith 1995 USA 72 NA  NA  
 
Locus of control: 
Internal: 
Author Year Country n OR Estimate r Estimate 
Frazier, Davis-Ali and Dahl 1994 USA 246 0.96 -0.01 
Lynam et al. 2009 USA 189 1.29 0.07 
Stanton 1987 USA 50 5.1 0.41 
 
Chance: 
Author Year Country n OR Estimate r Estimate 
Frazier, Davis-Ali and Dahl 1994 USA 246 NA  NA  
Lynam et al. 2009 USA 189 NA  NA  
 
Powerful others: 
Author Year Country n OR Estimate r Estimate 
Frazier, Davis-Ali and Dahl 1994 USA 246 NA  NA  
Lynam et al. 2009 USA 189 NA  NA  
 
Coping style: 
Active: 
Author Year Country n OR Estimate r Estimate 
Frazier, Davis-Ali and Dahl 1994 USA 246 0.75 -0.08 
Golin et al. 2002 USA 117 1.44 0.1 
Sewitch et al. 2004 Canada 127 1.03 0.01 
Singh et al. 1996 USA 46 0.3 -0.31 
 
Avoidant: 
Author Year Country n OR Estimate r Estimate 
Deschamps et al. 2004 Belgium 43 NA  NA  
Frazier, Davis-Ali and Dahl 1994 USA 246 NA  NA  
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Patient and Lifestyle 
Scale 
This questionnaire is to designed find out about you and how you 
feel about taking medicines. There are 5 sections and 20 questions 
in total.  
 The first section asks some general questions about you (4 
questions) 
 The second section asks about any help you need reading medical 
information. (1 question)  
 The third section asks your opinion on medicines in general. (8 
questions) 
 The fourth section asks about your mental health and whether you 
smoke or drink alcohol. (3 questions) 
 The final section asks about how you take your medicine. (4 
questions) 
For each question, tick the box that you think best describes you or your 
feelings. 
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Wellbeing and 
Medications Scale 
 
This questionnaire is designed to find out how you feel about 
your illness and your medicines.  There are 3 sections in total.  
 Section one is about any stress, anxiety or depression you 
may be experiencing. (9 questions) 
 Section two assesses how you feel taking your medicines 
influences your day to day life. (12 questions) 
 Section three assesses your relationship with the doctor 
that prescribed your medicines. (9 questions) 
For each question, tick the box that you think best describes 
your own feelings. 
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Scoring Guide for the 
Patient and Lifestyle 
Scale, and the 
Wellbeing and 
Medication Scale 
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Patient and Lifestyle 
Scale Scoring Guide 
This questionnaire is to designed find out about you and how you 
feel about taking medicines. There are 5 sections and 20 questions 
in total.  
 The first section asks some general questions about you (4 
questions) 
 The second section asks about any help you need reading medical 
information. (1 question)  
 The third section asks your opinion on medicines in general. (8 
questions) 
 The fourth section asks about your mental health and whether you 
smoke or drink alcohol. (3 questions) 
 The final section asks about how you take your medicine. (4 
questions) 
For each question, tick the box that you think best describes you or your 
feelings. 
 
© UEA School of Pharmacy 
Appendix G – PALS and WAMS scoring guide 
 
290 
 
  
  
  
 
  
 
   
 
 
  
 
Appendix G – PALS and WAMS scoring guide 
 
291 
 
  
©Robert Horne 
Horne, R., Weinman, J. & Hankins, M. 1999. The beliefs about medicines questionnaire: The development and evaluation of a new method for 
assessing the cognitive representation of medication. Psychology and Health, 14, 1-24.
Appendix G – PALS and WAMS scoring guide 
 
292 
 
 
 
 
  
 
 
  
 
 
 
Appendix G – PALS and WAMS scoring guide 
 
293 
 
 
Appendix G – PALS and WAMS scoring guide 
 
294 
 
 
 
 
 
Wellbeing and 
Medications Scale 
Scoring Guide 
 
This questionnaire is designed to find out how you feel about 
your illness and your medicines.  There are 3 sections in total.  
 Section one is about any stress, anxiety or depression you 
may be experiencing. (9 questions) 
 Section two assesses how you feel taking your medicines 
influences your day to day life. (12 questions) 
 Section three assesses your relationship with the doctor 
that prescribed your medicines. (9 questions) 
For each question, tick the box that you think best describes 
your own feelings. 
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Front: 
 
 
 
 
 
 
Recently you were sent a pack containing an invitation to take part in research run by the 
University of East Anglia and Elvington Medical Practice. We fully respect your decision to 
not take part and it will be useful to us when designing future research if you would tell 
us the reasons why you decided to not take part. Nobody will be able to identify you from 
your response. If you would like to help us, simply tick the boxes that apply to you 
overleaf and return this card in the prepaid envelope provided. You do not have to 
respond to this card if you do not wish. 
 
 
Back: 
) 
I did not find the research interesting  
  The questionnaire I was asked to complete seemed too long  
  I did not want to take part in the interviews  
  I did not want the researchers to access my medical records  
  I wasn’t sure what I was being asked to do  
  Too much information was sent at the same time  
  The questions on the questionnaire made me feel 
uncomfortable 
 
  I didn’t want the staff at the surgery to  see my results  
  I felt uncomfortable about posting the pack back to the 
surgery 
 
  Other (please state): 
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ELVINGTON MEDICAL PRACTICE 
YORK ROAD 
ELVINGTON 
YORK 
YO41 4DY 
Tel:  08450 71 71 70   
 
Fax. 01904 608710 
 
 
 
 
~[Title/Initial/Surname] 
~[Patient Address Block] 
 
 
 
~[Today...] 
 
 
Dear ~[Title] ~[Surname] 
 
According to our records you are due a blood pressure review/ blood test/ urine test. 
 
It is recommended that all people with known raised blood pressure either on medication 
or not should have their blood pressure checked six monthly and have annual blood and 
urine tests. 
 
Please make an appointment at your usual surgery with our Health Care Assistant. 
 
Elvington Medical Practice is also currently doing some research with the University of 
East Anglia. If you are interested in taking part all the information you need is included in 
this pack. You do not have to take part in this research if you do not want to. 
 
Yours sincerely 
 
 
 
 
 
 
Practice Nurse
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9 What if I change my mind about taking part? 
You do not have to take part in this research, and if you decide 
to take part you may withdraw at any point before the 
research is completed. 
10 Who is organising and funding the research? 
The study is being organised by Steven Watson, a PhD student 
at the University of East Anglia. The study is being supervised 
by Dr. Debi Bhattacharya, and by Dr. Tim Longmore at 
Elvington Medical Practice. The study is funded by the 
university. 
11 Who can I contact? 
You can contact the lead researcher Steven Watson by 
telephone or e-mail on 01603 59 1973 or 
steven.watson@uea.ac.uk. You can also speak to Dr. Tim 
Longmore from Elvington Medical Practice on 01904 60 8224.  
If you wish to make a complaint about this research please 
contact Dr Debi Bhattacharya on 01603 59 33 91, or the Patient 
Relations Team for North Yorkshire on 0800 06 88 000.  
12 Thank you for your time! 
If you decide you would like to take part, please keep this 
information sheet and one copy of the consent form for your 
own records. Please seal a second signed copy of the consent 
form in the envelope with the questionnaire you return. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medication adherence in hypertension 
Participant information sheet: Part 1 of 2 
We would like to invite you to take part in a 
questionnaire study conducted by the 
University of East Anglia and Elvington 
Medical Practice. 
Please read this leaflet carefully before you 
decide whether or not to take part. Feel free 
to contact us or to discuss this with others. 
You can contact us using the details at the 
end of this form. 
If you do not wish to take part, it will not 
affect the care you receive from your doctor 
in any way. We will also be running 
interviews with some of our participants. If 
you would be interested in taking part in 
these, please read the second leaflet. 
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1 What is the purpose of this study? 
This study hopes to find out about how patient beliefs and 
experiences affect how they take their hypertension 
medicines. 
2 Why have I been chosen to take part in this study? 
You are registered at Elvington Medical Practice and are due 
for a review of your hypertension. 
3 What will I have to do? 
There are two questionnaires that we would like you to 
complete. The first questionnaire has been posted to you in 
this pack. It should take less than 10 minutes to complete. In 
four weeks we will post a second questionnaire. This should 
also take less than 10 minutes to complete. We would also like 
to look at your medical records so that we can see how often 
you have ordered your prescription for your hypertension 
medicines, and look at your blood pressure history. 
4 What are the disadvantages or risks of taking part? 
Some questions may make you feel uncomfortable. You may 
choose to not respond to these questions if you wish. We may 
also inform your doctor if your results indicate that you have 
an undiagnosed condition such as depression. 
 
 
5 What are the benefits of taking part? 
There are no direct benefits to you, but this research may help 
us to better help patients to take their medicine in the future. 
6 How will my confidentiality be assured? 
No information that leaves the medical practice will have your 
name or address on it so that you cannot be recognised. The 
medical team at Elvington will use the questionnaire in this 
pack to update their records about whether you smoke or 
drink. The practice will not use any other information in the 
questionnaires. 
7 How will my data be stored and used? 
Your data will be kept in a locked filing cabinet, or on a 
password protected computer. Your data will be used for 
research and to update your doctor about how much you drink 
or smoke. This study is part of an educational thesis, may be 
published. If you would like a summary of the research contact 
Steven Watson using the details below. Your individual data 
will not be identifiable in any report that is published. 
8 How do I take part? 
Please sign the consent form and then complete the 
questionnaire. You can then either post or take these forms to 
Elvington Medical Practice. If you would like to post the forms 
a pre-paid envelope is provided.
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If you would like to take part in this study, please initial each of the boxes. You can only 
be included in the study if you indicate that you have read and understood the participant 
information leaflet that was posted to you along with this form. 
 
Please 
initial 
  
I confirm that I have read and understand the information sheet entitled 
“Medication adherence in hypertension - Participant information sheet: Part 1 
of 2” for the above study and have had the opportunity to ask questions. 
 
  
I understand that my participation is voluntary and that I am free to withdraw 
at any time without my medical care or legal rights being affected. 
 
  
I am willing to allow the research team access to my health care records but 
understand that strict confidentiality will be maintained. 
 
  
I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from regulatory authorities 
which monitor the quality of research. 
 
  
I give permission for individuals from the above mentioned regulatory 
authorities to have access to my records. 
 
  
I will allow my GP to use the information I provide in the “Patient and Lifestyle 
Scale” questionnaire to update my medical records about how much I smoke 
or drink. 
 
  
I agree to take part in the above study.  
 
………………………..…..                   ……/….../…...  ….……………………….. 
Name of participant                   Date         Signature 
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Please complete both copies of this form. Hand one in to the medical practice in the 
enclosed envelope with your questionnaires, and keep one copy for your own records. 
 
If you would be interested in taking part in an interview as part of this study, please see 
the separate information sheets and sign the separate consent forms. 
   
Researcher contact details:   To make a complaint: 
Steven Watson 
University of East Anglia 
Norwich 
Norfolk 
NR4 7TJ 
Tel: 01603 59 1973 
E-Mail: steven.watson@uea.ac.uk 
Dr. Tim Longmore 
Elvington Medical 
Practice 
York Road 
Elvington 
York 
YO41 4DY 
Tel: 01904 60 8224 
 
Patient Relations Team 
North Yorkshire and 
York PCT  
Freepost NEA 13107 
York 
North Yorkshire 
YO31 7ZX 
Tel: 0800 06 88 000 
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9 What if I change my mind about taking part? 
You do not have to take part, and if you decide to take part you 
may withdraw at any point before the research is completed. 
10 Who is organising and funding the research? 
The study is being organised by Steven Watson. The study is 
being supervised by Dr. Debi Bhattacharya, and by Dr. Tim 
Longmore at Elvington Medical Practice. The study is funded 
by the university. 
11 Who can I contact? 
You can contact Steven Watson by telephone or e-mail on 
01603 59 1973 or steven.watson@uea.ac.uk. You can also 
speak to Dr. Tim Longmore.  If you wish to make a complaint 
about this research please contact Dr Debi Bhattacharya on 
01603 59 33 91 or the Patient Relations Team for North 
Yorkshire on 0800 06 88 000.  
12 Thank you for your time! 
If you decide you would like to take part, please keep this 
information sheet and one copy of the consent form for your 
own records.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medication adherence in hypertension 
Participant information sheet: Part 2 of 2 
In addition to the main study described in part 1 
of this leaflet, we would also like to interview 
some of our participants. The questionnaires 
used in this study are still under development so 
we would like to talk to people that have used 
them to find out how they found the 
questionnaires and being part of the study. We 
think this will really help us to design better 
questionnaires and a better study to further test 
them later on. 
Please read this leaflet carefully before you 
decide whether or not to take part. You do not 
have to take part in this part of the study even if 
you take part in the main study. Feel free to 
contact us or to discuss this with others. You can 
contact us using the details at the end of this 
form. 
Appendix L – Participant interview information sheet 
307 
 
1 What is the purpose of this study? 
This study hopes to find out what our participants thought 
about two new questionnaires. We would also like to know 
what it was like taking part in the study.  
2 Why have I been chosen to take part in this study? 
You are registered at Elvington Medical Practice and are due 
for a review of your hypertension. 
3 What will I have to do? 
The interview will be with Steven Watson, a PhD student at the 
University of East Anglia. If you agree to be interviewed you 
may choose to have the interview either in your home or at 
Elvington Medical Practice. We will discuss the new 
questionnaires and the study design. At the end of the study, 
you will be invited to comment on a summary of the results. 
The interview will last for about an hour, and will be tape 
recorded to help with our analysis. This recording will be typed 
on paper after the interview, but we will remove any names or 
information that might identify you.  
4 What are the disadvantages or risks of taking part? 
Some questions may make you feel uncomfortable and you do 
not have to answer these. Some people find taking part in 
interviews upsetting, and you may stop the interview at any 
point. If you become upset we will offer you support from your 
doctor or a neutral party such as the patient relations team. 
We may inform your doctor if we feel that you have an 
undiagnosed condition such as depression. 
 
5 What are the benefits of taking part? 
There are no direct benefits to you, but this research may help 
us to help patients to take their medicine in the future. 
6 How will my confidentiality be assured? 
No information that leaves the medical practice will have your 
name or address on it so that you cannot be recognised. We 
may use direct quotes from the interview in study reports but 
we will make sure that these do not identify you. 
7 How will my data be stored and used? 
Your data will be kept in a locked filing cabinet, or on a 
password protected computer. Your data will be used for 
research. This study is part of an educational thesis, and may 
be published. 
8 How do I take part? 
Please sign the consent form and post this back with your 
“Patient and Lifestyle Scale” questionnaire. At the end of the 
main study, Steven Watson may  contact you to arrange an 
interview. We may not be able to interview everyone that 
agrees, and we will let you know if we cannot interview you. 
Appendix M – Participant interview consent form (text size reduced to fit thesis format) 
308 
 
 
 
 
 
 
We are conducting some interviews as part of this study to help us to improve the design of 
the new questionnaires and to improve the quality of future research that we conduct. If 
you would like to take part in these interviews, please initial each of the boxes. You can 
only be included in the study if you indicate that you have read and understood the 
participant information leaflet that was posted to you along with this form. 
 
Please 
initial 
  
I confirm that I have read and understand the information sheet entitled 
“Medication adherence in hypertension – Participant information sheet: Part 2 
of 2” for the above study and have had the opportunity to ask questions. 
 
  
I understand that my participation is voluntary and that I am free to withdraw at 
any time without my medical care or legal rights being affected. 
 
  
I agree to be contacted and invited to be interviewed as part of this study.  
  
I agree to have the interview recorded on an audio device.  
  
I permit the researchers to use direct quotes from the interviews so long as they 
do not reveal information which could be used to identify me 
 
  
I understand that data collected during the study may be looked at by 
individuals from regulatory authorities which monitor the quality of research. 
 
  
I give permission for individuals from the above mentioned regulatory 
authorities to have access to my records. 
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Please provide a contact telephone number to arrange an interview:  
………………………..…..      
 
………………………..…..                   ……/….../…...  
….……………………….. 
Name of participant                    Date         
Signature 
 
Please complete both copies of this form. Hand one in to the medical practice in the 
enclosed envelope with your “Patient and Lifestyle Scale” questionnaire, and keep one 
copy for your own records. 
 
 
 
   
Researcher contact details:   To make a complaint: 
Steven Watson 
University of East Anglia 
Norwich 
Norfolk 
NR4 7TJ 
Tel: 01603 59 1973 
E-Mail: steven.watson@uea.ac.uk 
Dr. Tim Longmore 
Elvington Medical 
Practice 
York Road 
Elvington 
York 
YO41 4DY 
Tel: 01904 60 8224 
 
Patient Relations Team 
North Yorkshire and 
York PCT  
Freepost NEA 13107 
York 
North Yorkshire 
YO31 7ZX 
Tel: 0800 06 88 000 
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9 What if I have changed my mind about taking part? 
You do not have to take part in this research, and if you decide 
to take part you may withdraw at any point before the 
research is completed. 
10 Who is organising and funding the research? 
The study is being organised by Steven Watson, a PhD student 
at the University of East Anglia. The study is being supervised 
by Dr. Debi Bhattacharya, and by Dr. Tim Longmore at 
Elvington Medical Practice. The study is funded by the 
university. 
11 Who can I contact? 
You can contact the lead researcher Steven Watson by 
telephone or e-mail on 01603 59 1973 or 
steven.watson@uea.ac.uk. You can also speak to Dr. Tim 
Longmore from Elvington Medical Practice on 01904 60 8224.  
If you wish to make a complaint about this research please 
contact Dr Debi Bhattacharya on 01603 59 33 91, or the 
Patient Relations Team for North Yorkshire on 0800 06 88 000.  
12 Thank you for your time! 
If you decide you would like to take part, please keep this 
information sheet for your records. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medication adherence in hypertension 
Participant information sheet 
We would like to thank you for taking part in this 
study. Please read this leaflet carefully to remind 
yourself of what to do now. If there is anything 
you would like to ask us feel free to contact us 
using the details at the end of this form. 
You do not have to continue to take part in the 
study if you do not want to. You may also request 
to have any information you have given to us so 
far to be withdrawn by contacting us using the 
details provided. If you no longer wish to take 
part, it will not affect the care you receive from 
your doctor in any way.  
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1 What is the purpose of this study? 
This study hopes to find out about how patient beliefs and 
experiences affect how they take their hypertension 
medicines. 
2 Why was I been chosen to take part in this study? 
You are registered at Elvington Medical Practice and are due 
for a review of your hypertension. 
3 What will I have to do? 
You have already completed one questionnaire for us. We 
would like you to complete a second questionnaire for us. This 
should not take more than 10 minutes to complete. As a 
reminder, we would also like to look at your medical records so 
that we can see how often you have ordered your prescription 
for your hypertension medicines, and look at your blood 
pressure history. 
4 What are the disadvantages or risks of taking part? 
Some questions may make you feel uncomfortable. You may 
choose to not respond to these questions if you wish. We may 
also inform your doctor if your results indicate that you have 
an undiagnosed condition such as depression. 
5 What are the benefits of taking part? 
There are no direct benefits to you, but this research may help 
us to better help patients to take their medicine in the future. 
 
6 How will my confidentiality be assured? 
No information that leaves the medical practice will have your 
name or address on it so that you cannot be recognised. The 
medical team at Elvington will not see your individual 
responses to this second questionnaire. Only the researchers 
from the University of East Anglia will see your individual 
responses. 
7 How will my data be stored and used? 
Your data will be kept in a locked filing cabinet, or on a 
password protected computer. Your data will be used for 
research and to update your doctor about how much you drink 
or smoke. This study is part of an educational thesis, may be 
published. If you would like a summary of the research contact 
Steven Watson using the details below. Your individual data 
will not be identifiable in any report that is published. 
8 How do I take part? 
Please complete the enclosed questionnaire. You can then post 
these forms to Elvington Medical Practice in the pre-paid and 
addressed envelope provided. The questionnaires will only be 
seen by a researcher from the University. The staff at Elvington 
Medical Practice will not see the responses you make to this 
questionnaire.
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8 What if I change my mind about taking part? 
You do not have to take part in this research, and if you decide 
to take part you may withdraw at any point before the 
research is completed. 
9 Who is organising and funding the research? 
The study is being organised by Steven Watson, a PhD student 
at the University of East Anglia. The study is being supervised 
by Dr. Debi Bhattacharya, and by Dr. Tim Longmore at 
Elvington Medical Practice. The study is funded by the 
university. 
10 Who can I contact? 
You can contact the lead researcher Steven Watson by 
telephone or e-mail on 01603 59 1973 or 
steven.watson@uea.ac.uk. You can also speak to Dr. Tim 
Longmore from Elvington Medical Practice on 01904 60 8224.  
If you wish to make a complaint about this research please 
contact Dr Debi Bhattacharya on 01603 59 33 91, or the 
Patient Relations Team for North Yorkshire on 0800 06 88 000.  
11 Thank you for your time! 
If you decide you would like to take part, please keep this 
information sheet and one copy of the consent form for your 
own records. Please seal a second signed copy of the consent 
form in the yellow envelope with the questionnaire you return. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medication adherence in hypertension 
Participant information sheet: Part 1 of 2 
We would like to offer you a reminder about a 
questionnaire study conducted by the University 
of East Anglia and Elvington Medical Practice. 
Please read this leaflet carefully before you 
decide whether or not to take part. Feel free to 
contact us or to discuss this with others. You can 
contact us using the details at the end of this 
form. 
If you do not wish to take part, it will not affect 
the care you receive from your doctor in any way. 
We will also be running interviews with some of 
our participants. If you would be interested in 
taking part in these, please read the second 
leaflet. 
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1 What is the purpose of this study? 
This study hopes to find out about how patient beliefs and 
experiences affect how they take their hypertension 
medicines. 
2 Why have I been chosen to take part in this study? 
You are registered at Elvington Medical Practice and are due 
for a review of your hypertension. 
3 What will I have to do? 
There are two questionnaires that we would like you to 
complete. Both questionnaires have been posted to you in this 
pack. It should take less than 20 minutes to complete them 
both. The two questionnaires are a different colour. This is 
because Elvington Medical Practice will use information in one 
questionnaire (Patient and Lifestyle Scale - yellow) to update 
your records about how much you smoke or drink. They will 
not see the second questionnaire (Wellbeing and Medications 
Scale - pink). Once you have completed the questionnaires 
please seal the yellow questionnaire in the yellow envelope, 
and the pink questionnaire in the pink envelope. We would 
also like to look at your medical records so that we can see 
how often you have ordered your prescription for your 
hypertension medicines, and look at your blood pressure 
history.  
 
4 What are the disadvantages or risks of taking part? 
Some questions may make you feel uncomfortable. You may 
choose to not answer these questions. We may also inform 
your doctor if your results indicate that have an undiagnosed 
condition such as depression. 
5 What are the benefits of taking part? 
There are no direct benefits to you, but this research may help 
us to better help patients to take their medicine in the future. 
6 How will my confidentiality be assured? 
No information that leaves the medical practice will have your 
name or address on it so that you cannot be recognised. The 
medical team at Elvington will use the yellow questionnaire in 
this pack to update their records about how much you smoke 
or drink. The medical team at Elvington will not see your 
individual responses to the pink questionnaire. 
7 How will my data be stored and used? 
Your data will be kept in a locked filing cabinet, or on a 
password protected computer. Your data will be used for 
research and to update your doctor about how much you drink 
or smoke. This study is part of an educational thesis, may be 
published. If you would like a summary of the research contact 
Steven Watson using the details below. Your individual data 
will not be identifiable in any report that is published.
Appendix P – Subscale Inter-item correlations and Cronbach’s alpha with item removed 
314 
 
BMQ Overuse subscale 
 Item 
 Doctors prescribe 
too many 
medicines 
People who take 
medicines should 
stop their 
treatment for a 
while every now 
and again 
Doctors place too 
much trust on 
medicines 
If doctors had 
more time with 
patients they 
would prescribe 
fewer medicines 
Item Rho p Rho p Rho p Rho p 
Doctors prescribe too 
many medicines 
- - 0.444 0.148 0.617 0.033 0.345 0.273 
People who take 
medicines should stop 
their treatment for a while 
every now and again 
  - - 0.376 0.206 -0.120 0.696 
Doctors place too much 
trust on medicines 
    - - 0.386 0.193 
If doctors had more time 
with patients they would 
prescribe fewer medicines 
      - - 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
 
 
Item-Total Statistics 
 Scale Mean if 
Item Deleted 
Scale 
Variance if 
Item Deleted 
Corrected 
Item-Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Doctors prescribe too many medicines 
100.0000 2386.364 .567 .595 
People who take medicines should stop 
their treatment for a while every now 
and again 
112.5000 3011.364 .397 .698 
Doctors place too much trust on 
medicines 
104.1667 2481.061 .692 .527 
If doctors had more time with patients 
they would prescribe fewer medicines 
83.3333 2878.788 .355 .730 
 
  
Appendix P – Subscale Inter-item correlations and Cronbach’s alpha with item removed 
315 
 
 
BMQ General Harm subscale 
 Item 
 
Most medicines 
are addictive 
Natural remedies 
are safer than 
medicines 
Medicines do 
more harm than 
good 
All medicines are 
poisons 
Item Rho p Rho p Rho p Rho p 
Most medicines are 
addictive 
- - 0.080 0.796 0.508 0.076 0.348 0.244 
Natural remedies are 
safer than medicines 
  - - 0.153 0.617 0.033 0.915 
Medicines do more harm 
than good 
    - - 0.618 0.024 
All medicines are poisons       - - 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
 
Item-Total Statistics 
 
Scale Mean if Item 
Deleted 
Scale Variance if 
Item Deleted 
Corrected Item-
Total Correlation 
Cronbach's Alpha 
if Item Deleted 
Most medicines are 
addictive 
111.5385 4022.436 .329 .565 
Natural remedies are safer 
than medicines 
101.9231 4214.744 .146 .667 
Medicines do more harm 
than good 
113.4615 2564.103 .662 .267 
All medicines are poisons 111.5385 2459.936 .445 .479 
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PSS-4: 
 Item 
 
In the last month, 
how often have 
you felt that you 
were unable to 
control the 
important things 
in your life? 
In the last month, 
how often have 
you felt confident 
about your ability 
to handle your 
personal 
problems? 
In the last month, 
how often have 
you felt that 
things were going 
your way? 
In the last month, 
how often have 
you felt 
difficulties were 
piling up so high 
that you could 
not overcome 
them? 
Item Rho p Rho p Rho p Rho p 
In the last month, how 
often have you felt that 
you were unable to 
control the important 
things in your life? 
- - 0.936 <0.001 0.664 0.010 0.788 0.001 
In the last month, how 
often have you felt 
confident about your 
ability to handle your 
personal problems? 
  - - 0.461 0.097 0.750 0.002 
In the last month, how 
often have you felt that 
things were going your 
way? 
    - - 0.594 0.025 
In the last month, how 
often have you felt 
difficulties were piling up 
so high that you could 
not overcome them? 
      - - 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
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PSS-4 
 
Scale Mean if 
Item Deleted 
Scale Variance if 
Item Deleted 
Corrected Item-
Total Correlation 
Cronbach's Alpha 
if Item Deleted 
In the last month, how 
often have you felt that 
you were unable to 
control the important 
things in your life? 
89.2857 4780.220 .916 .791 
In the last month, how 
often have you felt 
confident about your 
ability to handle your 
personal problems? 
103.5714 7390.110 .836 .849 
In the last month, how 
often have you felt that 
things were going your 
way? 
80.3571 7228.709 .564 .921 
In the last month, how 
often have you felt 
difficulties were piling up 
so high that you could not 
overcome them? 
101.7857 6198.489 .811 .831 
 
PHQ Depression 
Correlation between item “Having little interest or pleasure in doing things?” and “Feeling 
down, depressed or hopeless?” Rho = 0.910, p < 0.001 
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PHQ Anxiety 
 Item 
 
“Nerves”, or 
feeling anxious or 
on edge? 
Worrying about a 
lot of different 
things? 
During the last 
month, have you 
had an anxiety 
attack (suddenly 
feeling fear or 
panic)? 
Item Rho p Rho p Rho p 
“Nerves”, or feeling 
anxious or on edge? 
- - 0.802 0.001 0.577 0.031 
Worrying about a lot of 
different things? 
  - - 0.568 0.034 
During the last month, 
have you had an anxiety 
attack (suddenly feeling 
fear or panic)? 
    - - 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
 
 
Scale Mean if 
Item Deleted 
Scale Variance if 
Item Deleted 
Corrected Item-
Total Correlation 
Cronbach's Alpha 
if Item Deleted 
“Nerves”, or feeling 
anxious or on edge? 
35.5714 1955.341 .756 .547 
Worrying about a lot of 
different things? 
21.2857 951.451 .745 .713 
During the last month, 
have you had an anxiety 
attack (suddenly feeling 
fear or panic)? 
47.4286 2852.879 .683 .776 
 
Medications concerns 
Correlation between item “I think my medicines are giving me side effects” and “If my 
medicines are making me feel worse than my illness, I think it makes sense to stop taking it 
for a while” Rho = 0.502, p = 0.080. 
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Medication necessity 
 Item 
 I think my 
medicines make 
me feel better 
than I would 
without them 
I think my illness 
would be worse 
without my 
medicines 
I think my 
medicines help to 
keep me feeling 
as healthy as 
possible 
Item Rho p Rho p Rho p 
I think my medicines 
make me feel better than I 
would without them 
- - 0.714 0.006 0.800 0.002 
I think my illness would 
be worse without my 
medicines 
  - - 0.833 0.001 
I think my medicines help 
to keep me feeling as 
healthy as possible 
    - - 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
 
 
Scale Mean if Item 
Deleted 
Scale Variance if 
Item Deleted 
Corrected Item-
Total Correlation 
Cronbach's Alpha 
if Item Deleted 
I think my medicines 
make me feel better than 
I would without them 
39.5833 1302.083 .817 .815 
I think my illness would 
be worse without my 
medicines 
52.0833 1756.629 .694 .927 
I think my medicines help 
to keep me feeling as 
healthy as possible 
45.8333 1117.424 .894 .746 
 
Self-efficacy 
Correlation between “I find it hard to remember to take all of my medicines each day” and 
“I think I can cope with the number of medicines I am prescribed at the moment” Rho = 
0.314, p = 0.296. 
 
Social support: 
 Item 
 I am concerned 
about how others 
will react if I tell 
them what 
medicines I take 
There are people 
who will help me 
with my 
medicines if 
needed 
I have people I 
can talk to about 
my illness 
I can count on my 
family and 
friends to help me 
deal with my 
illness 
Item Rho p Rho p Rho p Rho p 
I am concerned about 
how others will react if I 
tell them what medicines 
I take 
- - -0.136 0.658 0.345 0.249 0.272 0.369 
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There are people who will 
help me with my 
medicines if needed 
  - - 0.707 0.007 0.536 0.059 
I have people I can talk to 
about my illness 
    - - 0.824 0.001 
I can count on my family 
and friends to help me 
deal with my illness 
      - - 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
 
 
Scale Mean if 
Item Deleted 
Scale Variance if 
Item Deleted 
Corrected Item-
Total Correlation 
Cronbach's Alpha 
if Item Deleted 
I am concerned about 
how others will react if I 
tell them what medicines 
I take 
98.0769 4839.744 .141 .849 
There are people who will 
help me with my 
medicines if needed 
88.4615 4022.436 .413 .675 
I have people I can talk to 
about my illness 
88.4615 3084.936 .840 .374 
I can count on my family 
and friends to help me 
deal with my illness 
88.4615 4022.436 .724 .520 
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PDRQ-9 
 Item 
 
My doctor 
helps me 
My doctor 
has enough 
time for me 
I trust my 
doctor 
My doctor 
understands 
me 
My doctor is 
dedicated to 
helping me 
My doctor 
and I agree 
on the nature 
of my medical 
symptoms 
I can talk to 
my doctor 
I feel content 
with the 
treatment I 
receive from 
my doctor 
I find my 
doctor easily 
accessible 
Item Rho p Rho p Rho p Rho p Rho p Rho p Rho p Rho p Rho p 
My doctor helps me 
- - 0.671 0.012 0.717 0.004 0.694 0.006 0.702 0.005 0.729 0.003 0.590 0.026 0.876 <0.00
1 
0.432 0.123 
My doctor has enough 
time for me 
  - - 0.835 <0.00
1 
0.794 0.001 0.511 0.074 0.766 0.002 0.592 0.033 0.710 0.007 0.512 0.074 
I trust my doctor     - - 0.631 0.016 0.780 0.001 0.690 0.006 0.468 0.092 0.780 0.001 0.513 0.061 
My doctor understands 
me 
      - - 0.448 0.109 0.653 0.011 0.460 0.098 0.768 0.001 0.168 0.567 
My doctor is dedicated to 
helping me 
        - - 0.820 <0.00
1 
0.464 0.095 0.801 0.001 0.497 0.070 
My doctor and I agree on 
the nature of my medical 
symptoms 
          - - 0.688 0.006 0.820 <0.00
1 
0.552 0.041 
I can talk to my doctor             - - 0.692 0.006 0.595 0.025 
I feel content with the 
treatment I receive from 
my doctor 
              - - 0.497 0.070 
I find my doctor easily 
accessible 
                - - 
Moderate (> 0.3) correlations are in italics, large (> 0.5) correlations are in bold 
Correlations significant at α = 0.1 are in italics, correlations significant at α = 0.05 are in bold 
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PDRQ-9 
 Scale Mean if 
Item Deleted 
Scale Variance if 
Item Deleted 
Corrected Item-
Total Correlation 
Cronbach's 
Alpha if Item 
Deleted 
My doctor helps me 186.5385 16834.936 .866 .943 
My doctor has enough 
time for me 
188.4615 17043.269 .889 .941 
I trust my doctor 194.2308 17932.692 .868 .942 
My doctor understands 
me 
176.9231 17860.577 .779 .947 
My doctor is dedicated to 
helping me 
186.5385 17459.936 .850 .943 
My doctor and I agree on 
the nature of my medical 
symptoms 
182.6923 17748.397 .920 .940 
I can talk to my doctor 190.3846 19951.923 .612 .954 
I feel content with the 
treatment I receive from 
my doctor 
186.5385 16939.103 .955 .937 
I find my doctor easily 
accessible 
184.6154 21097.756 .527 .958 
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Note that correlations with Morisky/Self-reported adherence are the reverse to those 
presented in the main text because correlations have not been reversed. I.e. higher scores 
on Morisky represent lower adherence. 
PALS: 
With self-reported adherence: 
 
Rho = 0.241, p = 0.427 
 
With retrospective refill adherence: 
 
Rho = 0.065, p = 0.879  
Appendix Q – Visual representations of correlations between PALS, WAMS, subscales and 
measures of adherence 
324 
 
With prospective refill adherence: 
 
Rho = -0.790, p = 0.020 
 
WAMS: 
With self-reported adherence: 
 
Rho = 0.520, p = 0.101 
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With retrospective refill adherence: 
 
Rho = 0.327, p = 0.428 
 
With prospective refill adherence: 
 
Rho = -0.610, p = 0.109 
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WAMS + PALS: 
With self-reported adherence: 
 
Rho = 0.391, p = 0.234 
 
With retrospective refill adherence: 
 
Rho = 0.122, p = 0.774 
  
Appendix Q – Visual representations of correlations between PALS, WAMS, subscales and 
measures of adherence 
327 
 
 
With prospective refill adherence: 
 
Rho = -0.724, p = 0.042 
 
Sex: 
With self-reported adherence: 
 
Rho = -0.463, p =0.111 
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With retrospective refill adherence: 
 
Rho = 0.173, p = 0.682 
 
With prospective refill adherence: 
 
Rho = 0.194, p = 0.646 
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Employment: 
With self-reported adherence: 
 
Rho = -0.249, p = 0.413 
 
With retrospective refill adherence: 
No unemployed participants consented to give access to medical records 
 
With prospective refill adherence: 
No unemployed participants consented to give access to medical records 
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Housing status: 
With self-reported adherence: 
 
Rho = -0.398, p = 0.254 
 
With retrospective refill adherence: 
 
Rho = 0.656, p = 0.109 
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With prospective refill adherence: 
 
Rho = 0.587, p = 0.126 
 
Age: 
With self-reported adherence: 
  
Rho = -0.275, p = 0.364 
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With retrospective refill adherence: 
 
Rho = 0.220, p = 0.601 
 
With prospective refill adherence: 
 
Rho = 0.546, p = 0.162 
  
Appendix Q – Visual representations of correlations between PALS, WAMS, subscales and 
measures of adherence 
333 
 
 
Health Literacy: 
With self-reported adherence: 
 
Rho = 0.615, p = 0.025 
 
With retrospective refill adherence: 
 
Rho = -0.872, p = 0.005 
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With prospective refill adherence: 
 
Rho = -0.860, p = 0.006 
 
BMQ overuse scale: 
With self-reported adherence: 
 
Rho = 0.086, p = 0.780 
With retrospective refill adherence: 
 
Rho = -0.075, p = 0.859 
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With prospective refill adherence: 
 
Rho = -0.394, p = 0.334 
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BMQ general harm scale: 
With self-reported adherence: 
 
Rho = -0.147, p = 0.632 
 
With retrospective refill adherence: 
 
Rho = -0.264, p = 0.527 
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With prospective refill adherence: 
 
Rho = -0.394, p = 0.334 
 
Mental health: 
With self-reported adherence: 
 
Rho = 0.070, p = 0.829 
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With retrospective refill adherence: 
 
Rho = 0.258. p = 0.537 
 
With prospective refill adherence: 
 
Rho = -0.289 , p = 0.488 
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Health behaviour – Drinking alcohol: 
With self-reported adherence: 
 
Rho = 0.433, p = 0.139 
 
With retrospective refill adherence: 
 
Rho = -0.050, p = 0.906 
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With prospective refill adherence: 
 
Rho = -0.280, p = 0.503 
 
PSS-4: 
With self-reported adherence: 
 
Rho = 0.720, p = 0.012 
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With retrospective refill adherence: 
 
Rho = -0.245, p = 0.558 
 
With prospective refill adherence: 
 
Rho = -0.878, p = 0.004 
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PHQ Depression: 
With self-reported adherence: 
 
Rho = 0.671, p = 0.024 
 
With retrospective refill adherence: 
 
Rho = 0.208, p = 0.622 
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With prospective refill adherence: 
 
Rho = -0.375, p = 0.360 
 
PHQ Anxiety: 
With self-reported adherence: 
 
Rho = 0.695, p = 0.018 
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With retrospective refill adherence: 
 
Rho = 0.127, p = 0.765 
 
With prospective refill adherence: 
 
Rho = -0.425, p = 0.294 
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Medication concerns: 
With self-reported adherence: 
 
Rho = 0.245, p = 0.496 
 
With retrospective refill adherence: 
 
Rho = 0.214, p = 0.611 
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With prospective refill adherence: 
 
Rho = 0.183, p = 0.665 
 
Medications necessity: 
With self-reported adherence: 
 
Rho = 0.319, p = 0.369 
  
Appendix Q – Visual representations of correlations between PALS, WAMS, subscales and 
measures of adherence 
347 
 
With retrospective refill adherence: 
 
Rho = 0.383, p = 0.349 
 
With prospective refill adherence: 
 
Rho = 0.097, p = 0.820 
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Self-efficacy: 
With self-reported adherence: 
 
Rho = 0.695, p = 0.018 
 
With retrospective refill adherence: 
 
Rho = -0.259, p = 0.535 
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With prospective refill adherence: 
 
Rho = -0.607, p = 0.110 
 
Social support: 
With self-reported adherence: 
 
Rho = 0.183, p = 0.614 
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With retrospective refill adherence: 
 
Rho = 0.491, p = 0.217 
 
With prospective refill adherence: 
 
Rho = 0.110, p = 0.796 
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Access to medications: 
With self-reported adherence: 
 
Rho = 0.739, p = 0.015 
 
With retrospective refill adherence: 
 
Rho = -0.264, p = 0.528 
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With prospective refill adherence: 
 
Rho = -0.471, p = 0.238 
 
PDRQ-9 
With self-reported adherence: 
 
Rho = 0.490, p = 0.126 
 
With retrospective refill adherence: 
 
Rho = -0.012, p = 0.977 
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With prospective refill adherence: 
 
Rho = -0.206, p = 0.625 
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ROC curve analyses were performed to illustrate the predictive power of the PALS and 
WAMS. However, the small sample size made these analyses unlikely to be informative. 
In the interests of transparency they were performed as planned and the results are 
presented. However, they were not used to evaluate the questionnaires because of their 
lack of explanatory power. 
 
Area Under Curve analysis for Morisky Adherence Measure: 
Positive state = No reported nonadherence 
Negative state = Any reported nonadherence 
 
Case Processing Summary 
MoriskySplit Valid N 
(listwise) 
dimensio
n0 
Positive
a
 5 
Negative 6 
Missing 6 
Larger values of the test result 
variable(s) indicate stronger 
evidence for a positive actual 
state. 
a. The positive actual state is 
.00. 
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Area Under the Curve 
Test Result Variable(s) 
Area Std. Error
a
 Asymptotic Sig.
b
 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
d
i
m
e
n
s
i
o
n
0 
PALS_Summary .400 .180 .584 .047 .753 
WAMS_Summary .200 .143 .100 .000 1.000 
OverallSummaryScore .400 .191 .584 .026 .774 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
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 Coordinates of the Curve 
 Test Result Variable(s) Positive if 
Greater Than or 
Equal To
a
 Sensitivity 1 - Specificity 
d
i
m
e
n
s
i
o
n
0 
PALS_Summary 4.7100 1.000 1.000 
10.9800 1.000 .833 
16.7700 .800 .833 
19.3750 .600 .833 
21.8000 .600 .667 
22.4250 .600 .500 
26.8000 .400 .500 
31.5150 .200 .500 
32.7350 .200 .333 
36.4550 .000 .333 
44.5000 .000 .167 
50.4200 .000 .000 
WAMS_Summary 5.9400 1.000 1.000 
7.7500 .800 1.000 
11.9200 .800 .833 
16.3600 .600 .833 
18.2900 .400 .833 
19.2150 .400 .667 
19.9650 .200 .667 
22.2350 .000 .667 
33.1600 .000 .500 
44.7550 .000 .333 
54.9200 .000 .167 
63.8200 .000 .000 
OverallSummaryScore 15.8500 1.000 1.000 
17.9250 .800 1.000 
19.6500 .600 1.000 
20.3250 .600 .833 
21.6700 .600 .667 
23.5450 .600 .500 
24.1650 .600 .333 
24.6600 .400 .333 
26.0400 .200 .333 
35.1450 .000 .333 
49.7100 .000 .167 
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57.1200 .000 .000 
 a. The smallest cutoff value is the minimum observed test value minus 1, 
and the largest cutoff value is the maximum observed test value plus 1. All 
the other cutoff values are the averages of two consecutive ordered 
observed test values. 
Area Under Curve analysis for Retrospective Refill adherence: 
Positive state = 100% refill adherence 
Negative state = <100% refill adherence 
 
Case Processing Summary 
PropDaysMed Valid N 
(listwise) 
dimension0 
Positive
a
 3 
Negative 5 
Missing 9 
Larger values of the test result 
variable(s) indicate stronger 
evidence for a positive actual 
state. 
a. The positive actual state is 
100.00. 
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Area Under the Curve 
Test Result 
Variable(s) 
Area 
Std. 
Error
a
 
Asymptotic 
Sig.
b
 
Asymptotic 95% 
Confidence Interval 
Lower 
Bound 
Upper 
Bound 
d
i
m
e
n
s
i
o
n
0 
PALS_Summary .667 .202 .456 .000 1.000 
WAMS_Summary .467 .218 .881 .040 .893 
OverallSummarySc
ore 
.600 .227 .655 .079 1.000 
a. Under the nonparametric assumption 
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b. Null hypothesis: true area = 0.5 
 Coordinates of the Curve 
 Test Result Variable(s) Positive if 
Greater Than or 
Equal To
a
 Sensitivity 1 - Specificity 
d
i
m
e
n
s
i
o
n
0 
PALS_Summary 15.2500 1.000 1.000 
18.8550 1.000 .800 
21.8000 1.000 .600 
22.4250 1.000 .400 
26.8000 .667 .400 
31.5150 .333 .400 
32.7350 .333 .200 
41.3750 .000 .200 
50.4200 .000 .000 
WAMS_Summary 7.5600 1.000 1.000 
11.9200 1.000 .800 
16.3600 .667 .800 
18.2900 .667 .600 
19.2150 .667 .400 
19.9650 .333 .400 
22.2350 .000 .400 
43.3250 .000 .200 
63.8200 .000 .000 
OverallSummaryScore 15.8500 1.000 1.000 
17.9250 1.000 .800 
19.6500 .667 .800 
20.3250 .667 .600 
21.6700 .667 .400 
24.0400 .667 .200 
26.0400 .333 .200 
41.5550 .000 .200 
57.1200 .000 .000 
 a. The smallest cutoff value is the minimum observed test value minus 1, 
and the largest cutoff value is the maximum observed test value plus 1. All 
the other cutoff values are the averages of two consecutive ordered 
observed test values. 
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Area Under Curve analysis for Prospective Refill adherence: 
Positive state = 100% refill adherence 
Negative state = <100% refill adherence 
Case Processing Summary 
ProsPropDaysMed Valid N 
(listwise) 
dimension0 
Positive
a
 5 
Negative 3 
Missing 9 
Larger values of the test result 
variable(s) indicate stronger evidence 
for a positive actual state. 
a. The positive actual state is 100.00. 
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Area Under the Curve 
Test Result Variable(s) 
Area Std. Error
a
 Asymptotic Sig.
b
 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
d
i
m
e
n
s
i
o
n
0 
PALS_Summary .267 .195 .297 .000 1.000 
WAMS_Summary .333 .272 .456 .000 1.000 
OverallSummaryScore .267 .192 .297 .000 1.000 
a. Under the nonparametric assumption 
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b. Null hypothesis: true area = 0.5 
 Coordinates of the Curve 
 Test Result Variable(s) Positive if 
Greater Than or 
Equal To
a
 Sensitivity 1 - Specificity 
d
i
m
e
n
s
i
o
n
0 
PALS_Summary 15.2500 1.000 1.000 
18.8550 .800 1.000 
21.8000 .600 1.000 
22.4250 .600 .667 
26.8000 .400 .667 
31.5150 .200 .667 
32.7350 .200 .333 
41.3750 .000 .333 
50.4200 .000 .000 
WAMS_Summary 7.5600 1.000 1.000 
11.9200 1.000 .667 
16.3600 .800 .667 
18.2900 .600 .667 
19.2150 .400 .667 
19.9650 .200 .667 
22.2350 .000 .667 
43.3250 .000 .333 
63.8200 .000 .000 
OverallSummaryScore 15.8500 1.000 1.000 
17.9250 .800 1.000 
19.6500 .600 1.000 
20.3250 .400 1.000 
21.6700 .400 .667 
24.0400 .400 .333 
26.0400 .200 .333 
41.5550 .000 .333 
57.1200 .000 .000 
 a. The smallest cutoff value is the minimum observed test value minus 
1, and the largest cutoff value is the maximum observed test value 
plus 1. All the other cutoff values are the averages of two consecutive 
ordered observed test values. 
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PALS summary scores: 
 
Statistics 
PALS_Summary 
N Valid 13 
Missing 4 
Skewness .282 
Std. Error of Skewness .616 
Kurtosis .082 
Std. Error of Kurtosis 1.191 
Percentiles 25 16.7700 
50 22.7100 
75 33.2900 
 
WAMS summary scores: 
  
Appendix S – Distributions of PALS, WAMS and subscales 
364 
 
Statistics 
WAMS_Summary 
N Valid 14 
Missing 3 
Skewness .768 
Std. Error of Skewness .597 
Kurtosis -.576 
Std. Error of Kurtosis 1.154 
Percentiles 25 16.9000 
50 21.3500 
75 43.6225 
 
PALS + WAMS summary scores: 
 
Statistics 
OverallSummaryScore 
N Valid 11 
Missing 6 
Skewness 1.898 
Std. Error of Skewness .661 
Kurtosis 3.137 
Std. Error of Kurtosis 1.279 
Percentiles 25 20.3000 
50 24.1000 
75 26.9900 
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Sex: 
 
Employment: 
 
Housing status: 
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Age: 
 
Statistics 
OverallSummaryScore 
N Valid 11 
Missing 6 
Skewness 1.898 
Std. Error of Skewness .661 
Kurtosis 3.137 
Std. Error of Kurtosis 1.279 
Percentiles 25 20.3000 
50 24.1000 
75 26.9900 
 
Health literacy: 
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Statistics 
PALS_5_HealthLit 
N Valid 13 
Missing 4 
Percentiles 25 .0000 
50 25.0000 
75 62.5000 
 
 
BMQ overuse: 
 
Statistics 
BMQ_Overuse 
N Valid 13 
Missing 4 
Skewness -.007 
Std. Error of Skewness .616 
Kurtosis 1.113 
Std. Error of Kurtosis 1.191 
Percentiles 25 25.0000 
50 31.2500 
75 43.7500 
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BMQ general harm: 
 
Statistics 
BMQ_GenHarm 
N Valid 13 
Missing 4 
Skewness -.016 
Std. Error of Skewness .616 
Kurtosis .554 
Std. Error of Kurtosis 1.191 
Percentiles 25 25.0000 
50 37.5000 
75 46.8750 
 
Mental health: 
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Health behaviour – Drinking alcohol: 
 
PSS-4: 
 
Statistics 
PSS4_Stress 
N Valid 14 
Missing 3 
Skewness .535 
Std. Error of Skewness .597 
Kurtosis -1.253 
Std. Error of Kurtosis 1.154 
Percentiles 25 6.2500 
50 28.1250 
75 62.5000 
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PHQ Depression: 
 
Statistics 
PHQ_Dep 
N Valid 14 
Missing 3 
Skewness 1.049 
Std. Error of Skewness .597 
Kurtosis -.305 
Std. Error of Kurtosis 1.154 
Percentiles 25 .0000 
50 .0000 
75 50.0000 
 
PHQ Anxiety: 
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Statistics 
PHQ_Anx 
N Valid 14 
Missing 3 
Skewness .993 
Std. Error of Skewness .597 
Kurtosis -.332 
Std. Error of Kurtosis 1.154 
Percentiles 25 .0000 
50 11.0000 
75 27.5825 
 
Medication concerns: 
 
Statistics 
Med_Concern 
N Valid 13 
Missing 4 
Skewness -.197 
Std. Error of Skewness .616 
Kurtosis -.462 
Std. Error of Kurtosis 1.191 
Percentiles 25 31.2500 
50 50.0000 
75 68.7500 
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Medications necessity: 
 
Statistics 
Med_Necessity 
N Valid 13 
Missing 4 
Skewness .402 
Std. Error of Skewness .616 
Kurtosis -.756 
Std. Error of Kurtosis 1.191 
Percentiles 25 8.3300 
50 25.0000 
75 41.6650 
 
Self-efficacy: 
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Statistics 
SelfEfficacy 
N Valid 13 
Missing 4 
Skewness .533 
Std. Error of Skewness .616 
Kurtosis -.788 
Std. Error of Kurtosis 1.191 
Percentiles 25 6.2500 
50 25.0000 
75 43.7500 
 
Social support: 
 
Statistics 
SocialSupport 
N Valid 13 
Missing 4 
Skewness .860 
Std. Error of Skewness .616 
Kurtosis .444 
Std. Error of Kurtosis 1.191 
Percentiles 25 15.6250 
50 25.0000 
75 46.8750 
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Access to medicines: 
 
Statistics 
WAMS_21_AccessMed 
N Valid 13 
Missing 4 
Percentiles 25 .0000 
50 25.0000 
75 62.5000 
 
PDRQ-9: 
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Statistics 
PDRQ9_ProvRel 
N Valid 14 
Missing 3 
Skewness .806 
Std. Error of Skewness .597 
Kurtosis .767 
Std. Error of Kurtosis 1.154 
Percentiles 25 12.5000 
50 23.6100 
75 27.8675 
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 Employ Housing 
Status 
Age Health 
Literacy 
BMQ-
Overuse 
BMQ-
Harm 
Mental 
Health 
Alcohol  PSS-4 PHQ-Dep PHQ-
Anxiety 
Med 
Concerns 
Med 
Necessity 
Self-
Efficacy 
Social 
Support 
Access 
to Meds 
PDRQ-9 Morisky Retro 
Refill 
Pro 
Refill 
Sex -0.415 0.102 -0.339 -0.045 -0.151 0.064 -0.316 -0.412 -0.163 -0.449 -0.282 0.039 -0.153 0.195 -0.077 -0.082 -0.162 -0.463 0.173 0.194 
Employed 1 0.102 0.620 -0.285 -0.211 0.189 0.529 -0.339 -0.409 0.067 -0.158 0.106 0.176 -0.25 0.281 0.075 0.058 -0.249 0.224 0.125 
Housing 
Status 
- 1 0.306 -0.467 0.045 0.177 -0.167 0.044 0.106 0.283 0.184 0 0.157 0.321 0.734 -0.456 -0.624 -0.398 0.656 0.394 
Age - - 1 -0.567 -0.149 0.069 0.13 -0.352 -0.599 -0.285 -0.379 -0.059 0.282 -0.218 0.193 -0.261 -0.389 -0.275 0.220 0.546 
Health 
Literacy 
- - - 1 0.267 0.24 0.068 0.25 0.493 0.112 0.066 -0.04 -0.245 0.491 -0.146 0.416 0.165 0.615 -0.872 -0.860 
BMQ-
Overuse 
- - - - 1 0.515 0.066 0.071 0.345 0 -0.257 -0.39 -0.162 0.038 -0.315 -0.501 -0.289 0.086 -0.075 -0.394 
BMQ-
Harm 
- - - - - 1 0.165 -0.604 -0.116 -0.162 -0.51 0.031 0.224 0.385 0.149 -0.195 -0.248 -0.147 -0.264 -0.394 
Mental 
Health 
- - - - - - 1 -0.033 0.075 0.259 0 0.31 0.483 0.089 0.307 0.467 0.487 0.070 0.258 -0.289 
Alcohol  - - - - - - - 1 0.647 0.426 0.562 -0.23 -0.344 -0.083 -0.059 0.05 0.042 0.433 -0.050 -0.280 
PSS-4 - - - - - - - - 1 0.813 0.760 0.225 0.282 0.534 0.471 0.507 0.173 0.720 -0.245 -0.878 
PHQ-
Depression 
- - - - - - - - - 1 0.865 0.573 0.609 0.343 0.778 0.538 0.397 0.671 0.208 -0.375 
PHQ-
Anxiety 
- - - - - - - - - - 1 0.465 0.477 0.307 0.647 0.628 0.444 0.684 0.127 -0.425 
Medication 
Concerns 
- - - - - - - - - - - 1 .706 0.071 0.624 0.398 0.653 0.245 0.214 0.183 
Medication 
Necessity 
- - - - - - - - - - - - 1 0.323 0.696 0.502 0.532 0.319 0.383 0.097 
Self-
Efficacy 
- - - - - - - - - - - - - 1 0.427 0.372 -0.18 0.627 -0.259 -0.607 
Social 
Support 
- - - - - - - - - - - - - - 1 0.354 0.205 0.183 0.491 0.110 
Access to 
Medicines 
- - - - - - - - - - - - - - - 1 0.620 0.739 -0.264 -0.471 
PDRQ-9 - - - - - - - - - - - - - - - - 1 0.490 -0.012 -0.206 
Items in bold have their strongest correlation with a measure of adherence 
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1. For the purposes of the recording, please introduce yourself:  
 What you would like to be called 
 Your current professional role 
2. How often do you use questionnaire type tools to help with decision making about 
individual patients? 
 For example, the PHQ9 
3. What features make a good tool? 
 Wording 
 No. Questions 
 Design 
 Scoring 
 Interpretation 
4. What is it about bad tools that make them bad? 
 Wording 
 No. Questions 
 Design 
 Scoring 
 Interpretation 
 Admin burden? 
5. Given the things we’ve talked about so far, what were the overall impressions of 
these two tools? 
 Did the content ‘make sense’? 
 Are there any questions are not clearly understood? 
 Are there any questions which may mean different things to different people? 
 Are there any concerns about the content? 
o Anything which you think might upset patients. Anything that might 
upset the practitioners. Anything which seems ethically dubious? 
 Is there anything that is missing? 
 Does it seem like these tools could be used to help identify non-adherent 
patients? 
 Does it seem like they could be used to identify other problems with patients? 
o Would you want it to be able to identify other problems? E.g 
depression/stress. 
 Would they help to make a decision about what to do with a particular 
patient? 
6. What are the best ways to get practitioners involved in research? 
 What sort of things can researchers do to encourage practitioners to take 
part? 
 What puts people off taking part in research? 
 If we were to run this study again, what could we do to make it easier for the 
practice? 
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Below is the interview guide for patient participants.  The questions are coloured to reflect the 
criteria outlined in the topic map above.  These will be used as prompts when necessary to 
encourage discussion. 
 
First: Run through confidentiality and procedures. Allow them to flick through questionnaire 
to refamiliarise themselves. 
 
Opening questions: 
1: If we can go right to the beginning, you received a letter that told you that you were due to 
attend for a hypertension review, and telling you about this study. How did you feel as you 
read that letter? 
 What were your thoughts before you decided to take part? 
 Did you decide straight away to take part or did you think about it for a while? 
 Why did you decide to take part? 
How did you feel about taking part in the research? 
Is there anything we could have done to make you feel better about taking part? 
  
2: How did you feel when completing the questionnaire? 
 Were there any sections you’d particularly like to comment on? 
 Were there any questions you didn’t like? (Also ask how felt about knowing doctors 
would use the questions on smoking and drinking to update their medical records) 
 Were there any times where you weren’t quite sure how to fill it in? 
 Can you think of anything we could do to make this a better questionnaire? 
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 What could we have done to make it easier to complete? 
 
3: Parts of the questionnaire were asking you about taking your medicines. Tell me, how do 
you feel about taking them? 
 How do you find taking them? Is it easy or difficult for you? 
 (Ask if feel the same or differently about other meds if on any) 
 
4: Do you talk to many people about your hypertension? 
 Do you talk to them about taking your medicines? 
  
5: How do you feel about talking to your doctor about your hypertension? 
 Is there anything you’d change about how you get on with your doctor?  
 
6: Overall how would you say you are managing your hypertension? 
 Would you say you are coping well or not? 
 Does it have much effect upon your day to day life or not? 
 
7: Is there anything further that you would like to add either about being involved in the study, 
the questionnaire, or your medicines. 
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Theme Subtheme 
1. Perception of questionnaire 
tools 
 
 1.1 Influence on decision making 
 1.2 Impact upon consultations 
 1.3 Influence on relationship with the patient 
 1.4 Motivations for use of tools 
2. Design of questionnaire tools  
 2.1 Wording of questionnaires 
 2.2 Length 
 2.3 Scoring and interpretation 
 2.4 Mode of administration 
 2.5 Patient perspectives 
 2.6 Deficiencies of current tools 
3. Ethical considerations  
 3.1 Dealing with sensitive questions 
 3.2 Managing responses 
4. Patient adherence  
 4.1 Identification 
 4.2 Causes 
 4.3 Management of non-adherence 
5. Participation in research  
 5.1 Incentives 
 5.2 Barriers 
 5.3 Logistics 
6. Perception of patients  
 6.1 As patients 
 6.2 As participants 
7. Practitioner focussed themes  
 7.1 Professional pride 
 7.2 Busyness 
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Items in bold are changed from initial framework
Theme Subtheme 
1. Patient factors  
 1.1 Demographic 
 1.2 Normalising – Merged with 8.2 
 1.3 Stress and anxiety 
 1.4 Emotive responses versus rationalisations 
 1.5 Social desirability 
 1.6 Desire for independence 
 1.7 Desire for information 
2. Perception of 
medicines 
 
 2.1 Aspects of the drug regimen 
 2.2 Perception of side effects 
 2.3 Positive aspects of the medicine 
 2.4 Reservations about medicines 
3. Perception of Illness  
 3.1 Causes of illness and exacerbating factors 
 3.2 Perception and impact of symptoms 
 3.3 Impact and role of comorbid conditions 
 3.4 Perception of health and health maintenance renamed 
4. Access to healthcare  
 4.1 Obtaining a new supply 
 4.2 Paying for medication 
 4.3 Getting a consultation 
 4.4 Dealing with problems 
 4.5 Literacy and understanding 
5. Social Factors  
 5.1 Practical help 
 5.2 Emotional Support 
 5.3 Role of romantic partners 
 5.4 Giving and receiving advice 
6. Relationship to 
health care providers 
 
 6.1 Relationship with individual doctors  
 6.2 Relationship to surgeries – suggest merging with 6.1 rename 
as “The doctor patient relationship”? 
 6.3 Trust 
 6.4 Time 
 6.5 Empathy and rapport 
7. Participation in 
research 
 
 7.1 Perceived benefits of participation 
 7.2 Perceived threats from participation renamed 
 7.3 Barriers to participation 
 7.4 Understanding Questions and instructions 
8. Recurrent themes  
 8.1 Trust 
 8.2 Normalisation 
 8.3 Motivations 
 8.4 Geography 
9. Adherence  
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Participant A 
This interview was conducted in the participant’s home at the end of a quiet cul-de-sac. The 
interview was very briefly interrupted by post being delivered but this did not faze the 
participant. The participant was keen to take part and was very talkative, with the interview 
over running the planned hour by 20 minutes. She seemed to be very motivated to take part 
in the interview. This motivation seems to have been driven partly by a desire to help a 
student with their course. Her niece is studying to be a doctor and this seems to have 
generated a desire to help students more generally. A second motive seemed to be a desire 
to be helpful mixed with a sense of duty. She feels that she should help whenever she can 
regardless of whether this was taking part in research or voting. She had a particular 
fondness for the NHS and showed understanding and concern regarding the consequences of 
wasting medicines. This desire to please was evident at times during the interview and 
resulted in the participant remaining slightly nervous throughout although she seemed to 
enjoy the process. The participant had a weekly routine in which she would engage in a 
number of social activities, part time work, and household chores throughout the days and 
weekend. However, this routine was not too rigid and she changed the type of activities she 
engaged in from time to time. She felt that this routine, which was rigid only in the morning 
and to an extent in the evening once her day was done, helped her to take her medicines 
without forgetting. 
 
Participant B 
The interview was conducted in the participant’s home and his family could be heard talking 
and cooking in nearby rooms. The door was left open and sometimes people passed by. 
Despite this lack of privacy the participant was very calm throughout and seemed entirely 
unperturbed by the possibility of being over heard. Despite this he was a very private man 
who was unwilling to talk about his condition with anyone other than his wife, sister, and 
closest friend. This default towards privacy resulted in the participant being reticent to share 
too much information. His willingness to confide in a only very small number of people also 
guided his choice of GP. He sought the same GP for appointments “nine times out of ten” 
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and said he was less open with other doctors. In this context the interview was short at 
approximately 45 minutes in length and the interview tended to be characterised by short 
exchanges and more closed questions than would be desired. 
 
Participant C 
This interview was conducted in one of the doctor’s rooms at Elvington medical practice. The 
participant approached the interview in a very frank and business-like manner. That is he 
seemed to enjoy the ability to give constructive feedback and considered himself to be 
competent to do so given his formerly senior roles. Further, his talk was often about how 
others may perceive the questionnaire rather than how he himself perceived it. At times the 
interview reflected a meeting not dissimilar to a student-supervisor meeting. He also 
demanded some give and take in the conversation, being unwilling to talk without some 
reciprocation from the interviewer. The setting of the doctor’s room may have contributed to 
the very pragmatic conversation that took place (Elwood and Martin, 2000). The participant 
seemed very honest and the opportunity to talk frankly about his history of mental health 
problems was a motivating factor for his participation. 
 
Participant D 
This interview also took place in a doctor’s room at Elvington surgery. However, unlike with 
participant C the interview felt did not have the character of a formal meeting and the 
participant seemed at home in the surroundings. The participant was happy to talk about 
private matters and voluntarily brought up sexual problems he has as a side effect of drugs 
after only a moment of hesitation. In particular he seemed to be grateful for an opportunity 
to talk about the difficulties his wife faces with degenerating sight. Much of this talk was 
unrelated to the study aims. However the participant was not rushed to change topic given 
the sensitivity of the issue and his clear desire to talk about it. This interview in particular 
includes a number of closed questions from the interviewer which limited the ability of the 
participant to express their own views. The participant does not have hypertension, although 
this was not known at the time of interview. However, he does take medicines for 
hypertension and it was felt on the part of the researcher and supervisory team that their 
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experiences with the survey and of taking medicines meant that their account remained 
relevant. There did not seem to be any great differences in the testimony of this participant 
compared to others that could be clearly attributed to their not having hypertension. 
 
Participant E 
This participant was conducted in a participant’s home whilst decorators were renovating the 
property. The interview was conducted in a large kitchen and dining space which was often 
used for the sink by the decorators. The interview was not disturbed although the decorators 
did enter the room shortly after its conclusion and so conceivably could have done so during 
the interview. The interruption did not put the participant off their stride in the post 
interview discussion however, so there is no reason to suspect this potential for interruption 
changed the interview meaningfully. A phone call that the participant received mid-way 
through the interview also did not faze the participant, although it did take the interviewer a 
moment to locate their place in the interview. The impact of this interruption was minimal 
however, and the conversation resumed its previous flow quickly. This participant seemed 
somewhat anxious throughout the interview and seemed especially keen to present 
themselves as an especially open and helpful person. In parallel with PA this anxiousness 
seemed to be in ensuring they presented themselves well rather than discomfort with the 
process of interview, the questions or interviewer. 
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NRES Committee East of England - Cambridge East 
Victoria House 
Capital Park 
Fulbourn 
Cambridge 
CB21 5XB 
Telephone: 01223 597653 
Facsimile: 01223 597645 
18 June 2012 
steven.watson@uea.ac.uk 
Mr Steven J Watson 
Doctoral Student 
University of East Anglia 
School of Pharmacy 
Norwich Research Park 
Norfolk NR4 7TJ 
Dear Mr Watson 
Study title: Prediction of current adherence to medication in 
patients with hypertension 
REC reference: 12/EE/0203 
Protocol number: N/A 
Thank you for your letter of 07 June 2012, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
The further information has been considered on behalf of the Committee by the Chair. 
Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below. 
Ethical review of research sites 
NHS sites 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see "Conditions of the favourable opinion" below). 
Non-NHS sites 
Conditions of the favourable opinion 
The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
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Management permission or approval must be obtained from each host organisation prior to  
the start of the study at the site concerned.  
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk. 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
Sponsors are not required to notify the Committee of approvals from host organisations 
It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable). 
Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
Document Version Date 
Covering Letter  18 April 2012 
Evidence of insurance or indemnity - Zurich Municipal   
GP/Consultant Information Sheets - Appendix 3e, phase 
1 practitioner 
2,  10 April 2012 
Interview Schedules/Topic Guides - Appendix 9 v5 30 May 2012 
Investigator CV - Steven James Watson  18 April 2012 
Letter from Sponsor - UEA  17 April 2012 
Letter of invitation to participant - Appendix 6a interview 3,  10 April 2012 
Letter of invitation to participant - Appendix 6b interview 
slots 
2, 10 April 2012 
Letter of invitation to participant - Appendix 8 v1 01 June 2012 
Other: Academic Supervisor CV - Debi Bhattacharya 1 30 March 2012 
Other: Appendix 3e Practitioner research notification 3 02 June 2012 
Participant Consent Form: Appendix 4a - Main study Version 11 30 May 2012 
Participant Consent Form: Appendix 4b - Patient 
interview 
Version 3 30 May 2012 
Participant Consent Form: Appendix 7 - Practitioner 
focus group 
Version 3 30 May 2012 
Participant Information Sheet: Appendix 3a, part 1 9 10 April 2012 
Participant Information Sheet: Appendix 3b, phase 2 4 10 April 2012 
Participant Information Sheet: Appendix 3c, follow up 4 10 April 2012 
Participant Information Sheet: Appendix 3d, practitioner 
participant 
4 10 April 2012 
Participant Information Sheet: Appendix 5, phase 1 9 10 April 2012 
Participant Information Sheet: Appendix 3a - Patient 
Main Study Part 1 
17 03 June 2012 
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Participant Information Sheet: Appendix 3b - 
Responders 
6 03 June 2012 
Participant Information Sheet: Appendix 3c - 
Nonresponders part 1 
7 03 June 2012 
Participant Information Sheet: Partitionor focus group 
part1 main study 
16 25 May 2012 
Participant Information Sheet: Appendix 5 - Patient 
interview part 2 
13 03 June 2012 
Protocol 13 18 April 2012 
Questionnaire: PALS, appendix 1 15 03 April 2012 
Questionnaire: WAMS, Appendix 2 14 08 February 2012 
REC application Submission code 
100149/314898/1/80 
18 April 2012 
Response to Request for Further Information from 
Steven Watson 
 07 June 2012 
 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
After ethical review 
Reporting requirements 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
Notifying substantial amendments 
Adding new sites and investigators 
Notification of serious breaches of the protocol 
Progress and safety reports 
Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
Feedback 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure. If you wish to make your views 
known please use the feedback form available on the website. 
Further information is available at National Research Ethics Service website > After Review 
12/EE/0203 Please quote this number on all correspondence 
With the Committee’s best wishes for the success of this project 
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Yours sincerely 
 
Dr Daryl Rees 
Chair 
Email: susan.davies@eoe.nhs.uk  
Enclosures: “After ethical review – guidance for researchers” [SL-AR2] 
Copy to: Mrs Sue Steel sue.steel@uea.ac.uk  
Ms Helen Webster helen.webster@york.nhs.uk  
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NRES Committee East of England - Cambridge East 
Victoria House 
Capital Park 
Fulbourn 
Cambridge 
CB21 5XB 
Tel: 01223 597750 
Fax: 01223 597645 
05 October 2012 
Mr Steven J Watson 
Doctoral Student 
University of East Anglia 
School of Pharmacy 
University of East Anglia 
Norwich Research Park 
NR4 7TJ 
Dear Mr Watson 
Study title: Prediction of current adherence to medication in patients 
with hypertension 
REC reference: 12/EE/0203 
Protocol number: N/A 
Amendment number: Substantial Amendment AM02 IRAS Code: 
100149/366008/13/33/15266 
Amendment date: 21 September 2012 
Amendment Summary: Request to follow up Patients not agreeing to fill in 
questionnaires with a postcard asking for feedback. 
The above amendment was reviewed at the meeting of the Sub-Committee held on 02 
October 2012 by email correspondence. 
Ethical opinion 
None 
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation. 
Approved documents 
The documents reviewed and approved at the meeting were: 
Document Version Date 
Participant Postcard Version 2 21 September 2012 
Protocol Version 14 21 September 2012 
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Notice of Substantial Amendment (non-CTIMPs) : Substantial 
Amendment AM02 IRAS Code: 100149/366008/13/33/15266 
 21 September 2012 
Covering Letter : From: Steven Watson  21 September 2012 
 
Membership of the Committee 
The members of the Committee who took part in the review are listed on the attached 
sheet. 
R&D approval 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
12/EE/0203: Please quote this number on all correspondence 
Yours sincerely 
PP   
Rebekah Lay 
Chair 
E-mail: melanie.johnson@eoe.nhs.uk 
Enclosures: List of names and professions of members who took part in the 
review 
Emailed To: Mr Steven J Watson: steven.watson@uea.ac.uk  
Ms Helen Webster, : helen.webster@york.nhs.uk 
Mrs Sue Steel: sue.steel@uea.ac.uk  
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NRES Committee East of England - Cambridge East 
Attendance at Sub-Committee of the REC meeting on 02 October 2012 
Also in attendance: 
Name Position (or reason for attending) 
Mrs Rebekah Ley Assistant Director Medico Legal and Patient 
Experience 
Mrs Alison Wooster Lay member 
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Dawn.Taylor@nyypct.nhs.uk 
Direct Tel: 01845 573863 
 
Reference: PhDStudy 
 
The Hamlet 
Hornbeam Park 
Harrogate 
North Yorkshire 
HG2 8RE 
Steven Watson 
School of Pharmacy 
University of East Anglia 
Norwich Research Park 
Norwich 
NR4 7TJ 
Tel:  01845 573863  
Fax:  01845 573805 
Website: www.northyorkshireandyork.nhs.uk 
 
 
 
 
30 July 2012 
  
 
Dear Steve 
 
Re:   Application for NHS Research Permission 
Project Title: Medication adherence in hypertension (PhD Study) 
 
Further to your recent request I am writing to inform you that NHS North Yorkshire 
and York give research governance permission for the above study. 
 
In accordance with the Trust policy for research governance you are required to 
inform Dawn Taylor (Head of Corporate Governance) at the Trust of any significant 
proposed challenges to the original protocol, adverse events or issues of safety. 
In addition also required will be progress reports and end of study notification. 
 
Wishing you every success with your study. 
 
Yours sincerely 
 
Dawn Taylor 
Head of Corporate Governance 
 
 
Cc: Dr Timothy Longmore 
 Elvington Medical Centre 
 York Road 
 Elvington 
 York 
 YO41 4DY 
    Timothy.Longmore@GP-B82081.NHS.U
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NHS 
North Yorkshire and York 
Our Ref: M-/ZF-SubAmd2 
19/11/2012 
Mr Steven J Watson 
School of Pharmacy 
University of East 
Anglia Norwich 
Research Park NR4 
7TJ 
The Hamlet 
Hornbeam Park 
Harrogate 
North Yorkshire 
HG2 8RE 
 
Dear Mr Steven J Watson 
Re: Substantial Amendment 2 Approval Letter 
-- 
Study Title: Prediction of current adherence to medication in patients with hypertension Local R&D No: 
178 
REC No: 121EE10203 
Thank you for informing myself of the notification of a substantial amendment and the 
favourable ethical opinion for the above study. The receipt of the necessary documents has been 
attained by the PCT. 
Further to your recent request I am writing to inform you that NHS North Yorkshire & York give 
research governance approval for the above study. 
In accordance with NHS North Yorkshire & York policy for research governance you are required to 
inform Dr Marie Girdham (Research Governance Manager) at the trust of any further significant 
proposed challenges to the original protocol adverse events or issues of safety. In addition Dr Marie 
Girdham will also require progress reports and end of study notification. 
Marie's contact details are as follows: 
Dr Marie Girdham 
Research Governance Manager 
NHS North Lincolnshire 
Health Place 
Wrawby Road 
Brigg 
North Lincolnshire 
DN20 8GS 
Tel: 01652 251000 E: marie.qirdham (nhs.net 
R&D Facilitator contact Email & Telephone details: 
Tel: 01652 251134 E: zowie.fusseNanhs.net 
 
Wishing you every success with your 
study. Yours sincerely 
Dawn Taylor 
Head of Corporate Governance 
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This abstract was submitted to the Health Services Research and Pharmacy Practice 
conference (HSRPP - 2011) where it won first prize in the poster abstract competition. 
 
Title: Systematic review and meta-analysis shows stress is negatively associated with 
adherence to medication 
Watson S, Bhattacharya D, Wood J, Smith J, Adams M, Song F. 
School of Pharmacy, University of East Anglia, Earlham Road, Norwich, nr4 7tj, United Kingdom 
Email: steven.watson@uea.ac.uk 
 
Background: Chronic illnesses are most commonly managed with prescribed medications. 
Such illnesses are associated with prolonged periods of physical and psychological stress. 
Prescribed medications may exacerbate stress if side-effects are experienced, or by 
reducing patient’s perceived control[1]. This may reduce a patient’s capacity or willingness 
to adhere to their medication[2]. This study provides a meta-analysis addressing the 
hypothesis that stress impairs patient adherence to medication. This study did not require 
ethical approval. 
 
Method: Articles were considered relevant if they were published in English and allowed 
a correlation between stress and medication adherence to be calculated. Articles were 
identified as part of a larger meta-analysis of adherence predictors by searching Medline, 
Embase and PsychInfo using the Ovid interface on the 26/04/2010. Variations of the 
terms “patient adherence” and “patient compliance” were searched alongside “medic*” 
and “predic* or influ* or determ* or caus* or correla* or associat*” to limit the search to 
articles examining correlates of medication adherence. No limits were placed on date of 
publication or study design. Excluded were studies from a mentally ill, institutionalised or 
paediatric population. Random effects meta-analysis was employed to estimate the size 
of the relationship between stress and adherence. Results are presented as Pearson’s 
coefficients with 95% confidence intervals. Calculations were performed using 
Comprehensive Meta-Analysis[3]. Quality assessment criteria were collected for post-hoc 
testing according to study methodology and the validity and reliability of the measures of 
adherence and stress employed. Potential reporting bias was explored by visual analysis 
of a funnel plot[4]. 
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Results: In total, 2007 articles were identified. Searching study abstracts identified 48 
articles potentially relevant to the stress hypothesis. Full publications revealed 27 
irrelevant articles, and 13 providing inadequate information to calculate an effect size. 
Inclusion criteria were met by eight studies providing a total sample size of 2603 
participants. The mean proportion of adherent patients was 69% based on six studies. 
Experience of stress was negatively associated with adherence (r = -0.248, 95% CI = -
0.297, -0.197, p < 0.001). The analysis was not significantly heterogeneous (Cochran’s Q = 
9.309, p = 0.231). The sample of studies used was too small to analyse the impact of study 
factors or possible covariates using meta-regression[5]. Lack of reporting for reliability and 
validity data prohibited further quality analysis. A funnel plot and the high number of 
studies not fully reporting the stress and adherence relationship may suggest an outcome 
bias in reporting. 
 
Discussion: Stress is a manageable condition[6] that has a direct impact on health 
outcomes, and has further damaging implications by lowering adherence to medication. It 
is therefore essential that healthcare professionals maintain an awareness of patient 
mental wellbeing and given that a number of treatments for stress exist, offer 
appropriate interventions[6]. The poor methodological consistency of studies is 
problematic and reflects a lack of validated measures; however, the low heterogeneity of 
this meta-analysis increases confidence in the findings. Covariance between stress and 
other adherence predictors was not addressed; nor was it identified whether the 
observed non-adherence was intentional or not. These shortfalls will be addressed by a 
larger meta-analysis examining the relationships between many more predictors of 
adherence. 
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This abstract was submitted to the Health Services Research and Pharmacy Practice 
conference (HSRPP - 2012) where it was accepted as an oral presentation 
 
Title: The impact of treatment side-effects upon medication adherence. 
Watson S, Bhattacharya D, Wood J, Smith J, Adams M, Song F. 
 
School of Pharmacy, University of East Anglia, Earlham Road, Norwich, nr4 7tj, United Kingdom 
Email: steven.watson@uea.ac.uk 
 
Background: Patient non-adherence to prescribed medication therapy is associated with lower 
treatment efficacy[1] and experience of side-effects is an often cited reason for non-adherence[2]. 
Meta-analytic treatment of this hypothesis is currently lacking. This study provides evidence for 
the size of the relationship between patient experience of side-effects and non-adherence to 
medication. This study did not require ethical approval. 
 
Method: Articles were considered relevant if they were published in English, and provided 
measures for which an effect size of the relationship between adherence and experience of side-
effects could be calculated. Articles were identified as part of a larger meta-analysis of adherence 
predictors by searching Medline, Embase and PsychInfo using the Ovid interface on the 
26/04/2010. Variations of the terms “patient adherence” and “patient compliance” were 
searched alongside “medic*” and “predic* or influ* or determ* or caus* or correla* or associat*” 
to limit the search to articles examining correlates of medication adherence. No limits were 
placed on date of publication or study design. Excluded were studies from a mentally ill, 
institutionalised or paediatric population. Random effects meta-analysis was employed to 
estimate the size of the odds ratio (OR) and 95% confidence interval between the presence or 
absence of side-effects and the proportion of adherent patients, as well as the Pearson’s 
correlation coefficients (r) between adherence behaviour and the number and severity of side-
effects. Quality assessment criteria were collected for post-hoc testing according to study 
methodology via the meta-regression procedures of Lipsey and Wilson[3]. Potential reporting bias 
was explored by visual analysis of a funnel plot. 
 
Results: In total, 1878 unique articles were identified. Only studies with sufficiently similar 
definitions of patient experience of side-effects were incorporated into meta-analyses. Full 
inclusion criteria were met for 11 articles examining the effects of the presence versus absence of 
side-effects upon adherence (n = 4161), five articles examining the effect of the number of side-
effects upon adherence (n = 1394), and a further five articles examining the severity of side-
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effects upon adherence (n = 3672). The presence of side-effects was associated with reduced 
adherence, OR (95% CI) = 0.40 (0.19, 0.84), p = 0.02. As the number of experienced side-effects 
increased, adherence decreased, r (95% CI) = -0.17 (-0.29, -0.04), p = 0.01. Similarly, more severe 
side-effects were associated with lowered adherence, r (95% CI) = -0.22 (-0.26, -0.18), p <0.01. 
Heterogeneity analysis identified no significant impacts upon effect size estimates from indicators 
of study quality, although study quality was low. There were no indications of bias in outcome 
displayed by funnel plots. 
 
Discussion:  
Recent national UK guidance to facilitate medication adherence recommended the discussion of 
side-effects with patients at the point of prescribing in order to allow patients to make an 
informed choice about their therapy[4]. The findings of this meta-analysis further highlight the 
relevance of side-effects to medication adherence and therefore the importance of these 
discussions occurring between healthcare professionals and patients.  
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